gs_row,outcome,study_id,title,main_aim_of_study,intervention,intervention_type,intervention_grouping,arm,ad_class,ad_dose_numerical_fixed_amount_range_or_mean_dose,ad_dose_categorised,dose_schedule,length_of_study_start_to_post_intervention,pain_condition,general_pain_grouping,iasp_pain_grouping,minimum_pain_inclusion,design,imputation_method,scale,timepoint,follow_up_timepoint,mean,sd,se,median,ci_lower,ci_upper,iqr_lower,iqr_higher,n,r,r_percent,change_score,adverse_events_definition,stats_notes,study_notes,date_checked,remove_row_for_mood_analysis,intervention_category,direction_of_improvement,outcome_nma,outcome_label,model_type,model_text,outcome_all,time_no_change
2,pain_int,abou-raya 2012,title: duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥40 on 100vas,parallel,itt unspecified method,womac pain subscale,baseline,NA,8.9,5.9,0.4916666666666667,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
3,pain_int,abou-raya 2012,title: duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,16 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥40 on 100vas,parallel,itt unspecified method,womac pain subscale,baseline,NA,9.1,4.6,0.3833333333333333,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
4,pain_int,abou-raya 2012,title: duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥40 on 100vas,parallel,itt unspecified method,womac pain subscale,post_int,NA,8.4,5.4,0.45,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
5,pain_int,abou-raya 2012,title: duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,16 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥40 on 100vas,parallel,itt unspecified method,womac pain subscale,post_int,NA,6,4.1,0.3416666666666666,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
6,physical,abou-raya 2012,title: duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥40 on 100vas,parallel,itt unspecified method,womac total score,baseline,NA,33.5,7.1,0.5916666666666667,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
7,physical,abou-raya 2012,title: duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,16 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥40 on 100vas,parallel,itt unspecified method,womac total score,baseline,NA,33.1,7.5,0.625,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
8,physical,abou-raya 2012,title: duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥40 on 100vas,parallel,itt unspecified method,womac total score,post_int,NA,30.3,9.8,0.8166666666666668,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
9,physical,abou-raya 2012,title: duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,16 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥40 on 100vas,parallel,itt unspecified method,womac total score,post_int,NA,24.6,8.4,0.7000000000000001,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
10,mood,abou-raya 2012,title: duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥40 on 100vas,parallel,itt unspecified method,geriatric depression scale,baseline,NA,9.8,2.5,0.20833333333333334,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
11,mood,abou-raya 2012,title: duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,16 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥40 on 100vas,parallel,itt unspecified method,geriatric depression scale,baseline,NA,9.9,2.7,0.225,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
12,mood,abou-raya 2012,title: duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥40 on 100vas,parallel,itt unspecified method,geriatric depression scale,post_int,NA,9.7,2.2,0.18333333333333335,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
13,mood,abou-raya 2012,title: duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,16 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥40 on 100vas,parallel,itt unspecified method,geriatric depression scale,post_int,NA,5.2,1.7,0.14166666666666666,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
14,withdrawal,abou-raya 2012,title: duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥40 on 100vas,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,144,13,0.09029999999999999,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
15,withdrawal,abou-raya 2012,title: duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,16 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥40 on 100vas,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,144,21,0.1458,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
16,adverse_dropout,abou-raya 2012,title: duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥40 on 100vas,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,144,6,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
17,adverse_dropout,abou-raya 2012,title: duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,16 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥40 on 100vas,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,144,9,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
18,adverse,agger 2017,"title: imipramine versus placebo for multiple functional somatic syndromes (stress-3): a double-blind, randomised study",global improvement,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,multiple functional somatic syndromes,primary,primary,no,parallel,itt unspecified method,count,baseline,NA,NA,NA,NA,NA,NA,NA,NA,NA,59,10,0.17,FALSE,NA,NA,at least one ae of moderate intensity,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,baseline
19,adverse,agger 2017,"title: imipramine versus placebo for multiple functional somatic syndromes (stress-3): a double-blind, randomised study",global improvement,imipramine,antidepressant,antidepressant,imipramine 25-75mg,tca,25-75mg,low,flexible,13 weeks,multiple functional somatic syndromes,primary,primary,no,parallel,itt unspecified method,count,baseline,NA,NA,NA,NA,NA,NA,NA,NA,NA,65,32,0.49,FALSE,NA,NA,at least one ae of moderate intensity,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,baseline
20,adverse_dropout,agger 2017,"title: imipramine versus placebo for multiple functional somatic syndromes (stress-3): a double-blind, randomised study",global improvement,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,multiple functional somatic syndromes,primary,primary,no,parallel,itt unspecified method,count,baseline,NA,NA,NA,NA,NA,NA,NA,NA,NA,60,3,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,baseline
21,adverse_dropout,agger 2017,"title: imipramine versus placebo for multiple functional somatic syndromes (stress-3): a double-blind, randomised study",global improvement,imipramine,antidepressant,antidepressant,imipramine 25-75mg,tca,25-75mg,low,flexible,13 weeks,multiple functional somatic syndromes,primary,primary,no,parallel,itt unspecified method,count,baseline,NA,NA,NA,NA,NA,NA,NA,NA,NA,65,4,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,baseline
22,withdrawal,agger 2017,"title: imipramine versus placebo for multiple functional somatic syndromes (stress-3): a double-blind, randomised study",global improvement,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,multiple functional somatic syndromes,primary,primary,no,parallel,itt unspecified method,count,baseline,NA,NA,NA,NA,NA,NA,NA,NA,NA,68,15,0.221,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,baseline
23,withdrawal,agger 2017,"title: imipramine versus placebo for multiple functional somatic syndromes (stress-3): a double-blind, randomised study",global improvement,imipramine,antidepressant,antidepressant,imipramine 25-75mg,tca,25-75mg,low,flexible,13 weeks,multiple functional somatic syndromes,primary,primary,no,parallel,itt unspecified method,count,baseline,NA,NA,NA,NA,NA,NA,NA,NA,NA,70,13,0.18600000000000003,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,baseline
24,sleep,ahmed 2016,"the effects of milnacipran on sleep disturbance in fibromyalgia: a randomized, double-blind, placebo-controlled, two-way crossover study",sleep,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,no,crossover,per-protocol,mos sleep problems index ii,baseline,NA,55.6,55.770960185386805,14.4,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
25,sleep,ahmed 2016,"the effects of milnacipran on sleep disturbance in fibromyalgia: a randomized, double-blind, placebo-controlled, two-way crossover study",sleep,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,no,crossover,per-protocol,mos sleep problems index ii,baseline,NA,55.6,55.770960185386805,14.4,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
26,sleep,ahmed 2016,"the effects of milnacipran on sleep disturbance in fibromyalgia: a randomized, double-blind, placebo-controlled, two-way crossover study",sleep,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,no,crossover,per-protocol,mos sleep problems index ii,post_int,NA,34.9,14.717336715588184,3.8,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
27,sleep,ahmed 2016,"the effects of milnacipran on sleep disturbance in fibromyalgia: a randomized, double-blind, placebo-controlled, two-way crossover study",sleep,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,no,crossover,per-protocol,mos sleep problems index ii,post_int,NA,37.8,17.041126723312637,4.4,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
28,qol,ahmed 2016,"the effects of milnacipran on sleep disturbance in fibromyalgia: a randomized, double-blind, placebo-controlled, two-way crossover study",sleep,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,no,crossover,per-protocol,fibromyalgia impact questionnaire total score,baseline,NA,56.7,48.799590162213455,12.6,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
29,qol,ahmed 2016,"the effects of milnacipran on sleep disturbance in fibromyalgia: a randomized, double-blind, placebo-controlled, two-way crossover study",sleep,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,no,crossover,per-protocol,fibromyalgia impact questionnaire total score,baseline,NA,56.7,48.799590162213455,12.6,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
30,qol,ahmed 2016,"the effects of milnacipran on sleep disturbance in fibromyalgia: a randomized, double-blind, placebo-controlled, two-way crossover study",sleep,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,no,crossover,per-protocol,fibromyalgia impact questionnaire total score,post_int,NA,45.3,15.491933384829668,4,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
31,qol,ahmed 2016,"the effects of milnacipran on sleep disturbance in fibromyalgia: a randomized, double-blind, placebo-controlled, two-way crossover study",sleep,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,no,crossover,per-protocol,fibromyalgia impact questionnaire total score,post_int,NA,40,26.336286754210434,6.8,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
32,pain_int,ahmed 2016,"the effects of milnacipran on sleep disturbance in fibromyalgia: a randomized, double-blind, placebo-controlled, two-way crossover study",sleep,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,no,crossover,per-protocol,bpi pain severity,baseline,NA,5.4,4.6475800154489,1.2,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
33,pain_int,ahmed 2016,"the effects of milnacipran on sleep disturbance in fibromyalgia: a randomized, double-blind, placebo-controlled, two-way crossover study",sleep,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,no,crossover,per-protocol,bpi pain severity,baseline,NA,5.4,4.6475800154489,1.2,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
34,pain_int,ahmed 2016,"the effects of milnacipran on sleep disturbance in fibromyalgia: a randomized, double-blind, placebo-controlled, two-way crossover study",sleep,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,no,crossover,per-protocol,bpi pain severity,post_int,NA,4.7,1.5491933384829668,0.4,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
35,pain_int,ahmed 2016,"the effects of milnacipran on sleep disturbance in fibromyalgia: a randomized, double-blind, placebo-controlled, two-way crossover study",sleep,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,no,crossover,per-protocol,bpi pain severity,post_int,NA,4.1,2.32379000772445,0.6,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
36,serious_adverse,ahmed 2016,"the effects of milnacipran on sleep disturbance in fibromyalgia: a randomized, double-blind, placebo-controlled, two-way crossover study",sleep,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,no,crossover,per-protocol,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,0,0,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
37,serious_adverse,ahmed 2016,"the effects of milnacipran on sleep disturbance in fibromyalgia: a randomized, double-blind, placebo-controlled, two-way crossover study",sleep,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,no,crossover,per-protocol,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,0,0,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
38,withdrawal,ahmed 2016,"the effects of milnacipran on sleep disturbance in fibromyalgia: a randomized, double-blind, placebo-controlled, two-way crossover study",sleep,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,no,crossover,per-protocol,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,1,0.055,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
39,withdrawal,ahmed 2016,"the effects of milnacipran on sleep disturbance in fibromyalgia: a randomized, double-blind, placebo-controlled, two-way crossover study",sleep,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,no,crossover,per-protocol,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,3,0.16699999999999998,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
40,adverse,ahmed 2016,"the effects of milnacipran on sleep disturbance in fibromyalgia: a randomized, double-blind, placebo-controlled, two-way crossover study",sleep,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,no,crossover,per-protocol,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,5,0.35700000000000004,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
41,adverse,ahmed 2016,"the effects of milnacipran on sleep disturbance in fibromyalgia: a randomized, double-blind, placebo-controlled, two-way crossover study",sleep,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,no,crossover,per-protocol,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,10,0.642,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
42,withdrawal,alcoff 1982,controlled trial of imipramine for chronic low back pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,low back pain,musculoskeletal,primary,no,parallel,unclear,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,2,0.091,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
43,withdrawal,alcoff 1982,controlled trial of imipramine for chronic low back pain,pain,imipramine,antidepressant,antidepressant,imipramine 150mg,tca,150mg,high,fixed,8 weeks,low back pain,musculoskeletal,primary,no,parallel,unclear,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,7,0.25,FALSE,NA,NA,NA,2021-09-27,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
44,pain_int,allen 2014,clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.61,1.6,0.16865480854231357,NA,NA,NA,NA,NA,90,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
45,pain_int,allen 2014,clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 50mg,snri,50mg,standard,fixed,13 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.44,1.66,0.20914034173177237,NA,NA,NA,NA,NA,63,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
46,pain_int,allen 2014,clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 100mg,snri,100mg,high,fixed,13 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.14,1.62,0.17368223064372276,NA,NA,NA,NA,NA,87,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
47,pain_int,allen 2014,clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 200mg,snri,200mg,high,fixed,13 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.55,1.52,0.15276574791940023,NA,NA,NA,NA,NA,99,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
48,pain_int,allen 2014,clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 400mg,snri,400mg,high,fixed,13 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.48,1.42,0.17094791138179224,NA,NA,NA,NA,NA,69,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
49,pain_int,allen 2014,clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-1.83,1.8667619023324853,0.22,NA,NA,NA,NA,NA,72,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
50,pain_int,allen 2014,clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 50mg,snri,50mg,standard,fixed,13 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-2.41,1.82,0.26,NA,NA,NA,NA,NA,49,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
51,pain_int,allen 2014,clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 100mg,snri,100mg,high,fixed,13 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-2.42,1.8543192821086665,0.23,NA,NA,NA,NA,NA,65,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
52,pain_int,allen 2014,clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 200mg,snri,200mg,high,fixed,13 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-2.93,1.8406520583749661,0.22,NA,NA,NA,NA,NA,70,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
53,pain_int,allen 2014,clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 400mg,snri,400mg,high,fixed,13 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-2.74,1.707629936490925,0.27,NA,NA,NA,NA,NA,40,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
54,pain_sub,allen 2014,clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,89,23,0.26,FALSE,NA,NA,NA,2021-09-27,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
55,pain_sub,allen 2014,clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 50mg,snri,50mg,standard,fixed,13 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,63,22,0.35,FALSE,NA,NA,NA,2021-09-27,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
56,pain_sub,allen 2014,clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 100mg,snri,100mg,high,fixed,13 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,32,0.37,FALSE,NA,NA,NA,2021-09-27,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
57,pain_sub,allen 2014,clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 200mg,snri,200mg,high,fixed,13 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,99,36,0.36,FALSE,NA,NA,NA,2021-09-27,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
58,pain_sub,allen 2014,clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 400mg,snri,400mg,high,fixed,13 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,68,22,0.32,FALSE,NA,NA,NA,2021-09-27,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
59,adverse,allen 2014,clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,90,68,0.7559999999999999,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
60,adverse,allen 2014,clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 50mg,snri,50mg,standard,fixed,13 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,63,47,0.746,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
61,adverse,allen 2014,clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 100mg,snri,100mg,high,fixed,13 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,87,65,0.747,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
62,adverse,allen 2014,clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 200mg,snri,200mg,high,fixed,13 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,99,82,0.828,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
63,adverse,allen 2014,clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 400mg,snri,400mg,high,fixed,13 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,69,63,0.9129999999999999,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
64,serious_adverse,allen 2014,clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,91,6,0.066,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
65,serious_adverse,allen 2014,clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 50mg,snri,50mg,standard,fixed,13 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,62,1,0.016,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
66,serious_adverse,allen 2014,clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 100mg,snri,100mg,high,fixed,13 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,91,1,0.011000000000000001,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
67,serious_adverse,allen 2014,clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 200mg,snri,200mg,high,fixed,13 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,100,1,0.01,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
68,serious_adverse,allen 2014,clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 400mg,snri,400mg,high,fixed,13 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,70,3,0.043,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
69,withdrawal,allen 2014,clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,90,15,0.16699999999999998,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
70,withdrawal,allen 2014,clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 50mg,snri,50mg,standard,fixed,13 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,63,12,0.19,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
71,withdrawal,allen 2014,clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 100mg,snri,100mg,high,fixed,13 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,87,18,0.207,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
72,withdrawal,allen 2014,clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 200mg,snri,200mg,high,fixed,13 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,99,31,0.313,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
73,withdrawal,allen 2014,clinical experience with desvenlafaxine in treatment of patients with diabetic peripheral neuropathy,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 400mg,snri,400mg,high,fixed,13 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,69,27,0.391,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
84,pain_sub,allen 2017,clinical experience with desvenlafaxine in treatment of patients with fibromyalgia syndrome,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,15 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,126,28,0.22,FALSE,NA,NA,study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
85,pain_sub,allen 2017,clinical experience with desvenlafaxine in treatment of patients with fibromyalgia syndrome,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 50mg,snri,50mg,standard,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,131,31,0.24,FALSE,NA,NA,study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
86,pain_sub,allen 2017,clinical experience with desvenlafaxine in treatment of patients with fibromyalgia syndrome,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 100mg,snri,100mg,high,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,131,29,0.22,FALSE,NA,NA,study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
87,pain_sub,allen 2017,clinical experience with desvenlafaxine in treatment of patients with fibromyalgia syndrome,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 200mg,snri,200mg,high,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,132,33,0.25,FALSE,NA,NA,study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
88,pain_sub,allen 2017,clinical experience with desvenlafaxine in treatment of patients with fibromyalgia syndrome,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 400mg,snri,400mg,high,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,139,25,0.18,FALSE,NA,NA,study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
89,adverse_dropout,allen 2017,clinical experience with desvenlafaxine in treatment of patients with fibromyalgia syndrome,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,15 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,safety population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,130,18,0.14,FALSE,NA,NA,study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
90,adverse_dropout,allen 2017,clinical experience with desvenlafaxine in treatment of patients with fibromyalgia syndrome,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 50mg,snri,50mg,standard,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,safety population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,136,19,0.14,FALSE,NA,NA,study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
91,adverse_dropout,allen 2017,clinical experience with desvenlafaxine in treatment of patients with fibromyalgia syndrome,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 100mg,snri,100mg,high,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,safety population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,140,39,0.28,FALSE,NA,NA,study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
92,adverse_dropout,allen 2017,clinical experience with desvenlafaxine in treatment of patients with fibromyalgia syndrome,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 200mg,snri,200mg,high,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,safety population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,142,40,0.28,FALSE,NA,NA,study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
93,adverse_dropout,allen 2017,clinical experience with desvenlafaxine in treatment of patients with fibromyalgia syndrome,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 400mg,snri,400mg,high,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,safety population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,149,52,0.35,FALSE,NA,NA,study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
94,adverse,allen 2017,clinical experience with desvenlafaxine in treatment of patients with fibromyalgia syndrome,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,15 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,safety population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,130,106,0.82,FALSE,NA,NA,study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
95,adverse,allen 2017,clinical experience with desvenlafaxine in treatment of patients with fibromyalgia syndrome,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 50mg,snri,50mg,standard,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,safety population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,136,123,0.9,FALSE,NA,NA,study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
96,adverse,allen 2017,clinical experience with desvenlafaxine in treatment of patients with fibromyalgia syndrome,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 100mg,snri,100mg,high,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,safety population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,139,122,0.88,FALSE,NA,NA,study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
97,adverse,allen 2017,clinical experience with desvenlafaxine in treatment of patients with fibromyalgia syndrome,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 200mg,snri,200mg,high,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,safety population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,142,122,0.86,FALSE,NA,NA,study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
98,adverse,allen 2017,clinical experience with desvenlafaxine in treatment of patients with fibromyalgia syndrome,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 400mg,snri,400mg,high,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,safety population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,149,136,0.91,FALSE,NA,NA,study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
99,serious_adverse,allen 2017,clinical experience with desvenlafaxine in treatment of patients with fibromyalgia syndrome,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,15 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,safety population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,130,6,0.05,FALSE,NA,NA,study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
100,serious_adverse,allen 2017,clinical experience with desvenlafaxine in treatment of patients with fibromyalgia syndrome,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 50mg,snri,50mg,standard,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,safety population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,136,3,0.02,FALSE,NA,NA,study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
101,serious_adverse,allen 2017,clinical experience with desvenlafaxine in treatment of patients with fibromyalgia syndrome,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 100mg,snri,100mg,high,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,safety population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,139,3,0.02,FALSE,NA,NA,study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
102,serious_adverse,allen 2017,clinical experience with desvenlafaxine in treatment of patients with fibromyalgia syndrome,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 200mg,snri,200mg,high,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,safety population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,142,6,0.04,FALSE,NA,NA,study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
103,serious_adverse,allen 2017,clinical experience with desvenlafaxine in treatment of patients with fibromyalgia syndrome,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 400mg,snri,400mg,high,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,safety population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,149,6,0.04,FALSE,NA,NA,study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
104,withdrawal,allen 2017,clinical experience with desvenlafaxine in treatment of patients with fibromyalgia syndrome,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,15 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,none - randomised population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,130,84,0.677,FALSE,NA,NA,study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
105,withdrawal,allen 2017,clinical experience with desvenlafaxine in treatment of patients with fibromyalgia syndrome,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 50mg,snri,50mg,standard,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,none - randomised population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,136,87,0.66,FALSE,NA,NA,study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
106,withdrawal,allen 2017,clinical experience with desvenlafaxine in treatment of patients with fibromyalgia syndrome,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 100mg,snri,100mg,high,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,none - randomised population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,140,81,0.62,FALSE,NA,NA,study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
107,withdrawal,allen 2017,clinical experience with desvenlafaxine in treatment of patients with fibromyalgia syndrome,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 200mg,snri,200mg,high,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,none - randomised population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,142,100,0.76,FALSE,NA,NA,study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
108,withdrawal,allen 2017,clinical experience with desvenlafaxine in treatment of patients with fibromyalgia syndrome,pain,desvenlafaxine,antidepressant,antidepressant,desvenlafaxine 400mg,snri,400mg,high,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,none - randomised population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,149,93,0.67,FALSE,NA,NA,study was discontinued by the sponsor at 15 weeks due to not meeting pre-specified efficacy interim measures.,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
109,adverse_dropout,anderberg 2000,"citalopram in patients with fibromyalgia--a randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
110,adverse_dropout,anderberg 2000,"citalopram in patients with fibromyalgia--a randomized, double-blind, placebo-controlled study",pain,citalopram,antidepressant,antidepressant,citalopram 30-40mg,ssri,30-40mg,standard,flexible,16 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,3,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
111,withdrawal,anderberg 2000,"citalopram in patients with fibromyalgia--a randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,1,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
112,withdrawal,anderberg 2000,"citalopram in patients with fibromyalgia--a randomized, double-blind, placebo-controlled study",pain,citalopram,antidepressant,antidepressant,citalopram 30-40mg,ssri,30-40mg,standard,flexible,16 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,4,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
113,pain_int,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioral therapy,n/a,n/a,n/a,n/a,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,0-10 numerical rating scale,baseline,NA,6.36,1.3,0.2982404540317303,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
114,pain_int,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,cognitive behavioral therapy and milnacipran,combined antidepressant intervention,antidepressant,cognitive behavioral therapy and milnacipran 100mg,snri,100mg,standard,fixed,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,0-10 numerical rating scale,baseline,NA,6.24,1.28,0.28621670111997305,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
115,pain_int,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,0-10 numerical rating scale,baseline,NA,6.33,1.3,0.2982404540317303,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
116,pain_int,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioral therapy,n/a,n/a,n/a,n/a,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,0-10 numerical rating scale,change_score,NA,-1.67,1.7428425057933377,0.45,NA,NA,NA,NA,NA,15,NA,NA,TRUE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
117,pain_int,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,cognitive behavioral therapy and milnacipran,combined antidepressant intervention,antidepressant,cognitive behavioral therapy and milnacipran 100mg,snri,100mg,standard,fixed,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,0-10 numerical rating scale,change_score,NA,-2.15,1.772935419015594,0.43,NA,NA,NA,NA,NA,17,NA,NA,TRUE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
118,pain_int,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,0-10 numerical rating scale,change_score,NA,-0.97,1.772935419015594,0.43,NA,NA,NA,NA,NA,17,NA,NA,TRUE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
119,pain_mod,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioral therapy,n/a,n/a,n/a,n/a,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,4,0.21100000000000002,FALSE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,non_pharm,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
120,pain_mod,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,cognitive behavioral therapy and milnacipran,combined antidepressant intervention,antidepressant,cognitive behavioral therapy and milnacipran 100mg,snri,100mg,standard,fixed,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,8,0.4,FALSE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
121,pain_mod,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,7,0.384,FALSE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
122,physical,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioral therapy,n/a,n/a,n/a,n/a,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,sf-36 physical component score,baseline,NA,43.95,22.15,5.081558505232942,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,non_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
123,physical,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,cognitive behavioral therapy and milnacipran,combined antidepressant intervention,antidepressant,cognitive behavioral therapy and milnacipran 100mg,snri,100mg,standard,fixed,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,sf-36 physical component score,baseline,NA,49.75,22.15,4.952890570162034,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
124,physical,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,sf-36 physical component score,baseline,NA,41.84,23.35,5.356857385877617,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
125,physical,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioral therapy,n/a,n/a,n/a,fixed,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,sf-36 physical component score,change_score,NA,15.04,15.53066321829174,4.01,NA,NA,NA,NA,NA,15,NA,NA,TRUE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,non_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
126,physical,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,cognitive behavioral therapy and milnacipran,combined antidepressant intervention,antidepressant,cognitive behavioral therapy and milnacipran 100mg,snri,100mg,standard,fixed,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,sf-36 physical component score,change_score,NA,13.47,15.420415039810052,3.74,NA,NA,NA,NA,NA,17,NA,NA,TRUE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
127,physical,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,sf-36 physical component score,change_score,NA,4.05,15.832725602371816,3.84,NA,NA,NA,NA,NA,17,NA,NA,TRUE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
128,qol,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioral therapy,n/a,n/a,n/a,fixed,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,fibromyalgia impact questionnaire total score,baseline,NA,61.62,12.59,2.8883440894303725,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,non_pharm,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
129,qol,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,cognitive behavioral therapy and milnacipran,combined antidepressant intervention,antidepressant,cognitive behavioral therapy and milnacipran 100mg,snri,100mg,standard,fixed,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,fibromyalgia impact questionnaire total score,baseline,NA,66.56,11.27,2.5200486106422626,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
130,qol,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,fibromyalgia impact questionnaire total score,baseline,NA,66.35,10.92,2.505219813866534,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
131,qol,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioral therapy,n/a,n/a,n/a,fixed,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,fibromyalgia impact questionnaire total score,change_score,NA,-11.16,15.685582552140039,4.05,NA,NA,NA,NA,NA,15,NA,NA,TRUE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,non_pharm,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
132,qol,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,cognitive behavioral therapy and milnacipran,combined antidepressant intervention,antidepressant,cognitive behavioral therapy and milnacipran 100mg,snri,100mg,standard,fixed,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,fibromyalgia impact questionnaire total score,change_score,NA,-15.2,16.038880883652702,3.89,NA,NA,NA,NA,NA,17,NA,NA,TRUE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
133,qol,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,fibromyalgia impact questionnaire total score,change_score,NA,-12.7,16.038880883652702,3.89,NA,NA,NA,NA,NA,17,NA,NA,TRUE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
134,mood,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioral therapy,n/a,n/a,n/a,fixed,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,phq8,baseline,NA,11.21,4.74,1.0874305785464626,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
135,mood,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,cognitive behavioral therapy and milnacipran,combined antidepressant intervention,antidepressant,cognitive behavioral therapy and milnacipran 100mg,snri,100mg,standard,fixed,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,phq8,baseline,NA,9.15,5.23,1.16946355223239,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
136,mood,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,phq8,baseline,NA,11.37,4.23,0.9704285542724763,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
137,mood,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioral therapy,n/a,n/a,n/a,fixed,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,phq8,change_score,NA,-3.19,4.299011514290234,1.11,NA,NA,NA,NA,NA,15,NA,NA,TRUE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
138,mood,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,cognitive behavioral therapy and milnacipran,combined antidepressant intervention,antidepressant,cognitive behavioral therapy and milnacipran 100mg,snri,100mg,standard,fixed,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,phq8,change_score,NA,-2.65,4.370491963154721,1.06,NA,NA,NA,NA,NA,17,NA,NA,TRUE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
139,mood,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,phq8,change_score,NA,-2.93,4.411723019410897,1.07,NA,NA,NA,NA,NA,17,NA,NA,TRUE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
140,adverse,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioral therapy,n/a,n/a,n/a,fixed,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,3,0.15789999999999998,FALSE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,non_pharm,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
141,adverse,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,cognitive behavioral therapy and milnacipran,combined antidepressant intervention,antidepressant,cognitive behavioral therapy and milnacipran 100mg,snri,100mg,standard,fixed,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,9,0.45,FALSE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
142,adverse,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,8,0.4211,FALSE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
143,serious_adverse,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioral therapy,n/a,n/a,n/a,fixed,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,FALSE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,non_pharm,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
144,serious_adverse,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,cognitive behavioral therapy and milnacipran,combined antidepressant intervention,antidepressant,cognitive behavioral therapy and milnacipran 100mg,snri,100mg,standard,fixed,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,FALSE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
145,serious_adverse,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,FALSE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
146,withdrawal,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioral therapy,n/a,n/a,n/a,fixed,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,4,0.21100000000000002,FALSE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,non_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
147,withdrawal,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,cognitive behavioral therapy and milnacipran,combined antidepressant intervention,antidepressant,cognitive behavioral therapy and milnacipran 100mg,snri,100mg,standard,fixed,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,3,0.15,FALSE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
148,withdrawal,ang 2013,combining cognitive-behavioral therapy and milnacipran for fibromyalgia: a feasibility randomized controlled trial,pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,21 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,2,0.10529999999999999,FALSE,NA,NA,milnacipran arm also received education about the condition as a placebo for cbt,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
149,pain_int,aragona 2005,"randomized double-blind comparison of serotonergic (citalopram) versus noradrenergic (reboxetine) upatke inhibitors in outpatients with somatoform, dsm-iv-tr pain disorder",pain,citalopram,antidepressant,antidepressant,citalopram 40mg,ssri,40mg,standard,fixed,8 weeks,somatoform pain disorder,primary,primary,no,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,3.5,1.1,0.28401877872187725,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,mcgill pain questionnaire present pain intensity,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
150,pain_int,aragona 2005,"randomized double-blind comparison of serotonergic (citalopram) versus noradrenergic (reboxetine) upatke inhibitors in outpatients with somatoform, dsm-iv-tr pain disorder",pain,reboxetine,antidepressant,antidepressant,reboxetine 8mg,nari,8mg,standard,fixed,8 weeks,somatoform pain disorder,primary,primary,no,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,3.7,1.1,0.2939873661036668,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,mcgill pain questionnaire present pain intensity,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
151,pain_int,aragona 2005,"randomized double-blind comparison of serotonergic (citalopram) versus noradrenergic (reboxetine) upatke inhibitors in outpatients with somatoform, dsm-iv-tr pain disorder",pain,citalopram,antidepressant,antidepressant,citalopram 40mg,ssri,40mg,standard,fixed,8 weeks,somatoform pain disorder,primary,primary,no,parallel,itt with locf,0-10 numerical rating scale,post_int,NA,2.8,0.9,0.232379000772445,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,mcgill pain questionnaire present pain intensity,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
152,pain_int,aragona 2005,"randomized double-blind comparison of serotonergic (citalopram) versus noradrenergic (reboxetine) upatke inhibitors in outpatients with somatoform, dsm-iv-tr pain disorder",pain,reboxetine,antidepressant,antidepressant,reboxetine 8mg,nari,8mg,standard,fixed,8 weeks,somatoform pain disorder,primary,primary,no,parallel,itt with locf,0-10 numerical rating scale,post_int,NA,3.1,0.9,0.24053511772118197,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,mcgill pain questionnaire present pain intensity,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
153,mood,aragona 2005,"randomized double-blind comparison of serotonergic (citalopram) versus noradrenergic (reboxetine) upatke inhibitors in outpatients with somatoform, dsm-iv-tr pain disorder",pain,citalopram,antidepressant,antidepressant,citalopram 40mg,ssri,40mg,standard,fixed,8 weeks,somatoform pain disorder,primary,primary,no,parallel,itt with locf,zung depression rating scale,baseline,NA,45.5,10.7,2.7627281202946237,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
154,mood,aragona 2005,"randomized double-blind comparison of serotonergic (citalopram) versus noradrenergic (reboxetine) upatke inhibitors in outpatients with somatoform, dsm-iv-tr pain disorder",pain,reboxetine,antidepressant,antidepressant,reboxetine 8mg,nari,8mg,standard,fixed,8 weeks,somatoform pain disorder,primary,primary,no,parallel,itt with locf,zung depression rating scale,baseline,NA,39.4,11.7,3.1269565303753653,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
155,mood,aragona 2005,"randomized double-blind comparison of serotonergic (citalopram) versus noradrenergic (reboxetine) upatke inhibitors in outpatients with somatoform, dsm-iv-tr pain disorder",pain,citalopram,antidepressant,antidepressant,citalopram 40mg,ssri,40mg,standard,fixed,8 weeks,somatoform pain disorder,primary,primary,no,parallel,itt with locf,zung depression rating scale,post_int,NA,42.9,12.8,3.3049457887636624,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
156,mood,aragona 2005,"randomized double-blind comparison of serotonergic (citalopram) versus noradrenergic (reboxetine) upatke inhibitors in outpatients with somatoform, dsm-iv-tr pain disorder",pain,reboxetine,antidepressant,antidepressant,reboxetine 8mg,nari,8mg,standard,fixed,8 weeks,somatoform pain disorder,primary,primary,no,parallel,itt with locf,zung depression rating scale,post_int,NA,38.9,10.7,2.859695288462941,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
157,adverse,aragona 2005,"randomized double-blind comparison of serotonergic (citalopram) versus noradrenergic (reboxetine) upatke inhibitors in outpatients with somatoform, dsm-iv-tr pain disorder",pain,citalopram,antidepressant,antidepressant,citalopram 40mg,ssri,40mg,standard,fixed,8 weeks,somatoform pain disorder,primary,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,15,1,FALSE,NA,NA,"physician rated adverse events, at least mild",NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
158,adverse,aragona 2005,"randomized double-blind comparison of serotonergic (citalopram) versus noradrenergic (reboxetine) upatke inhibitors in outpatients with somatoform, dsm-iv-tr pain disorder",pain,reboxetine,antidepressant,antidepressant,reboxetine 8mg,nari,8mg,standard,fixed,8 weeks,somatoform pain disorder,primary,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,14,1,FALSE,NA,NA,"physician rated adverse events, at least mild",NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
159,adverse_dropout,aragona 2005,"randomized double-blind comparison of serotonergic (citalopram) versus noradrenergic (reboxetine) upatke inhibitors in outpatients with somatoform, dsm-iv-tr pain disorder",pain,citalopram,antidepressant,antidepressant,citalopram 40mg,ssri,40mg,standard,fixed,8 weeks,somatoform pain disorder,primary,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,2,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
160,adverse_dropout,aragona 2005,"randomized double-blind comparison of serotonergic (citalopram) versus noradrenergic (reboxetine) upatke inhibitors in outpatients with somatoform, dsm-iv-tr pain disorder",pain,reboxetine,antidepressant,antidepressant,reboxetine 8mg,nari,8mg,standard,fixed,8 weeks,somatoform pain disorder,primary,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,4,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
161,serious_adverse,aragona 2005,"randomized double-blind comparison of serotonergic (citalopram) versus noradrenergic (reboxetine) upatke inhibitors in outpatients with somatoform, dsm-iv-tr pain disorder",pain,citalopram,antidepressant,antidepressant,citalopram 40mg,ssri,40mg,standard,fixed,8 weeks,somatoform pain disorder,primary,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,0,0,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
162,serious_adverse,aragona 2005,"randomized double-blind comparison of serotonergic (citalopram) versus noradrenergic (reboxetine) upatke inhibitors in outpatients with somatoform, dsm-iv-tr pain disorder",pain,reboxetine,antidepressant,antidepressant,reboxetine 8mg,nari,8mg,standard,fixed,8 weeks,somatoform pain disorder,primary,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,0,0,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
163,withdrawal,aragona 2005,"randomized double-blind comparison of serotonergic (citalopram) versus noradrenergic (reboxetine) upatke inhibitors in outpatients with somatoform, dsm-iv-tr pain disorder",pain,citalopram,antidepressant,antidepressant,citalopram 40mg,ssri,40mg,standard,fixed,8 weeks,somatoform pain disorder,primary,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,6,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
164,withdrawal,aragona 2005,"randomized double-blind comparison of serotonergic (citalopram) versus noradrenergic (reboxetine) upatke inhibitors in outpatients with somatoform, dsm-iv-tr pain disorder",pain,reboxetine,antidepressant,antidepressant,reboxetine 8mg,nari,8mg,standard,fixed,8 weeks,somatoform pain disorder,primary,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,9,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
165,pain_int,arnold 2002,"a randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt with locf,fiq pain,baseline,NA,6,1.9,0.34689095308660517,NA,NA,NA,NA,NA,30,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
166,pain_int,arnold 2002,"a randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",pain,fluoxetine,antidepressant,antidepressant,fluoxetine 10-80mg,ssri,10-80mg,unable to be categorised,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt with locf,fiq pain,baseline,NA,6.1,1.9,0.34689095308660517,NA,NA,NA,NA,NA,30,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
167,pain_int,arnold 2002,"a randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt with locf,fiq pain,change_score,NA,0.4,2.4,0.4706787243316417,NA,NA,NA,NA,NA,26,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
168,pain_int,arnold 2002,"a randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",pain,fluoxetine,antidepressant,antidepressant,fluoxetine 10-80mg,ssri,10-80mg,unable to be categorised,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt with locf,fiq pain,change_score,NA,-1.8,2.4,0.48,NA,NA,NA,NA,NA,25,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
169,qol,arnold 2002,"a randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt with locf,fibromyalgia impact questionnaire total score,baseline,NA,44,14,2.556038601690775,NA,NA,NA,NA,NA,30,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
170,qol,arnold 2002,"a randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",pain,fluoxetine,antidepressant,antidepressant,fluoxetine 10-80mg,ssri,10-80mg,unable to be categorised,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt with locf,fibromyalgia impact questionnaire total score,baseline,NA,42,14,2.556038601690775,NA,NA,NA,NA,NA,30,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
171,qol,arnold 2002,"a randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt with locf,fibromyalgia impact questionnaire total score,change_score,NA,2.9,13.6,2.667179437879303,NA,NA,NA,NA,NA,26,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
172,qol,arnold 2002,"a randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",pain,fluoxetine,antidepressant,antidepressant,fluoxetine 10-80mg,ssri,10-80mg,unable to be categorised,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt with locf,fibromyalgia impact questionnaire total score,change_score,NA,-8.6,14.5,2.9,NA,NA,NA,NA,NA,25,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
173,mood,arnold 2002,"a randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt with locf,fiq depression,baseline,NA,2.5,2,0.3651483716701107,NA,NA,NA,NA,NA,30,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
174,mood,arnold 2002,"a randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",pain,fluoxetine,antidepressant,antidepressant,fluoxetine 10-80mg,ssri,10-80mg,unable to be categorised,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt with locf,fiq depression,baseline,NA,2.7,2.7,0.49295030175464954,NA,NA,NA,NA,NA,30,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
175,mood,arnold 2002,"a randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt with locf,fiq depression,change_score,NA,1.1,2.5,0.4902903378454601,NA,NA,NA,NA,NA,26,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
176,mood,arnold 2002,"a randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",pain,fluoxetine,antidepressant,antidepressant,fluoxetine 10-80mg,ssri,10-80mg,unable to be categorised,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt with locf,fiq depression,change_score,NA,-0.9,2.8,0.5599999999999999,NA,NA,NA,NA,NA,25,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
181,physical,arnold 2002,"a randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt with locf,fiq physical functioning,baseline,NA,3.7,2.7,0.49295030175464954,NA,NA,NA,NA,NA,30,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
182,physical,arnold 2002,"a randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",pain,fluoxetine,antidepressant,antidepressant,fluoxetine 10-80mg,ssri,10-80mg,unable to be categorised,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt with locf,fiq physical functioning,baseline,NA,3.7,2.7,0.49295030175464954,NA,NA,NA,NA,NA,30,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
183,physical,arnold 2002,"a randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt with locf,fiq physical functioning,change_score,NA,-0.4,2.1,0.4118438837901865,NA,NA,NA,NA,NA,26,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
184,physical,arnold 2002,"a randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",pain,fluoxetine,antidepressant,antidepressant,fluoxetine 10-80mg,ssri,10-80mg,unable to be categorised,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt with locf,fiq physical functioning,change_score,NA,-1.1,2.3,0.45999999999999996,NA,NA,NA,NA,NA,25,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
185,withdrawal,arnold 2002,"a randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,12,0.4,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
186,withdrawal,arnold 2002,"a randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia",pain,fluoxetine,antidepressant,antidepressant,fluoxetine 10-80mg,ssri,10-80mg,unable to be categorised,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,11,0.36700000000000005,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
187,pain_int,arnold 2004,"a double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.1,1.7,0.16832508230603463,NA,NA,NA,NA,NA,102,NA,NA,FALSE,NA,NA,included and categorised people with mdd: 41/103 in placebo and 37/104 in duloxetine,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
188,pain_int,arnold 2004,"a double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.1,1.8,0.17735927006957278,NA,NA,NA,NA,NA,103,NA,NA,FALSE,NA,NA,included and categorised people with mdd: 41/103 in placebo and 37/104 in duloxetine,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
189,pain_int,arnold 2004,"a double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-0.94,2.322886135823278,0.23,NA,NA,NA,NA,NA,102,NA,NA,TRUE,NA,NA,included and categorised people with mdd: 41/103 in placebo and 37/104 in duloxetine,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
190,pain_int,arnold 2004,"a double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-1.83,2.4,0.24,NA,NA,NA,NA,NA,100,NA,NA,TRUE,NA,NA,included and categorised people with mdd: 41/103 in placebo and 37/104 in duloxetine,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
191,qol,arnold 2004,"a double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,fibromyalgia impact questionnaire total score,baseline,NA,50.2,13.3,1.3233994629792856,NA,NA,NA,NA,NA,101,NA,NA,FALSE,NA,NA,included and categorised people with mdd: 41/103 in placebo and 37/104 in duloxetine,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
192,qol,arnold 2004,"a double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,fibromyalgia impact questionnaire total score,baseline,NA,48.7,14.7,1.448434038901511,NA,NA,NA,NA,NA,103,NA,NA,FALSE,NA,NA,included and categorised people with mdd: 41/103 in placebo and 37/104 in duloxetine,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
193,qol,arnold 2004,"a double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,fibromyalgia impact questionnaire total score,change_score,NA,-7.93,17.472143543366393,1.73,NA,NA,NA,NA,NA,102,NA,NA,TRUE,NA,NA,included and categorised people with mdd: 41/103 in placebo and 37/104 in duloxetine,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
194,qol,arnold 2004,"a double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,fibromyalgia impact questionnaire total score,change_score,NA,-13.46,18.29077363044002,1.82,NA,NA,NA,NA,NA,101,NA,NA,TRUE,NA,NA,included and categorised people with mdd: 41/103 in placebo and 37/104 in duloxetine,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
203,physical,arnold 2004,"a double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sf-36 physical component score,baseline,NA,30.3,8,0.8340576562282991,NA,NA,NA,NA,NA,92,NA,NA,FALSE,NA,NA,included and categorised people with mdd: 41/103 in placebo and 37/104 in duloxetine,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
204,physical,arnold 2004,"a double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sf-36 physical component score,baseline,NA,29.3,8.8,0.9224906563152883,NA,NA,NA,NA,NA,91,NA,NA,FALSE,NA,NA,included and categorised people with mdd: 41/103 in placebo and 37/104 in duloxetine,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
205,physical,arnold 2004,"a double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sf-36 physical component score,change_score,NA,2.53,7.673330437300351,0.8,NA,NA,NA,NA,NA,92,NA,NA,TRUE,NA,NA,included and categorised people with mdd: 41/103 in placebo and 37/104 in duloxetine,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
206,physical,arnold 2004,"a double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sf-36 physical component score,change_score,NA,5.49,7.72690753147726,0.81,NA,NA,NA,NA,NA,91,NA,NA,TRUE,NA,NA,included and categorised people with mdd: 41/103 in placebo and 37/104 in duloxetine,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
207,mood,arnold 2004,"a double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sf-36 mental component score,baseline,NA,44,10.3,1.0738492323939353,NA,NA,NA,NA,NA,92,NA,NA,FALSE,NA,NA,included and categorised people with mdd: 41/103 in placebo and 37/104 in duloxetine,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
208,mood,arnold 2004,"a double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sf-36 mental component score,baseline,NA,46.3,11.8,1.2369761073318637,NA,NA,NA,NA,NA,91,NA,NA,FALSE,NA,NA,included and categorised people with mdd: 41/103 in placebo and 37/104 in duloxetine,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
209,mood,arnold 2004,"a double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sf-36 mental component score,change_score,NA,0.52,10.071246198956711,1.05,NA,NA,NA,NA,NA,92,NA,NA,TRUE,NA,NA,included and categorised people with mdd: 41/103 in placebo and 37/104 in duloxetine,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
210,mood,arnold 2004,"a double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sf-36 mental component score,change_score,NA,2.98,9.920967694736234,1.04,NA,NA,NA,NA,NA,91,NA,NA,TRUE,NA,NA,included and categorised people with mdd: 41/103 in placebo and 37/104 in duloxetine,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
211,adverse,arnold 2004,"a double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,103,77,0.748,FALSE,NA,NA,included and categorised people with mdd: 41/103 in placebo and 37/104 in duloxetine,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
212,adverse,arnold 2004,"a double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,104,94,0.904,FALSE,NA,NA,included and categorised people with mdd: 41/103 in placebo and 37/104 in duloxetine,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
213,adverse_dropout,arnold 2004,"a double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,103,11,NA,FALSE,NA,NA,included and categorised people with mdd: 41/103 in placebo and 37/104 in duloxetine,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
214,adverse_dropout,arnold 2004,"a double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,104,18,NA,FALSE,NA,NA,included and categorised people with mdd: 41/103 in placebo and 37/104 in duloxetine,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
215,withdrawal,arnold 2004,"a double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,103,37,NA,FALSE,NA,NA,included and categorised people with mdd: 41/103 in placebo and 37/104 in duloxetine,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
216,withdrawal,arnold 2004,"a double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,104,46,NA,FALSE,NA,NA,included and categorised people with mdd: 41/103 in placebo and 37/104 in duloxetine,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
217,pain_int,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,0-10 numerical rating scale,baseline,NA,6.5,1.5,0.13693063937629152,NA,NA,NA,NA,NA,120,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
218,pain_int,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,0-10 numerical rating scale,baseline,NA,6.4,1.4,0.12888044650576527,NA,NA,NA,NA,NA,118,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
219,pain_int,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,0-10 numerical rating scale,baseline,NA,6.4,1.6,0.1485562705416415,NA,NA,NA,NA,NA,116,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
220,pain_int,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,0-10 numerical rating scale,change_score,NA,-1.16,2.281183903152045,0.21,NA,NA,NA,NA,NA,118,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
221,pain_int,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,0-10 numerical rating scale,change_score,NA,-2.39,2.3694725151391816,0.22,NA,NA,NA,NA,NA,116,NA,NA,TRUE,NA,NA,NA,2021-09-27,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
222,pain_int,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,0-10 numerical rating scale,change_score,NA,-2.4,2.3489572154468883,0.22,NA,NA,NA,NA,NA,114,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
223,qol,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,fibromyalgia impact questionnaire total score,baseline,NA,53.2,12.4,1.14638040553214,NA,NA,NA,NA,NA,117,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
224,qol,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,fibromyalgia impact questionnaire total score,baseline,NA,51.4,12.2,1.1327415628800164,NA,NA,NA,NA,NA,116,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
225,qol,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,fibromyalgia impact questionnaire total score,baseline,NA,52.5,12.7,1.1842811064651986,NA,NA,NA,NA,NA,115,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
226,qol,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,fibromyalgia impact questionnaire total score,change_score,NA,-8.35,16.40742210098832,1.53,NA,NA,NA,NA,NA,115,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
227,qol,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,fibromyalgia impact questionnaire total score,change_score,NA,-16.72,16.335929725607908,1.53,NA,NA,NA,NA,NA,114,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
228,qol,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,fibromyalgia impact questionnaire total score,change_score,NA,-16.81,16.29782807615788,1.54,NA,NA,NA,NA,NA,112,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
235,physical,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,sf-36 physical component score,baseline,NA,28.8,7.5,0.7150969419341943,NA,NA,NA,NA,NA,110,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
236,physical,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,sf-36 physical component score,baseline,NA,28.8,7.6,0.7213600767718993,NA,NA,NA,NA,NA,111,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
237,physical,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,sf-36 physical component score,baseline,NA,28.7,7.9,0.7637218263460742,NA,NA,NA,NA,NA,107,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
238,physical,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,sf-36 physical component score,change_score,NA,3,8.390470785361213,0.8,NA,NA,NA,NA,NA,110,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
239,physical,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,sf-36 physical component score,change_score,NA,4.6,8.42852300228219,0.8,NA,NA,NA,NA,NA,111,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
240,physical,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,sf-36 physical component score,change_score,NA,4.9,8.275264346230882,0.8,NA,NA,NA,NA,NA,107,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
241,mood,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,sf-36 mental component score,baseline,NA,42.7,10.9,1.0392742222776956,NA,NA,NA,NA,NA,110,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
242,mood,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,sf-36 mental component score,baseline,NA,42.2,11.2,1.0630569552427989,NA,NA,NA,NA,NA,111,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
243,mood,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,sf-36 mental component score,baseline,NA,43.4,11.9,1.1504164219643396,NA,NA,NA,NA,NA,107,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
244,mood,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,sf-36 mental component score,change_score,NA,2.6,10.488088481701515,1,NA,NA,NA,NA,NA,110,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
245,mood,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,sf-36 mental component score,change_score,NA,7.3,10.535653752852738,1,NA,NA,NA,NA,NA,111,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
246,mood,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,sf-36 mental component score,change_score,NA,6.7,10.344080432788601,1,NA,NA,NA,NA,NA,107,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
247,pain_mod,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,118,39,0.33,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
248,pain_mod,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,64,0.55,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
249,pain_mod,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,113,61,0.54,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
250,pain_sub,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,117,27,0.23,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
251,pain_sub,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,117,48,0.41,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
252,pain_sub,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,115,47,0.41,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
253,adverse,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,120,95,0.792,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
254,adverse,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,118,109,0.924,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
255,adverse,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,105,0.905,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
256,adverse_dropout,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,120,14,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
257,adverse_dropout,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,118,25,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
258,adverse_dropout,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,27,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
259,serious_adverse,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
260,serious_adverse,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,125,1,0.008,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
261,serious_adverse,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,125,1,0.008,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
262,withdrawal,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,121,52,0.43,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
263,withdrawal,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,117,41,0.35,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
264,withdrawal,arnold 2005,"a randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,115,45,0.39,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
265,pain_int,arnold 2010: 1,"safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,"≥40 on 100vas for present pain intensity, ≥4 on 10nrs for weekly mean pain",parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.82,1.3839075113604955,0.12,NA,NA,NA,NA,NA,133,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
266,pain_int,arnold 2010: 1,"safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 2-8mg,snri,2-8mg,unable to be categorised,flexible,8 weeks,fibromyalgia,fibromyalgia,primary,"≥40 on 100vas for present pain intensity, ≥4 on 10nrs for weekly mean pain",parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.85,1.3839075113604955,0.12,NA,NA,NA,NA,NA,133,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
267,pain_int,arnold 2010: 1,"safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,"≥40 on 100vas for present pain intensity, ≥4 on 10nrs for weekly mean pain",parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-0.99,1.8452100151473274,0.16,NA,NA,NA,NA,NA,133,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
268,pain_int,arnold 2010: 1,"safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 2-8mg,snri,2-8mg,unable to be categorised,flexible,8 weeks,fibromyalgia,fibromyalgia,primary,"≥40 on 100vas for present pain intensity, ≥4 on 10nrs for weekly mean pain",parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-1.55,1.8452100151473274,0.16,NA,NA,NA,NA,NA,133,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
269,qol,arnold 2010: 1,"safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,"≥40 on 100vas for present pain intensity, ≥4 on 10nrs for weekly mean pain",parallel,itt with locf,fibromyalgia impact questionnaire total score,baseline,NA,62.76,13.442276592898986,1.17,NA,NA,NA,NA,NA,132,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
270,qol,arnold 2010: 1,"safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 2-8mg,snri,2-8mg,unable to be categorised,flexible,8 weeks,fibromyalgia,fibromyalgia,primary,"≥40 on 100vas for present pain intensity, ≥4 on 10nrs for weekly mean pain",parallel,itt with locf,fibromyalgia impact questionnaire total score,baseline,NA,61.37,15.839191898578665,1.4,NA,NA,NA,NA,NA,128,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
271,qol,arnold 2010: 1,"safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,"≥40 on 100vas for present pain intensity, ≥4 on 10nrs for weekly mean pain",parallel,itt with locf,fibromyalgia impact questionnaire total score,change_score,NA,-8.07,17.69325295133713,1.54,NA,NA,NA,NA,NA,132,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
272,qol,arnold 2010: 1,"safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 2-8mg,snri,2-8mg,unable to be categorised,flexible,8 weeks,fibromyalgia,fibromyalgia,primary,"≥40 on 100vas for present pain intensity, ≥4 on 10nrs for weekly mean pain",parallel,itt with locf,fibromyalgia impact questionnaire total score,change_score,NA,-15.63,17.649385258416228,1.56,NA,NA,NA,NA,NA,128,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
273,sleep,arnold 2010: 1,"safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,"≥40 on 100vas for present pain intensity, ≥4 on 10nrs for weekly mean pain",parallel,itt with locf,mos sleep problems index i,baseline,NA,63.19,16.904141504376966,1.5,NA,NA,NA,NA,NA,127,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
274,sleep,arnold 2010: 1,"safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 2-8mg,snri,2-8mg,unable to be categorised,flexible,8 weeks,fibromyalgia,fibromyalgia,primary,"≥40 on 100vas for present pain intensity, ≥4 on 10nrs for weekly mean pain",parallel,itt with locf,mos sleep problems index i,baseline,NA,60.88,16.72520851887952,1.49,NA,NA,NA,NA,NA,126,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
275,sleep,arnold 2010: 1,"safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,"≥40 on 100vas for present pain intensity, ≥4 on 10nrs for weekly mean pain",parallel,itt with locf,mos sleep problems index i,change_score,NA,-3.96,16.904141504376966,1.5,NA,NA,NA,NA,NA,127,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
276,sleep,arnold 2010: 1,"safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 2-8mg,snri,2-8mg,unable to be categorised,flexible,8 weeks,fibromyalgia,fibromyalgia,primary,"≥40 on 100vas for present pain intensity, ≥4 on 10nrs for weekly mean pain",parallel,itt with locf,mos sleep problems index i,change_score,NA,-5.47,16.949707962085956,1.51,NA,NA,NA,NA,NA,126,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
285,mood,arnold 2010: 1,"safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,"≥40 on 100vas for present pain intensity, ≥4 on 10nrs for weekly mean pain",parallel,itt with locf,sf-36 mental component score,baseline,NA,39.52,11.673971046734698,1.04,NA,NA,NA,NA,NA,126,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
286,mood,arnold 2010: 1,"safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 2-8mg,snri,2-8mg,unable to be categorised,flexible,8 weeks,fibromyalgia,fibromyalgia,primary,"≥40 on 100vas for present pain intensity, ≥4 on 10nrs for weekly mean pain",parallel,itt with locf,sf-36 mental component score,baseline,NA,41.47,12.684218541163661,1.13,NA,NA,NA,NA,NA,126,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
287,mood,arnold 2010: 1,"safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,"≥40 on 100vas for present pain intensity, ≥4 on 10nrs for weekly mean pain",parallel,itt with locf,sf-36 mental component score,change_score,NA,1.81,9.316726893067115,0.83,NA,NA,NA,NA,NA,126,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
288,mood,arnold 2010: 1,"safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 2-8mg,snri,2-8mg,unable to be categorised,flexible,8 weeks,fibromyalgia,fibromyalgia,primary,"≥40 on 100vas for present pain intensity, ≥4 on 10nrs for weekly mean pain",parallel,itt with locf,sf-36 mental component score,change_score,NA,4.25,9.316726893067115,0.83,NA,NA,NA,NA,NA,126,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
289,physical,arnold 2010: 1,"safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,"≥40 on 100vas for present pain intensity, ≥4 on 10nrs for weekly mean pain",parallel,itt with locf,sf-36 physical component score,baseline,NA,31.29,7.520731347415623,0.67,NA,NA,NA,NA,NA,126,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
290,physical,arnold 2010: 1,"safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 2-8mg,snri,2-8mg,unable to be categorised,flexible,8 weeks,fibromyalgia,fibromyalgia,primary,"≥40 on 100vas for present pain intensity, ≥4 on 10nrs for weekly mean pain",parallel,itt with locf,sf-36 physical component score,baseline,NA,30.5,7.632981069018841,0.68,NA,NA,NA,NA,NA,126,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
291,physical,arnold 2010: 1,"safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,"≥40 on 100vas for present pain intensity, ≥4 on 10nrs for weekly mean pain",parallel,itt with locf,sf-36 physical component score,change_score,NA,1.86,6.622733574589876,0.59,NA,NA,NA,NA,NA,126,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
292,physical,arnold 2010: 1,"safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 2-8mg,snri,2-8mg,unable to be categorised,flexible,8 weeks,fibromyalgia,fibromyalgia,primary,"≥40 on 100vas for present pain intensity, ≥4 on 10nrs for weekly mean pain",parallel,itt with locf,sf-36 physical component score,change_score,NA,4.36,6.622733574589876,0.59,NA,NA,NA,NA,NA,126,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
293,pain_mod,arnold 2010: 1,"safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,"≥40 on 100vas for present pain intensity, ≥4 on 10nrs for weekly mean pain",parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,133,30,0.226,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
294,pain_mod,arnold 2010: 1,"safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 2-8mg,snri,2-8mg,unable to be categorised,flexible,8 weeks,fibromyalgia,fibromyalgia,primary,"≥40 on 100vas for present pain intensity, ≥4 on 10nrs for weekly mean pain",parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,133,50,0.376,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
295,pain_sub,arnold 2010: 1,"safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,"≥40 on 100vas for present pain intensity, ≥4 on 10nrs for weekly mean pain",parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,133,11,0.083,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
296,pain_sub,arnold 2010: 1,"safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 2-8mg,snri,2-8mg,unable to be categorised,flexible,8 weeks,fibromyalgia,fibromyalgia,primary,"≥40 on 100vas for present pain intensity, ≥4 on 10nrs for weekly mean pain",parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,133,24,0.18,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
297,adverse,arnold 2010: 1,"safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,"≥40 on 100vas for present pain intensity, ≥4 on 10nrs for weekly mean pain",parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,133,76,0.5710000000000001,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
298,adverse,arnold 2010: 1,"safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 2-8mg,snri,2-8mg,unable to be categorised,flexible,8 weeks,fibromyalgia,fibromyalgia,primary,"≥40 on 100vas for present pain intensity, ≥4 on 10nrs for weekly mean pain",parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,134,96,0.716,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
299,adverse_dropout,arnold 2010: 1,"safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,"≥40 on 100vas for present pain intensity, ≥4 on 10nrs for weekly mean pain",parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,133,3,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
300,adverse_dropout,arnold 2010: 1,"safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 2-8mg,snri,2-8mg,unable to be categorised,flexible,8 weeks,fibromyalgia,fibromyalgia,primary,"≥40 on 100vas for present pain intensity, ≥4 on 10nrs for weekly mean pain",parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,134,14,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
301,serious_adverse,arnold 2010: 1,"safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,"≥40 on 100vas for present pain intensity, ≥4 on 10nrs for weekly mean pain",parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,133,11,0.083,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
302,serious_adverse,arnold 2010: 1,"safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 2-8mg,snri,2-8mg,unable to be categorised,flexible,8 weeks,fibromyalgia,fibromyalgia,primary,"≥40 on 100vas for present pain intensity, ≥4 on 10nrs for weekly mean pain",parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,134,20,0.149,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
303,withdrawal,arnold 2010: 1,"safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,"≥40 on 100vas for present pain intensity, ≥4 on 10nrs for weekly mean pain",parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,133,27,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
304,withdrawal,arnold 2010: 1,"safety and efficacy of esreboxetine in patients with fibromyalgia: an 8 week, multicenter, randomized, double-blind, placebo-controlled study",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 2-8mg,snri,2-8mg,unable to be categorised,flexible,8 weeks,fibromyalgia,fibromyalgia,primary,"≥40 on 100vas for present pain intensity, ≥4 on 10nrs for weekly mean pain",parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,134,27,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
305,pain_int,arnold 2010: 2,"efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-100 vas,baseline,NA,64.4,12.7,0.562917603115979,NA,NA,NA,NA,NA,509,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
306,pain_int,arnold 2010: 2,"efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-100 vas,baseline,NA,63.1,12.5,0.5502818164535149,NA,NA,NA,NA,NA,516,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
307,pain_int,arnold 2010: 2,"efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-100 vas,change_score,NA,-10.76,27.750064864789056,1.23,NA,NA,NA,NA,NA,509,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
308,pain_int,arnold 2010: 2,"efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-100 vas,change_score,NA,-17.7,27.940229061337345,1.23,NA,NA,NA,NA,NA,516,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
309,physical,arnold 2010: 2,"efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 physical component score,baseline,NA,32.9,7.8,0.34572892159879026,NA,NA,NA,NA,NA,509,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
310,physical,arnold 2010: 2,"efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 physical component score,baseline,NA,33,7.6,0.33457134440373704,NA,NA,NA,NA,NA,516,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
311,physical,arnold 2010: 2,"efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 physical component score,change_score,NA,2.89,9.475631905049921,0.42,NA,NA,NA,NA,NA,509,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
312,physical,arnold 2010: 2,"efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 physical component score,change_score,NA,4.62,9.76772235477647,0.43,NA,NA,NA,NA,NA,516,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
313,mood,arnold 2010: 2,"efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 mental component score,baseline,NA,46.6,11.4,0.5052961161828473,NA,NA,NA,NA,NA,509,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
314,mood,arnold 2010: 2,"efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 mental component score,baseline,NA,46.7,10.7,0.47104123488420874,NA,NA,NA,NA,NA,516,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
315,mood,arnold 2010: 2,"efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 mental component score,change_score,NA,-0.5,12.182955306492756,0.54,NA,NA,NA,NA,NA,509,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
316,mood,arnold 2010: 2,"efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 mental component score,change_score,NA,1.54,12.266442026928592,0.54,NA,NA,NA,NA,NA,516,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
317,qol,arnold 2010: 2,"efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,fibromyalgia impact questionnaire total score,baseline,NA,57.9,14.1,0.6249715121208901,NA,NA,NA,NA,NA,509,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
318,qol,arnold 2010: 2,"efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,fibromyalgia impact questionnaire total score,baseline,NA,56.7,2.7,0.11886087235395923,NA,NA,NA,NA,NA,516,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
319,qol,arnold 2010: 2,"efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,fibromyalgia impact questionnaire total score,change_score,NA,-7.12,1.08,0.04787015837521712,NA,NA,NA,NA,NA,509,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
320,qol,arnold 2010: 2,"efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,fibromyalgia impact questionnaire total score,change_score,NA,-12.34,1.09,0.0479845743947465,NA,NA,NA,NA,NA,516,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
329,pain_mod,arnold 2010: 2,"efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,509,156,0.306,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
330,pain_mod,arnold 2010: 2,"efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,516,230,0.446,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
331,pain_sub,arnold 2010: 2,"efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,509,92,0.18100000000000002,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
332,pain_sub,arnold 2010: 2,"efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,516,143,0.27699999999999997,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
333,adverse,arnold 2010: 2,"efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,509,382,0.75,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
334,adverse,arnold 2010: 2,"efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,516,434,0.841,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
335,adverse_dropout,arnold 2010: 2,"efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,509,71,0.139,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
336,adverse_dropout,arnold 2010: 2,"efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,516,92,0.17800000000000002,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
337,serious_adverse,arnold 2010: 2,"efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,509,6,0.012,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
338,serious_adverse,arnold 2010: 2,"efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,516,8,0.016,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
339,withdrawal,arnold 2010: 2,"efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,509,150,0.295,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
340,withdrawal,arnold 2010: 2,"efficacy and safety of milnacipran 100mg/day in patients with fibromyalgia: resuilts of a randomized, double-blind, placebo-controlled trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,516,159,0.308,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
341,pain_int,arnold 2010: 3,"flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.5,1.6,0.09791840981793674,NA,NA,NA,NA,NA,267,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
342,pain_int,arnold 2010: 3,"flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.5,1.5,0.0924939623967311,NA,NA,NA,NA,NA,263,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
343,pain_int,arnold 2010: 3,"flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-1.5,2.821347195933177,0.2,NA,NA,NA,NA,NA,199,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
344,pain_int,arnold 2010: 3,"flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-2.3,2.7422618401604177,0.2,NA,NA,NA,NA,NA,188,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
353,mood,arnold 2010: 3,"flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sf-36 mental component score,baseline,NA,42.9,12.6,0.7711074773162517,NA,NA,NA,NA,NA,267,NA,NA,FALSE,NA,"extraction form says se for baseline values, but this is wrong, should be sd",NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
354,mood,arnold 2010: 3,"flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sf-36 mental component score,baseline,NA,43.3,12.3,0.7584504916531951,NA,NA,NA,NA,NA,263,NA,NA,FALSE,NA,"extraction form says se for baseline values, but this is wrong, should be sd",NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
355,mood,arnold 2010: 3,"flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sf-36 mental component score,change_score,NA,1.3,11.438094246857734,0.7,NA,NA,NA,NA,NA,267,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
356,mood,arnold 2010: 3,"flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sf-36 mental component score,change_score,NA,5.1,11.352092318158798,0.7,NA,NA,NA,NA,NA,263,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
357,physical,arnold 2010: 3,"flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sf-36 physical component score,baseline,NA,31.3,8.2,0.5018318503169257,NA,NA,NA,NA,NA,267,NA,NA,FALSE,NA,"extraction form says se for baseline values, but this is wrong, should be sd",NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
358,physical,arnold 2010: 3,"flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sf-36 physical component score,baseline,NA,31,7.8,0.48096860446300177,NA,NA,NA,NA,NA,263,NA,NA,FALSE,NA,"extraction form says se for baseline values, but this is wrong, should be sd",NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
359,physical,arnold 2010: 3,"flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sf-36 physical component score,change_score,NA,4.8,9.804080783020915,0.6,NA,NA,NA,NA,NA,267,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
360,physical,arnold 2010: 3,"flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sf-36 physical component score,change_score,NA,6,9.730364844136114,0.6,NA,NA,NA,NA,NA,263,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
361,pain_mod,arnold 2010: 3,"flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with bocf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,248,66,0.266,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
362,pain_mod,arnold 2010: 3,"flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with bocf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,249,90,0.361,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
363,pain_sub,arnold 2010: 3,"flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with bocf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,248,41,0.165,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
364,pain_sub,arnold 2010: 3,"flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with bocf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,249,62,0.247,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
365,adverse,arnold 2010: 3,"flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,267,191,0.715,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
366,adverse,arnold 2010: 3,"flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,263,218,0.8290000000000001,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
367,adverse_dropout,arnold 2010: 3,"flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,267,24,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
368,adverse_dropout,arnold 2010: 3,"flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,263,41,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
369,serious_adverse,arnold 2010: 3,"flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,250,6,0.024,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
370,serious_adverse,arnold 2010: 3,"flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,250,1,0.004,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
371,withdrawal,arnold 2010: 3,"flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,267,80,0.3,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
372,withdrawal,arnold 2010: 3,"flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,263,87,0.331,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
373,pain_int,arnold 2012: 1,"efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.37,1.67,0.13501149793689202,NA,NA,NA,NA,NA,153,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
374,pain_int,arnold 2012: 1,"efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",pain,duloxetine,antidepressant,antidepressant,duloxetine 30mg,snri,30mg,low,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.5,1.47,0.11807324134866733,NA,NA,NA,NA,NA,155,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
375,pain_int,arnold 2012: 1,"efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-1.83,2.4738633753705965,0.2,NA,NA,NA,NA,NA,153,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
376,pain_int,arnold 2012: 1,"efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",pain,duloxetine,antidepressant,antidepressant,duloxetine 30mg,snri,30mg,low,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-2.14,2.4738633753705965,0.2,NA,NA,NA,NA,NA,153,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
377,mood,arnold 2012: 1,"efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,beck depression inventory,baseline,NA,16.84,11.47,0.9272945397222465,NA,NA,NA,NA,NA,153,NA,NA,FALSE,NA,NA,32/155 of duloxetine and 37 of 153 of placebo diagnosed with mdd at baseline,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
378,mood,arnold 2012: 1,"efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",pain,duloxetine,antidepressant,antidepressant,duloxetine 30mg,snri,30mg,low,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,beck depression inventory,baseline,NA,15,9.64,0.7743034330620089,NA,NA,NA,NA,NA,155,NA,NA,FALSE,NA,NA,32/155 of duloxetine and 37 of 153 of placebo diagnosed with mdd at baseline,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
379,mood,arnold 2012: 1,"efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,beck depression inventory,change_score,NA,-3.91,7.061260510702037,0.61,NA,NA,NA,NA,NA,134,NA,NA,TRUE,NA,NA,32/155 of duloxetine and 37 of 153 of placebo diagnosed with mdd at baseline,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
380,mood,arnold 2012: 1,"efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",pain,duloxetine,antidepressant,antidepressant,duloxetine 30mg,snri,30mg,low,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,beck depression inventory,change_score,NA,-5.47,7.0992957397195395,0.6,NA,NA,NA,NA,NA,140,NA,NA,TRUE,NA,NA,32/155 of duloxetine and 37 of 153 of placebo diagnosed with mdd at baseline,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
385,qol,arnold 2012: 1,"efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,fibromyalgia impact questionnaire total score,baseline,NA,50.44,13.71,1.1083878064160417,NA,NA,NA,NA,NA,153,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
386,qol,arnold 2012: 1,"efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",pain,duloxetine,antidepressant,antidepressant,duloxetine 30mg,snri,30mg,low,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,fibromyalgia impact questionnaire total score,baseline,NA,51.11,12.17,0.9775179232743411,NA,NA,NA,NA,NA,155,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
387,qol,arnold 2012: 1,"efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,fibromyalgia impact questionnaire total score,change_score,NA,-10.39,17.440736796362703,1.41,NA,NA,NA,NA,NA,153,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
388,qol,arnold 2012: 1,"efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",pain,duloxetine,antidepressant,antidepressant,duloxetine 30mg,snri,30mg,low,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,fibromyalgia impact questionnaire total score,change_score,NA,-14.78,17.440736796362703,1.41,NA,NA,NA,NA,NA,153,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
389,pain_mod,arnold 2012: 1,"efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,153,66,0.431,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
390,pain_mod,arnold 2012: 1,"efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",pain,duloxetine,antidepressant,antidepressant,duloxetine 30mg,snri,30mg,low,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,153,76,0.49700000000000005,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
391,pain_sub,arnold 2012: 1,"efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,153,55,0.359,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
392,pain_sub,arnold 2012: 1,"efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",pain,duloxetine,antidepressant,antidepressant,duloxetine 30mg,snri,30mg,low,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,153,56,0.366,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
393,adverse,arnold 2012: 1,"efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,153,79,0.516,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
394,adverse,arnold 2012: 1,"efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",pain,duloxetine,antidepressant,antidepressant,duloxetine 30mg,snri,30mg,low,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,155,100,0.645,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
395,adverse_dropout,arnold 2012: 1,"efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,153,9,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
396,adverse_dropout,arnold 2012: 1,"efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",pain,duloxetine,antidepressant,antidepressant,duloxetine 30mg,snri,30mg,low,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,155,14,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
397,serious_adverse,arnold 2012: 1,"efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,154,1,0.006500000000000001,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
398,serious_adverse,arnold 2012: 1,"efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",pain,duloxetine,antidepressant,antidepressant,duloxetine 30mg,snri,30mg,low,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
399,withdrawal,arnold 2012: 1,"efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,110,31,0.282,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
400,withdrawal,arnold 2012: 1,"efficacy and safety of duloxetine 30mg/day in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study",pain,duloxetine,antidepressant,antidepressant,duloxetine 30mg,snri,30mg,low,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,121,29,0.239,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
401,pain_int,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.52,1.4951922953252534,0.09,NA,NA,NA,NA,NA,276,NA,NA,FALSE,NA,"post-intervention continuous scores are labelled as sem estimate, rather than just sem? i don't know what this means.",NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
402,pain_int,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 4mg,snri,4mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.44,1.3218169313486643,0.08,NA,NA,NA,NA,NA,273,NA,NA,FALSE,NA,"post-intervention continuous scores are labelled as sem estimate, rather than just sem? i don't know what this means.",NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
403,pain_int,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 8mg,snri,8mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.5,1.503296377964106,0.09,NA,NA,NA,NA,NA,279,NA,NA,FALSE,NA,"post-intervention continuous scores are labelled as sem estimate, rather than just sem? i don't know what this means.",NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
404,pain_int,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 10mg,snri,10mg,high,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.54,1.5059880477613359,0.09,NA,NA,NA,NA,NA,280,NA,NA,FALSE,NA,"post-intervention continuous scores are labelled as sem estimate, rather than just sem? i don't know what this means.",NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
405,pain_int,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-10 numerical rating scale,post_int,NA,5.42,2.1597222043586997,0.13,NA,NA,NA,NA,NA,276,NA,NA,FALSE,NA,"post-intervention continuous scores are labelled as sem estimate, rather than just sem? i don't know what this means.",NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
406,pain_int,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 4mg,snri,4mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-10 numerical rating scale,post_int,NA,4.68,2.313179629860163,0.14,NA,NA,NA,NA,NA,273,NA,NA,FALSE,NA,"post-intervention continuous scores are labelled as sem estimate, rather than just sem? i don't know what this means.",NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
407,pain_int,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 8mg,snri,8mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-10 numerical rating scale,post_int,NA,4.65,2.3384610323886097,0.14,NA,NA,NA,NA,NA,279,NA,NA,FALSE,NA,"post-intervention continuous scores are labelled as sem estimate, rather than just sem? i don't know what this means.",NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
408,pain_int,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 10mg,snri,10mg,high,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-10 numerical rating scale,post_int,NA,4.99,2.3426480742954117,0.14,NA,NA,NA,NA,NA,280,NA,NA,FALSE,NA,"post-intervention continuous scores are labelled as sem estimate, rather than just sem? i don't know what this means.",NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
409,qol,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,fibromyalgia impact questionnaire total score,baseline,NA,54.93,13.758451947802849,0.85,NA,NA,NA,NA,NA,262,NA,NA,FALSE,NA,"post-intervention continuous scores are labelled as sem estimate, rather than just sem? i don't know what this means.",NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
410,qol,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 4mg,snri,4mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,fibromyalgia impact questionnaire total score,baseline,NA,54.04,14.932960188790432,0.97,NA,NA,NA,NA,NA,237,NA,NA,FALSE,NA,"post-intervention continuous scores are labelled as sem estimate, rather than just sem? i don't know what this means.",NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
411,qol,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 8mg,snri,8mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,fibromyalgia impact questionnaire total score,baseline,NA,55.27,15.7797338380595,1,NA,NA,NA,NA,NA,249,NA,NA,FALSE,NA,"post-intervention continuous scores are labelled as sem estimate, rather than just sem? i don't know what this means.",NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
412,qol,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 10mg,snri,10mg,high,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,fibromyalgia impact questionnaire total score,baseline,NA,56.38,14.388363353766126,0.91,NA,NA,NA,NA,NA,250,NA,NA,FALSE,NA,"post-intervention continuous scores are labelled as sem estimate, rather than just sem? i don't know what this means.",NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
413,qol,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,fibromyalgia impact questionnaire total score,post_int,NA,48.52,18.77624030523683,1.16,NA,NA,NA,NA,NA,262,NA,NA,FALSE,NA,"post-intervention continuous scores are labelled as sem estimate, rather than just sem? i don't know what this means.",NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
414,qol,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 4mg,snri,4mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,fibromyalgia impact questionnaire total score,post_int,NA,41.41,19.243505397925816,1.25,NA,NA,NA,NA,NA,237,NA,NA,FALSE,NA,"post-intervention continuous scores are labelled as sem estimate, rather than just sem? i don't know what this means.",NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
415,qol,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 8mg,snri,8mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,fibromyalgia impact questionnaire total score,post_int,NA,41.85,19.724667297574374,1.25,NA,NA,NA,NA,NA,249,NA,NA,FALSE,NA,"post-intervention continuous scores are labelled as sem estimate, rather than just sem? i don't know what this means.",NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
416,qol,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 10mg,snri,10mg,high,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,fibromyalgia impact questionnaire total score,post_int,NA,44.65,19.60612149304395,1.24,NA,NA,NA,NA,NA,250,NA,NA,FALSE,NA,"post-intervention continuous scores are labelled as sem estimate, rather than just sem? i don't know what this means.",NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
417,physical,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 physical component score,baseline,NA,36.32,8.623108488242508,0.54,NA,NA,NA,NA,NA,255,NA,NA,FALSE,NA,"post-intervention continuous scores are labelled as sem estimate, rather than just sem? i don't know what this means.",NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
418,physical,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 4mg,snri,4mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 physical component score,baseline,NA,35.92,9.159263070793413,0.59,NA,NA,NA,NA,NA,241,NA,NA,FALSE,NA,"post-intervention continuous scores are labelled as sem estimate, rather than just sem? i don't know what this means.",NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
419,physical,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 8mg,snri,8mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 physical component score,baseline,NA,34.28,9.901227196666078,0.63,NA,NA,NA,NA,NA,247,NA,NA,FALSE,NA,"post-intervention continuous scores are labelled as sem estimate, rather than just sem? i don't know what this means.",NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
420,physical,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 10mg,snri,10mg,high,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 physical component score,baseline,NA,35.03,9.01249133147988,0.57,NA,NA,NA,NA,NA,250,NA,NA,FALSE,NA,"post-intervention continuous scores are labelled as sem estimate, rather than just sem? i don't know what this means.",NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
421,physical,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 physical component score,post_int,NA,38.19,7.345610934428803,0.46,NA,NA,NA,NA,NA,255,NA,NA,FALSE,NA,"post-intervention continuous scores are labelled as sem estimate, rather than just sem? i don't know what this means.",NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
422,physical,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 4mg,snri,4mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 physical component score,post_int,NA,38.49,7.451603854204811,0.48,NA,NA,NA,NA,NA,241,NA,NA,FALSE,NA,"post-intervention continuous scores are labelled as sem estimate, rather than just sem? i don't know what this means.",NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
423,physical,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 8mg,snri,8mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 physical component score,post_int,NA,39.51,7.386629813385804,0.47,NA,NA,NA,NA,NA,247,NA,NA,FALSE,NA,"post-intervention continuous scores are labelled as sem estimate, rather than just sem? i don't know what this means.",NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
424,physical,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 10mg,snri,10mg,high,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 physical component score,post_int,NA,38.28,7.431352501395691,0.47,NA,NA,NA,NA,NA,250,NA,NA,FALSE,NA,"post-intervention continuous scores are labelled as sem estimate, rather than just sem? i don't know what this means.",NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
425,pain_mod,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,276,77,0.27899999999999997,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
426,pain_mod,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 4mg,snri,4mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,273,101,0.37,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
427,pain_mod,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 8mg,snri,8mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,279,110,0.39399999999999996,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
428,pain_mod,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 10mg,snri,10mg,high,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,280,95,0.33899999999999997,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
429,pain_sub,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,275,33,0.12,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
430,pain_sub,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 4mg,snri,4mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,274,49,0.179,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
431,pain_sub,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 8mg,snri,8mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,279,56,0.201,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
432,pain_sub,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 10mg,snri,10mg,high,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,280,42,0.15,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
433,adverse,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,277,85,0.307,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
434,adverse,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 4mg,snri,4mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,274,158,0.5770000000000001,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
435,adverse,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 8mg,snri,8mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,282,157,0.557,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
436,adverse,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 10mg,snri,10mg,high,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,107,62,0.5770000000000001,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
437,adverse_dropout,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,277,17,0.061,FALSE,NA,"extracted consensus data in covidence is based on the clinicaltrials.gov results, but better to actually use data in the paper",NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
438,adverse_dropout,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 4mg,snri,4mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,274,43,0.157,FALSE,NA,"extracted consensus data in covidence is based on the clinicaltrials.gov results, but better to actually use data in the paper",NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
439,adverse_dropout,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 8mg,snri,8mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,282,57,0.20199999999999999,FALSE,NA,"extracted consensus data in covidence is based on the clinicaltrials.gov results, but better to actually use data in the paper",NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
440,adverse_dropout,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 10mg,snri,10mg,high,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,281,51,0.18100000000000002,FALSE,NA,"extracted consensus data in covidence is based on the clinicaltrials.gov results, but better to actually use data in the paper",NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
441,serious_adverse,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
442,serious_adverse,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 4mg,snri,4mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,286,2,0.006999999999999999,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
443,serious_adverse,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 8mg,snri,8mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,250,1,0.004,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
444,serious_adverse,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 10mg,snri,10mg,high,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,286,2,0.006999999999999999,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
445,withdrawal,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,278,76,0.273,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
446,withdrawal,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 4mg,snri,4mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,277,103,0.37200000000000005,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
447,withdrawal,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 8mg,snri,8mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,284,111,0.391,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
448,withdrawal,arnold 2012: 2,"safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen week, randomized, double-blind, placebo-controlled, multicenter clinical trial",pain,esreboxetine,antidepressant,antidepressant,esreboxetine 10mg,snri,10mg,high,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,283,108,0.382,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
449,pain_int,ash 1999,the effects of dothiepin on subjects with rheumatoid arthritis and depression,mood and pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,10 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,no,parallel,itt unspecified method,0-100 vas,baseline,NA,59.7,21.04332091090345,4.387835729552022,NA,51.2,68.3,NA,NA,23,NA,NA,FALSE,NA,NA,"to be included, participants must be diagnosed as depressed, by either having scored ≥11 on hads or clinical assessment.",NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
450,pain_int,ash 1999,the effects of dothiepin on subjects with rheumatoid arthritis and depression,mood and pain,dothiepin,antidepressant,antidepressant,dothiepin 75-150mg,tca,75-150mg,standard,flexible,10 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,no,parallel,itt unspecified method,0-100 vas,baseline,NA,56.7,18.367684449287534,3.6735368898575067,NA,47.4,63.9,NA,NA,25,NA,NA,FALSE,NA,NA,"to be included, participants must be diagnosed as depressed, by either having scored ≥11 on hads or clinical assessment.",NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
451,pain_int,ash 1999,the effects of dothiepin on subjects with rheumatoid arthritis and depression,mood and pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,10 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,no,parallel,itt unspecified method,0-100 vas,post_int,NA,64,34.01187914669282,7.091967051252694,NA,50.6,77.9,NA,NA,23,NA,NA,FALSE,NA,NA,"to be included, participants must be diagnosed as depressed, by either having scored ≥11 on hads or clinical assessment.",NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
452,pain_int,ash 1999,the effects of dothiepin on subjects with rheumatoid arthritis and depression,mood and pain,dothiepin,antidepressant,antidepressant,dothiepin 75-150mg,tca,75-150mg,standard,flexible,10 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,no,parallel,itt unspecified method,0-100 vas,post_int,NA,46.9,33.92919488548951,6.785838977097901,NA,33.5,60.2,NA,NA,25,NA,NA,FALSE,NA,NA,"to be included, participants must be diagnosed as depressed, by either having scored ≥11 on hads or clinical assessment.",NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
453,mood,ash 1999,the effects of dothiepin on subjects with rheumatoid arthritis and depression,mood and pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,10 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,no,parallel,itt unspecified method,hads-d,baseline,NA,15.65,5.016140449692102,1.0459375866955403,NA,13.6,17.7,NA,NA,23,NA,NA,FALSE,NA,NA,"to be included, participants must be diagnosed as depressed, by either having scored ≥11 on hads or clinical assessment.",NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
454,mood,ash 1999,the effects of dothiepin on subjects with rheumatoid arthritis and depression,mood and pain,dothiepin,antidepressant,antidepressant,dothiepin 75-150mg,tca,75-150mg,standard,flexible,10 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,no,parallel,itt unspecified method,hads-d,baseline,NA,15.32,4.0306863097047625,0.8061372619409525,NA,13.8,16.9,NA,NA,25,NA,NA,FALSE,NA,NA,"to be included, participants must be diagnosed as depressed, by either having scored ≥11 on hads or clinical assessment.",NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
455,mood,ash 1999,the effects of dothiepin on subjects with rheumatoid arthritis and depression,mood and pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,10 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,no,parallel,itt unspecified method,hads-d,post_int,NA,7.94,6.9981276517655715,1.4592104868045108,NA,5.1,10.8,NA,NA,23,NA,NA,FALSE,NA,NA,"to be included, participants must be diagnosed as depressed, by either having scored ≥11 on hads or clinical assessment.",NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
456,mood,ash 1999,the effects of dothiepin on subjects with rheumatoid arthritis and depression,mood and pain,dothiepin,antidepressant,antidepressant,dothiepin 75-150mg,tca,75-150mg,standard,flexible,10 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,no,parallel,itt unspecified method,hads-d,post_int,NA,7.05,8.290968675025631,1.6581937350051263,NA,3.8,10.3,NA,NA,25,NA,NA,FALSE,NA,NA,"to be included, participants must be diagnosed as depressed, by either having scored ≥11 on hads or clinical assessment.",NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
457,physical,ash 1999,the effects of dothiepin on subjects with rheumatoid arthritis and depression,mood and pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,10 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,no,parallel,itt unspecified method,health assessment questionnaire,baseline,NA,1.88,0.8808832009215412,0.18367684449287563,NA,1.64,2.24,NA,NA,23,NA,NA,FALSE,NA,NA,"to be included, participants must be diagnosed as depressed, by either having scored ≥11 on hads or clinical assessment.",NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
458,physical,ash 1999,the effects of dothiepin on subjects with rheumatoid arthritis and depression,mood and pain,dothiepin,antidepressant,antidepressant,dothiepin 75-150mg,tca,75-150mg,standard,flexible,10 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,no,parallel,itt unspecified method,health assessment questionnaire,baseline,NA,1.85,0.7142988396945152,0.14285976793890304,NA,1.58,2.13,NA,NA,25,NA,NA,FALSE,NA,NA,"to be included, participants must be diagnosed as depressed, by either having scored ≥11 on hads or clinical assessment.",NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
459,physical,ash 1999,the effects of dothiepin on subjects with rheumatoid arthritis and depression,mood and pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,10 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,no,parallel,itt unspecified method,health assessment questionnaire,post_int,NA,1.82,0.9053521787249161,0.18877897906212193,NA,1.46,2.19,NA,NA,23,NA,NA,FALSE,NA,NA,"to be included, participants must be diagnosed as depressed, by either having scored ≥11 on hads or clinical assessment.",NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
460,physical,ash 1999,the effects of dothiepin on subjects with rheumatoid arthritis and depression,mood and pain,dothiepin,antidepressant,antidepressant,dothiepin 75-150mg,tca,75-150mg,standard,flexible,10 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,no,parallel,itt unspecified method,health assessment questionnaire,post_int,NA,1.85,0.8673628767719116,0.17347257535438232,NA,1.5,2.19,NA,NA,25,NA,NA,FALSE,NA,NA,"to be included, participants must be diagnosed as depressed, by either having scored ≥11 on hads or clinical assessment.",NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
465,withdrawal,ash 1999,the effects of dothiepin on subjects with rheumatoid arthritis and depression,mood and pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,10 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,10,0.435,FALSE,NA,NA,"to be included, participants must be diagnosed as depressed, by either having scored ≥11 on hads or clinical assessment.",NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
466,withdrawal,ash 1999,the effects of dothiepin on subjects with rheumatoid arthritis and depression,mood and pain,dothiepin,antidepressant,antidepressant,dothiepin 75-150mg,tca,75-150mg,standard,flexible,10 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,10,0.44,FALSE,NA,NA,"to be included, participants must be diagnosed as depressed, by either having scored ≥11 on hads or clinical assessment.",NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
467,pain_int,atkinson 1998,a placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt unspecified method,descriptor differential scale,baseline,NA,9.95,3.94,0.6229686990531706,NA,NA,NA,NA,NA,40,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
468,pain_int,atkinson 1998,a placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,pain,nortriptyline,antidepressant,antidepressant,nortriptyline 25-100mg,tca,25-100mg,unable to be categorised,flexible,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt unspecified method,descriptor differential scale,baseline,NA,11.66,4.38,0.7105298245527399,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
469,pain_int,atkinson 1998,a placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt unspecified method,descriptor differential scale,change_score,NA,0.91,3.43,0.542330618718877,NA,NA,NA,NA,NA,40,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
470,pain_int,atkinson 1998,a placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,pain,nortriptyline,antidepressant,antidepressant,nortriptyline 25-100mg,tca,25-100mg,unable to be categorised,flexible,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt unspecified method,descriptor differential scale,change_score,NA,2.59,4,0.6488856845230502,NA,NA,NA,NA,NA,38,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
471,physical,atkinson 1998,a placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt unspecified method,sickness impact profile - physical subscale,baseline,NA,7.01,7.31,1.1558124847915425,NA,NA,NA,NA,NA,40,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
472,physical,atkinson 1998,a placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,pain,nortriptyline,antidepressant,antidepressant,nortriptyline 25-100mg,tca,25-100mg,unable to be categorised,flexible,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt unspecified method,sickness impact profile - physical subscale,baseline,NA,10.49,11.02,1.7876800608610033,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
473,physical,atkinson 1998,a placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt unspecified method,sickness impact profile - physical subscale,change_score,NA,1.56,3.1,0.4901530373260988,NA,NA,NA,NA,NA,40,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
474,physical,atkinson 1998,a placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,pain,nortriptyline,antidepressant,antidepressant,nortriptyline 25-100mg,tca,25-100mg,unable to be categorised,flexible,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt unspecified method,sickness impact profile - physical subscale,change_score,NA,2.17,4.49,0.7283741808771239,NA,NA,NA,NA,NA,38,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
475,mood,atkinson 1998,a placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt unspecified method,sickness impact profile - psychosocial subscale,baseline,NA,8.16,8.74,1.3819153374935818,NA,NA,NA,NA,NA,40,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
476,mood,atkinson 1998,a placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,pain,nortriptyline,antidepressant,antidepressant,nortriptyline 25-100mg,tca,25-100mg,unable to be categorised,flexible,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt unspecified method,sickness impact profile - psychosocial subscale,baseline,NA,15.35,14.66,2.378166033776979,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
477,mood,atkinson 1998,a placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt unspecified method,sickness impact profile - psychosocial subscale,change_score,NA,0.24,6.35,1.0040231571034604,NA,NA,NA,NA,NA,40,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
478,mood,atkinson 1998,a placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,pain,nortriptyline,antidepressant,antidepressant,nortriptyline 25-100mg,tca,25-100mg,unable to be categorised,flexible,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt unspecified method,sickness impact profile - psychosocial subscale,change_score,NA,3.96,5.04,0.8175959624990432,NA,NA,NA,NA,NA,38,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
479,qol,atkinson 1998,a placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt unspecified method,quality of well-being scale,baseline,NA,0.616,0.71,0.11226085693597745,NA,NA,NA,NA,NA,40,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
480,qol,atkinson 1998,a placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,pain,nortriptyline,antidepressant,antidepressant,nortriptyline 25-100mg,tca,25-100mg,unable to be categorised,flexible,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt unspecified method,quality of well-being scale,baseline,NA,0.614,0.65,0.10544392373499566,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
481,qol,atkinson 1998,a placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt unspecified method,quality of well-being scale,change_score,NA,-0.03,0.05,0.007905694150420948,NA,NA,NA,NA,NA,40,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
482,qol,atkinson 1998,a placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,pain,nortriptyline,antidepressant,antidepressant,nortriptyline 25-100mg,tca,25-100mg,unable to be categorised,flexible,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt unspecified method,quality of well-being scale,change_score,NA,-0.02,0.05,0.008111071056538128,NA,NA,NA,NA,NA,38,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
491,adverse,atkinson 1998,a placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,low back pain,musculoskeletal,primary,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,29,1,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
492,adverse,atkinson 1998,a placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,pain,nortriptyline,antidepressant,antidepressant,nortriptyline 25-100mg,tca,25-100mg,unable to be categorised,flexible,8 weeks,low back pain,musculoskeletal,primary,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,28,1,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
493,adverse_dropout,atkinson 1998,a placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,low back pain,musculoskeletal,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,2,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
494,adverse_dropout,atkinson 1998,a placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,pain,nortriptyline,antidepressant,antidepressant,nortriptyline 25-100mg,tca,25-100mg,unable to be categorised,flexible,8 weeks,low back pain,musculoskeletal,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,2,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
495,withdrawal,atkinson 1998,a placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,low back pain,musculoskeletal,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,11,0.275,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
496,withdrawal,atkinson 1998,a placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain,pain,nortriptyline,antidepressant,antidepressant,nortriptyline 25-100mg,tca,25-100mg,unable to be categorised,flexible,8 weeks,low back pain,musculoskeletal,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,10,0.2632,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
497,pain_int,atkinson 1999,effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity,pain,maprotiline,antidepressant,antidepressant,maprotiline 50-150mg,teca,50-150mg,low,fixed,8 weeks,low back pain,musculoskeletal,primary,no,parallel,completer analysis,descriptor differential scale,baseline,NA,12.21,4.52,1.0107027258299048,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
498,pain_int,atkinson 1999,effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity,pain,paroxetine,antidepressant,antidepressant,paroxetine 10-30mg,ssri,10-30mg,unable to be categorised,flexible,8 weeks,low back pain,musculoskeletal,primary,no,parallel,completer analysis,descriptor differential scale,baseline,NA,10.54,3.71,0.7909746576793146,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
499,pain_int,atkinson 1999,effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity,pain,active placebo,placebo,placebo,diphenhydramine,n/a,n/a,n/a,n/a,8 weeks,low back pain,musculoskeletal,primary,no,parallel,completer analysis,descriptor differential scale,baseline,NA,10.53,3.74,0.6611448404094219,NA,NA,NA,NA,NA,32,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
500,pain_int,atkinson 1999,effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity,pain,maprotiline,antidepressant,antidepressant,maprotiline 50-150mg,teca,50-150mg,low,fixed,8 weeks,low back pain,musculoskeletal,primary,no,parallel,completer analysis,descriptor differential scale,post_int,NA,6.8,4.72,1.0554240853799006,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
501,pain_int,atkinson 1999,effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity,pain,paroxetine,antidepressant,antidepressant,paroxetine 10-30mg,ssri,10-30mg,unable to be categorised,flexible,8 weeks,low back pain,musculoskeletal,primary,no,parallel,completer analysis,descriptor differential scale,post_int,NA,8.2,4,0.8528028654224417,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
502,pain_int,atkinson 1999,effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity,pain,active placebo,placebo,placebo,diphenhydramine,n/a,n/a,n/a,n/a,8 weeks,low back pain,musculoskeletal,primary,no,parallel,completer analysis,descriptor differential scale,post_int,NA,7.7,4.63,0.8184760992234287,NA,NA,NA,NA,NA,32,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
503,adverse,atkinson 1999,effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity,pain,maprotiline,antidepressant,antidepressant,maprotiline 50-150mg,teca,50-150mg,low,fixed,8 weeks,low back pain,musculoskeletal,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,18,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
504,adverse,atkinson 1999,effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity,pain,paroxetine,antidepressant,antidepressant,paroxetine 10-30mg,ssri,10-30mg,unable to be categorised,flexible,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,34,20,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
505,adverse,atkinson 1999,effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity,pain,active placebo,placebo,placebo,diphenhydramine,n/a,n/a,n/a,n/a,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,36,31,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
506,withdrawal,atkinson 1999,effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity,pain,maprotiline,antidepressant,antidepressant,maprotiline 50-150mg,teca,50-150mg,low,fixed,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,13,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
507,withdrawal,atkinson 1999,effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity,pain,paroxetine,antidepressant,antidepressant,paroxetine 10-30mg,ssri,10-30mg,unable to be categorised,flexible,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,34,12,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
508,withdrawal,atkinson 1999,effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity,pain,active placebo,placebo,placebo,diphenhydramine,n/a,n/a,n/a,n/a,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,36,4,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
509,NA,atkinson 2007,efficacy of noradrenergic and seotonergic antidepressants in chronic back pain: a preliminary concentration-controlled trial,pain,benztroptine mesylate,active placebo,placebo,benztropine mesylate 0.5mg,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,no,parallel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,placebo,NA,NA,NA,NA,NA,no_useable_data,NA
510,NA,atkinson 2007,efficacy of noradrenergic and seotonergic antidepressants in chronic back pain: a preliminary concentration-controlled trial,pain,desipramine,antidepressant,antidepressant,desipramine 50mg,tca,50mg,low,fixed,12 weeks,low back pain,musculoskeletal,primary,no,parallel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,ad,NA,NA,NA,NA,NA,no_useable_data,NA
511,NA,atkinson 2007,efficacy of noradrenergic and seotonergic antidepressants in chronic back pain: a preliminary concentration-controlled trial,pain,desipramine,antidepressant,antidepressant,desipramine 100mg,tca,100mg,standard,fixed,12 weeks,low back pain,musculoskeletal,primary,no,parallel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,ad,NA,NA,NA,NA,NA,no_useable_data,NA
512,NA,atkinson 2007,efficacy of noradrenergic and seotonergic antidepressants in chronic back pain: a preliminary concentration-controlled trial,pain,desipramine,antidepressant,antidepressant,desipramine 150mg,tca,150mg,standard,fixed,12 weeks,low back pain,musculoskeletal,primary,no,parallel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,ad,NA,NA,NA,NA,NA,no_useable_data,NA
513,NA,atkinson 2007,efficacy of noradrenergic and seotonergic antidepressants in chronic back pain: a preliminary concentration-controlled trial,pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,12 weeks,low back pain,musculoskeletal,primary,no,parallel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,ad,NA,NA,NA,NA,NA,no_useable_data,NA
514,NA,atkinson 2007,efficacy of noradrenergic and seotonergic antidepressants in chronic back pain: a preliminary concentration-controlled trial,pain,fluoxetine,antidepressant,antidepressant,fluoxetine 40mg,ssri,40mg,high,fixed,12 weeks,low back pain,musculoskeletal,primary,no,parallel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,ad,NA,NA,NA,NA,NA,no_useable_data,NA
515,NA,atkinson 2007,efficacy of noradrenergic and seotonergic antidepressants in chronic back pain: a preliminary concentration-controlled trial,pain,fluoxetine,antidepressant,antidepressant,fluoxetine 60mg,ssri,60mg,high,fixed,12 weeks,low back pain,musculoskeletal,primary,no,parallel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,ad,NA,NA,NA,NA,NA,no_useable_data,NA
516,pain_int,bansal 2009,amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double-blind clinical trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10-50mg,tca,16mg,low,flexible,5 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥50 on 100vas,crossover,itt unspecified method,0-100 vas,baseline,NA,73.33333333333333,7.663666097609354,1.1553411347426095,70,NA,NA,70,80,44,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
517,pain_int,bansal 2009,amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double-blind clinical trial,pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 75-300mg,n/a,n/a,n/a,n/a,5 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥50 on 100vas,crossover,itt unspecified method,0-100 vas,baseline,NA,70,7.663666097609354,1.1553411347426095,70,NA,NA,65,75,44,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
518,pain_int,bansal 2009,amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double-blind clinical trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10-50mg,tca,16mg,low,flexible,5 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥50 on 100vas,crossover,itt unspecified method,0-100 vas,post_int,NA,43.166666666666664,20.691898463545257,3.119421063805046,42.5,NA,NA,30,57,44,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
519,pain_int,bansal 2009,amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double-blind clinical trial,pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 75-300mg,n/a,n/a,n/a,n/a,5 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥50 on 100vas,crossover,itt unspecified method,0-100 vas,post_int,NA,43.333333333333336,22.990998292828063,3.466023404227829,40,NA,NA,30,60,44,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
520,adverse_dropout,bansal 2009,amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double-blind clinical trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10-50mg,tca,16mg,low,flexible,5 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥50 on 100vas,crossover,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,44,17,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
521,adverse_dropout,bansal 2009,amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double-blind clinical trial,pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 75-300mg,n/a,n/a,n/a,n/a,5 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥50 on 100vas,crossover,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,44,6,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
522,withdrawal,bansal 2009,amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double-blind clinical trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10-50mg,tca,16mg,low,flexible,5 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥50 on 100vas,crossover,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,3,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
523,withdrawal,bansal 2009,amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double-blind clinical trial,pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 75-300mg,n/a,n/a,n/a,n/a,5 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥50 on 100vas,crossover,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,4,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
524,pain_int,bateman 2011,results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase iv pilot study,pain,milnacipran,antidepressant,antidepressant,milnacipran 50-200mg,snri,50-200mg,unable to be categorised,flexible,10 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-100 vas,baseline,NA,65.4,13.2,1.4851160292223515,NA,NA,NA,NA,NA,79,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
525,pain_int,bateman 2011,results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase iv pilot study,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,10 weels,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-100 vas,baseline,NA,62.2,12.2,2.662258260879107,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
526,pain_int,bateman 2011,results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase iv pilot study,pain,milnacipran,antidepressant,antidepressant,milnacipran 50-200mg,snri,50-200mg,unable to be categorised,flexible,10 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-100 vas,change_score,NA,-12.3,27.286756861158857,3.07,NA,NA,NA,NA,NA,79,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
527,pain_int,bateman 2011,results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase iv pilot study,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,10 weels,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-100 vas,change_score,NA,-1.3,22.500446662233173,4.91,NA,NA,NA,NA,NA,21,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
528,qol,bateman 2011,results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase iv pilot study,pain,milnacipran,antidepressant,antidepressant,milnacipran 50-200mg,snri,50-200mg,unable to be categorised,flexible,10 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-100 vas,baseline,NA,57.4,18.6,2.092663495722405,NA,NA,NA,NA,NA,79,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
529,qol,bateman 2011,results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase iv pilot study,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,10 weels,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-100 vas,baseline,NA,48.4,16.5,3.6005951888938745,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
530,qol,bateman 2011,results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase iv pilot study,pain,milnacipran,antidepressant,antidepressant,milnacipran 50-200mg,snri,50-200mg,unable to be categorised,flexible,10 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-100 vas,change_score,NA,0.75,22.842659652501062,2.57,NA,NA,NA,NA,NA,79,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
531,qol,bateman 2011,results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase iv pilot study,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,10 weels,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-100 vas,change_score,NA,3.05,28.641098093474,6.25,NA,NA,NA,NA,NA,21,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
532,pain_mod,bateman 2011,results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase iv pilot study,pain,milnacipran,antidepressant,antidepressant,milnacipran 50-200mg,snri,50-200mg,unable to be categorised,flexible,10 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,79,27,0.342,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
533,pain_mod,bateman 2011,results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase iv pilot study,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,10 weels,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,6,0.28600000000000003,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
534,pain_sub,bateman 2011,results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase iv pilot study,pain,milnacipran,antidepressant,antidepressant,milnacipran 50-200mg,snri,50-200mg,unable to be categorised,flexible,10 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,79,20,0.253,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
535,pain_sub,bateman 2011,results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase iv pilot study,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,10 weels,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,3,0.14300000000000002,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
536,adverse,bateman 2011,results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase iv pilot study,pain,milnacipran,antidepressant,antidepressant,milnacipran 50-200mg,snri,50-200mg,unable to be categorised,flexible,10 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,85,63,0.741,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
537,adverse,bateman 2011,results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase iv pilot study,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,10 weels,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,16,0.762,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
538,adverse_dropout,bateman 2011,results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase iv pilot study,pain,milnacipran,antidepressant,antidepressant,milnacipran 50-200mg,snri,50-200mg,unable to be categorised,flexible,10 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,15,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
539,adverse_dropout,bateman 2011,results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase iv pilot study,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,10 weels,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,2,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
540,serious_adverse,bateman 2011,results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase iv pilot study,pain,milnacipran,antidepressant,antidepressant,milnacipran 50-200mg,snri,50-200mg,unable to be categorised,flexible,10 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,80,2,0.025,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
541,serious_adverse,bateman 2011,results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase iv pilot study,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,10 weels,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
542,withdrawal,bateman 2011,results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase iv pilot study,pain,milnacipran,antidepressant,antidepressant,milnacipran 50-200mg,snri,50-200mg,unable to be categorised,flexible,10 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,35,0.40700000000000003,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
543,withdrawal,bateman 2011,results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase iv pilot study,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,10 weels,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,10,0.47600000000000003,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
544,mood,bird 2000,"paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double-blind, parallel group study",depression,paroxetine,antidepressant,antidepressant,paroxetine 20-40mg,ssri,20-40mg,unable to be categorised,flexible,8 weeks,rheumatoid arthritis,musculoskeletal,primary,no,parallel,itt unspecified method,madrs,baseline,NA,24.4,5.1,0.5260248355919845,NA,NA,NA,NA,NA,94,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
545,mood,bird 2000,"paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double-blind, parallel group study",depression,amitriptyline,antidepressant,antidepressant,amitriptyline 75-150mg,tca,75-150mg,high,NA,8 weeks,rheumatoid arthritis,musculoskeletal,primary,no,parallel,itt unspecified method,madrs,baseline,NA,24.3,5.5,0.5672816854423364,NA,NA,NA,NA,NA,94,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
548,adverse,bird 2000,"paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double-blind, parallel group study",depression,paroxetine,antidepressant,antidepressant,paroxetine 20-40mg,ssri,20-40mg,unable to be categorised,flexible,8 weeks,rheumatoid arthritis,musculoskeletal,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,94,53,0.56,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
549,adverse,bird 2000,"paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double-blind, parallel group study",depression,amitriptyline,antidepressant,antidepressant,amitriptyline 75-150mg,tca,75-150mg,high,flexible,8 weeks,rheumatoid arthritis,musculoskeletal,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,96,65,0.68,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
550,adverse_dropout,bird 2000,"paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double-blind, parallel group study",depression,paroxetine,antidepressant,antidepressant,paroxetine 20-40mg,ssri,20-40mg,unable to be categorised,flexible,8 weeks,rheumatoid arthritis,musculoskeletal,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,94,15,0.16,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
551,adverse_dropout,bird 2000,"paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double-blind, parallel group study",depression,amitriptyline,antidepressant,antidepressant,amitriptyline 75-150mg,tca,75-150mg,high,flexible,8 weeks,rheumatoid arthritis,musculoskeletal,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,93,14,0.15,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
552,serious_adverse,bird 2000,"paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double-blind, parallel group study",depression,paroxetine,antidepressant,antidepressant,paroxetine 20-40mg,ssri,20-40mg,unable to be categorised,flexible,8 weeks,rheumatoid arthritis,musculoskeletal,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,94,0,0,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
553,serious_adverse,bird 2000,"paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double-blind, parallel group study",depression,amitriptyline,antidepressant,antidepressant,amitriptyline 75-150mg,tca,75-150mg,high,flexible,8 weeks,rheumatoid arthritis,musculoskeletal,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,96,4,0.042,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
554,withdrawal,bird 2000,"paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double-blind, parallel group study",depression,paroxetine,antidepressant,antidepressant,paroxetine 20-40mg,ssri,20-40mg,unable to be categorised,flexible,8 weeks,rheumatoid arthritis,musculoskeletal,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,95,18,0.19,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
555,withdrawal,bird 2000,"paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double-blind, parallel group study",depression,amitriptyline,antidepressant,antidepressant,amitriptyline 75-150mg,tca,75-150mg,high,flexible,8 weeks,rheumatoid arthritis,musculoskeletal,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,105,20,0.19,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
556,pain_int,boyle 2012,"randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,0-10 numerical rating scale,baseline,NA,3.1,1.9595917942265424,0.4,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,"identifier in covidence is nct 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. as participants cannot be included in the nma more than once, only the high-dose outcomes are reported.",NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
557,pain_int,boyle 2012,"randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 75mg,tca,75mg,standard,fixed,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,0-10 numerical rating scale,baseline,NA,3.5,2.078460969082653,0.4,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,"identifier in covidence is nct 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. as participants cannot be included in the nma more than once, only the high-dose outcomes are reported.",NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
558,pain_int,boyle 2012,"randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,0-10 numerical rating scale,baseline,NA,3.4,2.3979157616563596,0.5,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,"identifier in covidence is nct 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. as participants cannot be included in the nma more than once, only the high-dose outcomes are reported.",NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
559,pain_int,boyle 2012,"randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,0-10 numerical rating scale,post_int,NA,2.4,1.7435595774162698,0.4,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,"identifier in covidence is nct 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. as participants cannot be included in the nma more than once, only the high-dose outcomes are reported.",NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
560,pain_int,boyle 2012,"randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 75mg,tca,75mg,standard,fixed,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,0-10 numerical rating scale,post_int,NA,2.6,2.8774989139876315,0.6,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,"identifier in covidence is nct 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. as participants cannot be included in the nma more than once, only the high-dose outcomes are reported.",NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
561,pain_int,boyle 2012,"randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,0-10 numerical rating scale,post_int,NA,2.2,1.9183326093250876,0.4,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,"identifier in covidence is nct 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. as participants cannot be included in the nma more than once, only the high-dose outcomes are reported.",NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
562,sleep,boyle 2012,"randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,bpi sleep,baseline,NA,3.1,2.449489742783178,0.5,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,"identifier in covidence is nct 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. as participants cannot be included in the nma more than once, only the high-dose outcomes are reported.",NA,NA,non_ad_pharm,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
563,sleep,boyle 2012,"randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 75mg,tca,75mg,standard,fixed,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,bpi sleep,baseline,NA,3.8,2.598076211353316,0.5,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,"identifier in covidence is nct 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. as participants cannot be included in the nma more than once, only the high-dose outcomes are reported.",NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
564,sleep,boyle 2012,"randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,bpi sleep,baseline,NA,3.9,3.3570820663189034,0.7,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,"identifier in covidence is nct 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. as participants cannot be included in the nma more than once, only the high-dose outcomes are reported.",NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
565,sleep,boyle 2012,"randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,bpi sleep,post_int,NA,2.9,3.0512292604784714,0.7,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,"identifier in covidence is nct 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. as participants cannot be included in the nma more than once, only the high-dose outcomes are reported.",NA,NA,non_ad_pharm,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
566,sleep,boyle 2012,"randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 75mg,tca,75mg,standard,fixed,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,bpi sleep,post_int,NA,2,2.3979157616563596,0.5,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,"identifier in covidence is nct 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. as participants cannot be included in the nma more than once, only the high-dose outcomes are reported.",NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
567,sleep,boyle 2012,"randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,bpi sleep,post_int,NA,2.5,2.8774989139876315,0.6,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,"identifier in covidence is nct 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. as participants cannot be included in the nma more than once, only the high-dose outcomes are reported.",NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
568,physical,boyle 2012,"randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,sf-36 physical component score,baseline,NA,34.2,40.171631781644116,8.2,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,"identifier in covidence is nct 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. as participants cannot be included in the nma more than once, only the high-dose outcomes are reported.",NA,NA,non_ad_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
569,physical,boyle 2012,"randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 75mg,tca,75mg,standard,fixed,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,sf-36 physical component score,baseline,NA,39.5,48.32421753117168,9.3,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,"identifier in covidence is nct 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. as participants cannot be included in the nma more than once, only the high-dose outcomes are reported.",NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
570,physical,boyle 2012,"randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,sf-36 physical component score,baseline,NA,37.8,47.958315233127195,10,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,"identifier in covidence is nct 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. as participants cannot be included in the nma more than once, only the high-dose outcomes are reported.",NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
571,physical,boyle 2012,"randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,sf-36 physical component score,post_int,NA,31.1,47.51199848459335,10.9,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,"identifier in covidence is nct 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. as participants cannot be included in the nma more than once, only the high-dose outcomes are reported.",NA,NA,non_ad_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
572,physical,boyle 2012,"randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 75mg,tca,75mg,standard,fixed,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,sf-36 physical component score,post_int,NA,38.5,42.20331740515193,8.8,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,"identifier in covidence is nct 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. as participants cannot be included in the nma more than once, only the high-dose outcomes are reported.",NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
573,physical,boyle 2012,"randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,sf-36 physical component score,post_int,NA,36.6,45.08081631913956,9.4,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,"identifier in covidence is nct 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. as participants cannot be included in the nma more than once, only the high-dose outcomes are reported.",NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
574,mood,boyle 2012,"randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,sf-36 mental component score,baseline,NA,52.8,45.56050921576711,9.3,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,"identifier in covidence is nct 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. as participants cannot be included in the nma more than once, only the high-dose outcomes are reported.",NA,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
575,mood,boyle 2012,"randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 75mg,tca,75mg,standard,fixed,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,sf-36 mental component score,baseline,NA,51.1,37.93191268575841,7.3,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,"identifier in covidence is nct 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. as participants cannot be included in the nma more than once, only the high-dose outcomes are reported.",NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
576,mood,boyle 2012,"randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,sf-36 mental component score,baseline,NA,50.2,43.162483709814474,9,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,"identifier in covidence is nct 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. as participants cannot be included in the nma more than once, only the high-dose outcomes are reported.",NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
577,mood,boyle 2012,"randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,sf-36 mental component score,post_int,NA,52.4,43.58898943540674,10,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,"identifier in covidence is nct 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. as participants cannot be included in the nma more than once, only the high-dose outcomes are reported.",NA,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
578,mood,boyle 2012,"randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 75mg,tca,75mg,standard,fixed,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,sf-36 mental component score,post_int,NA,51.7,38.36665218650175,8,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,"identifier in covidence is nct 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. as participants cannot be included in the nma more than once, only the high-dose outcomes are reported.",NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
579,mood,boyle 2012,"randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,sf-36 mental component score,post_int,NA,51,42.20331740515193,8.8,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,"identifier in covidence is nct 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. as participants cannot be included in the nma more than once, only the high-dose outcomes are reported.",NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
580,adverse_dropout,boyle 2012,"randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,27,6,NA,FALSE,NA,NA,"identifier in covidence is nct 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. as participants cannot be included in the nma more than once, only the high-dose outcomes are reported.",NA,NA,non_ad_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
581,adverse_dropout,boyle 2012,"randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 75mg,tca,75mg,standard,fixed,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,1,NA,FALSE,NA,NA,"identifier in covidence is nct 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. as participants cannot be included in the nma more than once, only the high-dose outcomes are reported.",NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
582,adverse_dropout,boyle 2012,"randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,3,NA,FALSE,NA,NA,"identifier in covidence is nct 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. as participants cannot be included in the nma more than once, only the high-dose outcomes are reported.",NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
583,withdrawal,boyle 2012,"randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,27,5,NA,FALSE,NA,NA,"identifier in covidence is nct 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. as participants cannot be included in the nma more than once, only the high-dose outcomes are reported.",NA,NA,non_ad_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
584,withdrawal,boyle 2012,"randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 75mg,tca,75mg,standard,fixed,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,4,NA,FALSE,NA,NA,"identifier in covidence is nct 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. as participants cannot be included in the nma more than once, only the high-dose outcomes are reported.",NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
585,withdrawal,boyle 2012,"randomized, placebo-controlled comparison of amitriptyline, duloxetine and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning and quality of life",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,0,NA,FALSE,NA,NA,"identifier in covidence is nct 2006 || this study had two stages over 4 weeks 1) low-dose treatment for 2 weeks then 2) high-dose treatment for 2 weeks. as participants cannot be included in the nma more than once, only the high-dose outcomes are reported.",NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
586,pain_int,branco 2010,a european multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-100 vas,baseline,NA,65,12.7,0.6013624292391806,NA,NA,NA,NA,NA,446,NA,NA,FALSE,NA,NA,sensitivity analysis with bocf,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
587,pain_int,branco 2010,a european multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,16 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-100 vas,baseline,NA,65.5,12.9,0.6220932405998316,NA,NA,NA,NA,NA,430,NA,NA,FALSE,NA,NA,sensitivity analysis with bocf,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
588,pain_int,branco 2010,a european multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-100 vas,change_score,NA,-11.97,24.075331773414874,1.14,NA,NA,NA,NA,NA,446,NA,NA,TRUE,NA,NA,sensitivity analysis with bocf,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
589,pain_int,branco 2010,a european multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,16 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-100 vas,change_score,NA,-16.5,24.469000796926707,1.18,NA,NA,NA,NA,NA,430,NA,NA,TRUE,NA,NA,sensitivity analysis with bocf,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
590,qol,branco 2010,a european multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,fibromyalgia impact questionnaire total score,baseline,NA,57,11.8,0.5587461940962466,NA,NA,NA,NA,NA,446,NA,NA,FALSE,NA,NA,sensitivity analysis with bocf,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
591,qol,branco 2010,a european multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,16 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,fibromyalgia impact questionnaire total score,baseline,NA,56.7,11.9,0.5738689583827905,NA,NA,NA,NA,NA,430,NA,NA,FALSE,NA,NA,sensitivity analysis with bocf,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
592,qol,branco 2010,a european multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,fibromyalgia impact questionnaire total score,change_score,NA,-11.18,20.907524961123446,0.99,NA,NA,NA,NA,NA,446,NA,NA,TRUE,NA,NA,sensitivity analysis with bocf,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
593,qol,branco 2010,a european multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,16 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,fibromyalgia impact questionnaire total score,change_score,NA,14.18,21.35853459392755,1.03,NA,NA,NA,NA,NA,430,NA,NA,TRUE,NA,NA,sensitivity analysis with bocf,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
594,physical,branco 2010,a european multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 physical component score,baseline,NA,33.7,6.8,0.3219893321910573,NA,NA,NA,NA,NA,446,NA,NA,FALSE,NA,NA,sensitivity analysis with bocf,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
595,physical,branco 2010,a european multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,16 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 physical component score,baseline,NA,33.4,6.7,0.32310269085417614,NA,NA,NA,NA,NA,430,NA,NA,FALSE,NA,NA,sensitivity analysis with bocf,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
596,physical,branco 2010,a european multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 physical component score,change_score,NA,3.57,7.391549228680005,0.35,NA,NA,NA,NA,NA,446,NA,NA,TRUE,NA,NA,sensitivity analysis with bocf,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
597,physical,branco 2010,a european multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,16 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 physical component score,change_score,NA,4.55,7.465118887197979,0.36,NA,NA,NA,NA,NA,430,NA,NA,TRUE,NA,NA,sensitivity analysis with bocf,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
598,mood,branco 2010,a european multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 mental component score,baseline,NA,46.3,9.8,0.4640434493341709,NA,NA,NA,NA,NA,446,NA,NA,FALSE,NA,NA,sensitivity analysis with bocf,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
599,mood,branco 2010,a european multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,16 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 mental component score,baseline,NA,47,9.8,0.4725979657270039,NA,NA,NA,NA,NA,430,NA,NA,FALSE,NA,NA,sensitivity analysis with bocf,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
600,mood,branco 2010,a european multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 mental component score,change_score,NA,-0.23,9.081046195235436,0.43,NA,NA,NA,NA,NA,446,NA,NA,TRUE,NA,NA,sensitivity analysis with bocf,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
601,mood,branco 2010,a european multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,16 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 mental component score,change_score,NA,1.23,9.331398608997475,0.45,NA,NA,NA,NA,NA,430,NA,NA,TRUE,NA,NA,sensitivity analysis with bocf,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
610,adverse,branco 2010,a european multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,446,331,0.742,FALSE,NA,NA,sensitivity analysis with bocf,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
611,adverse,branco 2010,a european multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,16 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,431,363,0.8420000000000001,FALSE,NA,NA,sensitivity analysis with bocf,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
612,adverse_dropout,branco 2010,a european multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,449,44,NA,FALSE,NA,NA,sensitivity analysis with bocf,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
613,adverse_dropout,branco 2010,a european multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,16 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,435,96,NA,FALSE,NA,NA,sensitivity analysis with bocf,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
614,serious_adverse,branco 2010,a european multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,440,11,0.025,FALSE,NA,NA,sensitivity analysis with bocf,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
615,serious_adverse,branco 2010,a european multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,16 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,423,11,0.026000000000000002,FALSE,NA,NA,sensitivity analysis with bocf,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
616,withdrawal,branco 2010,a european multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,449,79,0.17600000000000002,FALSE,NA,NA,sensitivity analysis with bocf,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
617,withdrawal,branco 2010,a european multicenter randomized double-blind placebo-controlled monotherapy clinical trial in treatment of fibromyalgia,pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,16 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,435,127,0.292,FALSE,NA,NA,sensitivity analysis with bocf,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
618,withdrawal,braz 2013,"effects of panax ginseng extract in patients with fibromyalgia: a 12-week, randomized, double-blind, placebo-controlled trial",fibromyalgia symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,4,0.235,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
619,withdrawal,braz 2013,"effects of panax ginseng extract in patients with fibromyalgia: a 12-week, randomized, double-blind, placebo-controlled trial",fibromyalgia symptoms,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,16,3,0.1875,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
620,withdrawal,braz 2013,"effects of panax ginseng extract in patients with fibromyalgia: a 12-week, randomized, double-blind, placebo-controlled trial",fibromyalgia symptoms,panax ginseng,plant extract,non-pharmacological,panax ginseng 100mg,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,7,0.368,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
623,mood,brown 2015,a randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,beck depression inventory,post_int,NA,10.21,6.44,1.4774373261264178,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
624,mood,brown 2015,a randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,beck depression inventory,post_int,NA,6.41,5.42,1.4485559311653402,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
625,physical,brown 2015,a randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,sf-36 physical component score,baseline,NA,36.82,7.22,1.614441079754848,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
626,physical,brown 2015,a randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,sf-36 physical component score,baseline,NA,32,7.98,1.8809040379562167,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
627,physical,brown 2015,a randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,sf-36 physical component score,change_score,NA,0.22,4.94,1.1046175808848961,NA,NA,NA,NA,NA,20,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
628,physical,brown 2015,a randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,sf-36 physical component score,change_score,NA,0.74,5.65,1.4588237270714604,NA,NA,NA,NA,NA,15,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
629,mood,brown 2015,a randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,sf-36 mental component score,baseline,NA,47.31,11.19,2.5021600668222646,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
630,mood,brown 2015,a randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,sf-36 mental component score,baseline,NA,50.01,11.56,2.7247181301721635,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
631,mood,brown 2015,a randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,sf-36 mental component score,change_score,NA,2.18,7.52,1.6815231190798416,NA,NA,NA,NA,NA,20,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
632,mood,brown 2015,a randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,sf-36 mental component score,change_score,NA,3.39,8.69,2.24374835190283,NA,NA,NA,NA,NA,15,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
633,pain_int,brown 2015,a randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,0-10 numerical rating scale,baseline,NA,4.41,1.43,0.3197577207824699,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
634,pain_int,brown 2015,a randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,0-10 numerical rating scale,baseline,NA,4.73,1.66,0.3912657522565563,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
635,pain_int,brown 2015,a randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,0-10 numerical rating scale,post_int,NA,3.79,1.32,0.311126983722081,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
636,pain_int,brown 2015,a randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,0-10 numerical rating scale,post_int,NA,2.96,1.99,0.5318498714057245,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
637,sleep,brown 2015,a randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,0-10 numerical rating scale [higher=better],baseline,NA,4.6,2.04,0.45615786740995706,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
638,sleep,brown 2015,a randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,0-10 numerical rating scale [higher=better],baseline,NA,4.23,2.25,0.5303300858899107,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
639,sleep,brown 2015,a randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,0-10 numerical rating scale [higher=better],post_int,NA,3.95,2.16,0.5091168824543143,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
640,sleep,brown 2015,a randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,0-10 numerical rating scale [higher=better],post_int,NA,2.95,1.72,0.47704216875369704,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
641,pain_mod,brown 2015,a randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,1,0.05,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
642,pain_mod,brown 2015,a randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,8,0.44,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
643,adverse_dropout,brown 2015,a randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,2,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
644,adverse_dropout,brown 2015,a randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,1,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
645,withdrawal,brown 2015,a randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,2,0.1,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
646,withdrawal,brown 2015,a randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,4,0.222,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
647,withdrawal,calderon 2011,effectiveness of cognitive-behavioral therapy and amitriptyline in patients with chronic temporomandibular disorders - a pilot study,"pain, depression, qol, sleep",placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,7 weeks,temporomandibular disorder,musculoskeletal,primary,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,2,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
648,withdrawal,calderon 2011,effectiveness of cognitive-behavioral therapy and amitriptyline in patients with chronic temporomandibular disorders - a pilot study,"pain, depression, qol, sleep",cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioural therapy,n/a,n/a,n/a,n/a,7 weeks,temporomandibular disorder,musculoskeletal,primary,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,2,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
649,withdrawal,calderon 2011,effectiveness of cognitive-behavioral therapy and amitriptyline in patients with chronic temporomandibular disorders - a pilot study,"pain, depression, qol, sleep",amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,7 weeks,temporomandibular disorder,musculoskeletal,primary,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,2,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
650,withdrawal,calderon 2011,effectiveness of cognitive-behavioral therapy and amitriptyline in patients with chronic temporomandibular disorders - a pilot study,"pain, depression, qol, sleep",cognitive behavioural therapy and amitriptyline,combined antidepressant intervention,antidepressant,cognitive behavioural therapy + amitriptyline 25mg,tca,25mg,standard,fixed,7 weeks,temporomandibular disorder,musculoskeletal,primary,≥40 on 100vas,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,4,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
651,adverse,cannon 1994,imipramine in patients with chest pain despite normal coronary angiograms,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,3 weeks,chest pain,non-cardiac chest pain,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,11,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
652,adverse,cannon 1994,imipramine in patients with chest pain despite normal coronary angiograms,pain,clonidine,antihypertensive,non-antidepressant pharmacological,clonidine 0.2mg,n/a,n/a,n/a,n/a,3 weeks,chest pain,non-cardiac chest pain,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,14,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
653,adverse,cannon 1994,imipramine in patients with chest pain despite normal coronary angiograms,pain,imipramine,antidepressant,antidepressant,imipramine 50mg,tca,50mg,low,fixed,3 weeks,chest pain,non-cardiac chest pain,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,15,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
654,pain_int,cardenas 2002,efficacy of amitriptyline relief for pain in spinal cord injury: results of a randomized controlled trial,pain,benzotropine mesylate,active placebo,placebo,benzotropine mesylate 0.5mg,n/a,n/a,n/a,n/a,6 weeks,spinal cord injury,neuropathic,neuropathic,≥3 on 10nrs,parallel,itt unspecified method,0-10 numerical rating scale,baseline,NA,5,1.7,0.2687936011143122,NA,NA,NA,NA,NA,40,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
655,pain_int,cardenas 2002,efficacy of amitriptyline relief for pain in spinal cord injury: results of a randomized controlled trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10-125mg,tca,10-125mg,unable to be categorised,flexible,6 weeks,spinal cord injury,neuropathic,neuropathic,≥3 on 10nrs,parallel,itt unspecified method,0-10 numerical rating scale,baseline,NA,5.5,1.8,0.2713602101199873,NA,NA,NA,NA,NA,44,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
656,pain_int,cardenas 2002,efficacy of amitriptyline relief for pain in spinal cord injury: results of a randomized controlled trial,pain,benzotropine mesylate,active placebo,placebo,benzotropine mesylate 0.5mg,n/a,n/a,n/a,n/a,6 weeks,spinal cord injury,neuropathic,neuropathic,≥3 on 10nrs,parallel,itt unspecified method,0-10 numerical rating scale,post_int,NA,4,2,0.31622776601683794,NA,NA,NA,NA,NA,40,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
657,pain_int,cardenas 2002,efficacy of amitriptyline relief for pain in spinal cord injury: results of a randomized controlled trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10-125mg,tca,10-125mg,unable to be categorised,flexible,6 weeks,spinal cord injury,neuropathic,neuropathic,≥3 on 10nrs,parallel,itt unspecified method,0-10 numerical rating scale,post_int,NA,4.5,1.9,0.28643577734887543,NA,NA,NA,NA,NA,44,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
658,mood,cardenas 2002,efficacy of amitriptyline relief for pain in spinal cord injury: results of a randomized controlled trial,pain,benzotropine mesylate,active placebo,placebo,benzotropine mesylate 0.5mg,n/a,n/a,n/a,n/a,6 weeks,spinal cord injury,neuropathic,neuropathic,≥3 on 10nrs,parallel,itt unspecified method,ces-d,baseline,NA,13.3,8.6,1.359779393872403,NA,NA,NA,NA,NA,40,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
659,mood,cardenas 2002,efficacy of amitriptyline relief for pain in spinal cord injury: results of a randomized controlled trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10-125mg,tca,10-125mg,unable to be categorised,flexible,6 weeks,spinal cord injury,neuropathic,neuropathic,≥3 on 10nrs,parallel,itt unspecified method,ces-d,baseline,NA,17.1,9.7,1.4623300212021535,NA,NA,NA,NA,NA,44,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
660,mood,cardenas 2002,efficacy of amitriptyline relief for pain in spinal cord injury: results of a randomized controlled trial,pain,benzotropine mesylate,active placebo,placebo,benzotropine mesylate 0.5mg,n/a,n/a,n/a,n/a,6 weeks,spinal cord injury,neuropathic,neuropathic,≥3 on 10nrs,parallel,itt unspecified method,ces-d,post_int,NA,11.2,8.6,1.359779393872403,NA,NA,NA,NA,NA,40,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
661,mood,cardenas 2002,efficacy of amitriptyline relief for pain in spinal cord injury: results of a randomized controlled trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10-125mg,tca,10-125mg,unable to be categorised,flexible,6 weeks,spinal cord injury,neuropathic,neuropathic,≥3 on 10nrs,parallel,itt unspecified method,ces-d,post_int,NA,12.4,10.9,1.6432368279488119,NA,NA,NA,NA,NA,44,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
662,physical,cardenas 2002,efficacy of amitriptyline relief for pain in spinal cord injury: results of a randomized controlled trial,pain,benzotropine mesylate,active placebo,placebo,benzotropine mesylate 0.5mg,n/a,n/a,n/a,n/a,6 weeks,spinal cord injury,neuropathic,neuropathic,≥3 on 10nrs,parallel,itt unspecified method,functional independence measure,baseline,NA,64.7,17.5,2.766992952647332,NA,NA,NA,NA,NA,40,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
663,physical,cardenas 2002,efficacy of amitriptyline relief for pain in spinal cord injury: results of a randomized controlled trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10-125mg,tca,10-125mg,unable to be categorised,flexible,6 weeks,spinal cord injury,neuropathic,neuropathic,≥3 on 10nrs,parallel,itt unspecified method,functional independence measure,baseline,NA,66.8,15.2,2.2914862187910034,NA,NA,NA,NA,NA,44,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
664,physical,cardenas 2002,efficacy of amitriptyline relief for pain in spinal cord injury: results of a randomized controlled trial,pain,benzotropine mesylate,active placebo,placebo,benzotropine mesylate 0.5mg,n/a,n/a,n/a,n/a,6 weeks,spinal cord injury,neuropathic,neuropathic,≥3 on 10nrs,parallel,itt unspecified method,functional independence measure,post_int,NA,53.7,18.3,2.893484059054067,NA,NA,NA,NA,NA,40,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
665,physical,cardenas 2002,efficacy of amitriptyline relief for pain in spinal cord injury: results of a randomized controlled trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10-125mg,tca,10-125mg,unable to be categorised,flexible,6 weeks,spinal cord injury,neuropathic,neuropathic,≥3 on 10nrs,parallel,itt unspecified method,functional independence measure,post_int,NA,66.3,16.7,2.5176197272243264,NA,NA,NA,NA,NA,44,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
666,adverse,cardenas 2002,efficacy of amitriptyline relief for pain in spinal cord injury: results of a randomized controlled trial,pain,benzotropine mesylate,active placebo,placebo,benzotropine mesylate 0.5mg,n/a,n/a,n/a,n/a,6 weeks,spinal cord injury,neuropathic,neuropathic,≥3 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,36,0.9,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
667,adverse,cardenas 2002,efficacy of amitriptyline relief for pain in spinal cord injury: results of a randomized controlled trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10-125mg,tca,10-125mg,unable to be categorised,flexible,6 weeks,spinal cord injury,neuropathic,neuropathic,≥3 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,44,43,0.977,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
668,withdrawal,cardenas 2002,efficacy of amitriptyline relief for pain in spinal cord injury: results of a randomized controlled trial,pain,benzotropine mesylate,active placebo,placebo,benzotropine mesylate 0.5mg,n/a,n/a,n/a,n/a,6 weeks,spinal cord injury,neuropathic,neuropathic,≥3 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,3,0.08,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
669,withdrawal,cardenas 2002,efficacy of amitriptyline relief for pain in spinal cord injury: results of a randomized controlled trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10-125mg,tca,10-125mg,unable to be categorised,flexible,6 weeks,spinal cord injury,neuropathic,neuropathic,≥3 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,44,8,0.18,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
670,pain_int,carette 1986,"evaluation of amitriptyline in primary fibrositis. a double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,9 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,unsure,0-10 numerical rating scale,baseline,NA,5.8,2.4,0.42426406871192845,NA,NA,NA,NA,NA,32,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
671,pain_int,carette 1986,"evaluation of amitriptyline in primary fibrositis. a double-blind, placebo-controlled study",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10-50mg,tca,10-50mg,unable to be categorised,flexible,9 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,unsure,0-10 numerical rating scale,baseline,NA,6.3,2.3,0.44263520637871306,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
672,pain_int,carette 1986,"evaluation of amitriptyline in primary fibrositis. a double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,9 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,unsure,0-10 numerical rating scale,post_int,NA,5,3,0.5303300858899106,NA,NA,NA,NA,NA,32,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
673,pain_int,carette 1986,"evaluation of amitriptyline in primary fibrositis. a double-blind, placebo-controlled study",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10-50mg,tca,10-50mg,unable to be categorised,flexible,9 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,unsure,0-10 numerical rating scale,post_int,NA,4.3,3,0.5773502691896257,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
674,adverse,carette 1986,"evaluation of amitriptyline in primary fibrositis. a double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,9 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,unsure,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,4,0.12,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
675,adverse,carette 1986,"evaluation of amitriptyline in primary fibrositis. a double-blind, placebo-controlled study",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10-50mg,tca,10-50mg,unable to be categorised,flexible,9 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,unsure,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,27,19,0.7,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
676,adverse_dropout,carette 1986,"evaluation of amitriptyline in primary fibrositis. a double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,9 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,32,2,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
677,adverse_dropout,carette 1986,"evaluation of amitriptyline in primary fibrositis. a double-blind, placebo-controlled study",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10-50mg,tca,10-50mg,unable to be categorised,flexible,9 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,27,2,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
678,withdrawal,carette 1986,"evaluation of amitriptyline in primary fibrositis. a double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,9 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,32,4,0.11109999999999999,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
679,withdrawal,carette 1986,"evaluation of amitriptyline in primary fibrositis. a double-blind, placebo-controlled study",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10-50mg,tca,10-50mg,unable to be categorised,flexible,9 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,27,7,0.20600000000000002,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
680,pain_int,carette 1994,"comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,25 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,mcgill pain questionnaire total score,baseline,NA,28.6,12.4,1.9133615395299397,NA,NA,NA,NA,NA,42,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
681,pain_int,carette 1994,"comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 50mg,tca,50mg,standard,fixed,25 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,mcgill pain questionnaire total score,baseline,NA,28.2,12.5,1.3638618139749525,NA,NA,NA,NA,NA,84,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
682,pain_int,carette 1994,"comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial",pain,cyclobenzaprine,muscle relaxant,non-antidepressant pharmacological,cyclobenzaprine 20-30mg,n/a,n/a,n/a,n/a,25 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,mcgill pain questionnaire total score,baseline,NA,28.2,13.2,1.457696144187974,NA,NA,NA,NA,NA,82,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
683,pain_int,carette 1994,"comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,25 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,mcgill pain questionnaire total score,post_int,NA,21.6,14.4,2.4,NA,NA,NA,NA,NA,36,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
684,pain_int,carette 1994,"comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 50mg,tca,50mg,standard,fixed,25 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,mcgill pain questionnaire total score,post_int,NA,19.5,13.5,1.528573996095204,NA,NA,NA,NA,NA,78,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
685,pain_int,carette 1994,"comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial",pain,cyclobenzaprine,muscle relaxant,non-antidepressant pharmacological,cyclobenzaprine 20-30mg,n/a,n/a,n/a,n/a,25 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,mcgill pain questionnaire total score,post_int,NA,19.3,14.8,1.7689383418149027,NA,NA,NA,NA,NA,70,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
686,physical,carette 1994,"comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,25 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,sickness impact profile - physical subscale,baseline,NA,13.1,9.54,1.4720539586383568,NA,NA,NA,NA,NA,42,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
687,physical,carette 1994,"comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 50mg,tca,50mg,standard,fixed,25 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,sickness impact profile - physical subscale,baseline,NA,9.83,8.18,0.8925111710652088,NA,NA,NA,NA,NA,84,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
688,physical,carette 1994,"comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial",pain,cyclobenzaprine,muscle relaxant,non-antidepressant pharmacological,cyclobenzaprine 20-30mg,n/a,n/a,n/a,n/a,25 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,sickness impact profile - physical subscale,baseline,NA,9.95,8.71,0.9618585921119134,NA,NA,NA,NA,NA,82,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
689,physical,carette 1994,"comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,25 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,sickness impact profile - physical subscale,post_int,NA,9.01,10.6,1.7666666666666666,NA,NA,NA,NA,NA,36,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
690,physical,carette 1994,"comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 50mg,tca,50mg,standard,fixed,25 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,sickness impact profile - physical subscale,post_int,NA,8.3,8.25,0.9341285531692914,NA,NA,NA,NA,NA,78,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
691,physical,carette 1994,"comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial",pain,cyclobenzaprine,muscle relaxant,non-antidepressant pharmacological,cyclobenzaprine 20-30mg,n/a,n/a,n/a,n/a,25 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,sickness impact profile - physical subscale,post_int,NA,6.65,6.82,0.8151459115660565,NA,NA,NA,NA,NA,70,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
692,mood,carette 1994,"comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,25 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,aims - depression,baseline,NA,3.76,1.98,0.30552063292494197,NA,NA,NA,NA,NA,42,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
693,mood,carette 1994,"comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 50mg,tca,50mg,standard,fixed,25 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,aims - depression,baseline,NA,3.55,1.92,0.2094891746265527,NA,NA,NA,NA,NA,84,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
694,mood,carette 1994,"comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial",pain,cyclobenzaprine,muscle relaxant,non-antidepressant pharmacological,cyclobenzaprine 20-30mg,n/a,n/a,n/a,n/a,25 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,aims - depression,baseline,NA,3.55,1.89,0.20871558428145995,NA,NA,NA,NA,NA,82,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
695,mood,carette 1994,"comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,25 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,aims - depression,post_int,NA,2.57,1.84,0.3066666666666667,NA,NA,NA,NA,NA,36,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
696,mood,carette 1994,"comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 50mg,tca,50mg,standard,fixed,25 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,aims - depression,post_int,NA,2.41,1.86,0.2106035283508948,NA,NA,NA,NA,NA,78,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
697,mood,carette 1994,"comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial",pain,cyclobenzaprine,muscle relaxant,non-antidepressant pharmacological,cyclobenzaprine 20-30mg,n/a,n/a,n/a,n/a,25 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,aims - depression,post_int,NA,2.2,1.59,0.1900413488841686,NA,NA,NA,NA,NA,70,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
704,adverse,carette 1994,"comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,25 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,84,52,0.62,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
705,adverse,carette 1994,"comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 50mg,tca,50mg,standard,fixed,25 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,82,78,0.95,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
706,adverse,carette 1994,"comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial",pain,cyclobenzaprine,muscle relaxant,non-antidepressant pharmacological,cyclobenzaprine 20-30mg,n/a,n/a,n/a,n/a,25 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,42,41,0.98,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
707,adverse_dropout,carette 1994,"comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,25 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,84,5,0.06,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
708,adverse_dropout,carette 1994,"comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 50mg,tca,50mg,standard,fixed,25 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,82,11,0.13,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
709,adverse_dropout,carette 1994,"comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial",pain,cyclobenzaprine,muscle relaxant,non-antidepressant pharmacological,cyclobenzaprine 20-30mg,n/a,n/a,n/a,n/a,25 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,42,2,0.05,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
710,withdrawal,carette 1994,"comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,25 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,84,14,0.33299999999999996,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
711,withdrawal,carette 1994,"comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 50mg,tca,50mg,standard,fixed,25 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,82,14,0.16699999999999998,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
712,withdrawal,carette 1994,"comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial",pain,cyclobenzaprine,muscle relaxant,non-antidepressant pharmacological,cyclobenzaprine 20-30mg,n/a,n/a,n/a,n/a,25 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,42,24,0.293,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
713,adverse,caruso 1987,double-blind study of dothiepin versus placebo in the treatment of primary fibromyalgia syndrome,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,6,0.2,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
714,adverse,caruso 1987,double-blind study of dothiepin versus placebo in the treatment of primary fibromyalgia syndrome,pain,dothiepin,antidepressant,antidepressant,dothiepin 75mg,tca,75mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,18,0.6,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
715,withdrawal,caruso 1987,double-blind study of dothiepin versus placebo in the treatment of primary fibromyalgia syndrome,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,4,0.133,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
716,withdrawal,caruso 1987,double-blind study of dothiepin versus placebo in the treatment of primary fibromyalgia syndrome,pain,dothiepin,antidepressant,antidepressant,dothiepin 75mg,tca,75mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,4,0.133,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
717,pain_int,chappell 2008,"a six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,27 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,0-10 numerical rating scale,baseline,NA,6.43,1.48,0.11418447897194801,NA,NA,NA,NA,NA,168,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
718,pain_int,chappell 2008,"a six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,113.4mg,high,fixed,27 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,0-10 numerical rating scale,baseline,NA,6.58,1.52,0.11942247860039469,NA,NA,NA,NA,NA,162,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
719,pain_int,chappell 2008,"a six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,27 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,0-10 numerical rating scale,change_score,NA,-1.13,2.4553411168308164,0.19,NA,NA,NA,NA,NA,167,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
720,pain_int,chappell 2008,"a six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,113.4mg,high,fixed,27 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,0-10 numerical rating scale,change_score,NA,-1.62,2.513961017995307,0.2,NA,NA,NA,NA,NA,158,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
721,qol,chappell 2008,"a six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,27 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,eq-5d,baseline,NA,50.62,12.47,0.9620813870136431,NA,NA,NA,NA,NA,168,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
722,qol,chappell 2008,"a six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,113.4mg,high,fixed,27 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,eq-5d,baseline,NA,49.55,11.28,0.8862404990871395,NA,NA,NA,NA,NA,162,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
723,qol,chappell 2008,"a six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,27 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,eq-5d,change_score,NA,0.05,0.2529822128134704,0.02,NA,NA,NA,NA,NA,160,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
724,qol,chappell 2008,"a six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,113.4mg,high,fixed,27 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,eq-5d,change_score,NA,0.1,0.36249137920783714,0.03,NA,NA,NA,NA,NA,146,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
725,mood,chappell 2008,"a six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,27 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,hamilton rating depression scale,baseline,NA,9.31,5.41,0.41739056164745864,NA,NA,NA,NA,NA,168,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
726,mood,chappell 2008,"a six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,113.4mg,high,fixed,27 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,hamilton rating depression scale,baseline,NA,9.32,5.27,0.4140503040947895,NA,NA,NA,NA,NA,162,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
727,mood,chappell 2008,"a six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,27 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,hamilton rating depression scale,change_score,NA,-1.7,4.424556474947518,0.37,NA,NA,NA,NA,NA,143,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
728,mood,chappell 2008,"a six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,113.4mg,high,fixed,27 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,hamilton rating depression scale,change_score,NA,-2.04,5.027922035990614,0.4,NA,NA,NA,NA,NA,158,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
729,physical,chappell 2008,"a six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,27 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,sf-36 physical component score,change_score,NA,2.06,8.018590898655448,0.63,NA,NA,NA,NA,NA,162,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
730,physical,chappell 2008,"a six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,113.4mg,high,fixed,27 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,sf-36 physical component score,change_score,NA,2.61,8.095640802308363,0.67,NA,NA,NA,NA,NA,146,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
731,pain_mod,chappell 2008,"a six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,27 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,167,55,0.32899999999999996,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
732,pain_mod,chappell 2008,"a six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,113.4mg,high,fixed,27 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,158,60,0.38,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
733,pain_sub,chappell 2008,"a six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,27 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,167,30,0.18,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
734,pain_sub,chappell 2008,"a six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,113.4mg,high,fixed,27 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,158,37,0.23399999999999999,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
735,adverse,chappell 2008,"a six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,27 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,168,137,0.815,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
736,adverse,chappell 2008,"a six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,113.4mg,high,fixed,27 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,162,145,0.895,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
737,serious_adverse,chappell 2008,"a six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,27 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,167,4,0.024,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
738,serious_adverse,chappell 2008,"a six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,113.4mg,high,fixed,27 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,160,4,0.025,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
739,adverse_dropout,chappell 2008,"a six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,27 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,168,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
740,adverse_dropout,chappell 2008,"a six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,113.4mg,high,fixed,27 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,162,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
741,withdrawal,chappell 2008,"a six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,27 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,168,65,0.387,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
742,withdrawal,chappell 2008,"a six-month double-blind, palcebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,113.4mg,high,fixed,27 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,162,61,0.377,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
743,pain_int,chappell 2009: 1,a 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,52 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-0.37,2.651490147068248,0.26,NA,NA,NA,NA,NA,104,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
744,pain_int,chappell 2009: 1,a 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,52 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-0.16,2.707083301267251,0.19,NA,NA,NA,NA,NA,203,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
745,qol,chappell 2009: 1,a 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,52 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,fibromyalgia impact questionnaire total score,change_score,NA,-0.69,18.560431029477737,1.82,NA,NA,NA,NA,NA,104,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
746,qol,chappell 2009: 1,a 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,52 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,fibromyalgia impact questionnaire total score,change_score,NA,3.49,19.09206117735851,1.34,NA,NA,NA,NA,NA,203,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
747,physical,chappell 2009: 1,a 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,52 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sheehan disability scale,change_score,NA,-0.49,8.260411612020311,0.81,NA,NA,NA,NA,NA,104,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
748,physical,chappell 2009: 1,a 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,52 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sheehan disability scale,change_score,NA,1.47,8.406206040777253,0.59,NA,NA,NA,NA,NA,203,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
749,sleep,chappell 2009: 1,a 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,52 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,bpi sleep,change_score,NA,-1.16,3.2633724886993822,0.32,NA,NA,NA,NA,NA,104,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
750,sleep,chappell 2009: 1,a 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,52 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,bpi sleep,change_score,NA,-0.23,3.2769955752182516,0.23,NA,NA,NA,NA,NA,203,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
751,mood,chappell 2009: 1,a 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,52 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,bpi mood,change_score,NA,-0.11,2.8554509276119595,0.28,NA,NA,NA,NA,NA,104,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
752,mood,chappell 2009: 1,a 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,52 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,bpi mood,change_score,NA,0.49,2.992039438242751,0.21,NA,NA,NA,NA,NA,203,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
753,adverse,chappell 2009: 1,a 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,52 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,104,89,0.856,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
754,adverse,chappell 2009: 1,a 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,52 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,203,179,0.882,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
755,serious_adverse,chappell 2009: 1,a 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,52 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,103,6,0.057999999999999996,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
756,serious_adverse,chappell 2009: 1,a 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,52 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,203,12,0.059000000000000004,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
757,adverse_dropout,chappell 2009: 1,a 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,52 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,104,14,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
758,adverse_dropout,chappell 2009: 1,a 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,52 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,203,34,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
759,withdrawal,chappell 2009: 1,a 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,52 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,96,31,0.33,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
760,withdrawal,chappell 2009: 1,a 1-year safety and efficacy study of duloxetine in patients with fibromyalgia,pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,52 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,49,38,0.79,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
761,pain_int,chappell 2009: 2,"duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.18,1.32,0.12049896265113655,NA,NA,NA,NA,NA,120,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
762,pain_int,chappell 2009: 2,"duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.1,1.34,0.12718717143083488,NA,NA,NA,NA,NA,111,NA,NA,FALSE,NA,NA,duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
763,pain_int,chappell 2009: 2,"duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,post_int,NA,5.54,2.29,0.2099239558194604,NA,NA,NA,NA,NA,119,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
764,pain_int,chappell 2009: 2,"duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,post_int,NA,4.64,2.32,0.22324210408665526,NA,NA,NA,NA,NA,108,NA,NA,FALSE,NA,NA,duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
773,sleep,chappell 2009: 2,"duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,bpi sleep,baseline,NA,4.16,2.98,0.27433123613370036,NA,NA,NA,NA,NA,118,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
774,sleep,chappell 2009: 2,"duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,bpi sleep,baseline,NA,4.23,2.91,0.2853489766260578,NA,NA,NA,NA,NA,104,NA,NA,FALSE,NA,NA,duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
775,sleep,chappell 2009: 2,"duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,bpi sleep,post_int,NA,2.59,2.52,0.2319848037103775,NA,NA,NA,NA,NA,118,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
776,sleep,chappell 2009: 2,"duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,bpi sleep,post_int,NA,2.05,2.56,0.2510286529768756,NA,NA,NA,NA,NA,104,NA,NA,FALSE,NA,NA,duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
777,qol,chappell 2009: 2,"duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,eq-5d,baseline,NA,0.7,0.16,0.014985372985307104,NA,NA,NA,NA,NA,114,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
778,qol,chappell 2009: 2,"duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,eq-5d,baseline,NA,0.68,0.18,0.017735927006957277,NA,NA,NA,NA,NA,103,NA,NA,FALSE,NA,NA,duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
779,qol,chappell 2009: 2,"duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,eq-5d,post_int,NA,0.77,0.15,0.01404878717372541,NA,NA,NA,NA,NA,114,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
780,qol,chappell 2009: 2,"duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,eq-5d,post_int,NA,0.82,0.14,0.013794609894300106,NA,NA,NA,NA,NA,103,NA,NA,FALSE,NA,NA,duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
781,mood,chappell 2009: 2,"duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,sf-36 mental component score,baseline,NA,56.58,10.38,0.976468261382174,NA,NA,NA,NA,NA,113,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
782,mood,chappell 2009: 2,"duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,sf-36 mental component score,baseline,NA,56.43,10.36,1.0208011321782078,NA,NA,NA,NA,NA,103,NA,NA,FALSE,NA,NA,duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
783,mood,chappell 2009: 2,"duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,sf-36 mental component score,change_score,NA,-1.03,9.34,0.8786332910702798,NA,NA,NA,NA,NA,113,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
784,mood,chappell 2009: 2,"duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,sf-36 mental component score,change_score,NA,1.06,8.84,0.8710310818972352,NA,NA,NA,NA,NA,103,NA,NA,TRUE,NA,NA,duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
785,physical,chappell 2009: 2,"duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,sf-36 physical component score,baseline,NA,30.57,8.13,0.7648060659958646,NA,NA,NA,NA,NA,113,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
786,physical,chappell 2009: 2,"duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,sf-36 physical component score,baseline,NA,31.56,8.9,0.8769430575662209,NA,NA,NA,NA,NA,103,NA,NA,FALSE,NA,NA,duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
787,physical,chappell 2009: 2,"duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,sf-36 physical component score,change_score,NA,6.36,9.24,0.8692260823864438,NA,NA,NA,NA,NA,113,NA,NA,TRUE,NA,NA,NA,2021-09-27,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
788,physical,chappell 2009: 2,"duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,sf-36 physical component score,change_score,NA,7.71,8.61,0.8483685084994563,NA,NA,NA,NA,NA,103,NA,NA,TRUE,NA,NA,duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
789,pain_mod,chappell 2009: 2,"duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,120,53,0.445,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
790,pain_mod,chappell 2009: 2,"duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,111,64,0.593,FALSE,NA,NA,duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
791,pain_sub,chappell 2009: 2,"duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,120,35,0.294,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
792,pain_sub,chappell 2009: 2,"duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,111,52,0.47200000000000003,FALSE,NA,NA,duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
793,adverse,chappell 2009: 2,"duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,120,49,0.408,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
794,adverse,chappell 2009: 2,"duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,111,55,0.495,FALSE,NA,NA,duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
795,serious_adverse,chappell 2009: 2,"duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,118,2,0.017,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
796,serious_adverse,chappell 2009: 2,"duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,111,1,0.009000000000000001,FALSE,NA,NA,duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
797,adverse_dropout,chappell 2009: 2,"duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,120,5,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
798,adverse_dropout,chappell 2009: 2,"duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,111,9,NA,FALSE,NA,NA,duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
799,withdrawal,chappell 2009: 2,"duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,120,24,0.2,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
800,withdrawal,chappell 2009: 2,"duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,111,34,0.306,FALSE,NA,NA,duloxetine group is formed of 2 groups that were reported together: 1) 60mg 2) 120mg,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
801,pain_int,chappell 2011,"a double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.1,1.3,0.11490485194281397,NA,NA,NA,NA,NA,128,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
802,pain_int,chappell 2011,"a double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.1,1.4,0.1237436867076458,NA,NA,NA,NA,NA,128,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
803,pain_int,chappell 2011,"a double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-1.72,2.0364675298172568,0.18,NA,NA,NA,NA,NA,128,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
804,pain_int,chappell 2011,"a double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-2.51,2.2627416997969525,0.2,NA,NA,NA,NA,NA,128,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
805,physical,chappell 2011,"a double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,sf-36 physical component score,change_score,NA,4.41,9.164103884177656,0.81,NA,NA,NA,NA,NA,128,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
806,physical,chappell 2011,"a double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,sf-36 physical component score,change_score,NA,7.82,9.616652224137047,0.85,NA,NA,NA,NA,NA,128,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
807,pain_mod,chappell 2011,"a double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,count,baseline,NA,NA,NA,NA,NA,NA,NA,NA,NA,128,58,0.452,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,baseline
808,pain_mod,chappell 2011,"a double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,count,baseline,NA,NA,NA,NA,NA,NA,NA,NA,NA,128,79,0.621,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,baseline
809,pain_sub,chappell 2011,"a double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,128,28,0.222,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
810,pain_sub,chappell 2011,"a double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,128,49,0.379,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
811,adverse,chappell 2011,"a double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,128,42,0.32799999999999996,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
812,adverse,chappell 2011,"a double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,128,65,0.508,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
813,serious_adverse,chappell 2011,"a double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,125,2,0.016,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
814,serious_adverse,chappell 2011,"a double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,130,3,0.023,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
815,adverse_dropout,chappell 2011,"a double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,128,7,0.055,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
816,adverse_dropout,chappell 2011,"a double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,128,24,0.188,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
817,withdrawal,chappell 2011,"a double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,128,17,0.133,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
818,withdrawal,chappell 2011,"a double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,128,35,0.273,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
819,pain_int,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-100 vas,baseline,NA,65.7,13.3,0.6641703053537666,NA,NA,NA,NA,NA,401,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
820,pain_int,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-100 vas,baseline,NA,64.6,13.5,0.6758453353343745,NA,NA,NA,NA,NA,399,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
821,pain_int,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-100 vas,baseline,NA,64.5,13.8,0.6934760925288563,NA,NA,NA,NA,NA,396,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
822,pain_int,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-100 vas,change_score,NA,-13,20.024984394500787,1,NA,NA,NA,NA,NA,401,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
823,pain_int,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-100 vas,change_score,NA,-15.7,21.917344729688406,1.1,NA,NA,NA,NA,NA,397,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
824,pain_int,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-100 vas,change_score,NA,-17.4,21.806650361758912,1.1,NA,NA,NA,NA,NA,393,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
825,physical,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 physical component score,baseline,NA,32.1,7.4,0.3695383653848025,NA,NA,NA,NA,NA,401,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
826,physical,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 physical component score,baseline,NA,31.9,7.5,0.37546963074131917,NA,NA,NA,NA,NA,399,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
827,physical,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 physical component score,baseline,NA,32.4,7.3,0.3668388025696124,NA,NA,NA,NA,NA,396,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
828,physical,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 physical component score,change_score,NA,2.3,8.009993757800315,0.4,NA,NA,NA,NA,NA,401,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
829,physical,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 physical component score,change_score,NA,3.7,7.96994353806851,0.4,NA,NA,NA,NA,NA,397,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
830,physical,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 physical component score,change_score,NA,2.9,7.929691040639604,0.4,NA,NA,NA,NA,NA,393,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
831,mood,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 mental component score,baseline,NA,41.6,11.7,0.584270118243539,NA,NA,NA,NA,NA,401,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
832,mood,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 mental component score,baseline,NA,42.9,11.5,0.5757201004700228,NA,NA,NA,NA,NA,399,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
833,mood,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 mental component score,baseline,NA,40.7,11.3,0.5678463656214549,NA,NA,NA,NA,NA,396,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
834,mood,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 mental component score,change_score,NA,2.1,12.014990636700473,0.6,NA,NA,NA,NA,NA,401,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
835,mood,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 mental component score,change_score,NA,2,11.954915307102764,0.6,NA,NA,NA,NA,NA,397,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
836,mood,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 mental component score,change_score,NA,4,11.894536560959406,0.6,NA,NA,NA,NA,NA,393,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
837,qol,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,fibromyalgia impact questionnaire total score,baseline,NA,62.5,14.1,0.7041203989088805,NA,NA,NA,NA,NA,401,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
838,qol,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,fibromyalgia impact questionnaire total score,baseline,NA,62.3,13.7,0.6858578588208096,NA,NA,NA,NA,NA,399,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
839,qol,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,fibromyalgia impact questionnaire total score,baseline,NA,61.9,14.1,0.7085516597577445,NA,NA,NA,NA,NA,396,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
840,qol,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,fibromyalgia impact questionnaire total score,change_score,NA,-12,20.024984394500787,1,NA,NA,NA,NA,NA,401,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
841,qol,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,fibromyalgia impact questionnaire total score,change_score,NA,-16.6,19.974984355438178,1,NA,NA,NA,NA,NA,399,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
842,qol,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,fibromyalgia impact questionnaire total score,change_score,NA,-15.4,19.8997487421324,1,NA,NA,NA,NA,NA,396,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
849,sleep,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,mos sleep problems index ii,change_score,NA,3,22.027482833950867,1.1,NA,NA,NA,NA,NA,401,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
850,sleep,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,mos sleep problems index ii,change_score,NA,1.7,21.944931077586006,1.1,NA,NA,NA,NA,NA,398,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
851,sleep,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,mos sleep problems index ii,change_score,NA,2.3,23.879698490558877,1.2,NA,NA,NA,NA,NA,396,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
852,adverse,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,401,317,0.7909999999999999,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
853,adverse,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,399,358,0.897,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
854,adverse,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,396,346,0.8740000000000001,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
855,serious_adverse,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,400,6,0.015,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
856,serious_adverse,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,385,5,0.013000000000000001,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
857,serious_adverse,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,400,4,0.01,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
858,adverse_dropout,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,405,38,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
859,adverse_dropout,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,401,78,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
860,adverse_dropout,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,401,94,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
861,withdrawal,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,405,115,0.284,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
862,withdrawal,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,401,137,0.342,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
863,withdrawal,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,401,144,0.359,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
864,pain_mod,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,401,115,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
865,pain_mod,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,399,149,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
866,pain_mod,clauw 2008,"milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,15 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,396,158,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
867,pain_int,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",psychotherapy,psychological therapy,non-pharmacological,psychotherapy,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,0-100 vas,baseline,NA,67.8,16.687375467700125,1.81,NA,NA,NA,NA,NA,85,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
868,pain_int,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",paroxetine,antidepressant,antidepressant,paroxetine 20mg,ssri,20mg,low,fixed,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,0-100 vas,baseline,NA,67.5,15.02326196270304,1.62,NA,NA,NA,NA,NA,86,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
869,pain_int,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",usual treatment,usual treatment,non-pharmacological,usual treatment,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,0-100 vas,baseline,NA,66.7,16.043359997207567,1.73,NA,NA,NA,NA,NA,86,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
870,pain_int,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",psychotherapy,psychological therapy,non-pharmacological,psychotherapy,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,0-100 vas,change_score,NA,-16.1,28.387673381240667,3.3,NA,NA,NA,NA,NA,74,NA,NA,TRUE,NA,NA,NA,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
871,pain_int,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",paroxetine,antidepressant,antidepressant,paroxetine 20mg,ssri,20mg,low,fixed,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,0-100 vas,change_score,NA,-20.6,30.194161687319617,3.51,NA,NA,NA,NA,NA,74,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
872,pain_int,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",usual treatment,usual treatment,non-pharmacological,usual treatment,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,0-100 vas,change_score,NA,-11.4,27.375638805332013,3.08,NA,NA,NA,NA,NA,79,NA,NA,TRUE,NA,NA,NA,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
873,pain_int,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",psychotherapy,psychological therapy,non-pharmacological,psychotherapy,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,0-100 vas,change_score,1 year,-15,30.122748878546922,3.55,NA,NA,NA,NA,NA,72,NA,NA,TRUE,NA,NA,NA,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,follow_up
874,pain_int,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",paroxetine,antidepressant,antidepressant,paroxetine 20mg,ssri,20mg,low,fixed,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,0-100 vas,change_score,1 year,-16.3,28.971178781678873,3.18,NA,NA,NA,NA,NA,83,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,follow_up
875,pain_int,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",usual treatment,usual treatment,non-pharmacological,usual treatment,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,0-100 vas,change_score,1 year,-15.6,27.99213639578087,3.19,NA,NA,NA,NA,NA,77,NA,NA,TRUE,NA,NA,NA,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,follow_up
876,physical,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",psychotherapy,psychological therapy,non-pharmacological,psychotherapy,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,sf-36 physical component score,baseline,NA,38.2,9.417600543662914,1.04,NA,NA,NA,NA,NA,82,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
877,physical,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",paroxetine,antidepressant,antidepressant,paroxetine 20mg,ssri,20mg,low,fixed,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,sf-36 physical component score,baseline,NA,36.7,11.296937638138932,1.24,NA,NA,NA,NA,NA,83,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
878,physical,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",usual treatment,usual treatment,non-pharmacological,usual treatment,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,sf-36 physical component score,baseline,NA,38.3,11.16,1.24,NA,NA,NA,NA,NA,81,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
879,physical,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",psychotherapy,psychological therapy,non-pharmacological,psychotherapy,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,sf-36 physical component score,change_score,NA,2.2,6.930353526336157,0.91,NA,NA,NA,NA,NA,58,NA,NA,TRUE,NA,NA,NA,NA,NA,non_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
880,physical,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",paroxetine,antidepressant,antidepressant,paroxetine 20mg,ssri,20mg,low,fixed,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,sf-36 physical component score,change_score,NA,2.4,10.21592384466525,1.33,NA,NA,NA,NA,NA,59,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
881,physical,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",usual treatment,usual treatment,non-pharmacological,usual treatment,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,sf-36 physical component score,change_score,NA,-0.5,6.98478346121052,0.88,NA,NA,NA,NA,NA,63,NA,NA,TRUE,NA,NA,NA,NA,NA,non_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
882,physical,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",psychotherapy,psychological therapy,non-pharmacological,psychotherapy,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,sf-36 physical component score,change_score,1 year,5.2,9.678243642314445,1.26,NA,NA,NA,NA,NA,59,NA,NA,TRUE,NA,NA,NA,NA,NA,non_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,follow_up
883,physical,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",paroxetine,antidepressant,antidepressant,paroxetine 20mg,ssri,20mg,low,fixed,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,sf-36 physical component score,change_score,1 year,5.8,8.48528137423857,1,NA,NA,NA,NA,NA,72,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,follow_up
884,physical,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",usual treatment,usual treatment,non-pharmacological,usual treatment,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,sf-36 physical component score,change_score,1 year,-0.3,9.137992120810784,1.17,NA,NA,NA,NA,NA,61,NA,NA,TRUE,NA,NA,NA,NA,NA,non_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,follow_up
885,mood,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",psychotherapy,psychological therapy,non-pharmacological,psychotherapy,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,sf-36 mental component score,baseline,NA,39.9,13.22086230168063,1.46,NA,NA,NA,NA,NA,82,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
886,mood,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",paroxetine,antidepressant,antidepressant,paroxetine 20mg,ssri,20mg,low,fixed,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,sf-36 mental component score,baseline,NA,41,12.390189667636248,1.36,NA,NA,NA,NA,NA,83,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
887,mood,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",usual treatment,usual treatment,non-pharmacological,usual treatment,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,sf-36 mental component score,baseline,NA,40.6,12.78,1.42,NA,NA,NA,NA,NA,81,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
888,mood,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",psychotherapy,psychological therapy,non-pharmacological,psychotherapy,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,sf-36 mental component score,change_score,NA,5.4,12.794498817851366,1.68,NA,NA,NA,NA,NA,58,NA,NA,TRUE,NA,NA,NA,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
889,mood,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",paroxetine,antidepressant,antidepressant,paroxetine 20mg,ssri,20mg,low,fixed,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,sf-36 mental component score,change_score,NA,3.7,13.442005058770064,1.75,NA,NA,NA,NA,NA,59,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
890,mood,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",usual treatment,usual treatment,non-pharmacological,usual treatment,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,sf-36 mental component score,change_score,NA,-0.5,12.699606293110037,1.6,NA,NA,NA,NA,NA,63,NA,NA,TRUE,NA,NA,NA,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
891,mood,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",psychotherapy,psychological therapy,non-pharmacological,psychotherapy,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,sf-36 mental component score,change_score,1 year,1.9,13.057947771376632,1.7,NA,NA,NA,NA,NA,59,NA,NA,TRUE,NA,NA,NA,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_overall,follow_up
892,mood,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",paroxetine,antidepressant,antidepressant,paroxetine 20mg,ssri,20mg,low,fixed,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,sf-36 mental component score,change_score,1 year,2.2,13.152186130069783,1.55,NA,NA,NA,NA,NA,72,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,follow_up
893,mood,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",usual treatment,usual treatment,non-pharmacological,usual treatment,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,sf-36 mental component score,change_score,1 year,3.8,12.262091991173447,1.57,NA,NA,NA,NA,NA,61,NA,NA,TRUE,NA,NA,NA,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_overall,follow_up
894,withdrawal,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",psychotherapy,psychological therapy,non-pharmacological,psychotherapy,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,44,26,0.6,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
895,withdrawal,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",paroxetine,antidepressant,antidepressant,paroxetine 20mg,ssri,20mg,low,fixed,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,49,32,0.66,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
896,withdrawal,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",usual treatment,usual treatment,non-pharmacological,usual treatment,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,11,0.38,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
897,withdrawal,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",psychotherapy,psychological therapy,non-pharmacological,psychotherapy,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,count,follow_up,1 year,NA,NA,NA,NA,NA,NA,NA,NA,46,29,0.622,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,follow_up
898,withdrawal,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",paroxetine,antidepressant,antidepressant,paroxetine 20mg,ssri,20mg,low,fixed,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,count,follow_up,1 year,NA,NA,NA,NA,NA,NA,NA,NA,48,27,0.5710000000000001,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,follow_up
899,withdrawal,creed 2003,psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowl syndrome,"interpersonal problems, ibs symptoms, hrqol",usual treatment,usual treatment,non-pharmacological,usual treatment,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥59 on 100vas,parallel,itt unspecified method,count,follow_up,1 year,NA,NA,NA,NA,NA,NA,NA,NA,40,21,0.513,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,follow_up
900,pain_int,dezanette 2014,"melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase ii, randomized, double-dummy, controlled trial",pain,melatonin,hormone,non-antidepressant pharmacological,melatonin 10mg,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt unspecified method,0-100 vas,baseline,NA,64.9,15.44,3.3692842252437223,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
901,pain_int,dezanette 2014,"melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase ii, randomized, double-dummy, controlled trial",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt unspecified method,0-100 vas,baseline,NA,62.88,14.26,3.1117871147652516,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
902,pain_int,dezanette 2014,"melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase ii, randomized, double-dummy, controlled trial",pain,melatonin + amitriptyline,combined antidepressant intervention,antidepressant,melatonin + amitriptyline,tca,25mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt unspecified method,0-100 vas,baseline,NA,69.57,10.94,2.3873037191817565,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
903,pain_int,dezanette 2014,"melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase ii, randomized, double-dummy, controlled trial",pain,melatonin,hormone,non-antidepressant pharmacological,melatonin 10mg,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt unspecified method,0-100 vas,post_int,NA,47.53,21.96,4.792064869582393,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
904,pain_int,dezanette 2014,"melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase ii, randomized, double-dummy, controlled trial",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt unspecified method,0-100 vas,post_int,NA,50.02,25.6,5.586377990041406,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
905,pain_int,dezanette 2014,"melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase ii, randomized, double-dummy, controlled trial",pain,melatonin + amitriptyline,combined antidepressant intervention,antidepressant,melatonin + amitriptyline,tca,25mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt unspecified method,0-100 vas,post_int,NA,48.64,15.38,3.356191151829563,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
906,qol,dezanette 2014,"melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase ii, randomized, double-dummy, controlled trial",pain,melatonin,hormone,non-antidepressant pharmacological,melatonin 10mg,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt unspecified method,fibromyalgia impact questionnaire total score,baseline,NA,64.87,12.83,2.7997355317277823,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
907,qol,dezanette 2014,"melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase ii, randomized, double-dummy, controlled trial",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt unspecified method,fibromyalgia impact questionnaire total score,baseline,NA,53.78,12.83,2.7997355317277823,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
908,qol,dezanette 2014,"melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase ii, randomized, double-dummy, controlled trial",pain,melatonin + amitriptyline,combined antidepressant intervention,antidepressant,melatonin + amitriptyline,tca,25mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt unspecified method,fibromyalgia impact questionnaire total score,baseline,NA,65.15,9.94,2.1690858289457644,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
909,qol,dezanette 2014,"melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase ii, randomized, double-dummy, controlled trial",pain,melatonin,hormone,non-antidepressant pharmacological,melatonin 10mg,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt unspecified method,fibromyalgia impact questionnaire total score,post_int,NA,46.42,16.18,3.530765464018357,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
910,qol,dezanette 2014,"melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase ii, randomized, double-dummy, controlled trial",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt unspecified method,fibromyalgia impact questionnaire total score,post_int,NA,41.16,14.61,3.1881633763478487,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
911,qol,dezanette 2014,"melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase ii, randomized, double-dummy, controlled trial",pain,melatonin + amitriptyline,combined antidepressant intervention,antidepressant,melatonin + amitriptyline,tca,25mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt unspecified method,fibromyalgia impact questionnaire total score,post_int,NA,40.89,10.94,2.3873037191817565,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
912,sleep,dezanette 2014,"melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase ii, randomized, double-dummy, controlled trial",pain,melatonin,hormone,non-antidepressant pharmacological,melatonin 10mg,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt unspecified method,pittsburgh sleep quality index,baseline,NA,22.67,7.69,1.6780955759147815,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
913,sleep,dezanette 2014,"melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase ii, randomized, double-dummy, controlled trial",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt unspecified method,pittsburgh sleep quality index,baseline,NA,19.31,6.58,1.43587371775283,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
914,sleep,dezanette 2014,"melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase ii, randomized, double-dummy, controlled trial",pain,melatonin + amitriptyline,combined antidepressant intervention,antidepressant,melatonin + amitriptyline,tca,25mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt unspecified method,pittsburgh sleep quality index,baseline,NA,24.28,7.79,1.6999173649383807,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
915,sleep,dezanette 2014,"melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase ii, randomized, double-dummy, controlled trial",pain,melatonin,hormone,non-antidepressant pharmacological,melatonin 10mg,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt unspecified method,pittsburgh sleep quality index,post_int,NA,16.68,8.38,1.8286659201776163,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
916,sleep,dezanette 2014,"melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase ii, randomized, double-dummy, controlled trial",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt unspecified method,pittsburgh sleep quality index,post_int,NA,11.84,5.82,1.2700281211734759,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
917,sleep,dezanette 2014,"melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase ii, randomized, double-dummy, controlled trial",pain,melatonin + amitriptyline,combined antidepressant intervention,antidepressant,melatonin + amitriptyline,tca,25mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt unspecified method,pittsburgh sleep quality index,post_int,NA,16.11,8.4,1.8330302779823362,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
918,adverse,dezanette 2014,"melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase ii, randomized, double-dummy, controlled trial",pain,melatonin,hormone,non-antidepressant pharmacological,melatonin 10mg,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,10,NA,FALSE,NA,NA,"combined mild and major, serious adverse events not reported",NA,NA,non_ad_pharm,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
919,adverse,dezanette 2014,"melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase ii, randomized, double-dummy, controlled trial",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,18,NA,FALSE,NA,NA,"combined mild and major, serious adverse events not reported",NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
920,adverse,dezanette 2014,"melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase ii, randomized, double-dummy, controlled trial",pain,melatonin + amitriptyline,combined antidepressant intervention,antidepressant,melatonin + amitriptyline,tca,25mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,9,NA,FALSE,NA,NA,"combined mild and major, serious adverse events not reported",NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
921,adverse_dropout,dezanette 2014,"melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase ii, randomized, double-dummy, controlled trial",pain,melatonin,hormone,non-antidepressant pharmacological,melatonin 10mg,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,2,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
922,adverse_dropout,dezanette 2014,"melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase ii, randomized, double-dummy, controlled trial",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,2,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
923,adverse_dropout,dezanette 2014,"melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase ii, randomized, double-dummy, controlled trial",pain,melatonin + amitriptyline,combined antidepressant intervention,antidepressant,melatonin + amitriptyline,tca,25mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,2,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
924,withdrawal,dezanette 2014,"melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase ii, randomized, double-dummy, controlled trial",pain,melatonin,hormone,non-antidepressant pharmacological,melatonin 10mg,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,2,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
925,withdrawal,dezanette 2014,"melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase ii, randomized, double-dummy, controlled trial",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,2,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
926,withdrawal,dezanette 2014,"melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase ii, randomized, double-dummy, controlled trial",pain,melatonin + amitriptyline,combined antidepressant intervention,antidepressant,melatonin + amitriptyline,tca,25mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,2,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
927,pain_int,dickens 2000,the relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain,mood and pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt with locf,0-100 vas,baseline,NA,56.1,21.4,3.088823940164498,NA,NA,NA,NA,NA,48,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
928,pain_int,dickens 2000,the relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain,mood and pain,paroxetine,antidepressant,antidepressant,paroxetine 20mg,ssri,20mg,low,fixed,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt with locf,0-100 vas,baseline,NA,55.1,22.8,3.4372293281865054,NA,NA,NA,NA,NA,44,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
929,pain_int,dickens 2000,the relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain,mood and pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt with locf,0-100 vas,post_int,NA,57,24.3,3.507402885326977,NA,NA,NA,NA,NA,48,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
930,pain_int,dickens 2000,the relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain,mood and pain,paroxetine,antidepressant,antidepressant,paroxetine 20mg,ssri,20mg,low,fixed,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt with locf,0-100 vas,post_int,NA,57,23.8,3.587985000475387,NA,NA,NA,NA,NA,44,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
931,physical,dickens 2000,the relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain,mood and pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt with locf,oswestry disability index,baseline,NA,54.7,10.3,1.4866769431632865,NA,NA,NA,NA,NA,48,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
932,physical,dickens 2000,the relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain,mood and pain,paroxetine,antidepressant,antidepressant,paroxetine 20mg,ssri,20mg,low,fixed,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt with locf,oswestry disability index,baseline,NA,54.2,13.7,2.0653527103576805,NA,NA,NA,NA,NA,44,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
933,physical,dickens 2000,the relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain,mood and pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt with locf,oswestry disability index,post_int,NA,52.4,13.6,1.9629909152447276,NA,NA,NA,NA,NA,48,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
934,physical,dickens 2000,the relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain,mood and pain,paroxetine,antidepressant,antidepressant,paroxetine 20mg,ssri,20mg,low,fixed,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt with locf,oswestry disability index,post_int,NA,50.2,15.2,2.2914862187910034,NA,NA,NA,NA,NA,44,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
935,mood,dickens 2000,the relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain,mood and pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt with locf,madrs,baseline,NA,26.2,5.8,0.8371578903249574,NA,NA,NA,NA,NA,48,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
936,mood,dickens 2000,the relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain,mood and pain,paroxetine,antidepressant,antidepressant,paroxetine 20mg,ssri,20mg,low,fixed,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt with locf,madrs,baseline,NA,28.4,5.3,0.7990050631310736,NA,NA,NA,NA,NA,44,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
937,mood,dickens 2000,the relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain,mood and pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt with locf,madrs,post_int,NA,23.3,9,1.299038105676658,NA,NA,NA,NA,NA,48,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
938,mood,dickens 2000,the relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain,mood and pain,paroxetine,antidepressant,antidepressant,paroxetine 20mg,ssri,20mg,low,fixed,8 weeks,low back pain,musculoskeletal,primary,no,parallel,itt with locf,madrs,post_int,NA,23.2,8.3,1.251272079997719,NA,NA,NA,NA,NA,44,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
939,pain_int,drossman 2003,cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,bowel disorder symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,functional bowel disorders,gastrointestinal,primary,no,parallel,itt unspecified method,mcgill pain questionnaire pain rating index,baseline,NA,12.2,8.5,1.0017346066809425,NA,NA,NA,NA,NA,72,NA,NA,FALSE,NA,NA,the study authors calculated nnt: nnt is 8.1 for des and 3.1 for cb,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
940,pain_int,drossman 2003,cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,bowel disorder symptoms,desipramine,antidepressant,antidepressant,desipramine 150mg,tca,150mg,standard,fixed,12 weeks,functional bowel disorders,gastrointestinal,primary,no,parallel,itt unspecified method,mcgill pain questionnaire pain rating index,baseline,NA,13.5,10.2,0.85,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,the study authors calculated nnt: nnt is 8.1 for des and 3.1 for cb,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
941,pain_int,drossman 2003,cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,bowel disorder symptoms,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioural therapy,n/a,n/a,n/a,n/a,12 weeks,functional bowel disorders,gastrointestinal,primary,no,parallel,itt unspecified method,mcgill pain questionnaire pain rating index,baseline,NA,14.1,10.3,0.8583333333333334,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,the study authors calculated nnt: nnt is 8.1 for des and 3.1 for cb,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
942,pain_int,drossman 2003,cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,bowel disorder symptoms,education,education,non-pharmacological,education,n/a,n/a,n/a,n/a,12 weeks,functional bowel disorders,gastrointestinal,primary,no,parallel,itt unspecified method,mcgill pain questionnaire pain rating index,baseline,NA,12.9,9.4,1.1155747587022222,NA,NA,NA,NA,NA,71,NA,NA,FALSE,NA,NA,the study authors calculated nnt: nnt is 8.1 for des and 3.1 for cb,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
943,pain_int,drossman 2003,cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,bowel disorder symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,functional bowel disorders,gastrointestinal,primary,no,parallel,itt unspecified method,mcgill pain questionnaire pain rating index,post_int,NA,10.73,6.742951875847847,0.83,NA,NA,NA,NA,NA,66,NA,NA,FALSE,NA,there's a footnote at the bottom of this table that says that these values are adjusted for baseline,the study authors calculated nnt: nnt is 8.1 for des and 3.1 for cb,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
944,pain_int,drossman 2003,cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,bowel disorder symptoms,desipramine,antidepressant,antidepressant,desipramine 150mg,tca,150mg,standard,fixed,12 weeks,functional bowel disorders,gastrointestinal,primary,no,parallel,itt unspecified method,mcgill pain questionnaire pain rating index,post_int,NA,8.94,7.203749023945795,0.62,NA,NA,NA,NA,NA,135,NA,NA,FALSE,NA,there's a footnote at the bottom of this table that says that these values are adjusted for baseline,the study authors calculated nnt: nnt is 8.1 for des and 3.1 for cb,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
945,pain_int,drossman 2003,cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,bowel disorder symptoms,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioural therapy,n/a,n/a,n/a,n/a,12 weeks,functional bowel disorders,gastrointestinal,primary,no,parallel,itt unspecified method,mcgill pain questionnaire pain rating index,post_int,NA,9.52,6.274233020856015,0.54,NA,NA,NA,NA,NA,135,NA,NA,FALSE,NA,there's a footnote at the bottom of this table that says that these values are adjusted for baseline,the study authors calculated nnt: nnt is 8.1 for des and 3.1 for cb,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
946,pain_int,drossman 2003,cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,bowel disorder symptoms,education,education,non-pharmacological,education,n/a,n/a,n/a,n/a,12 weeks,functional bowel disorders,gastrointestinal,primary,no,parallel,itt unspecified method,mcgill pain questionnaire pain rating index,post_int,NA,10.13,7.230394180126005,0.89,NA,NA,NA,NA,NA,66,NA,NA,FALSE,NA,there's a footnote at the bottom of this table that says that these values are adjusted for baseline,the study authors calculated nnt: nnt is 8.1 for des and 3.1 for cb,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
947,qol,drossman 2003,cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,bowel disorder symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,functional bowel disorders,gastrointestinal,primary,no,parallel,itt unspecified method,ibs-qol,baseline,NA,64.3,20.4,2.4041630560342617,NA,NA,NA,NA,NA,72,NA,NA,FALSE,NA,NA,the study authors calculated nnt: nnt is 8.1 for des and 3.1 for cb,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
948,qol,drossman 2003,cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,bowel disorder symptoms,desipramine,antidepressant,antidepressant,desipramine 150mg,tca,150mg,standard,fixed,12 weeks,functional bowel disorders,gastrointestinal,primary,no,parallel,itt unspecified method,ibs-qol,baseline,NA,62.8,20.4,1.7,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,the study authors calculated nnt: nnt is 8.1 for des and 3.1 for cb,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
949,qol,drossman 2003,cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,bowel disorder symptoms,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioural therapy,n/a,n/a,n/a,n/a,12 weeks,functional bowel disorders,gastrointestinal,primary,no,parallel,itt unspecified method,ibs-qol,baseline,NA,67.2,20.7,1.7249999999999999,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,the study authors calculated nnt: nnt is 8.1 for des and 3.1 for cb,NA,NA,non_pharm,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
950,qol,drossman 2003,cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,bowel disorder symptoms,education,education,non-pharmacological,education,n/a,n/a,n/a,n/a,12 weeks,functional bowel disorders,gastrointestinal,primary,no,parallel,itt unspecified method,ibs-qol,baseline,NA,68.8,18.8,2.2311495174044444,NA,NA,NA,NA,NA,71,NA,NA,FALSE,NA,NA,the study authors calculated nnt: nnt is 8.1 for des and 3.1 for cb,NA,NA,non_pharm,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
951,qol,drossman 2003,cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,bowel disorder symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,functional bowel disorders,gastrointestinal,primary,no,parallel,itt unspecified method,ibs-qol,post_int,NA,72.02,16.32931719331828,2.01,NA,NA,NA,NA,NA,66,NA,NA,FALSE,NA,there's a footnote at the bottom of this table that says that these values are adjusted for baseline,the study authors calculated nnt: nnt is 8.1 for des and 3.1 for cb,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
952,qol,drossman 2003,cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,bowel disorder symptoms,desipramine,antidepressant,antidepressant,desipramine 150mg,tca,150mg,standard,fixed,12 weeks,functional bowel disorders,gastrointestinal,primary,no,parallel,itt unspecified method,ibs-qol,post_int,NA,76.31,17.079856556774708,1.47,NA,NA,NA,NA,NA,135,NA,NA,FALSE,NA,there's a footnote at the bottom of this table that says that these values are adjusted for baseline,the study authors calculated nnt: nnt is 8.1 for des and 3.1 for cb,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
953,qol,drossman 2003,cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,bowel disorder symptoms,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioural therapy,n/a,n/a,n/a,n/a,12 weeks,functional bowel disorders,gastrointestinal,primary,no,parallel,itt unspecified method,ibs-qol,post_int,NA,76.55,13.47798204480181,1.16,NA,NA,NA,NA,NA,135,NA,NA,FALSE,NA,there's a footnote at the bottom of this table that says that these values are adjusted for baseline,the study authors calculated nnt: nnt is 8.1 for des and 3.1 for cb,NA,NA,non_pharm,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
954,qol,drossman 2003,cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,bowel disorder symptoms,education,education,non-pharmacological,education,n/a,n/a,n/a,n/a,12 weeks,functional bowel disorders,gastrointestinal,primary,no,parallel,itt unspecified method,ibs-qol,post_int,NA,73.6,13.973346055973852,1.72,NA,NA,NA,NA,NA,66,NA,NA,FALSE,NA,there's a footnote at the bottom of this table that says that these values are adjusted for baseline,the study authors calculated nnt: nnt is 8.1 for des and 3.1 for cb,NA,NA,non_pharm,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
955,withdrawal,drossman 2003,cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,bowel disorder symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,functional bowel disorders,gastrointestinal,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,72,16,NA,FALSE,NA,NA,the study authors calculated nnt: nnt is 8.1 for des and 3.1 for cb,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
956,withdrawal,drossman 2003,cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,bowel disorder symptoms,desipramine,antidepressant,antidepressant,desipramine 150mg,tca,150mg,standard,fixed,12 weeks,functional bowel disorders,gastrointestinal,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,144,49,NA,FALSE,NA,NA,the study authors calculated nnt: nnt is 8.1 for des and 3.1 for cb,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
957,withdrawal,drossman 2003,cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,bowel disorder symptoms,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioural therapy,n/a,n/a,n/a,n/a,12 weeks,functional bowel disorders,gastrointestinal,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,144,33,NA,FALSE,NA,NA,the study authors calculated nnt: nnt is 8.1 for des and 3.1 for cb,NA,NA,non_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
958,withdrawal,drossman 2003,cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,bowel disorder symptoms,education,education,non-pharmacological,education,n/a,n/a,n/a,n/a,12 weeks,functional bowel disorders,gastrointestinal,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,71,25,NA,FALSE,NA,NA,the study authors calculated nnt: nnt is 8.1 for des and 3.1 for cb,NA,NA,non_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
959,adverse_dropout,drossman 2003,cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,bowel disorder symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,functional bowel disorders,gastrointestinal,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,72,3,NA,FALSE,NA,NA,the study authors calculated nnt: nnt is 8.1 for des and 3.1 for cb,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
960,adverse_dropout,drossman 2003,cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,bowel disorder symptoms,desipramine,antidepressant,antidepressant,desipramine 150mg,tca,150mg,standard,fixed,12 weeks,functional bowel disorders,gastrointestinal,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,144,23,NA,FALSE,NA,NA,the study authors calculated nnt: nnt is 8.1 for des and 3.1 for cb,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
961,adverse_dropout,drossman 2003,cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,bowel disorder symptoms,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioural therapy,n/a,n/a,n/a,n/a,12 weeks,functional bowel disorders,gastrointestinal,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,144,0,NA,FALSE,NA,NA,the study authors calculated nnt: nnt is 8.1 for des and 3.1 for cb,NA,NA,non_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
962,adverse_dropout,drossman 2003,cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders,bowel disorder symptoms,education,education,non-pharmacological,education,n/a,n/a,n/a,n/a,12 weeks,functional bowel disorders,gastrointestinal,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,71,0,NA,FALSE,NA,NA,the study authors calculated nnt: nnt is 8.1 for des and 3.1 for cb,NA,NA,non_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
963,pain_int,eberhard 1988,a double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes,pain,maprotiline,antidepressant,antidepressant,maprotiline 25-150mg,teca,100mg,low,flexible,6 weeks,idiopathic pain syndrome,primary,primary,no,parallel,completer analysis,0-100 numerical rating scale,baseline,NA,73.8,16.9,3.38,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
964,pain_int,eberhard 1988,a double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes,pain,clomipramine,antidepressant,antidepressant,clomipramine 25-150mg,tca,97.2mg,standard,flexible,6 weeks,idiopathic pain syndrome,primary,primary,no,parallel,completer analysis,0-100 numerical rating scale,baseline,NA,68.9,22.7,4.368617036868168,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
965,pain_int,eberhard 1988,a double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes,pain,maprotiline,antidepressant,antidepressant,maprotiline 25-150mg,teca,100mg,low,flexible,6 weeks,idiopathic pain syndrome,primary,primary,no,parallel,completer analysis,0-100 numerical rating scale,post_int,NA,62,26.2,5.24,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
966,pain_int,eberhard 1988,a double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes,pain,clomipramine,antidepressant,antidepressant,clomipramine 25-150mg,tca,97.2mg,standard,flexible,6 weeks,idiopathic pain syndrome,primary,primary,no,parallel,completer analysis,0-100 numerical rating scale,post_int,NA,45.4,29,5.581052602166382,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
967,mood,eberhard 1988,a double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes,pain,maprotiline,antidepressant,antidepressant,maprotiline 25-150mg,teca,100mg,low,flexible,6 weeks,idiopathic pain syndrome,primary,primary,no,parallel,completer analysis,0-100 numerical rating scale,baseline,NA,32.6,28.9,5.779999999999999,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,nrs measures sadness,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
968,mood,eberhard 1988,a double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes,pain,clomipramine,antidepressant,antidepressant,clomipramine 25-150mg,tca,97.2mg,standard,flexible,6 weeks,idiopathic pain syndrome,primary,primary,no,parallel,completer analysis,0-100 numerical rating scale,baseline,NA,37.4,34.6,6.658773104653684,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,nrs measures sadness,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
969,mood,eberhard 1988,a double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes,pain,maprotiline,antidepressant,antidepressant,maprotiline 25-150mg,teca,100mg,low,flexible,6 weeks,idiopathic pain syndrome,primary,primary,no,parallel,completer analysis,0-100 numerical rating scale,post_int,NA,31.4,27.4,5.4799999999999995,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,nrs measures sadness,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
970,mood,eberhard 1988,a double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes,pain,clomipramine,antidepressant,antidepressant,clomipramine 25-150mg,tca,97.2mg,standard,flexible,6 weeks,idiopathic pain syndrome,primary,primary,no,parallel,completer analysis,0-100 numerical rating scale,post_int,NA,23.4,26.7,5.138417395787669,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,nrs measures sadness,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
971,adverse_dropout,eberhard 1988,a double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes,pain,maprotiline,antidepressant,antidepressant,maprotiline 25-150mg,teca,100mg,low,flexible,6 weeks,idiopathic pain syndrome,primary,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,1,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
972,adverse_dropout,eberhard 1988,a double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes,pain,clomipramine,antidepressant,antidepressant,clomipramine 25-150mg,tca,97.2mg,standard,flexible,6 weeks,idiopathic pain syndrome,primary,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,8,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
973,withdrawal,eberhard 1988,a double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes,pain,maprotiline,antidepressant,antidepressant,maprotiline 25-150mg,teca,100mg,low,flexible,6 weeks,idiopathic pain syndrome,primary,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,5,NA,FALSE,NA,NA,NA,2021-09-27,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
974,withdrawal,eberhard 1988,a double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes,pain,clomipramine,antidepressant,antidepressant,clomipramine 25-150mg,tca,97.2mg,standard,flexible,6 weeks,idiopathic pain syndrome,primary,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,13,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
975,NA,engel 1998,"a randomized, double-blind crossover trial of sertraline in women with chronic pelvic pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,pelvic pain,musculoskeletal,primary,no,parallel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,placebo,NA,NA,NA,NA,NA,no_useable_data,NA
976,NA,engel 1998,"a randomized, double-blind crossover trial of sertraline in women with chronic pelvic pain",pain,sertraline,antidepressant,antidepressant,sertraline 100mg,ssri,100mg,high,fixed,6 weeks,pelvic pain,musculoskeletal,primary,no,parallel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,ad,NA,NA,NA,NA,NA,no_useable_data,NA
977,pain_int,enomoto 2018,"duloxetine in diabetic peripheral neuropathic pain in japan: a randomized, double-blind, noninferiority comparative study with pregabalin",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300-600mg,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,0-10 numerical rating scale,baseline,NA,5.35,1.13,0.09195809584114101,NA,NA,NA,NA,NA,151,NA,NA,FALSE,NA,NA,reference in covidence is nct 2015,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
978,pain_int,enomoto 2018,"duloxetine in diabetic peripheral neuropathic pain in japan: a randomized, double-blind, noninferiority comparative study with pregabalin",pain,duloxetine,antidepressant,antidepressant,duloxetine 40-60mg,snri,45.2mg,low,flexible,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,0-10 numerical rating scale,baseline,NA,5.38,1.08,0.08759956741061178,NA,NA,NA,NA,NA,152,NA,NA,FALSE,NA,NA,reference in covidence is nct 2015,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
979,pain_int,enomoto 2018,"duloxetine in diabetic peripheral neuropathic pain in japan: a randomized, double-blind, noninferiority comparative study with pregabalin",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300-600mg,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,0-10 numerical rating scale,change_score,NA,-2.36,1.5868522300453813,0.13,NA,NA,NA,NA,NA,149,NA,NA,TRUE,NA,NA,reference in covidence is nct 2015,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
980,pain_int,enomoto 2018,"duloxetine in diabetic peripheral neuropathic pain in japan: a randomized, double-blind, noninferiority comparative study with pregabalin",pain,duloxetine,antidepressant,antidepressant,duloxetine 40-60mg,snri,45.2mg,low,flexible,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,0-10 numerical rating scale,change_score,NA,-2.29,1.6027476407719339,0.13,NA,NA,NA,NA,NA,152,NA,NA,TRUE,NA,NA,reference in covidence is nct 2015,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
981,qol,enomoto 2018,"duloxetine in diabetic peripheral neuropathic pain in japan: a randomized, double-blind, noninferiority comparative study with pregabalin",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300-600mg,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,eq-5d,baseline,NA,0.73,0.09,0.007324096128940434,NA,NA,NA,NA,NA,151,NA,NA,FALSE,NA,NA,reference in covidence is nct 2015,NA,NA,non_ad_pharm,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
982,qol,enomoto 2018,"duloxetine in diabetic peripheral neuropathic pain in japan: a randomized, double-blind, noninferiority comparative study with pregabalin",pain,duloxetine,antidepressant,antidepressant,duloxetine 40-60mg,snri,45.2mg,low,flexible,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,eq-5d,baseline,NA,0.73,0.12,0.009733285267845752,NA,NA,NA,NA,NA,152,NA,NA,FALSE,NA,NA,reference in covidence is nct 2015,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
983,qol,enomoto 2018,"duloxetine in diabetic peripheral neuropathic pain in japan: a randomized, double-blind, noninferiority comparative study with pregabalin",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300-600mg,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,eq-5d,change_score,NA,0.1,0.12206555615733702,0.01,NA,NA,NA,NA,NA,149,NA,NA,TRUE,NA,NA,reference in covidence is nct 2015,NA,NA,non_ad_pharm,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
984,qol,enomoto 2018,"duloxetine in diabetic peripheral neuropathic pain in japan: a randomized, double-blind, noninferiority comparative study with pregabalin",pain,duloxetine,antidepressant,antidepressant,duloxetine 40-60mg,snri,45.2mg,low,flexible,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,eq-5d,change_score,NA,0.11,0.12328828005937953,0.01,NA,NA,NA,NA,NA,152,NA,NA,TRUE,NA,NA,reference in covidence is nct 2015,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
985,mood,enomoto 2018,"duloxetine in diabetic peripheral neuropathic pain in japan: a randomized, double-blind, noninferiority comparative study with pregabalin",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300-600mg,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,beck depression inventory,baseline,NA,6.2,5.41,0.44025955619519724,NA,NA,NA,NA,NA,151,NA,NA,FALSE,NA,NA,reference in covidence is nct 2015,NA,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
986,mood,enomoto 2018,"duloxetine in diabetic peripheral neuropathic pain in japan: a randomized, double-blind, noninferiority comparative study with pregabalin",pain,duloxetine,antidepressant,antidepressant,duloxetine 40-60mg,snri,45.2mg,low,flexible,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,beck depression inventory,baseline,NA,6.8,5.9,0.47855319233574956,NA,NA,NA,NA,NA,152,NA,NA,FALSE,NA,NA,reference in covidence is nct 2015,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
987,mood,enomoto 2018,"duloxetine in diabetic peripheral neuropathic pain in japan: a randomized, double-blind, noninferiority comparative study with pregabalin",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300-600mg,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,beck depression inventory,change_score,NA,-2.5,3.6619666847201104,0.3,NA,NA,NA,NA,NA,149,NA,NA,TRUE,NA,NA,reference in covidence is nct 2015,NA,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
988,mood,enomoto 2018,"duloxetine in diabetic peripheral neuropathic pain in japan: a randomized, double-blind, noninferiority comparative study with pregabalin",pain,duloxetine,antidepressant,antidepressant,duloxetine 40-60mg,snri,45.2mg,low,flexible,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,beck depression inventory,change_score,NA,-2.3,3.6986484017813854,0.3,NA,NA,NA,NA,NA,152,NA,NA,TRUE,NA,NA,reference in covidence is nct 2015,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
989,pain_mod,enomoto 2018,"duloxetine in diabetic peripheral neuropathic pain in japan: a randomized, double-blind, noninferiority comparative study with pregabalin",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300-600mg,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,151,94,0.631,FALSE,NA,NA,reference in covidence is nct 2015,NA,NA,non_ad_pharm,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
990,pain_mod,enomoto 2018,"duloxetine in diabetic peripheral neuropathic pain in japan: a randomized, double-blind, noninferiority comparative study with pregabalin",pain,duloxetine,antidepressant,antidepressant,duloxetine 40-60mg,snri,45.2mg,low,flexible,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,152,100,0.6579999999999999,FALSE,NA,NA,reference in covidence is nct 2015,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
991,pain_sub,enomoto 2018,"duloxetine in diabetic peripheral neuropathic pain in japan: a randomized, double-blind, noninferiority comparative study with pregabalin",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300-600mg,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,149,62,0.41600000000000004,FALSE,NA,NA,reference in covidence is nct 2015,NA,NA,non_ad_pharm,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
992,pain_sub,enomoto 2018,"duloxetine in diabetic peripheral neuropathic pain in japan: a randomized, double-blind, noninferiority comparative study with pregabalin",pain,duloxetine,antidepressant,antidepressant,duloxetine 40-60mg,snri,45.2mg,low,flexible,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,152,62,0.408,FALSE,NA,NA,reference in covidence is nct 2015,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
993,adverse,enomoto 2018,"duloxetine in diabetic peripheral neuropathic pain in japan: a randomized, double-blind, noninferiority comparative study with pregabalin",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300-600mg,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,151,54,0.358,FALSE,NA,NA,reference in covidence is nct 2015,NA,NA,non_ad_pharm,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
994,adverse,enomoto 2018,"duloxetine in diabetic peripheral neuropathic pain in japan: a randomized, double-blind, noninferiority comparative study with pregabalin",pain,duloxetine,antidepressant,antidepressant,duloxetine 40-60mg,snri,45.2mg,low,flexible,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,152,45,0.29600000000000004,FALSE,NA,NA,reference in covidence is nct 2015,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
995,serious_adverse,enomoto 2018,"duloxetine in diabetic peripheral neuropathic pain in japan: a randomized, double-blind, noninferiority comparative study with pregabalin",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300-600mg,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,151,6,0.04,FALSE,NA,NA,reference in covidence is nct 2015,NA,NA,non_ad_pharm,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
996,serious_adverse,enomoto 2018,"duloxetine in diabetic peripheral neuropathic pain in japan: a randomized, double-blind, noninferiority comparative study with pregabalin",pain,duloxetine,antidepressant,antidepressant,duloxetine 40-60mg,snri,45.2mg,low,flexible,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,152,1,0.006999999999999999,FALSE,NA,NA,reference in covidence is nct 2015,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
997,adverse_dropout,enomoto 2018,"duloxetine in diabetic peripheral neuropathic pain in japan: a randomized, double-blind, noninferiority comparative study with pregabalin",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300-600mg,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,151,12,NA,FALSE,NA,NA,reference in covidence is nct 2015,NA,NA,non_ad_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
998,adverse_dropout,enomoto 2018,"duloxetine in diabetic peripheral neuropathic pain in japan: a randomized, double-blind, noninferiority comparative study with pregabalin",pain,duloxetine,antidepressant,antidepressant,duloxetine 40-60mg,snri,45.2mg,low,flexible,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,152,10,NA,FALSE,NA,NA,reference in covidence is nct 2015,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
999,withdrawal,enomoto 2018,"duloxetine in diabetic peripheral neuropathic pain in japan: a randomized, double-blind, noninferiority comparative study with pregabalin",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300-600mg,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,151,21,NA,FALSE,NA,NA,reference in covidence is nct 2015,NA,NA,non_ad_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1000,withdrawal,enomoto 2018,"duloxetine in diabetic peripheral neuropathic pain in japan: a randomized, double-blind, noninferiority comparative study with pregabalin",pain,duloxetine,antidepressant,antidepressant,duloxetine 40-60mg,snri,45.2mg,low,flexible,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,152,15,NA,FALSE,NA,NA,reference in covidence is nct 2015,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1001,adverse,enteshari-moghaddam 2019,efficacy of duloxetine and gabapentin in pain reduction in patients with knee osteoarthritis,pain,acetaminophen,analgesic,non-antidepressant pharmacological,acetaminophen 2000mg,n/a,n/a,n/a,n/a,12 weeks,knee osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,no dropout,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,50,0,NA,FALSE,NA,"this study reports percent change (mean and sd) for the primary outcomes, any use?",NA,NA,NA,non_ad_pharm,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1002,adverse,enteshari-moghaddam 2019,efficacy of duloxetine and gabapentin in pain reduction in patients with knee osteoarthritis,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,knee osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,no dropout,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,50,8,NA,FALSE,NA,"this study reports percent change (mean and sd) for the primary outcomes, any use?",NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1003,adverse,enteshari-moghaddam 2019,efficacy of duloxetine and gabapentin in pain reduction in patients with knee osteoarthritis,pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin 600mg,n/a,n/a,n/a,n/a,12 weeks,knee osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,no dropout,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,50,9,NA,FALSE,NA,"this study reports percent change (mean and sd) for the primary outcomes, any use?",NA,NA,NA,non_ad_pharm,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1004,adverse_dropout,enteshari-moghaddam 2019,efficacy of duloxetine and gabapentin in pain reduction in patients with knee osteoarthritis,pain,acetaminophen,analgesic,non-antidepressant pharmacological,acetaminophen 2000mg,n/a,n/a,n/a,n/a,12 weeks,knee osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,no dropout,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,50,0,NA,FALSE,NA,"this study reports percent change (mean and sd) for the primary outcomes, any use?",NA,NA,NA,non_ad_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1005,adverse_dropout,enteshari-moghaddam 2019,efficacy of duloxetine and gabapentin in pain reduction in patients with knee osteoarthritis,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,knee osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,no dropout,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,50,0,NA,FALSE,NA,"this study reports percent change (mean and sd) for the primary outcomes, any use?",NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1006,adverse_dropout,enteshari-moghaddam 2019,efficacy of duloxetine and gabapentin in pain reduction in patients with knee osteoarthritis,pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin 600mg,n/a,n/a,n/a,n/a,12 weeks,knee osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,no dropout,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,50,0,NA,FALSE,NA,"this study reports percent change (mean and sd) for the primary outcomes, any use?",NA,NA,NA,non_ad_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1007,withdrawal,enteshari-moghaddam 2019,efficacy of duloxetine and gabapentin in pain reduction in patients with knee osteoarthritis,pain,acetaminophen,analgesic,non-antidepressant pharmacological,acetaminophen 2000mg,n/a,n/a,n/a,n/a,12 weeks,knee osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,no dropout,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,50,0,NA,FALSE,NA,"this study reports percent change (mean and sd) for the primary outcomes, any use?",NA,NA,NA,non_ad_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1008,withdrawal,enteshari-moghaddam 2019,efficacy of duloxetine and gabapentin in pain reduction in patients with knee osteoarthritis,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,knee osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,no dropout,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,50,0,NA,FALSE,NA,"this study reports percent change (mean and sd) for the primary outcomes, any use?",NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1009,withdrawal,enteshari-moghaddam 2019,efficacy of duloxetine and gabapentin in pain reduction in patients with knee osteoarthritis,pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin 600mg,n/a,n/a,n/a,n/a,12 weeks,knee osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,no dropout,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,50,0,NA,FALSE,NA,"this study reports percent change (mean and sd) for the primary outcomes, any use?",NA,NA,NA,non_ad_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1010,pain_int,forssell 2004,venlafaxine in the treatment of atypical facial pain: a randomized controlled trial,pain,venlafaxine,antidepressant,antidepressant,venlafaxine 37.5-70mg,snri,72.9mg,low,flexible,4 weeks,atypical facial pain,atypical facial pain,primary,≥3 on 10nrs,crossover,completer analysis,0-100 vas,baseline,NA,42,112.56192331614464,26.531099760082014,NA,16,94,NA,NA,18,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1011,pain_int,forssell 2004,venlafaxine in the treatment of atypical facial pain: a randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,atypical facial pain,atypical facial pain,primary,≥3 on 10nrs,crossover,completer analysis,0-100 vas,baseline,NA,45,114.72657568760896,27.041313217006664,NA,21,98,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1012,pain_int,forssell 2004,venlafaxine in the treatment of atypical facial pain: a randomized controlled trial,pain,venlafaxine,antidepressant,antidepressant,venlafaxine 37.5-70mg,snri,72.9mg,low,flexible,4 weeks,atypical facial pain,atypical facial pain,primary,≥3 on 10nrs,crossover,completer analysis,0-100 vas,post_int,NA,34,80.09213774417984,18.8778979062122,NA,0,71,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1013,pain_int,forssell 2004,venlafaxine in the treatment of atypical facial pain: a randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,atypical facial pain,atypical facial pain,primary,≥3 on 10nrs,crossover,completer analysis,0-100 vas,post_int,NA,47,73.59818062978688,17.34725753543824,NA,13,81,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1018,mood,forssell 2004,venlafaxine in the treatment of atypical facial pain: a randomized controlled trial,pain,venlafaxine,antidepressant,antidepressant,venlafaxine 37.5-70mg,snri,72.9mg,low,flexible,4 weeks,atypical facial pain,atypical facial pain,primary,≥3 on 10nrs,crossover,completer analysis,beck depression inventory,baseline,NA,12,25.97582845757184,6.122561483095849,NA,1,24,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1019,mood,forssell 2004,venlafaxine in the treatment of atypical facial pain: a randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,atypical facial pain,atypical facial pain,primary,≥3 on 10nrs,crossover,completer analysis,beck depression inventory,baseline,NA,11,38.96374268635776,9.183842224643774,NA,1,29,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1020,mood,forssell 2004,venlafaxine in the treatment of atypical facial pain: a randomized controlled trial,pain,venlafaxine,antidepressant,antidepressant,venlafaxine 37.5-70mg,snri,72.9mg,low,flexible,4 weeks,atypical facial pain,atypical facial pain,primary,≥3 on 10nrs,crossover,completer analysis,beck depression inventory,post_int,NA,9,49.78700454367936,11.734909509267043,NA,1,32,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1021,mood,forssell 2004,venlafaxine in the treatment of atypical facial pain: a randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,atypical facial pain,atypical facial pain,primary,≥3 on 10nrs,crossover,completer analysis,beck depression inventory,post_int,NA,11,30.30513320050048,7.1429883969451575,NA,0,25,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1022,adverse_dropout,forssell 2004,venlafaxine in the treatment of atypical facial pain: a randomized controlled trial,pain,venlafaxine,antidepressant,antidepressant,venlafaxine 37.5-70mg,snri,72.9mg,low,flexible,4 weeks,atypical facial pain,atypical facial pain,primary,≥3 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,6,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1023,adverse_dropout,forssell 2004,venlafaxine in the treatment of atypical facial pain: a randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,atypical facial pain,atypical facial pain,primary,≥3 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,2,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1024,withdrawal,forssell 2004,venlafaxine in the treatment of atypical facial pain: a randomized controlled trial,pain,venlafaxine,antidepressant,antidepressant,venlafaxine 37.5-70mg,snri,72.9mg,low,flexible,4 weeks,atypical facial pain,atypical facial pain,primary,≥3 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,6,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1025,withdrawal,forssell 2004,venlafaxine in the treatment of atypical facial pain: a randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,atypical facial pain,atypical facial pain,primary,≥3 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,4,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1030,pain_int,foster 2010: 1,oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,vulvodynia,vulvodynia,primary,≥4 on 10nrs,parallel,itt with locf,sf-mpq total score,change_score,NA,-4.57,5.86,1.088174681717524,NA,NA,NA,NA,NA,29,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1031,pain_int,foster 2010: 1,oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,pain,lidocaine,local anaesthetic,non-antidepressant pharmacological,lidocaine 5%,n/a,n/a,n/a,n/a,12 weeks,vulvodynia,vulvodynia,primary,≥4 on 10nrs,parallel,itt with locf,sf-mpq total score,change_score,NA,-3.1,6.77,1.3028871074712554,NA,NA,NA,NA,NA,27,NA,NA,TRUE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1032,pain_int,foster 2010: 1,oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,pain,desipramine,antidepressant,antidepressant,desipramine 150mg,tca,150mg,standard,fixed,12 weeks,vulvodynia,vulvodynia,primary,≥4 on 10nrs,parallel,itt with locf,sf-mpq total score,change_score,NA,-5.48,7.8,1.7020995438407407,NA,NA,NA,NA,NA,21,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1033,pain_int,foster 2010: 1,oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,pain,desipramine + lidocaine,combined antidepressant intervention,antidepressant,desipramine 150mg + lidocaine 5%,tca,150mg,standard,fixed,12 weeks,vulvodynia,vulvodynia,primary,≥4 on 10nrs,parallel,itt with locf,sf-mpq total score,change_score,NA,-6.44,8.54,1.5591835470313726,NA,NA,NA,NA,NA,30,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1038,mood,foster 2010: 1,oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,vulvodynia,vulvodynia,primary,≥4 on 10nrs,parallel,itt with locf,beck depression inventory,change_score,NA,-1.92,5.44,1.0101826396831624,NA,NA,NA,NA,NA,29,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1039,mood,foster 2010: 1,oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,pain,lidocaine,local anaesthetic,non-antidepressant pharmacological,lidocaine 5%,n/a,n/a,n/a,n/a,12 weeks,vulvodynia,vulvodynia,primary,≥4 on 10nrs,parallel,itt with locf,beck depression inventory,change_score,NA,-0.86,5.9,1.0771876964268268,NA,NA,NA,NA,NA,30,NA,NA,TRUE,NA,NA,NA,NA,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1040,mood,foster 2010: 1,oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,pain,desipramine,antidepressant,antidepressant,desipramine 150mg,tca,150mg,standard,fixed,12 weeks,vulvodynia,vulvodynia,primary,≥4 on 10nrs,parallel,itt with locf,beck depression inventory,change_score,NA,-3.33,5.26,1.0122874719791437,NA,NA,NA,NA,NA,27,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1041,mood,foster 2010: 1,oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,pain,desipramine + lidocaine,combined antidepressant intervention,antidepressant,desipramine 150mg + lidocaine 5%,tca,150mg,standard,fixed,12 weeks,vulvodynia,vulvodynia,primary,≥4 on 10nrs,parallel,itt with locf,beck depression inventory,change_score,NA,-1.77,7.58,1.3399673503485074,NA,NA,NA,NA,NA,32,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1042,adverse_dropout,foster 2010: 1,oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,vulvodynia,vulvodynia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,1,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1043,adverse_dropout,foster 2010: 1,oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,pain,lidocaine,local anaesthetic,non-antidepressant pharmacological,lidocaine 5%,n/a,n/a,n/a,n/a,12 weeks,vulvodynia,vulvodynia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,1,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1044,adverse_dropout,foster 2010: 1,oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,pain,desipramine,antidepressant,antidepressant,desipramine 150mg,tca,150mg,standard,fixed,12 weeks,vulvodynia,vulvodynia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,3,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1045,adverse_dropout,foster 2010: 1,oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,pain,desipramine + lidocaine,combined antidepressant intervention,antidepressant,desipramine 150mg + lidocaine 5%,tca,150mg,standard,fixed,12 weeks,vulvodynia,vulvodynia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,34,3,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1046,withdrawal,foster 2010: 1,oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,vulvodynia,vulvodynia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,2,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1047,withdrawal,foster 2010: 1,oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,pain,lidocaine,local anaesthetic,non-antidepressant pharmacological,lidocaine 5%,n/a,n/a,n/a,n/a,12 weeks,vulvodynia,vulvodynia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,5,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1048,withdrawal,foster 2010: 1,oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,pain,desipramine,antidepressant,antidepressant,desipramine 150mg,tca,150mg,standard,fixed,12 weeks,vulvodynia,vulvodynia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,6,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1049,withdrawal,foster 2010: 1,oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial,pain,desipramine + lidocaine,combined antidepressant intervention,antidepressant,desipramine 150mg + lidocaine 5%,tca,150mg,standard,fixed,12 weeks,vulvodynia,vulvodynia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,34,6,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1050,pain_int,foster 2010: 2,effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome,global improvement,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,painful bladder syndrome,painful bladder syndrome,visceral,≥3 on 10nrs,parallel,unclear,0-10 numerical rating scale,baseline,NA,6,1.8,0.15434872662825794,NA,NA,NA,NA,NA,136,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1051,pain_int,foster 2010: 2,effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome,global improvement,amitriptyline,antidepressant,antidepressant,amitriptyline 25-75mg,tca,25-75mg,standard,flexible,12 weeks,painful bladder syndrome,painful bladder syndrome,visceral,≥3 on 10nrs,parallel,unclear,0-10 numerical rating scale,baseline,NA,5.8,1.5,0.12909944487358058,NA,NA,NA,NA,NA,135,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1052,pain_int,foster 2010: 2,effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome,global improvement,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,painful bladder syndrome,painful bladder syndrome,visceral,≥3 on 10nrs,parallel,unclear,0-10 numerical rating scale,change_score,NA,-2.3,2.4,0.22000763928677072,NA,NA,NA,NA,NA,119,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1053,pain_int,foster 2010: 2,effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome,global improvement,amitriptyline,antidepressant,antidepressant,amitriptyline 25-75mg,tca,25-75mg,standard,flexible,12 weeks,painful bladder syndrome,painful bladder syndrome,visceral,≥3 on 10nrs,parallel,unclear,0-10 numerical rating scale,change_score,NA,-2.6,2.5,0.23728949893812476,NA,NA,NA,NA,NA,111,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1054,adverse,foster 2010: 2,effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome,global improvement,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,painful bladder syndrome,painful bladder syndrome,visceral,≥3 on 10nrs,parallel,unclear,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,136,98,0.72,FALSE,any ae,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1055,adverse,foster 2010: 2,effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome,global improvement,amitriptyline,antidepressant,antidepressant,amitriptyline 25-75mg,tca,25-75mg,standard,flexible,12 weeks,painful bladder syndrome,painful bladder syndrome,visceral,≥3 on 10nrs,parallel,unclear,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,135,119,0.88,FALSE,any ae,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1056,adverse_dropout,foster 2010: 2,effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome,global improvement,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,painful bladder syndrome,painful bladder syndrome,visceral,≥3 on 10nrs,parallel,unclear,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,136,2,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1057,adverse_dropout,foster 2010: 2,effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome,global improvement,amitriptyline,antidepressant,antidepressant,amitriptyline 25-75mg,tca,25-75mg,standard,flexible,12 weeks,painful bladder syndrome,painful bladder syndrome,visceral,≥3 on 10nrs,parallel,unclear,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,135,7,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1058,withdrawal,foster 2010: 2,effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome,global improvement,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,painful bladder syndrome,painful bladder syndrome,visceral,≥3 on 10nrs,parallel,unclear,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,136,17,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1059,withdrawal,foster 2010: 2,effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome,global improvement,amitriptyline,antidepressant,antidepressant,amitriptyline 25-75mg,tca,25-75mg,standard,flexible,12 weeks,painful bladder syndrome,painful bladder syndrome,visceral,≥3 on 10nrs,parallel,unclear,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,135,23,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1060,pain_int,frakes 2011,"duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.36,1.41,0.08744448788539196,NA,NA,NA,NA,NA,260,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1061,pain_int,frakes 2011,"duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.27,1.41,0.08677950114042957,NA,NA,NA,NA,NA,264,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1062,pain_int,frakes 2011,"duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-1.55,1.7565591364938442,0.11,NA,NA,NA,NA,NA,255,NA,NA,TRUE,NA,least squares,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1063,pain_int,frakes 2011,"duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-2.46,1.770282463337419,0.11,NA,NA,NA,NA,NA,259,NA,NA,TRUE,NA,least squares,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1064,physical,frakes 2011,"duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,womac physical function subscale,baseline,NA,37.5,9.4,0.5829632525692798,NA,NA,NA,NA,NA,260,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1065,physical,frakes 2011,"duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,womac physical function subscale,baseline,NA,37.4,10.1,0.6216120294456302,NA,NA,NA,NA,NA,264,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1066,physical,frakes 2011,"duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,womac physical function subscale,change_score,NA,-13.81,18.08,1.13,NA,NA,NA,NA,NA,256,NA,NA,TRUE,NA,least squares,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1067,physical,frakes 2011,"duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,womac physical function subscale,change_score,NA,-21.1,17.90256685506299,1.13,NA,NA,NA,NA,NA,251,NA,NA,TRUE,NA,least squares,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1068,mood,frakes 2011,"duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,profile of mood states - brief form,change_score,NA,-4.15,13.20083330703028,0.89,NA,NA,NA,NA,NA,220,NA,NA,TRUE,NA,no baseline values given || least squares,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
1069,mood,frakes 2011,"duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,profile of mood states - brief form,change_score,NA,-4.98,12.93330584189518,0.88,NA,NA,NA,NA,NA,216,NA,NA,TRUE,NA,no baseline values given || least squares,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
1074,sleep,frakes 2011,"duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,bpi sleep,change_score,NA,-2.01,2.24,0.14,NA,NA,NA,NA,NA,256,NA,NA,TRUE,NA,no baseline values given || least squares,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1075,sleep,frakes 2011,"duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,bpi sleep,change_score,NA,-2.69,2.2487329765892614,0.14,NA,NA,NA,NA,NA,258,NA,NA,TRUE,NA,no baseline values given || least squares,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1076,adverse,frakes 2011,"duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,260,130,0.5,FALSE,≥5% of participants,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1077,adverse,frakes 2011,"duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,264,167,0.633,FALSE,≥5% of participants,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1078,serious_adverse,frakes 2011,"duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,250,3,0.012,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1079,serious_adverse,frakes 2011,"duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,263,5,0.019,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1080,adverse_dropout,frakes 2011,"duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,260,23,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1081,adverse_dropout,frakes 2011,"duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,264,40,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1082,withdrawal,frakes 2011,"duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,260,61,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1083,withdrawal,frakes 2011,"duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,264,75,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1084,pain_mod,frakes 2011,"duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with bocf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,260,76,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
1085,pain_mod,frakes 2011,"duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with bocf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,264,111,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
1086,pain_sub,frakes 2011,"duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with bocf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,260,35,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
1087,pain_sub,frakes 2011,"duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with bocf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,264,73,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
1088,pain_int,gao 2010,duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in china,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,5.5,1.4,0.1340956799309612,NA,NA,NA,NA,NA,109,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1089,pain_int,gao 2010,duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in china,pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,5.5,1.3,0.12626716210644434,NA,NA,NA,NA,NA,106,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1090,pain_int,gao 2010,duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in china,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-2.31,1.879255171603899,0.18,NA,NA,NA,NA,NA,109,NA,NA,TRUE,NA,least squares,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1091,pain_int,gao 2010,duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in china,pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-2.69,1.9376274151652582,0.19,NA,NA,NA,NA,NA,104,NA,NA,TRUE,NA,least squares,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1092,sleep,gao 2010,duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in china,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,bpi sleep,change_score,NA,-2.67,2.818882757405849,0.27,NA,NA,NA,NA,NA,109,NA,NA,TRUE,NA,no baseline values given || least squares,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1093,sleep,gao 2010,duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in china,pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,bpi sleep,change_score,NA,-2.85,2.8827764394763604,0.28,NA,NA,NA,NA,NA,106,NA,NA,TRUE,NA,no baseline values given || least squares,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1094,mood,gao 2010,duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in china,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,bpi mood,change_score,NA,-1.85,2.4012704970494267,0.23,NA,NA,NA,NA,NA,109,NA,NA,TRUE,NA,no baseline values given || least squares,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
1095,mood,gao 2010,duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in china,pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,bpi mood,change_score,NA,-2.32,2.47095123383688,0.24,NA,NA,NA,NA,NA,106,NA,NA,TRUE,NA,no baseline values given || least squares,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
1096,qol,gao 2010,duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in china,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,eq-5d,change_score,NA,0.1,0.208806130178211,0.02,NA,NA,NA,NA,NA,109,NA,NA,TRUE,NA,no baseline values given || least squares,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
1097,qol,gao 2010,duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in china,pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,eq-5d,change_score,NA,0.12,0.20591260281974003,0.02,NA,NA,NA,NA,NA,106,NA,NA,TRUE,NA,no baseline values given || least squares,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
1098,mood,gao 2010,duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in china,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,beck depression inventory,baseline,NA,15.27,11.49,1.100542401719103,NA,NA,NA,NA,NA,109,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1099,mood,gao 2010,duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in china,pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,beck depression inventory,baseline,NA,15.97,10.66,1.0353907292728435,NA,NA,NA,NA,NA,106,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1100,pain_mod,gao 2010,duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in china,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,109,67,0.615,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
1101,pain_mod,gao 2010,duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in china,pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,106,74,0.7120000000000001,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
1102,pain_sub,gao 2010,duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in china,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,109,55,0.505,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
1103,pain_sub,gao 2010,duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in china,pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,106,57,0.5479999999999999,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
1104,adverse,gao 2010,duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in china,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,109,78,NA,FALSE,≥5% of participants,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1105,adverse,gao 2010,duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in china,pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,106,86,NA,FALSE,≥5% of participants,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1106,serious_adverse,gao 2010,duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in china,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,109,2,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1107,serious_adverse,gao 2010,duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in china,pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,106,2,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1108,adverse_dropout,gao 2010,duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in china,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,109,4,0.037000000000000005,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1109,adverse_dropout,gao 2010,duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in china,pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,106,15,0.1427,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1110,withdrawal,gao 2010,duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in china,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,109,17,0.156,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1111,withdrawal,gao 2010,duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in china,pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,60-120mg,high,flexible,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,106,19,0.179,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1112,pain_int,gao 2015,treatment of patients with diabetic peripheral neuropathic pain in china: a double-blind randomised trial of duloxetine vs. placebo,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,5.6,1.7,0.11961158260414961,NA,NA,NA,NA,NA,202,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1113,pain_int,gao 2015,treatment of patients with diabetic peripheral neuropathic pain in china: a double-blind randomised trial of duloxetine vs. placebo,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,5.6,1.7,0.11961158260414961,NA,NA,NA,NA,NA,202,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1114,pain_int,gao 2015,treatment of patients with diabetic peripheral neuropathic pain in china: a double-blind randomised trial of duloxetine vs. placebo,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-1.97,1.841412501315227,0.14,NA,NA,NA,NA,NA,173,NA,NA,TRUE,NA,least squares,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1115,pain_int,gao 2015,treatment of patients with diabetic peripheral neuropathic pain in china: a double-blind randomised trial of duloxetine vs. placebo,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-2.4,1.8360827868045604,0.14,NA,NA,NA,NA,NA,172,NA,NA,TRUE,NA,least squares,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1116,physical,gao 2015,treatment of patients with diabetic peripheral neuropathic pain in china: a double-blind randomised trial of duloxetine vs. placebo,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sheehan disability scale,baseline,NA,10.5,7.3,0.5136262076531131,NA,NA,NA,NA,NA,202,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1117,physical,gao 2015,treatment of patients with diabetic peripheral neuropathic pain in china: a double-blind randomised trial of duloxetine vs. placebo,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sheehan disability scale,baseline,NA,11.2,7.6,0.5334154288211332,NA,NA,NA,NA,NA,203,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1118,physical,gao 2015,treatment of patients with diabetic peripheral neuropathic pain in china: a double-blind randomised trial of duloxetine vs. placebo,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sheehan disability scale,change_score,NA,-5.09,5.55607775323564,0.42,NA,NA,NA,NA,NA,175,NA,NA,TRUE,NA,least squares,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1119,physical,gao 2015,treatment of patients with diabetic peripheral neuropathic pain in china: a double-blind randomised trial of duloxetine vs. placebo,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sheehan disability scale,change_score,NA,-6.36,5.2459508194416005,0.4,NA,NA,NA,NA,NA,172,NA,NA,TRUE,NA,least squares,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1120,sleep,gao 2015,treatment of patients with diabetic peripheral neuropathic pain in china: a double-blind randomised trial of duloxetine vs. placebo,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,bpi sleep,change_score,NA,-2.04,2.255304857441672,0.17,NA,NA,NA,NA,NA,176,NA,NA,TRUE,NA,no baseline values given || least squares,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1121,sleep,gao 2015,treatment of patients with diabetic peripheral neuropathic pain in china: a double-blind randomised trial of duloxetine vs. placebo,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,bpi sleep,change_score,NA,-2.63,2.2360008944542042,0.17,NA,NA,NA,NA,NA,173,NA,NA,TRUE,NA,no baseline values given || least squares,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1122,pain_mod,gao 2015,treatment of patients with diabetic peripheral neuropathic pain in china: a double-blind randomised trial of duloxetine vs. placebo,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,198,97,0.49,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
1123,pain_mod,gao 2015,treatment of patients with diabetic peripheral neuropathic pain in china: a double-blind randomised trial of duloxetine vs. placebo,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,200,123,0.615,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
1124,pain_sub,gao 2015,treatment of patients with diabetic peripheral neuropathic pain in china: a double-blind randomised trial of duloxetine vs. placebo,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,198,57,0.28800000000000003,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
1125,pain_sub,gao 2015,treatment of patients with diabetic peripheral neuropathic pain in china: a double-blind randomised trial of duloxetine vs. placebo,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,200,84,0.42,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
1126,adverse,gao 2015,treatment of patients with diabetic peripheral neuropathic pain in china: a double-blind randomised trial of duloxetine vs. placebo,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,202,72,0.35600000000000004,FALSE,≥5% of participants,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1127,adverse,gao 2015,treatment of patients with diabetic peripheral neuropathic pain in china: a double-blind randomised trial of duloxetine vs. placebo,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,202,94,0.465,FALSE,≥5% of participants,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1128,serious_adverse,gao 2015,treatment of patients with diabetic peripheral neuropathic pain in china: a double-blind randomised trial of duloxetine vs. placebo,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,202,2,0.01,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1129,serious_adverse,gao 2015,treatment of patients with diabetic peripheral neuropathic pain in china: a double-blind randomised trial of duloxetine vs. placebo,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,202,3,0.015,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1130,adverse_dropout,gao 2015,treatment of patients with diabetic peripheral neuropathic pain in china: a double-blind randomised trial of duloxetine vs. placebo,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,202,8,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1131,adverse_dropout,gao 2015,treatment of patients with diabetic peripheral neuropathic pain in china: a double-blind randomised trial of duloxetine vs. placebo,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,203,17,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1132,withdrawal,gao 2015,treatment of patients with diabetic peripheral neuropathic pain in china: a double-blind randomised trial of duloxetine vs. placebo,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,202,26,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1133,withdrawal,gao 2015,treatment of patients with diabetic peripheral neuropathic pain in china: a double-blind randomised trial of duloxetine vs. placebo,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,203,30,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1134,pain_int,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin ≤3600mg,n/a,n/a,n/a,n/a,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,0-10 numerical rating scale,baseline,NA,5.4,1.5272351599468779,0.20408538276986135,NA,5,5.8,NA,NA,56,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1135,pain_int,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,nortriptyline,antidepressant,antidepressant,nortriptyline ≤100mg,tca,≤100mg,unable to be categorised,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,0-10 numerical rating scale,baseline,NA,5.4,1.5272351599468779,0.20408538276986135,NA,5,5.8,NA,NA,56,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1136,pain_int,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,gabapentin + nortriptyline,combined antidepressant intervention,antidepressant,gabapentin ≤3600mg + nortriptyline ≤100mg,tca,≤100mg,unable to be categorised,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,0-10 numerical rating scale,baseline,NA,5.4,1.5272351599468779,0.20408538276986135,NA,5,5.8,NA,NA,56,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1137,pain_int,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin ≤3600mg,n/a,n/a,n/a,n/a,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,0-10 numerical rating scale,post_int,NA,3.2,2.076261616016443,0.30612807415479226,NA,2.5,3.8,NA,NA,46,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1138,pain_int,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,nortriptyline,antidepressant,antidepressant,nortriptyline ≤100mg,tca,≤100mg,unable to be categorised,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,0-10 numerical rating scale,post_int,NA,2.9,1.8038769762202669,0.255106728462327,NA,2.4,3.4,NA,NA,50,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1139,pain_int,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,gabapentin + nortriptyline,combined antidepressant intervention,antidepressant,gabapentin ≤3600mg + nortriptyline ≤100mg,tca,≤100mg,unable to be categorised,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,0-10 numerical rating scale,post_int,NA,2.3,1.8038769762202669,0.255106728462327,NA,1.8,2.8,NA,NA,50,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1140,sleep,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin ≤3600mg,n/a,n/a,n/a,n/a,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,bpi sleep,baseline,NA,5.1,2.9933259094191533,0.4,NA,NA,NA,NA,NA,56,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
1141,sleep,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,nortriptyline,antidepressant,antidepressant,nortriptyline ≤100mg,tca,≤100mg,unable to be categorised,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,bpi sleep,baseline,NA,5.1,2.9933259094191533,0.4,NA,NA,NA,NA,NA,56,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
1142,sleep,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,gabapentin + nortriptyline,combined antidepressant intervention,antidepressant,gabapentin ≤3600mg + nortriptyline ≤100mg,tca,≤100mg,unable to be categorised,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,bpi sleep,baseline,NA,5.1,2.9933259094191533,0.4,NA,NA,NA,NA,NA,56,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
1143,sleep,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin ≤3600mg,n/a,n/a,n/a,n/a,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,bpi sleep,post_int,NA,2.2,2.0346989949375804,0.3,NA,NA,NA,NA,NA,46,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1144,sleep,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,nortriptyline,antidepressant,antidepressant,nortriptyline ≤100mg,tca,≤100mg,unable to be categorised,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,bpi sleep,post_int,NA,2.3,2.1213203435596424,0.3,NA,NA,NA,NA,NA,50,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1145,sleep,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,gabapentin + nortriptyline,combined antidepressant intervention,antidepressant,gabapentin ≤3600mg + nortriptyline ≤100mg,tca,≤100mg,unable to be categorised,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,bpi sleep,post_int,NA,1,2.1213203435596424,0.3,NA,NA,NA,NA,NA,50,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1146,mood,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin ≤3600mg,n/a,n/a,n/a,n/a,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,sf-36 mental health subscale,baseline,NA,57.1,28.436596139481953,3.8,NA,NA,NA,NA,NA,56,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
1147,mood,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,nortriptyline,antidepressant,antidepressant,nortriptyline ≤100mg,tca,≤100mg,unable to be categorised,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,sf-36 mental health subscale,baseline,NA,57.1,28.436596139481953,3.8,NA,NA,NA,NA,NA,56,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
1148,mood,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,gabapentin + nortriptyline,combined antidepressant intervention,antidepressant,gabapentin ≤3600mg + nortriptyline ≤100mg,tca,≤100mg,unable to be categorised,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,sf-36 mental health subscale,baseline,NA,57.1,28.436596139481953,3.8,NA,NA,NA,NA,NA,56,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
1149,mood,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin ≤3600mg,n/a,n/a,n/a,n/a,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,sf-36 mental health subscale,post_int,NA,61.6,17.634057956125698,2.6,NA,NA,NA,NA,NA,46,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
1150,mood,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,nortriptyline,antidepressant,antidepressant,nortriptyline ≤100mg,tca,≤100mg,unable to be categorised,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,sf-36 mental health subscale,post_int,NA,61.7,17.67766952966369,2.5,NA,NA,NA,NA,NA,50,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
1151,mood,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,gabapentin + nortriptyline,combined antidepressant intervention,antidepressant,gabapentin ≤3600mg + nortriptyline ≤100mg,tca,≤100mg,unable to be categorised,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,sf-36 mental health subscale,post_int,NA,64.3,17.67766952966369,2.5,NA,NA,NA,NA,NA,50,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
1158,physical,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin ≤3600mg,n/a,n/a,n/a,n/a,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,sf-36 physical functioning subscale,baseline,NA,57.1,28.436596139481953,3.8,NA,NA,NA,NA,NA,56,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1159,physical,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,nortriptyline,antidepressant,antidepressant,nortriptyline ≤100mg,tca,≤100mg,unable to be categorised,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,sf-36 physical functioning subscale,baseline,NA,57.1,28.436596139481953,3.8,NA,NA,NA,NA,NA,56,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1160,physical,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,gabapentin + nortriptyline,combined antidepressant intervention,antidepressant,gabapentin ≤3600mg + nortriptyline ≤100mg,tca,≤100mg,unable to be categorised,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,sf-36 physical functioning subscale,baseline,NA,57.1,28.436596139481953,3.8,NA,NA,NA,NA,NA,56,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1161,physical,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin ≤3600mg,n/a,n/a,n/a,n/a,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,sf-36 physical functioning subscale,post_int,NA,61.6,17.634057956125698,2.6,NA,NA,NA,NA,NA,46,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1162,physical,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,nortriptyline,antidepressant,antidepressant,nortriptyline ≤100mg,tca,≤100mg,unable to be categorised,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,sf-36 physical functioning subscale,post_int,NA,61.7,17.67766952966369,2.5,NA,NA,NA,NA,NA,50,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1163,physical,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,gabapentin + nortriptyline,combined antidepressant intervention,antidepressant,gabapentin ≤3600mg + nortriptyline ≤100mg,tca,≤100mg,unable to be categorised,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,sf-36 physical functioning subscale,post_int,NA,64.3,17.67766952966369,2.5,NA,NA,NA,NA,NA,50,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1164,serious_adverse,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin ≤3600mg,n/a,n/a,n/a,n/a,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,56,0,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1165,serious_adverse,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,nortriptyline,antidepressant,antidepressant,nortriptyline ≤100mg,tca,≤100mg,unable to be categorised,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,56,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1166,serious_adverse,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,gabapentin + nortriptyline,combined antidepressant intervention,antidepressant,gabapentin ≤3600mg + nortriptyline ≤100mg,tca,≤100mg,unable to be categorised,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,56,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1167,adverse_dropout,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin ≤3600mg,n/a,n/a,n/a,n/a,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,56,4,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1168,adverse_dropout,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,nortriptyline,antidepressant,antidepressant,nortriptyline ≤100mg,tca,≤100mg,unable to be categorised,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,56,1,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1169,adverse_dropout,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,gabapentin + nortriptyline,combined antidepressant intervention,antidepressant,gabapentin ≤3600mg + nortriptyline ≤100mg,tca,≤100mg,unable to be categorised,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,56,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1170,withdrawal,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin ≤3600mg,n/a,n/a,n/a,n/a,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,56,8,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1171,withdrawal,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,nortriptyline,antidepressant,antidepressant,nortriptyline ≤100mg,tca,≤100mg,unable to be categorised,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,56,1,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1172,withdrawal,gilron 2009,"nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial",pain,gabapentin + nortriptyline,combined antidepressant intervention,antidepressant,gabapentin ≤3600mg + nortriptyline ≤100mg,tca,≤100mg,unable to be categorised,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,56,2,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1173,pain_int,gilron 2015,combination of morphine with nortriptyline for neuropathic pain,pain,morphine,anaesthetic,non-antidepressant pharmacological,morphine ≤100mg,n/a,n/a,n/a,n/a,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on dn4,crossover,not reported,0-10 numerical rating scale,baseline,NA,5.3,1.4422205101855958,0.2,NA,NA,NA,NA,NA,52,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1174,pain_int,gilron 2015,combination of morphine with nortriptyline for neuropathic pain,pain,nortriptyline,antidepressant,antidepressant,nortriptyline ≤100mg,tca,83.9mg,standard,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on dn4,crossover,not reported,0-10 numerical rating scale,baseline,NA,5.3,1.4422205101855958,0.2,NA,NA,NA,NA,NA,52,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1175,pain_int,gilron 2015,combination of morphine with nortriptyline for neuropathic pain,pain,nortriptyline + morphine,combined antidepressant intervention,antidepressant,nortriptyline ≤100mg + morphine ≤100mg,tca,60.2mg,low,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on dn4,crossover,not reported,0-10 numerical rating scale,baseline,NA,5.3,1.4422205101855958,0.2,NA,NA,NA,NA,NA,52,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1176,pain_int,gilron 2015,combination of morphine with nortriptyline for neuropathic pain,pain,morphine,anaesthetic,non-antidepressant pharmacological,morphine ≤100mg,n/a,n/a,n/a,n/a,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on dn4,crossover,not reported,0-10 numerical rating scale,post_int,NA,3.4,2.8565713714171403,0.4,NA,NA,NA,NA,NA,51,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1177,pain_int,gilron 2015,combination of morphine with nortriptyline for neuropathic pain,pain,nortriptyline,antidepressant,antidepressant,nortriptyline ≤100mg,tca,83.9mg,standard,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on dn4,crossover,not reported,0-10 numerical rating scale,post_int,NA,3.1,2.8565713714171403,0.4,NA,NA,NA,NA,NA,51,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1178,pain_int,gilron 2015,combination of morphine with nortriptyline for neuropathic pain,pain,nortriptyline + morphine,combined antidepressant intervention,antidepressant,nortriptyline ≤100mg + morphine ≤100mg,tca,60.2mg,low,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on dn4,crossover,not reported,0-10 numerical rating scale,post_int,NA,2.6,2.8565713714171403,0.4,NA,NA,NA,NA,NA,51,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1179,mood,gilron 2015,combination of morphine with nortriptyline for neuropathic pain,pain,morphine,anaesthetic,non-antidepressant pharmacological,morphine ≤100mg,n/a,n/a,n/a,n/a,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on dn4,crossover,not reported,bpi mood,baseline,NA,3.2,2.8844410203711917,0.4,NA,NA,NA,NA,NA,52,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
1180,mood,gilron 2015,combination of morphine with nortriptyline for neuropathic pain,pain,nortriptyline,antidepressant,antidepressant,nortriptyline ≤100mg,tca,83.9mg,standard,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on dn4,crossover,not reported,bpi mood,baseline,NA,3.2,2.8844410203711917,0.4,NA,NA,NA,NA,NA,52,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
1181,mood,gilron 2015,combination of morphine with nortriptyline for neuropathic pain,pain,nortriptyline + morphine,combined antidepressant intervention,antidepressant,nortriptyline ≤100mg + morphine ≤100mg,tca,60.2mg,low,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on dn4,crossover,not reported,bpi mood,baseline,NA,3.2,2.8844410203711917,0.4,NA,NA,NA,NA,NA,52,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
1182,mood,gilron 2015,combination of morphine with nortriptyline for neuropathic pain,pain,morphine,anaesthetic,non-antidepressant pharmacological,morphine ≤100mg,n/a,n/a,n/a,n/a,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on dn4,crossover,not reported,bpi mood,post_int,NA,2.1,2.8565713714171403,0.4,NA,NA,NA,NA,NA,51,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
1183,mood,gilron 2015,combination of morphine with nortriptyline for neuropathic pain,pain,nortriptyline,antidepressant,antidepressant,nortriptyline ≤100mg,tca,83.9mg,standard,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on dn4,crossover,not reported,bpi mood,post_int,NA,1.5,2.8565713714171403,0.4,NA,NA,NA,NA,NA,51,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
1184,mood,gilron 2015,combination of morphine with nortriptyline for neuropathic pain,pain,nortriptyline + morphine,combined antidepressant intervention,antidepressant,nortriptyline ≤100mg + morphine ≤100mg,tca,60.2mg,low,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on dn4,crossover,not reported,bpi mood,post_int,NA,1.8,2.8565713714171403,0.4,NA,NA,NA,NA,NA,51,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
1185,sleep,gilron 2015,combination of morphine with nortriptyline for neuropathic pain,pain,morphine,anaesthetic,non-antidepressant pharmacological,morphine ≤100mg,n/a,n/a,n/a,n/a,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on dn4,crossover,not reported,bpi sleep,baseline,NA,4,3.605551275463989,0.5,NA,NA,NA,NA,NA,52,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
1186,sleep,gilron 2015,combination of morphine with nortriptyline for neuropathic pain,pain,nortriptyline,antidepressant,antidepressant,nortriptyline ≤100mg,tca,83.9mg,standard,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on dn4,crossover,not reported,bpi sleep,baseline,NA,4,3.605551275463989,0.5,NA,NA,NA,NA,NA,52,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
1187,sleep,gilron 2015,combination of morphine with nortriptyline for neuropathic pain,pain,nortriptyline + morphine,combined antidepressant intervention,antidepressant,nortriptyline ≤100mg + morphine ≤100mg,tca,60.2mg,low,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on dn4,crossover,not reported,bpi sleep,baseline,NA,4,3.605551275463989,0.5,NA,NA,NA,NA,NA,52,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
1188,sleep,gilron 2015,combination of morphine with nortriptyline for neuropathic pain,pain,morphine,anaesthetic,non-antidepressant pharmacological,morphine ≤100mg,n/a,n/a,n/a,n/a,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on dn4,crossover,not reported,bpi sleep,post_int,NA,1.5,2.8565713714171403,0.4,NA,NA,NA,NA,NA,51,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1189,sleep,gilron 2015,combination of morphine with nortriptyline for neuropathic pain,pain,nortriptyline,antidepressant,antidepressant,nortriptyline ≤100mg,tca,83.9mg,standard,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on dn4,crossover,not reported,bpi sleep,post_int,NA,1.6,2.8565713714171403,0.4,NA,NA,NA,NA,NA,51,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1190,sleep,gilron 2015,combination of morphine with nortriptyline for neuropathic pain,pain,nortriptyline + morphine,combined antidepressant intervention,antidepressant,nortriptyline ≤100mg + morphine ≤100mg,tca,60.2mg,low,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on dn4,crossover,not reported,bpi sleep,post_int,NA,1.3,2.8565713714171403,0.4,NA,NA,NA,NA,NA,51,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1197,pain_mod,gilron 2015,combination of morphine with nortriptyline for neuropathic pain,pain,morphine,anaesthetic,non-antidepressant pharmacological,morphine ≤100mg,n/a,n/a,n/a,n/a,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on dn4,crossover,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,26,0.513,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
1198,pain_mod,gilron 2015,combination of morphine with nortriptyline for neuropathic pain,pain,nortriptyline,antidepressant,antidepressant,nortriptyline ≤100mg,tca,83.9mg,standard,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on dn4,crossover,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,34,0.6579999999999999,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
1199,pain_mod,gilron 2015,combination of morphine with nortriptyline for neuropathic pain,pain,nortriptyline + morphine,combined antidepressant intervention,antidepressant,nortriptyline ≤100mg + morphine ≤100mg,tca,60.2mg,low,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on dn4,crossover,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,36,0.711,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
1200,pain_sub,gilron 2015,combination of morphine with nortriptyline for neuropathic pain,pain,morphine,anaesthetic,non-antidepressant pharmacological,morphine ≤100mg,n/a,n/a,n/a,n/a,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on dn4,crossover,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,13,0.256,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
1201,pain_sub,gilron 2015,combination of morphine with nortriptyline for neuropathic pain,pain,nortriptyline,antidepressant,antidepressant,nortriptyline ≤100mg,tca,83.9mg,standard,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on dn4,crossover,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,19,0.368,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
1202,pain_sub,gilron 2015,combination of morphine with nortriptyline for neuropathic pain,pain,nortriptyline + morphine,combined antidepressant intervention,antidepressant,nortriptyline ≤100mg + morphine ≤100mg,tca,60.2mg,low,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on dn4,crossover,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,27,0.526,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
1203,adverse_dropout,gilron 2015,combination of morphine with nortriptyline for neuropathic pain,pain,morphine,anaesthetic,non-antidepressant pharmacological,morphine ≤100mg,n/a,n/a,n/a,n/a,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on dn4,crossover,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,52,7,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1204,adverse_dropout,gilron 2015,combination of morphine with nortriptyline for neuropathic pain,pain,nortriptyline,antidepressant,antidepressant,nortriptyline ≤100mg,tca,83.9mg,standard,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on dn4,crossover,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,52,1,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1205,adverse_dropout,gilron 2015,combination of morphine with nortriptyline for neuropathic pain,pain,nortriptyline + morphine,combined antidepressant intervention,antidepressant,nortriptyline ≤100mg + morphine ≤100mg,tca,60.2mg,low,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on dn4,crossover,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,52,4,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1206,withdrawal,gilron 2015,combination of morphine with nortriptyline for neuropathic pain,pain,morphine,anaesthetic,non-antidepressant pharmacological,morphine ≤100mg,n/a,n/a,n/a,n/a,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on dn4,crossover,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,52,9,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1207,withdrawal,gilron 2015,combination of morphine with nortriptyline for neuropathic pain,pain,nortriptyline,antidepressant,antidepressant,nortriptyline ≤100mg,tca,83.9mg,standard,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on dn4,crossover,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,52,2,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1208,withdrawal,gilron 2015,combination of morphine with nortriptyline for neuropathic pain,pain,nortriptyline + morphine,combined antidepressant intervention,antidepressant,nortriptyline ≤100mg + morphine ≤100mg,tca,60.2mg,low,flexible,6 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on dn4,crossover,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,52,7,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1209,pain_int,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,0-10 numerical rating scale,baseline,NA,5.7,1.3,0.2030258904551879,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1210,pain_int,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin ≤450mg,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,0-10 numerical rating scale,baseline,NA,5.7,1.3,0.2030258904551879,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1211,pain_int,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine ≤120mg,snri,≤120mg,unable to be categorised,flexible,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,0-10 numerical rating scale,baseline,NA,5.7,1.3,0.2030258904551879,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1212,pain_int,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,pregabalin + duloxetine,combined antidepressant intervention,antidepressant,pregabalin ≤450mg + duloxetine ≤120mg,snri,≤120mg,unable to be categorised,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,0-10 numerical rating scale,baseline,NA,5.7,1.3,0.2030258904551879,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1213,pain_int,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,0-10 numerical rating scale,post_int,NA,5.1,1.8734993995195195,0.3,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1214,pain_int,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin ≤450mg,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,0-10 numerical rating scale,post_int,NA,5,1.8734993995195195,0.3,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1215,pain_int,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine ≤120mg,snri,≤120mg,unable to be categorised,flexible,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,0-10 numerical rating scale,post_int,NA,4.1,1.8734993995195195,0.3,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1216,pain_int,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,pregabalin + duloxetine,combined antidepressant intervention,antidepressant,pregabalin ≤450mg + duloxetine ≤120mg,snri,≤120mg,unable to be categorised,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,0-10 numerical rating scale,post_int,NA,3.7,1.8734993995195195,0.3,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1217,qol,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,fibromyalgia impact questionnaire total score,baseline,NA,45.2,12.165936051122411,1.9,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
1218,qol,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin ≤450mg,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,fibromyalgia impact questionnaire total score,baseline,NA,45.2,12.165936051122411,1.9,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
1219,qol,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine ≤120mg,snri,≤120mg,unable to be categorised,flexible,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,fibromyalgia impact questionnaire total score,baseline,NA,45.2,12.165936051122411,1.9,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
1220,qol,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,pregabalin + duloxetine,combined antidepressant intervention,antidepressant,pregabalin ≤450mg + duloxetine ≤120mg,snri,≤120mg,unable to be categorised,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,fibromyalgia impact questionnaire total score,baseline,NA,45.2,12.165936051122411,1.9,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
1221,qol,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,fibromyalgia impact questionnaire total score,post_int,NA,42.9,14.363495396316315,2.3,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
1222,qol,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin ≤450mg,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,fibromyalgia impact questionnaire total score,post_int,NA,37.4,14.363495396316315,2.3,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
1223,qol,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine ≤120mg,snri,≤120mg,unable to be categorised,flexible,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,fibromyalgia impact questionnaire total score,post_int,NA,36,14.987995196156156,2.4,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
1224,qol,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,pregabalin + duloxetine,combined antidepressant intervention,antidepressant,pregabalin ≤450mg + duloxetine ≤120mg,snri,≤120mg,unable to be categorised,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,fibromyalgia impact questionnaire total score,post_int,NA,29.8,15.612494995995995,2.5,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
1225,physical,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,sf-36 physical functioning subscale,baseline,NA,53.6,17.928747864811974,2.8,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1226,physical,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin ≤450mg,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,sf-36 physical functioning subscale,baseline,NA,53.6,17.928747864811974,2.8,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1227,physical,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine ≤120mg,snri,≤120mg,unable to be categorised,flexible,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,sf-36 physical functioning subscale,baseline,NA,53.6,17.928747864811974,2.8,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1228,physical,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,pregabalin + duloxetine,combined antidepressant intervention,antidepressant,pregabalin ≤450mg + duloxetine ≤120mg,snri,≤120mg,unable to be categorised,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,sf-36 physical functioning subscale,baseline,NA,53.6,17.928747864811974,2.8,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1229,physical,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,sf-36 physical functioning subscale,post_int,NA,52.9,19.359493795035036,3.1,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1230,physical,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin ≤450mg,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,sf-36 physical functioning subscale,post_int,NA,57.1,19.359493795035036,3.1,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1231,physical,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine ≤120mg,snri,≤120mg,unable to be categorised,flexible,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,sf-36 physical functioning subscale,post_int,NA,61.4,19.983993594874875,3.2,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1232,physical,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,pregabalin + duloxetine,combined antidepressant intervention,antidepressant,pregabalin ≤450mg + duloxetine ≤120mg,snri,≤120mg,unable to be categorised,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,sf-36 physical functioning subscale,post_int,NA,65.3,20.608493394714714,3.3,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1233,mood,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,sf-36 mental health subscale,baseline,NA,69.8,17.928747864811974,2.8,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
1234,mood,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin ≤450mg,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,sf-36 mental health subscale,baseline,NA,69.8,17.928747864811974,2.8,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
1235,mood,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine ≤120mg,snri,≤120mg,unable to be categorised,flexible,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,sf-36 mental health subscale,baseline,NA,69.8,17.928747864811974,2.8,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
1236,mood,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,pregabalin + duloxetine,combined antidepressant intervention,antidepressant,pregabalin ≤450mg + duloxetine ≤120mg,snri,≤120mg,unable to be categorised,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,sf-36 mental health subscale,baseline,NA,69.8,17.928747864811974,2.8,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
1237,mood,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,sf-36 mental health subscale,post_int,NA,70.3,17.485994395515515,2.8,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
1238,mood,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin ≤450mg,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,sf-36 mental health subscale,post_int,NA,76.1,17.485994395515515,2.8,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
1239,mood,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine ≤120mg,snri,≤120mg,unable to be categorised,flexible,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,sf-36 mental health subscale,post_int,NA,75.8,17.485994395515515,2.8,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
1240,mood,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,pregabalin + duloxetine,combined antidepressant intervention,antidepressant,pregabalin ≤450mg + duloxetine ≤120mg,snri,≤120mg,unable to be categorised,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,sf-36 mental health subscale,post_int,NA,78.9,18.110494195355354,2.9,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
1241,sleep,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,bpi sleep,baseline,NA,6,2.5612496949731396,0.4,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
1242,sleep,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin ≤450mg,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,bpi sleep,baseline,NA,6,2.5612496949731396,0.4,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
1243,sleep,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine ≤120mg,snri,≤120mg,unable to be categorised,flexible,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,bpi sleep,baseline,NA,6,2.5612496949731396,0.4,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
1244,sleep,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,pregabalin + duloxetine,combined antidepressant intervention,antidepressant,pregabalin ≤450mg + duloxetine ≤120mg,snri,≤120mg,unable to be categorised,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,bpi sleep,baseline,NA,6,2.5612496949731396,0.4,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
1245,sleep,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,bpi sleep,post_int,NA,5.1,3.122498999199199,0.5,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1246,sleep,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin ≤450mg,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,bpi sleep,post_int,NA,3.3,3.122498999199199,0.5,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1247,sleep,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine ≤120mg,snri,≤120mg,unable to be categorised,flexible,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,bpi sleep,post_int,NA,4.9,3.122498999199199,0.5,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1248,sleep,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,pregabalin + duloxetine,combined antidepressant intervention,antidepressant,pregabalin ≤450mg + duloxetine ≤120mg,snri,≤120mg,unable to be categorised,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,bpi sleep,post_int,NA,2.8,3.122498999199199,0.5,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1265,adverse_dropout,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,1,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1266,adverse_dropout,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin ≤450mg,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,1,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1267,adverse_dropout,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine ≤120mg,snri,≤120mg,unable to be categorised,flexible,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,3,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1268,adverse_dropout,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,pregabalin + duloxetine,combined antidepressant intervention,antidepressant,pregabalin ≤450mg + duloxetine ≤120mg,snri,≤120mg,unable to be categorised,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,2,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1269,withdrawal,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,1,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1270,withdrawal,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin ≤450mg,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,1,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1271,withdrawal,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine ≤120mg,snri,≤120mg,unable to be categorised,flexible,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,3,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1272,withdrawal,gilron 2016,combination of pregabalin with duloxetine for fibromyalgia: a randomized controlled trial,pain,pregabalin + duloxetine,combined antidepressant intervention,antidepressant,pregabalin ≤450mg + duloxetine ≤120mg,snri,≤120mg,unable to be categorised,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,crossover,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,4,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1273,pain_int,ginsberg 1996,a randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,0-10 numerical rating scale,baseline,NA,7.1,1.4,0.29848100289785456,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1274,pain_int,ginsberg 1996,a randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,0-10 numerical rating scale,baseline,NA,7.3,1.4,0.28577380332470415,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1275,pain_int,ginsberg 1996,a randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,0-10 numerical rating scale,post_int,NA,7,1.3,0.2771609312622936,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1276,pain_int,ginsberg 1996,a randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,0-10 numerical rating scale,post_int,NA,3.8,2.4,0.48989794855663565,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1277,sleep,ginsberg 1996,a randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,0-10 numerical rating scale,baseline,NA,5.4,3,0.6396021490668313,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
1278,sleep,ginsberg 1996,a randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,0-10 numerical rating scale,baseline,NA,5.2,2.5,0.5103103630798288,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
1279,sleep,ginsberg 1996,a randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,0-10 numerical rating scale,post_int,NA,5.1,3,0.6396021490668313,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1280,sleep,ginsberg 1996,a randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,0-10 numerical rating scale,post_int,NA,2.6,3.1,0.6327848502189878,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1281,adverse,ginsberg 1996,a randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1282,adverse,ginsberg 1996,a randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,7,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1283,withdrawal,ginsberg 1996,a randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,3,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1284,withdrawal,ginsberg 1996,a randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,2,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1285,pain_int,ginsberg 1998,a pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,fibromyalgia,fibromyalgia,primary,≥11/18 tender points,parallel,not reported,0-10 numerical rating scale,baseline,NA,7.1,1.54,0.29103264421710495,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1286,pain_int,ginsberg 1998,a pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia,pain,pirlindole,antidepressant,antidepressant,pirlindole 150mg,maoi_rev,150mg,low,fixed,4 weeks,fibromyalgia,fibromyalgia,primary,≥11/18 tender points,parallel,not reported,0-10 numerical rating scale,baseline,NA,7.34,1.21,0.21063396370639437,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1287,pain_int,ginsberg 1998,a pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,fibromyalgia,fibromyalgia,primary,≥11/18 tender points,parallel,not reported,0-10 numerical rating scale,post_int,NA,6.79,1.53,0.2891428218520588,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1288,pain_int,ginsberg 1998,a pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia,pain,pirlindole,antidepressant,antidepressant,pirlindole 150mg,maoi_rev,150mg,low,fixed,4 weeks,fibromyalgia,fibromyalgia,primary,≥11/18 tender points,parallel,not reported,0-10 numerical rating scale,post_int,NA,4.85,2.11,0.36730385406652244,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1289,mood,ginsberg 1998,a pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,fibromyalgia,fibromyalgia,primary,≥11/18 tender points,parallel,not reported,scl-90-r,baseline,NA,163,52,9.827076298239907,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1290,mood,ginsberg 1998,a pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia,pain,pirlindole,antidepressant,antidepressant,pirlindole 150mg,maoi_rev,150mg,low,fixed,4 weeks,fibromyalgia,fibromyalgia,primary,≥11/18 tender points,parallel,not reported,scl-90-r,baseline,NA,174,54,9.400193421607684,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1291,mood,ginsberg 1998,a pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,fibromyalgia,fibromyalgia,primary,≥11/18 tender points,parallel,not reported,scl-90-r,post_int,NA,156,51,9.638094061735293,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1292,mood,ginsberg 1998,a pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia,pain,pirlindole,antidepressant,antidepressant,pirlindole 150mg,maoi_rev,150mg,low,fixed,4 weeks,fibromyalgia,fibromyalgia,primary,≥11/18 tender points,parallel,not reported,scl-90-r,post_int,NA,153,51,8.87796045374059,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1293,adverse,ginsberg 1998,a pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,fibromyalgia,fibromyalgia,primary,≥11/18 tender points,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,44,16,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1294,adverse,ginsberg 1998,a pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia,pain,pirlindole,antidepressant,antidepressant,pirlindole 150mg,maoi_rev,150mg,low,fixed,4 weeks,fibromyalgia,fibromyalgia,primary,≥11/18 tender points,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,45,18,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1295,adverse_dropout,ginsberg 1998,a pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,fibromyalgia,fibromyalgia,primary,≥11/18 tender points,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,44,3,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1296,adverse_dropout,ginsberg 1998,a pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia,pain,pirlindole,antidepressant,antidepressant,pirlindole 150mg,maoi_rev,150mg,low,fixed,4 weeks,fibromyalgia,fibromyalgia,primary,≥11/18 tender points,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,45,6,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1297,withdrawal,ginsberg 1998,a pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,fibromyalgia,fibromyalgia,primary,≥11/18 tender points,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,44,22,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1298,withdrawal,ginsberg 1998,a pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia,pain,pirlindole,antidepressant,antidepressant,pirlindole 150mg,maoi_rev,150mg,low,fixed,4 weeks,fibromyalgia,fibromyalgia,primary,≥11/18 tender points,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,45,17,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1299,serious_adverse,glaxosmithkline 2005,"treatment of fibromyalgia: a randomized, double-blind, placebo-controlled study of paroxetine, a selective serotonin re-uptake inhibitor.",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,2,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1300,serious_adverse,glaxosmithkline 2005,"treatment of fibromyalgia: a randomized, double-blind, placebo-controlled study of paroxetine, a selective serotonin re-uptake inhibitor.",pain,paroxetine,antidepressant,antidepressant,paroxetine 20mg,ssri,20mg,low,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,1,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1301,adverse_dropout,glaxosmithkline 2005,"treatment of fibromyalgia: a randomized, double-blind, placebo-controlled study of paroxetine, a selective serotonin re-uptake inhibitor.",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,4,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1302,adverse_dropout,glaxosmithkline 2005,"treatment of fibromyalgia: a randomized, double-blind, placebo-controlled study of paroxetine, a selective serotonin re-uptake inhibitor.",pain,paroxetine,antidepressant,antidepressant,paroxetine 20mg,ssri,20mg,low,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,5,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1303,withdrawal,glaxosmithkline 2005,"treatment of fibromyalgia: a randomized, double-blind, placebo-controlled study of paroxetine, a selective serotonin re-uptake inhibitor.",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,5,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1304,withdrawal,glaxosmithkline 2005,"treatment of fibromyalgia: a randomized, double-blind, placebo-controlled study of paroxetine, a selective serotonin re-uptake inhibitor.",pain,paroxetine,antidepressant,antidepressant,paroxetine 20mg,ssri,20mg,low,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,8,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1305,adverse_dropout,goldenberg 1986,"a randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia",pain,amitriptyline + naproxen,combined antidepressant intervention,antidepressant,amitriptyline 25mg + naproxen 1000mg,tca,25mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,1,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1306,adverse_dropout,goldenberg 1986,"a randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia",pain,naproxen,nsaid,non-antidepressant pharmacological,naproxen 100mg,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,0,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1307,adverse_dropout,goldenberg 1986,"a randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1308,adverse_dropout,goldenberg 1986,"a randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,1,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1309,withdrawal,goldenberg 1986,"a randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia",pain,amitriptyline + naproxen,combined antidepressant intervention,antidepressant,amitriptyline 25mg + naproxen 1000mg,tca,25mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,1,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1310,withdrawal,goldenberg 1986,"a randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia",pain,naproxen,nsaid,non-antidepressant pharmacological,naproxen 100mg,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,1,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1311,withdrawal,goldenberg 1986,"a randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,1,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1312,withdrawal,goldenberg 1986,"a randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,1,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1313,qol,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,fibromyalgia impact questionnaire total score,baseline,NA,57.3,17.6,3.161053315671239,NA,NA,NA,NA,NA,31,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
1314,qol,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,fibromyalgia impact questionnaire total score,baseline,NA,57.3,17.6,3.161053315671239,NA,NA,NA,NA,NA,31,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
1315,qol,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,fibromyalgia impact questionnaire total score,baseline,NA,57.3,17.6,3.161053315671239,NA,NA,NA,NA,NA,31,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
1316,qol,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,amitriptyline + fluoxetine,combined antidepressant intervention,antidepressant,amitriptyline 25mg + fluoxetine 20mg,tca + ssri,25mg + 20mg,low,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,fibromyalgia impact questionnaire total score,baseline,NA,57.3,17.6,3.161053315671239,NA,NA,NA,NA,NA,31,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
1317,qol,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,fibromyalgia impact questionnaire total score,post_int,NA,58.5,17.1,3.9230090491866063,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
1318,qol,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,fibromyalgia impact questionnaire total score,post_int,NA,52.3,22.9,4.997189686404226,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
1319,qol,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,fibromyalgia impact questionnaire total score,post_int,NA,47.6,19.8,4.221374183841086,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
1320,qol,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,amitriptyline + fluoxetine,combined antidepressant intervention,antidepressant,amitriptyline 25mg + fluoxetine 20mg,tca + ssri,25mg + 20mg,low,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,fibromyalgia impact questionnaire total score,post_int,NA,38,21.2,4.863613558055909,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
1321,pain_int,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,0-100 vas,baseline,NA,68.4,20.4,3.663948161346208,NA,NA,NA,NA,NA,31,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1322,pain_int,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,0-100 vas,baseline,NA,68.4,20.4,3.663948161346208,NA,NA,NA,NA,NA,31,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1323,pain_int,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,0-100 vas,baseline,NA,68.4,20.4,3.663948161346208,NA,NA,NA,NA,NA,31,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1324,pain_int,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,amitriptyline + fluoxetine,combined antidepressant intervention,antidepressant,amitriptyline 25mg + fluoxetine 20mg,tca + ssri,25mg + 20mg,low,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,0-100 vas,baseline,NA,68.4,20.4,3.663948161346208,NA,NA,NA,NA,NA,31,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1325,pain_int,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,0-100 vas,post_int,NA,81.5,16.5,3.785359608864269,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1326,pain_int,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,0-100 vas,post_int,NA,64.4,28.3,6.1755662936785845,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1327,pain_int,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,0-100 vas,post_int,NA,57.5,25.7,5.479258410339188,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1328,pain_int,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,amitriptyline + fluoxetine,combined antidepressant intervention,antidepressant,amitriptyline 25mg + fluoxetine 20mg,tca + ssri,25mg + 20mg,low,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,0-100 vas,post_int,NA,42.9,28.5,6.717514421272202,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1329,sleep,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,0-100 vas,baseline,NA,68,26.6,4.777501033912213,NA,NA,NA,NA,NA,31,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
1330,sleep,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,0-100 vas,baseline,NA,68,26.6,4.777501033912213,NA,NA,NA,NA,NA,31,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
1331,sleep,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,0-100 vas,baseline,NA,68,26.6,4.777501033912213,NA,NA,NA,NA,NA,31,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
1332,sleep,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,amitriptyline + fluoxetine,combined antidepressant intervention,antidepressant,amitriptyline 25mg + fluoxetine 20mg,tca + ssri,25mg + 20mg,low,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,0-100 vas,baseline,NA,68,26.6,4.777501033912213,NA,NA,NA,NA,NA,31,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
1333,sleep,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,0-100 vas,post_int,NA,74.6,23.9,5.483036039506425,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1334,sleep,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,0-100 vas,post_int,NA,57,34.8,7.5939825802125345,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1335,sleep,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,0-100 vas,post_int,NA,66,26.6,5.671139055059237,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1336,sleep,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,amitriptyline + fluoxetine,combined antidepressant intervention,antidepressant,amitriptyline 25mg + fluoxetine 20mg,tca + ssri,25mg + 20mg,low,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,0-100 vas,post_int,NA,39.9,29.2,6.882506003549063,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1337,mood,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,beck depression inventory,baseline,NA,12.4,8.5,1.5266450672275869,NA,NA,NA,NA,NA,31,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1338,mood,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,beck depression inventory,baseline,NA,12.4,8.5,1.5266450672275869,NA,NA,NA,NA,NA,31,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1339,mood,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,beck depression inventory,baseline,NA,12.4,8.5,1.5266450672275869,NA,NA,NA,NA,NA,31,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1340,mood,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,amitriptyline + fluoxetine,combined antidepressant intervention,antidepressant,amitriptyline 25mg + fluoxetine 20mg,tca + ssri,25mg + 20mg,low,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,beck depression inventory,baseline,NA,12.4,8.5,1.5266450672275869,NA,NA,NA,NA,NA,31,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1341,mood,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,beck depression inventory,post_int,NA,9.3,6.5,1.4912022701586514,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1342,mood,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,beck depression inventory,post_int,NA,8.7,6,1.3416407864998738,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1343,mood,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,beck depression inventory,post_int,NA,7.8,4.7,1.002043366871369,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1344,mood,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,amitriptyline + fluoxetine,combined antidepressant intervention,antidepressant,amitriptyline 25mg + fluoxetine 20mg,tca + ssri,25mg + 20mg,low,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,beck depression inventory,post_int,NA,7.4,4.4,1.0370899457402698,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1345,adverse_dropout,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,31,1,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1346,adverse_dropout,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,31,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1347,adverse_dropout,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,31,1,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1348,adverse_dropout,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,amitriptyline + fluoxetine,combined antidepressant intervention,antidepressant,amitriptyline 25mg + fluoxetine 20mg,tca + ssri,25mg + 20mg,low,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,31,3,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1349,withdrawal,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,31,1,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1350,withdrawal,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,31,1,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1351,withdrawal,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,31,4,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1352,withdrawal,goldenberg 1996,"a randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia",pain,amitriptyline + fluoxetine,combined antidepressant intervention,antidepressant,amitriptyline 25mg + fluoxetine 20mg,tca + ssri,25mg + 20mg,low,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥30 on 100vas,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,31,5,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1353,pain_int,goldman 2010,low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,arm pain,musculoskeletal,primary,≥3 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,4.3,1.8,0.23434003976548298,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1354,pain_int,goldman 2010,low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,6 weeks,arm pain,musculoskeletal,primary,≥3 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,4.7,1.8,0.23434003976548298,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1355,pain_int,goldman 2010,low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,arm pain,musculoskeletal,primary,≥3 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,post_int,NA,3.9,1.9,0.24735893086356533,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1356,pain_int,goldman 2010,low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,6 weeks,arm pain,musculoskeletal,primary,≥3 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,post_int,NA,4,1.8,0.23434003976548298,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1357,sleep,goldman 2010,low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,arm pain,musculoskeletal,primary,≥3 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,1.7,1.5,0.19528336647123581,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
1358,sleep,goldman 2010,low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,6 weeks,arm pain,musculoskeletal,primary,≥3 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,1.7,1.5,0.19528336647123581,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
1359,sleep,goldman 2010,low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,arm pain,musculoskeletal,primary,≥3 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,post_int,NA,1.8,1.5,0.19528336647123581,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1360,sleep,goldman 2010,low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,6 weeks,arm pain,musculoskeletal,primary,≥3 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,post_int,NA,1.4,1.1,0.14320780207890627,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1361,mood,goldman 2010,low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,arm pain,musculoskeletal,primary,≥3 on 10nrs,parallel,itt with locf,ces-d,baseline,NA,9.6,6.9,0.8983034857676848,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1362,mood,goldman 2010,low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,6 weeks,arm pain,musculoskeletal,primary,≥3 on 10nrs,parallel,itt with locf,ces-d,baseline,NA,10,7.7,1.0024546145523439,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1363,mood,goldman 2010,low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,arm pain,musculoskeletal,primary,≥3 on 10nrs,parallel,itt with locf,ces-d,post_int,NA,10.2,7.7,1.0024546145523439,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1364,mood,goldman 2010,low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,6 weeks,arm pain,musculoskeletal,primary,≥3 on 10nrs,parallel,itt with locf,ces-d,post_int,NA,8.4,6.9,0.8983034857676848,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1365,adverse,goldman 2010,low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,arm pain,musculoskeletal,primary,≥3 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,59,13,0.22,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1366,adverse,goldman 2010,low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,6 weeks,arm pain,musculoskeletal,primary,≥3 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,59,18,0.31,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1367,serious_adverse,goldman 2010,low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,arm pain,musculoskeletal,primary,≥3 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,59,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1368,serious_adverse,goldman 2010,low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,6 weeks,arm pain,musculoskeletal,primary,≥3 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,59,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1369,adverse_dropout,goldman 2010,low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,arm pain,musculoskeletal,primary,≥3 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,59,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1370,adverse_dropout,goldman 2010,low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,6 weeks,arm pain,musculoskeletal,primary,≥3 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,59,2,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1371,withdrawal,goldman 2010,low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,arm pain,musculoskeletal,primary,≥3 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,59,4,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1372,withdrawal,goldman 2010,low-dose amitriptyline for treatment of persistent arm pain due to repetitive use,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,6 weeks,arm pain,musculoskeletal,primary,≥3 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,59,8,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1373,pain_int,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,5.8,1.5,0.13987572123604708,NA,NA,NA,NA,NA,115,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1374,pain_int,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg,snri,20mg,low,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,5.9,1.6,0.14920076931845022,NA,NA,NA,NA,NA,115,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1375,pain_int,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6,1.7,0.15921958796888797,NA,NA,NA,NA,NA,114,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1376,pain_int,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,5.9,1.4,0.1317009215737036,NA,NA,NA,NA,NA,113,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1377,pain_int,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-1.91,2.063782934322309,0.22,NA,NA,NA,NA,NA,88,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1378,pain_int,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg,snri,20mg,low,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-2.36,2.0032723229755858,0.21,NA,NA,NA,NA,NA,91,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1379,pain_int,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-2.89,2.063782934322309,0.22,NA,NA,NA,NA,NA,88,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1380,pain_int,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-3.24,2.0571825392998067,0.23,NA,NA,NA,NA,NA,80,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1381,physical,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sf-36 physical component score,change_score,NA,3.94,7.7766188025388,0.77,NA,NA,NA,NA,NA,102,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1382,physical,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg,snri,20mg,low,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sf-36 physical component score,change_score,NA,3.67,7.721606050557099,0.78,NA,NA,NA,NA,NA,98,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1383,physical,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sf-36 physical component score,change_score,NA,5.86,7.738404228263086,0.77,NA,NA,NA,NA,NA,101,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1384,physical,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sf-36 physical component score,change_score,NA,5.85,7.637905472051877,0.76,NA,NA,NA,NA,NA,101,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1389,qol,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,eq-5d,change_score,NA,0.08,0.20688160865577204,0.02,NA,NA,NA,NA,NA,107,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
1390,qol,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg,snri,20mg,low,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,eq-5d,change_score,NA,0.1,0.2009975124224178,0.02,NA,NA,NA,NA,NA,101,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
1391,qol,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,eq-5d,change_score,NA,0.13,0.2039607805437114,0.02,NA,NA,NA,NA,NA,104,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
1392,qol,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,eq-5d,change_score,NA,0.13,0.20493901531919195,0.02,NA,NA,NA,NA,NA,105,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
1393,mood,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,beck depression inventory,baseline,NA,7.3,7.8,0.7273537504274448,NA,NA,NA,NA,NA,115,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1394,mood,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg,snri,20mg,low,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,beck depression inventory,baseline,NA,8.1,6.8,0.6341032696034133,NA,NA,NA,NA,NA,115,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1395,mood,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,beck depression inventory,baseline,NA,7.1,6.4,0.5994149194122842,NA,NA,NA,NA,NA,114,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1396,mood,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,beck depression inventory,baseline,NA,6.7,5.5,0.5173964776109785,NA,NA,NA,NA,NA,113,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1397,mood,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,beck depression inventory,change_score,NA,-1.74,4.266333320311483,0.48,NA,NA,NA,NA,NA,79,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1398,mood,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg,snri,20mg,low,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,beck depression inventory,change_score,NA,-2.44,4.34658486630596,0.48,NA,NA,NA,NA,NA,82,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1399,mood,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,beck depression inventory,change_score,NA,-2.71,4.327562824500645,0.49,NA,NA,NA,NA,NA,78,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1400,mood,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,beck depression inventory,change_score,NA,-3.11,4.301162633521313,0.5,NA,NA,NA,NA,NA,74,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1401,mood,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,beck anxiety inventory,post_int,NA,8.4,7.5,0.6993786061802354,NA,NA,NA,NA,NA,115,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_anxiety,post_int
1402,mood,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg,snri,20mg,low,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,beck anxiety inventory,post_int,NA,9.2,7.4,0.6900535580978323,NA,NA,NA,NA,NA,115,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_anxiety,post_int
1403,mood,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,beck anxiety inventory,post_int,NA,7.8,6.1,0.5713173450648333,NA,NA,NA,NA,NA,114,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_anxiety,post_int
1404,mood,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,beck anxiety inventory,post_int,NA,8.8,8.6,0.8090199468098936,NA,NA,NA,NA,NA,113,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_anxiety,post_int
1409,pain_sub,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,952.4704719832527,90,NA,NA,NA,NA,NA,112,29,0.26,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
1410,pain_sub,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg,snri,20mg,low,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,941.8874667389942,89,NA,NA,NA,NA,NA,112,46,0.41,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
1411,pain_sub,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,941.8874667389942,89,NA,NA,NA,NA,NA,112,55,0.49,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
1412,pain_sub,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,954.416051834838,91,NA,NA,NA,NA,NA,110,57,0.52,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
1413,adverse_dropout,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,115,6,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1414,adverse_dropout,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg,snri,20mg,low,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,115,5,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1415,adverse_dropout,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,114,15,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1416,adverse_dropout,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,113,22,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1417,withdrawal,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,115,28,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1418,withdrawal,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg,snri,20mg,low,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,115,24,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1419,withdrawal,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,114,28,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1420,withdrawal,goldstein 2005,duloxetine vs. placebo in patients with painful diabetic neuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,113,33,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1421,pain_int,gonzalez-viejo 2005,a comparative study of fibromyalgia treatment: ultrasonography and physiotherapy versus sertraline treatment,pain,physical therapy,physical therapy,non-pharmacological,physical therapy,n/a,n/a,n/a,n/a,24 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,no dropout,0-10 numerical rating scale,baseline,NA,7,0.9,0.15434872662825794,NA,NA,NA,NA,NA,34,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1422,pain_int,gonzalez-viejo 2005,a comparative study of fibromyalgia treatment: ultrasonography and physiotherapy versus sertraline treatment,pain,sertraline,antidepressant,antidepressant,sertraline 50mg,ssri,50mg,standard,fixed,24 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,no dropout,0-10 numerical rating scale,baseline,NA,7.2,1.1,0.18333333333333335,NA,NA,NA,NA,NA,36,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1423,pain_int,gonzalez-viejo 2005,a comparative study of fibromyalgia treatment: ultrasonography and physiotherapy versus sertraline treatment,pain,physical therapy,physical therapy,non-pharmacological,physical therapy,n/a,n/a,n/a,n/a,24 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,no dropout,0-10 numerical rating scale,post_int,NA,5.2,0.7,0.12004900959975617,NA,NA,NA,NA,NA,34,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1424,pain_int,gonzalez-viejo 2005,a comparative study of fibromyalgia treatment: ultrasonography and physiotherapy versus sertraline treatment,pain,sertraline,antidepressant,antidepressant,sertraline 50mg,ssri,50mg,standard,fixed,24 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,no dropout,0-10 numerical rating scale,post_int,NA,3,0.7,0.11666666666666665,NA,NA,NA,NA,NA,36,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1425,sleep,gonzalez-viejo 2005,a comparative study of fibromyalgia treatment: ultrasonography and physiotherapy versus sertraline treatment,pain,physical therapy,physical therapy,non-pharmacological,physical therapy,n/a,n/a,n/a,n/a,24 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,no dropout,0-10 numerical rating scale [higher=better],baseline,NA,2.3,0.4,0.06859943405700354,NA,NA,NA,NA,NA,34,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
1426,sleep,gonzalez-viejo 2005,a comparative study of fibromyalgia treatment: ultrasonography and physiotherapy versus sertraline treatment,pain,sertraline,antidepressant,antidepressant,sertraline 50mg,ssri,50mg,standard,fixed,24 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,no dropout,0-10 numerical rating scale [higher=better],baseline,NA,2,0.9,0.15,NA,NA,NA,NA,NA,36,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
1427,sleep,gonzalez-viejo 2005,a comparative study of fibromyalgia treatment: ultrasonography and physiotherapy versus sertraline treatment,pain,physical therapy,physical therapy,non-pharmacological,physical therapy,n/a,n/a,n/a,n/a,24 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,no dropout,0-10 numerical rating scale [higher=better],post_int,NA,2.8,0.4,0.06859943405700354,NA,NA,NA,NA,NA,34,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1428,sleep,gonzalez-viejo 2005,a comparative study of fibromyalgia treatment: ultrasonography and physiotherapy versus sertraline treatment,pain,sertraline,antidepressant,antidepressant,sertraline 50mg,ssri,50mg,standard,fixed,24 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,no dropout,0-10 numerical rating scale [higher=better],post_int,NA,7.8,0.2,0.03333333333333333,NA,NA,NA,NA,NA,36,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1429,adverse_dropout,gonzalez-viejo 2005,a comparative study of fibromyalgia treatment: ultrasonography and physiotherapy versus sertraline treatment,pain,physical therapy,physical therapy,non-pharmacological,physical therapy,n/a,n/a,n/a,n/a,24 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,no dropout,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,34,0,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1430,adverse_dropout,gonzalez-viejo 2005,a comparative study of fibromyalgia treatment: ultrasonography and physiotherapy versus sertraline treatment,pain,sertraline,antidepressant,antidepressant,sertraline 50mg,ssri,50mg,standard,fixed,24 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,no dropout,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,36,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1431,withdrawal,gonzalez-viejo 2005,a comparative study of fibromyalgia treatment: ultrasonography and physiotherapy versus sertraline treatment,pain,physical therapy,physical therapy,non-pharmacological,physical therapy,n/a,n/a,n/a,n/a,24 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,no dropout,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,34,0,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1432,withdrawal,gonzalez-viejo 2005,a comparative study of fibromyalgia treatment: ultrasonography and physiotherapy versus sertraline treatment,pain,sertraline,antidepressant,antidepressant,sertraline 50mg,ssri,50mg,standard,fixed,24 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,no dropout,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,36,0,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1433,pain_int,goodkin 1990,"a randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.51,1.49,0.33317412864746865,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1434,pain_int,goodkin 1990,"a randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome",pain,trazodone,antidepressant,antidepressant,trazodone ≤600mg,sari,201mg,standard,flexible,6 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.45,1.7,0.3624412178045377,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1435,pain_int,goodkin 1990,"a randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,post_int,NA,5.88,2.62,0.6010692227408718,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1436,pain_int,goodkin 1990,"a randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome",pain,trazodone,antidepressant,antidepressant,trazodone ≤600mg,sari,201mg,standard,flexible,6 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,post_int,NA,5.34,2.99,0.6524714918056173,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1441,physical,goodkin 1990,"a randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,sickness impact profile - physical subscale,baseline,NA,27.65,10.53,2.3545795803072784,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1442,physical,goodkin 1990,"a randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome",pain,trazodone,antidepressant,antidepressant,trazodone ≤600mg,sari,201mg,standard,flexible,6 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,sickness impact profile - physical subscale,baseline,NA,26.69,15.62,3.330195189474635,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1443,physical,goodkin 1990,"a randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,sickness impact profile - physical subscale,post_int,NA,22.84,12.72,2.9181681348335453,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1444,physical,goodkin 1990,"a randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome",pain,trazodone,antidepressant,antidepressant,trazodone ≤600mg,sari,201mg,standard,flexible,6 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,sickness impact profile - physical subscale,post_int,NA,25.41,17.04,3.71843284962131,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1445,mood,goodkin 1990,"a randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,sickness impact profile - psychosocial subscale,baseline,NA,27.04,18.49,4.1344896903971105,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
1446,mood,goodkin 1990,"a randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome",pain,trazodone,antidepressant,antidepressant,trazodone ≤600mg,sari,201mg,standard,flexible,6 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,sickness impact profile - psychosocial subscale,baseline,NA,28.54,20.21,4.308786477546887,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
1447,mood,goodkin 1990,"a randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,sickness impact profile - psychosocial subscale,post_int,NA,20.77,16.7,3.831242755638381,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
1448,mood,goodkin 1990,"a randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome",pain,trazodone,antidepressant,antidepressant,trazodone ≤600mg,sari,201mg,standard,flexible,6 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,sickness impact profile - psychosocial subscale,post_int,NA,28.97,25.05,5.46635815041161,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
1449,withdrawal,goodkin 1990,"a randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,4,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1450,withdrawal,goodkin 1990,"a randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome",pain,trazodone,antidepressant,antidepressant,trazodone ≤600mg,sari,201mg,standard,flexible,6 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,9,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1451,pain_int,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,benzotropine mesylate,active placebo,placebo,benzotropine mesylate 0.125mg,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,descriptor differential scale,baseline,NA,11.96,4.63,0.805979547074881,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1452,pain_int,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,desipramine,antidepressant,antidepressant,desipramine 20-60mg,tca,20-60mg,low,flexible,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,descriptor differential scale,baseline,NA,9.97,5.05,0.8302148858920543,NA,NA,NA,NA,NA,37,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1453,pain_int,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,benzotropine mesylate + cognitive behavioural therapy,psychological therapy,non-pharmacological,benzotropine mesylate 0.125mg + cognitive behavioural therapy,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,descriptor differential scale,baseline,NA,11.6,4.37,0.7494488170727636,NA,NA,NA,NA,NA,34,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1454,pain_int,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,desipramine + cognitive behavioural therapy,combined antidepressant intervention,antidepressant,desipramine 20-60mg + cognitive behavioural therapy,tca,20-60mg,low,flexible,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,descriptor differential scale,baseline,NA,11.91,5.07,0.8335028656381616,NA,NA,NA,NA,NA,37,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1455,pain_int,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,benzotropine mesylate,active placebo,placebo,benzotropine mesylate 0.125mg,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,descriptor differential scale,post_int,NA,8.72,5.49,0.9556863311967811,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1456,pain_int,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,desipramine,antidepressant,antidepressant,desipramine 20-60mg,tca,20-60mg,low,flexible,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,descriptor differential scale,post_int,NA,7.55,5.63,0.9255662985291616,NA,NA,NA,NA,NA,37,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1457,pain_int,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,benzotropine mesylate + cognitive behavioural therapy,psychological therapy,non-pharmacological,benzotropine mesylate 0.125mg + cognitive behavioural therapy,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,descriptor differential scale,post_int,NA,7.61,5.32,0.912372472958147,NA,NA,NA,NA,NA,34,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1458,pain_int,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,desipramine + cognitive behavioural therapy,combined antidepressant intervention,antidepressant,desipramine 20-60mg + cognitive behavioural therapy,tca,20-60mg,low,flexible,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,descriptor differential scale,post_int,NA,8.74,5.55,0.9124143795447329,NA,NA,NA,NA,NA,37,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1459,physical,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,benzotropine mesylate,active placebo,placebo,benzotropine mesylate 0.125mg,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,rmdq-24,baseline,NA,12.47,3.75,0.6527912098338668,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1460,physical,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,desipramine,antidepressant,antidepressant,desipramine 20-60mg,tca,20-60mg,low,flexible,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,rmdq-24,baseline,NA,10.51,5.44,0.8943304909411438,NA,NA,NA,NA,NA,37,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1461,physical,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,benzotropine mesylate + cognitive behavioural therapy,psychological therapy,non-pharmacological,benzotropine mesylate 0.125mg + cognitive behavioural therapy,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,rmdq-24,baseline,NA,12.97,4.33,0.7425888736670633,NA,NA,NA,NA,NA,34,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1462,physical,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,desipramine + cognitive behavioural therapy,combined antidepressant intervention,antidepressant,desipramine 20-60mg + cognitive behavioural therapy,tca,20-60mg,low,flexible,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,rmdq-24,baseline,NA,11.65,5.41,0.889398521321983,NA,NA,NA,NA,NA,37,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1463,physical,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,benzotropine mesylate,active placebo,placebo,benzotropine mesylate 0.125mg,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,rmdq-24,post_int,NA,9.5,5.15,0.896499928171844,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1464,physical,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,desipramine,antidepressant,antidepressant,desipramine 20-60mg,tca,20-60mg,low,flexible,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,rmdq-24,post_int,NA,7.65,5.99,0.9847499339590903,NA,NA,NA,NA,NA,37,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1465,physical,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,benzotropine mesylate + cognitive behavioural therapy,psychological therapy,non-pharmacological,benzotropine mesylate 0.125mg + cognitive behavioural therapy,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,rmdq-24,post_int,NA,9.33,5.74,0.9844018787180007,NA,NA,NA,NA,NA,34,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1466,physical,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,desipramine + cognitive behavioural therapy,combined antidepressant intervention,antidepressant,desipramine 20-60mg + cognitive behavioural therapy,tca,20-60mg,low,flexible,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,rmdq-24,post_int,NA,8.66,5.79,0.9518701364980188,NA,NA,NA,NA,NA,37,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1467,pain_mod,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,benzotropine mesylate,active placebo,placebo,benzotropine mesylate 0.125mg,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,13,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
1468,pain_mod,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,desipramine,antidepressant,antidepressant,desipramine 20-60mg,tca,20-60mg,low,flexible,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,37,18,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
1469,pain_mod,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,benzotropine mesylate + cognitive behavioural therapy,psychological therapy,non-pharmacological,benzotropine mesylate 0.125mg + cognitive behavioural therapy,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,34,12,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
1470,pain_mod,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,desipramine + cognitive behavioural therapy,combined antidepressant intervention,antidepressant,desipramine 20-60mg + cognitive behavioural therapy,tca,20-60mg,low,flexible,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,37,15,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
1471,adverse,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,benzotropine mesylate,active placebo,placebo,benzotropine mesylate 0.125mg,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,6,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1472,adverse,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,desipramine,antidepressant,antidepressant,desipramine 20-60mg,tca,20-60mg,low,flexible,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,12,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1473,adverse,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,benzotropine mesylate + cognitive behavioural therapy,psychological therapy,non-pharmacological,benzotropine mesylate 0.125mg + cognitive behavioural therapy,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,34,8,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1474,adverse,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,desipramine + cognitive behavioural therapy,combined antidepressant intervention,antidepressant,desipramine 20-60mg + cognitive behavioural therapy,tca,20-60mg,low,flexible,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,37,7,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1475,serious_adverse,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,benzotropine mesylate,active placebo,placebo,benzotropine mesylate 0.125mg,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1476,serious_adverse,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,desipramine,antidepressant,antidepressant,desipramine 20-60mg,tca,20-60mg,low,flexible,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,1,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1477,serious_adverse,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,benzotropine mesylate + cognitive behavioural therapy,psychological therapy,non-pharmacological,benzotropine mesylate 0.125mg + cognitive behavioural therapy,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,34,0,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1478,serious_adverse,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,desipramine + cognitive behavioural therapy,combined antidepressant intervention,antidepressant,desipramine 20-60mg + cognitive behavioural therapy,tca,20-60mg,low,flexible,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,37,1,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1479,adverse_dropout,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,benzotropine mesylate,active placebo,placebo,benzotropine mesylate 0.125mg,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,2,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1480,adverse_dropout,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,desipramine,antidepressant,antidepressant,desipramine 20-60mg,tca,20-60mg,low,flexible,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,3,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1481,adverse_dropout,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,benzotropine mesylate + cognitive behavioural therapy,psychological therapy,non-pharmacological,benzotropine mesylate 0.125mg + cognitive behavioural therapy,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,34,1,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1482,adverse_dropout,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,desipramine + cognitive behavioural therapy,combined antidepressant intervention,antidepressant,desipramine 20-60mg + cognitive behavioural therapy,tca,20-60mg,low,flexible,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,37,5,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1483,withdrawal,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,benzotropine mesylate,active placebo,placebo,benzotropine mesylate 0.125mg,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,9,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1484,withdrawal,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,desipramine,antidepressant,antidepressant,desipramine 20-60mg,tca,20-60mg,low,flexible,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,11,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1485,withdrawal,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,benzotropine mesylate + cognitive behavioural therapy,psychological therapy,non-pharmacological,benzotropine mesylate 0.125mg + cognitive behavioural therapy,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,34,7,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1486,withdrawal,gould 2020,"a randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain",pain,desipramine + cognitive behavioural therapy,combined antidepressant intervention,antidepressant,desipramine 20-60mg + cognitive behavioural therapy,tca,20-60mg,low,flexible,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,37,16,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1487,adverse_dropout,grace 1985,"controlled, double-blind, randomized trial of amitriptyline in relieving articular pain and tenderness in patients with rheumatoid arthritis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,no,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,3,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1488,adverse_dropout,grace 1985,"controlled, double-blind, randomized trial of amitriptyline in relieving articular pain and tenderness in patients with rheumatoid arthritis",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 50-75mg,tca,50-75mg,standard,flexible,12 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,no,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,3,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1489,withdrawal,grace 1985,"controlled, double-blind, randomized trial of amitriptyline in relieving articular pain and tenderness in patients with rheumatoid arthritis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,no,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,4,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1490,withdrawal,grace 1985,"controlled, double-blind, randomized trial of amitriptyline in relieving articular pain and tenderness in patients with rheumatoid arthritis",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 50-75mg,tca,50-75mg,standard,flexible,12 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,no,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,4,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1491,pain_int,graff-radford 2000,amitriptyline and fluphenazine in the treatment of postherpetic neuralgia,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 12.5-200mg,tca,12.5-200mg,unable to be categorised,flexible,8 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,parallel,completer analysis,0-10 numerical rating scale,baseline,NA,55.9,19.58,5.903592126832612,NA,NA,NA,NA,NA,11,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1492,pain_int,graff-radford 2000,amitriptyline and fluphenazine in the treatment of postherpetic neuralgia,pain,amitriptyline + fluphenazine,combined antidepressant intervention,antidepressant,amitriptyline 12.5-200mg + fluphenazine 1-3mg,tca,12.5-200mg,unable to be categorised,flexible,8 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,parallel,completer analysis,0-10 numerical rating scale,baseline,NA,47.6,13.43,3.8769070576083373,NA,NA,NA,NA,NA,12,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1493,pain_int,graff-radford 2000,amitriptyline and fluphenazine in the treatment of postherpetic neuralgia,pain,fluphenazine,antipsychotic,non-antidepressant pharmacological,fluphenazine 1-3mg,n/a,n/a,n/a,n/a,8 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,parallel,completer analysis,0-10 numerical rating scale,baseline,NA,65.4,10.87,3.0147955664841204,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1494,pain_int,graff-radford 2000,amitriptyline and fluphenazine in the treatment of postherpetic neuralgia,pain,glycopyrrolate,active placebo,placebo,glycopyrrolate,n/a,n/a,n/a,n/a,8 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,parallel,completer analysis,0-10 numerical rating scale,baseline,NA,53.92,17.05,4.728819172820079,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1495,pain_int,graff-radford 2000,amitriptyline and fluphenazine in the treatment of postherpetic neuralgia,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 12.5-200mg,tca,12.5-200mg,unable to be categorised,flexible,8 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,parallel,completer analysis,0-10 numerical rating scale,post_int,NA,26.6,16.77,5.056345248569096,NA,NA,NA,NA,NA,11,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1496,pain_int,graff-radford 2000,amitriptyline and fluphenazine in the treatment of postherpetic neuralgia,pain,amitriptyline + fluphenazine,combined antidepressant intervention,antidepressant,amitriptyline 12.5-200mg + fluphenazine 1-3mg,tca,12.5-200mg,unable to be categorised,flexible,8 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,parallel,completer analysis,0-10 numerical rating scale,post_int,NA,35.41,24.53,7.081201051610761,NA,NA,NA,NA,NA,12,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1497,pain_int,graff-radford 2000,amitriptyline and fluphenazine in the treatment of postherpetic neuralgia,pain,fluphenazine,antipsychotic,non-antidepressant pharmacological,fluphenazine 1-3mg,n/a,n/a,n/a,n/a,8 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,parallel,completer analysis,0-10 numerical rating scale,post_int,NA,53.9,27.79,7.7075592265495585,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1498,pain_int,graff-radford 2000,amitriptyline and fluphenazine in the treatment of postherpetic neuralgia,pain,glycopyrrolate,active placebo,placebo,glycopyrrolate,n/a,n/a,n/a,n/a,8 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,parallel,completer analysis,0-10 numerical rating scale,post_int,NA,48.53,24.99,6.930978951834238,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1499,mood,graff-radford 2000,amitriptyline and fluphenazine in the treatment of postherpetic neuralgia,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 12.5-200mg,tca,12.5-200mg,unable to be categorised,flexible,8 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,parallel,completer analysis,beck depression inventory,baseline,NA,12.1,7.3,2.2010328154176744,NA,NA,NA,NA,NA,11,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1500,mood,graff-radford 2000,amitriptyline and fluphenazine in the treatment of postherpetic neuralgia,pain,amitriptyline + fluphenazine,combined antidepressant intervention,antidepressant,amitriptyline 12.5-200mg + fluphenazine 1-3mg,tca,12.5-200mg,unable to be categorised,flexible,8 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,parallel,completer analysis,beck depression inventory,baseline,NA,15.9,24,6.92820323027551,NA,NA,NA,NA,NA,12,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1501,mood,graff-radford 2000,amitriptyline and fluphenazine in the treatment of postherpetic neuralgia,pain,fluphenazine,antipsychotic,non-antidepressant pharmacological,fluphenazine 1-3mg,n/a,n/a,n/a,n/a,8 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,parallel,completer analysis,beck depression inventory,baseline,NA,9.5,5.8,1.6086305690531644,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1502,mood,graff-radford 2000,amitriptyline and fluphenazine in the treatment of postherpetic neuralgia,pain,glycopyrrolate,active placebo,placebo,glycopyrrolate,n/a,n/a,n/a,n/a,8 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,parallel,completer analysis,beck depression inventory,baseline,NA,13.2,6.7,1.8582456573545176,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1503,mood,graff-radford 2000,amitriptyline and fluphenazine in the treatment of postherpetic neuralgia,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 12.5-200mg,tca,12.5-200mg,unable to be categorised,flexible,8 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,parallel,completer analysis,beck depression inventory,post_int,NA,11.1,7.5,2.2613350843332274,NA,NA,NA,NA,NA,11,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1504,mood,graff-radford 2000,amitriptyline and fluphenazine in the treatment of postherpetic neuralgia,pain,amitriptyline + fluphenazine,combined antidepressant intervention,antidepressant,amitriptyline 12.5-200mg + fluphenazine 1-3mg,tca,12.5-200mg,unable to be categorised,flexible,8 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,parallel,completer analysis,beck depression inventory,post_int,NA,7.2,6.03,1.7407110616067218,NA,NA,NA,NA,NA,12,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1505,mood,graff-radford 2000,amitriptyline and fluphenazine in the treatment of postherpetic neuralgia,pain,fluphenazine,antipsychotic,non-antidepressant pharmacological,fluphenazine 1-3mg,n/a,n/a,n/a,n/a,8 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,parallel,completer analysis,beck depression inventory,post_int,NA,14.2,6.5,1.8027756377319948,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1506,mood,graff-radford 2000,amitriptyline and fluphenazine in the treatment of postherpetic neuralgia,pain,glycopyrrolate,active placebo,placebo,glycopyrrolate,n/a,n/a,n/a,n/a,8 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,parallel,completer analysis,beck depression inventory,post_int,NA,14,14.3,3.9661064030103885,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1515,adverse_dropout,graff-radford 2000,amitriptyline and fluphenazine in the treatment of postherpetic neuralgia,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 12.5-200mg,tca,12.5-200mg,unable to be categorised,flexible,8 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,1,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1516,adverse_dropout,graff-radford 2000,amitriptyline and fluphenazine in the treatment of postherpetic neuralgia,pain,amitriptyline + fluphenazine,combined antidepressant intervention,antidepressant,amitriptyline 12.5-200mg + fluphenazine 1-3mg,tca,12.5-200mg,unable to be categorised,flexible,8 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1517,adverse_dropout,graff-radford 2000,amitriptyline and fluphenazine in the treatment of postherpetic neuralgia,pain,fluphenazine,antipsychotic,non-antidepressant pharmacological,fluphenazine 1-3mg,n/a,n/a,n/a,n/a,8 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,0,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1518,adverse_dropout,graff-radford 2000,amitriptyline and fluphenazine in the treatment of postherpetic neuralgia,pain,glycopyrrolate,active placebo,placebo,glycopyrrolate,n/a,n/a,n/a,n/a,8 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1519,withdrawal,graff-radford 2000,amitriptyline and fluphenazine in the treatment of postherpetic neuralgia,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 12.5-200mg,tca,12.5-200mg,unable to be categorised,flexible,8 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,1,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1520,withdrawal,graff-radford 2000,amitriptyline and fluphenazine in the treatment of postherpetic neuralgia,pain,amitriptyline + fluphenazine,combined antidepressant intervention,antidepressant,amitriptyline 12.5-200mg + fluphenazine 1-3mg,tca,12.5-200mg,unable to be categorised,flexible,8 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,0,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1521,withdrawal,graff-radford 2000,amitriptyline and fluphenazine in the treatment of postherpetic neuralgia,pain,fluphenazine,antipsychotic,non-antidepressant pharmacological,fluphenazine 1-3mg,n/a,n/a,n/a,n/a,8 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,0,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1522,withdrawal,graff-radford 2000,amitriptyline and fluphenazine in the treatment of postherpetic neuralgia,pain,glycopyrrolate,active placebo,placebo,glycopyrrolate,n/a,n/a,n/a,n/a,8 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1523,pain_int,hadianfard 2012,a randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine,pain,acupuncture,acupuncture,non-pharmacological,acupuncture,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt method unspecified,0-10 numerical rating scale,baseline,NA,6.2,2.2,0.5680375574437545,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1524,pain_int,hadianfard 2012,a randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine,pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt method unspecified,0-10 numerical rating scale,baseline,NA,7.6,1.8,0.46475800154489,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1525,pain_int,hadianfard 2012,a randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine,pain,acupuncture,acupuncture,non-pharmacological,acupuncture,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt method unspecified,0-10 numerical rating scale,post_int,NA,5.5,2.3,0.5938574464184705,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1526,pain_int,hadianfard 2012,a randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine,pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt method unspecified,0-10 numerical rating scale,post_int,NA,6.4,2.1,0.5422176684690384,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1527,qol,hadianfard 2012,a randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine,pain,acupuncture,acupuncture,non-pharmacological,acupuncture,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt method unspecified,fibromyalgia impact questionnaire total score,baseline,NA,42.4,11,2.840187787218772,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
1528,qol,hadianfard 2012,a randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine,pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt method unspecified,fibromyalgia impact questionnaire total score,baseline,NA,43.8,9.8,2.530349119522179,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
1529,qol,hadianfard 2012,a randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine,pain,acupuncture,acupuncture,non-pharmacological,acupuncture,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt method unspecified,fibromyalgia impact questionnaire total score,post_int,NA,38.1,12.1,3.1242065659406495,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
1530,qol,hadianfard 2012,a randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine,pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt method unspecified,fibromyalgia impact questionnaire total score,post_int,NA,42.7,9.6,2.478709341572747,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
1531,mood,hadianfard 2012,a randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine,pain,acupuncture,acupuncture,non-pharmacological,acupuncture,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt method unspecified,0-10 numerical rating scale,baseline,NA,2.9,3,0.7745966692414834,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1532,mood,hadianfard 2012,a randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine,pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt method unspecified,0-10 numerical rating scale,baseline,NA,4,3.1,0.8004165582161995,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1533,mood,hadianfard 2012,a randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine,pain,acupuncture,acupuncture,non-pharmacological,acupuncture,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt method unspecified,0-10 numerical rating scale,post_int,NA,2.2,2.6,0.6713171133426189,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1534,mood,hadianfard 2012,a randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine,pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt method unspecified,0-10 numerical rating scale,post_int,NA,3.6,3.1,0.8004165582161995,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1539,physical,hadianfard 2012,a randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine,pain,acupuncture,acupuncture,non-pharmacological,acupuncture,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt method unspecified,0-10 numerical rating scale,baseline,NA,4.1,2.4,0.6196773353931867,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1540,physical,hadianfard 2012,a randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine,pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt method unspecified,0-10 numerical rating scale,baseline,NA,2.7,2,0.5163977794943222,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1541,physical,hadianfard 2012,a randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine,pain,acupuncture,acupuncture,non-pharmacological,acupuncture,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt method unspecified,0-10 numerical rating scale,post_int,NA,3.5,2.5,0.6454972243679028,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1542,physical,hadianfard 2012,a randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine,pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt method unspecified,0-10 numerical rating scale,post_int,NA,3.3,2.2,0.5680375574437545,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1543,adverse_dropout,hameroff 1984,doxepin's effects on chronic pain and depression: a controlled study,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,cervical/lumbar spine pain,musculoskeletal,musculoskeletal,no,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,3,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1544,adverse_dropout,hameroff 1984,doxepin's effects on chronic pain and depression: a controlled study,pain,doxepin,antidepressant,antidepressant,doxepin ≤300mg,tca,50-300mg,unable to be categorised,flexible,6 weeks,cervical/lumbar spine pain,musculoskeletal,musculoskeletal,no,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,3,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1545,withdrawal,hameroff 1984,doxepin's effects on chronic pain and depression: a controlled study,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,cervical/lumbar spine pain,musculoskeletal,musculoskeletal,no,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,6,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1546,withdrawal,hameroff 1984,doxepin's effects on chronic pain and depression: a controlled study,pain,doxepin,antidepressant,antidepressant,doxepin ≤300mg,tca,50-300mg,unable to be categorised,flexible,6 weeks,cervical/lumbar spine pain,musculoskeletal,musculoskeletal,no,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,3,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1547,pain_int,hammody 2015,pregabalin versus amitriptyline in the treatment of fibromyalgia patients (a double blind comparative study),pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 75mg,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,widespread pain index wolfe 2010,post_int,NA,7.12,4.601,0.8009312950521658,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1548,pain_int,hammody 2015,pregabalin versus amitriptyline in the treatment of fibromyalgia patients (a double blind comparative study),pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,widespread pain index wolfe 2010,post_int,NA,8.71,3.727,0.5555883568094477,NA,NA,NA,NA,NA,45,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1549,qol,hammody 2015,pregabalin versus amitriptyline in the treatment of fibromyalgia patients (a double blind comparative study),pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 75mg,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fiqr,post_int,NA,40.06,26.1,6.975518413914277,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
1550,qol,hammody 2015,pregabalin versus amitriptyline in the treatment of fibromyalgia patients (a double blind comparative study),pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fiqr,post_int,NA,60.98,19.01,4.2507652252271,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
1551,pain_int,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,moclobemide,antidepressant,antidepressant,moclobemide 450-600mg,maoi_rev,450-600mg,high,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,0-10 numerical rating scale,baseline,NA,5.7,2.1,0.3202469976984698,NA,NA,NA,NA,NA,43,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1552,pain_int,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25-37.5mg,tca,25-37.5mg,standard,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,0-10 numerical rating scale,baseline,NA,6,2.1,0.32403703492039304,NA,NA,NA,NA,NA,42,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1553,pain_int,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,0-10 numerical rating scale,baseline,NA,5.7,2.3,0.3428637565499677,NA,NA,NA,NA,NA,45,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1554,pain_int,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,moclobemide,antidepressant,antidepressant,moclobemide 450-600mg,maoi_rev,450-600mg,high,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,0-10 numerical rating scale,post_int,NA,4.5,2.7,0.41174613989803266,NA,NA,NA,NA,NA,43,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1555,pain_int,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25-37.5mg,tca,25-37.5mg,standard,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,0-10 numerical rating scale,post_int,NA,4.5,2.8,0.43204937989385733,NA,NA,NA,NA,NA,42,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1556,pain_int,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,0-10 numerical rating scale,post_int,NA,5.2,2.7,0.40249223594996214,NA,NA,NA,NA,NA,45,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1557,sleep,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,moclobemide,antidepressant,antidepressant,moclobemide 450-600mg,maoi_rev,450-600mg,high,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,0-10 numerical rating scale,baseline,NA,5.8,2,0.30499714066520933,NA,NA,NA,NA,NA,43,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
1558,sleep,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25-37.5mg,tca,25-37.5mg,standard,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,0-10 numerical rating scale,baseline,NA,5.9,2.2,0.3394673699166022,NA,NA,NA,NA,NA,42,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
1559,sleep,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,0-10 numerical rating scale,baseline,NA,5.5,2.7,0.40249223594996214,NA,NA,NA,NA,NA,45,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
1560,sleep,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,moclobemide,antidepressant,antidepressant,moclobemide 450-600mg,maoi_rev,450-600mg,high,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,0-10 numerical rating scale,post_int,NA,5.8,3,0.457495710997814,NA,NA,NA,NA,NA,43,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1561,sleep,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25-37.5mg,tca,25-37.5mg,standard,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,0-10 numerical rating scale,post_int,NA,3.6,2.8,0.43204937989385733,NA,NA,NA,NA,NA,42,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1562,sleep,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,0-10 numerical rating scale,post_int,NA,4.8,2.9,0.4422458539645535,NA,NA,NA,NA,NA,43,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1563,mood,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,moclobemide,antidepressant,antidepressant,moclobemide 450-600mg,maoi_rev,450-600mg,high,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,nottingham health profile emotions subscale,baseline,NA,13.9,20.6,3.1414705488516566,NA,NA,NA,NA,NA,43,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
1564,mood,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25-37.5mg,tca,25-37.5mg,standard,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,nottingham health profile emotions subscale,baseline,NA,6.7,10.4,1.6047548396057558,NA,NA,NA,NA,NA,42,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
1565,mood,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,nottingham health profile emotions subscale,baseline,NA,15.7,20.2,3.0112382096997163,NA,NA,NA,NA,NA,45,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
1566,mood,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,moclobemide,antidepressant,antidepressant,moclobemide 450-600mg,maoi_rev,450-600mg,high,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,nottingham health profile emotions subscale,post_int,NA,15.4,21.1,3.217719834017959,NA,NA,NA,NA,NA,43,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
1567,mood,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25-37.5mg,tca,25-37.5mg,standard,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,nottingham health profile emotions subscale,post_int,NA,2.9,7.7,1.1881357947081077,NA,NA,NA,NA,NA,42,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
1568,mood,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,nottingham health profile emotions subscale,post_int,NA,13.2,20.2,3.0112382096997163,NA,NA,NA,NA,NA,45,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
1569,physical,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,moclobemide,antidepressant,antidepressant,moclobemide 450-600mg,maoi_rev,450-600mg,high,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,nottingham health profile mobility subscale,baseline,NA,22.3,15.4,2.348477983122112,NA,NA,NA,NA,NA,43,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1570,physical,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25-37.5mg,tca,25-37.5mg,standard,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,nottingham health profile mobility subscale,baseline,NA,23,17.9,2.762029964321445,NA,NA,NA,NA,NA,42,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1571,physical,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,nottingham health profile mobility subscale,baseline,NA,24.7,14.7,2.191346617949794,NA,NA,NA,NA,NA,45,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1572,physical,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,moclobemide,antidepressant,antidepressant,moclobemide 450-600mg,maoi_rev,450-600mg,high,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,nottingham health profile mobility subscale,post_int,NA,19.6,17.6,2.6839748378538424,NA,NA,NA,NA,NA,43,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1573,physical,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25-37.5mg,tca,25-37.5mg,standard,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,nottingham health profile mobility subscale,post_int,NA,20.7,18.3,2.823751304306282,NA,NA,NA,NA,NA,42,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1574,physical,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,nottingham health profile mobility subscale,post_int,NA,25.4,17.7,2.6385602134497517,NA,NA,NA,NA,NA,45,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1575,adverse,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,moclobemide,antidepressant,antidepressant,moclobemide 450-600mg,maoi_rev,450-600mg,high,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,43,33,0.77,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1576,adverse,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25-37.5mg,tca,25-37.5mg,standard,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,42,31,0.74,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1577,adverse,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,45,36,0.8,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1578,adverse_dropout,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,moclobemide,antidepressant,antidepressant,moclobemide 450-600mg,maoi_rev,450-600mg,high,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,43,6,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1579,adverse_dropout,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25-37.5mg,tca,25-37.5mg,standard,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,42,5,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1580,adverse_dropout,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,45,5,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1581,withdrawal,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,moclobemide,antidepressant,antidepressant,moclobemide 450-600mg,maoi_rev,450-600mg,high,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,43,13,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1582,withdrawal,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25-37.5mg,tca,25-37.5mg,standard,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,42,10,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1583,withdrawal,hannonen 1998,"a randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,45,15,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1584,qol,heymann 2001,"a double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. an analysis of outcome measures",fibromyalgia symptoms,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fibromyalgia impact questionnaire total score,baseline,NA,63.17,50.60858425208119,8.32,NA,NA,NA,NA,NA,37,NA,NA,FALSE,NA,*study reports these as 2 se,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
1585,qol,heymann 2001,"a double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. an analysis of outcome measures",fibromyalgia symptoms,nortriptyline,antidepressant,antidepressant,nortriptyline 25mg,tca,25mg,low,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fibromyalgia impact questionnaire total score,baseline,NA,67.3,56.16,9.36,NA,NA,NA,NA,NA,36,NA,NA,FALSE,NA,*study reports these as 2 se,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
1586,qol,heymann 2001,"a double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. an analysis of outcome measures",fibromyalgia symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fibromyalgia impact questionnaire total score,baseline,NA,67.45,49.862803771950084,8.68,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,*study reports these as 2 se,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
1587,qol,heymann 2001,"a double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. an analysis of outcome measures",fibromyalgia symptoms,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fibromyalgia impact questionnaire total score,post_int,NA,39.97,79.5625338963007,13.08,NA,NA,NA,NA,NA,37,NA,NA,FALSE,NA,*study reports these as 2 se,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
1588,qol,heymann 2001,"a double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. an analysis of outcome measures",fibromyalgia symptoms,nortriptyline,antidepressant,antidepressant,nortriptyline 25mg,tca,25mg,low,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fibromyalgia impact questionnaire total score,post_int,NA,48.78,87.36,14.56,NA,NA,NA,NA,NA,36,NA,NA,FALSE,NA,*study reports these as 2 se,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
1589,qol,heymann 2001,"a double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. an analysis of outcome measures",fibromyalgia symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fibromyalgia impact questionnaire total score,post_int,NA,51.68,91.68321983874694,15.96,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,*study reports these as 2 se,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
1590,serious_adverse,heymann 2001,"a double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. an analysis of outcome measures",fibromyalgia symptoms,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1591,serious_adverse,heymann 2001,"a double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. an analysis of outcome measures",fibromyalgia symptoms,nortriptyline,antidepressant,antidepressant,nortriptyline 25mg,tca,25mg,low,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1592,serious_adverse,heymann 2001,"a double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. an analysis of outcome measures",fibromyalgia symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1593,withdrawal,heymann 2001,"a double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. an analysis of outcome measures",fibromyalgia symptoms,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,3,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1594,withdrawal,heymann 2001,"a double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. an analysis of outcome measures",fibromyalgia symptoms,nortriptyline,antidepressant,antidepressant,nortriptyline 25mg,tca,25mg,low,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,2,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1595,withdrawal,heymann 2001,"a double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. an analysis of outcome measures",fibromyalgia symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,7,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1596,pain_mod,holbech 2015,imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,69,10,0.14,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
1597,pain_mod,holbech 2015,imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,69,16,0.23,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
1598,pain_mod,holbech 2015,imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,pain,imipramine,antidepressant,antidepressant,imipramine 75mg,tca,75mg,standard,fixed,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,69,20,0.29,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
1599,pain_mod,holbech 2015,imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,pain,pregabalin + imipramine,combined antidepressant intervention,antidepressant,pregabalin 300mg + imipramine 75mg,tca,75mg,standard,fixed,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,69,36,0.52,FALSE,NA,NA,NA,2021-09-27,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
1600,pain_sub,holbech 2015,imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,69,4,0.06,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
1601,pain_sub,holbech 2015,imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,69,8,0.12,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
1602,pain_sub,holbech 2015,imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,pain,imipramine,antidepressant,antidepressant,imipramine 75mg,tca,75mg,standard,fixed,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,69,14,0.2,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
1603,pain_sub,holbech 2015,imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,pain,pregabalin + imipramine,combined antidepressant intervention,antidepressant,pregabalin 300mg + imipramine 75mg,tca,75mg,standard,fixed,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,69,19,0.28,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
1604,adverse,holbech 2015,imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,69,24,0.35,FALSE,patients with at least 1ae of moderate intensity,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1605,adverse,holbech 2015,imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,69,25,0.36,FALSE,patients with at least 1ae of moderate intensity,NA,NA,NA,NA,non_ad_pharm,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1606,adverse,holbech 2015,imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,pain,imipramine,antidepressant,antidepressant,imipramine 75mg,tca,75mg,standard,fixed,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,70,30,0.43,FALSE,patients with at least 1ae of moderate intensity,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1607,adverse,holbech 2015,imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,pain,pregabalin + imipramine,combined antidepressant intervention,antidepressant,pregabalin 300mg + imipramine 75mg,tca,75mg,standard,fixed,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,69,40,0.58,FALSE,patients with at least 1ae of moderate intensity,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1608,adverse_dropout,holbech 2015,imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,73,1,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1609,adverse_dropout,holbech 2015,imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,73,2,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1610,adverse_dropout,holbech 2015,imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,pain,imipramine,antidepressant,antidepressant,imipramine 75mg,tca,75mg,standard,fixed,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,73,3,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1611,adverse_dropout,holbech 2015,imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,pain,pregabalin + imipramine,combined antidepressant intervention,antidepressant,pregabalin 300mg + imipramine 75mg,tca,75mg,standard,fixed,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,73,7,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1612,withdrawal,holbech 2015,imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,73,5,0.06849999999999999,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1613,withdrawal,holbech 2015,imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,73,5,0.06849999999999999,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1614,withdrawal,holbech 2015,imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,pain,imipramine,antidepressant,antidepressant,imipramine 75mg,tca,75mg,standard,fixed,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,73,4,0.0548,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1615,withdrawal,holbech 2015,imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial,pain,pregabalin + imipramine,combined antidepressant intervention,antidepressant,pregabalin 300mg + imipramine 75mg,tca,75mg,standard,fixed,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,73,9,0.1304,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1616,qol,hussain 2011,adjuvant use of melatonin for treatment of fibromyalgia,fibromyalgia symptoms,melatonin,hormone,non-antidepressant pharmacological,melatonin 5mg,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fibromyalgia impact questionnaire total score,baseline,NA,60.42,15.1208035500763,2.91,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
1617,qol,hussain 2011,adjuvant use of melatonin for treatment of fibromyalgia,fibromyalgia symptoms,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fibromyalgia impact questionnaire total score,baseline,NA,61.18,15.43178537953402,3.15,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
1618,qol,hussain 2011,adjuvant use of melatonin for treatment of fibromyalgia,fibromyalgia symptoms,fluoxetine + melatonin,combined antidepressant intervention,antidepressant,fluoxetine 20mg + melatonin 3mg,ssri,20mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fibromyalgia impact questionnaire total score,baseline,NA,59.42,6.235382907247958,1.2,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
1619,qol,hussain 2011,adjuvant use of melatonin for treatment of fibromyalgia,fibromyalgia symptoms,fluoxetine + melatonin,combined antidepressant intervention,antidepressant,fluoxetine 20mg + melatonin 5mg,ssri,20mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fibromyalgia impact questionnaire total score,baseline,NA,61.9,8.009038643932241,1.67,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
1620,qol,hussain 2011,adjuvant use of melatonin for treatment of fibromyalgia,fibromyalgia symptoms,melatonin,hormone,non-antidepressant pharmacological,melatonin 5mg,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fibromyalgia impact questionnaire total score,post_int,NA,49,17.562995188748417,3.38,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
1621,qol,hussain 2011,adjuvant use of melatonin for treatment of fibromyalgia,fibromyalgia symptoms,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fibromyalgia impact questionnaire total score,post_int,NA,48,19.00804040399746,3.88,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
1622,qol,hussain 2011,adjuvant use of melatonin for treatment of fibromyalgia,fibromyalgia symptoms,fluoxetine + melatonin,combined antidepressant intervention,antidepressant,fluoxetine 20mg + melatonin 3mg,ssri,20mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fibromyalgia impact questionnaire total score,post_int,NA,42.33,9.716805030461403,1.87,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
1623,qol,hussain 2011,adjuvant use of melatonin for treatment of fibromyalgia,fibromyalgia symptoms,fluoxetine + melatonin,combined antidepressant intervention,antidepressant,fluoxetine 20mg + melatonin 5mg,ssri,20mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fibromyalgia impact questionnaire total score,post_int,NA,44,13.81199478714063,2.88,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
1624,pain_int,hussain 2011,adjuvant use of melatonin for treatment of fibromyalgia,fibromyalgia symptoms,melatonin,hormone,non-antidepressant pharmacological,melatonin 5mg,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fiq pain,baseline,NA,8.33,1.143153532995459,0.22,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1625,pain_int,hussain 2011,adjuvant use of melatonin for treatment of fibromyalgia,fibromyalgia symptoms,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fiq pain,baseline,NA,7.64,1.763632614803888,0.36,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1626,pain_int,hussain 2011,adjuvant use of melatonin for treatment of fibromyalgia,fibromyalgia symptoms,fluoxetine + melatonin,combined antidepressant intervention,antidepressant,fluoxetine 20mg + melatonin 3mg,ssri,20mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fiq pain,baseline,NA,7.33,2.078460969082653,0.4,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1627,pain_int,hussain 2011,adjuvant use of melatonin for treatment of fibromyalgia,fibromyalgia symptoms,fluoxetine + melatonin,combined antidepressant intervention,antidepressant,fluoxetine 20mg + melatonin 5mg,ssri,20mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fiq pain,baseline,NA,7.7,1.4387494569938157,0.3,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1628,pain_int,hussain 2011,adjuvant use of melatonin for treatment of fibromyalgia,fibromyalgia symptoms,melatonin,hormone,non-antidepressant pharmacological,melatonin 5mg,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fiq pain,post_int,NA,6.08,1.8706148721743874,0.36,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1629,pain_int,hussain 2011,adjuvant use of melatonin for treatment of fibromyalgia,fibromyalgia symptoms,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fiq pain,post_int,NA,6.55,1.665653025092561,0.34,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1630,pain_int,hussain 2011,adjuvant use of melatonin for treatment of fibromyalgia,fibromyalgia symptoms,fluoxetine + melatonin,combined antidepressant intervention,antidepressant,fluoxetine 20mg + melatonin 3mg,ssri,20mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fiq pain,post_int,NA,5.33,2.4421916386721167,0.47,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1631,pain_int,hussain 2011,adjuvant use of melatonin for treatment of fibromyalgia,fibromyalgia symptoms,fluoxetine + melatonin,combined antidepressant intervention,antidepressant,fluoxetine 20mg + melatonin 5mg,ssri,20mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fiq pain,post_int,NA,5.4,1.7744576636257061,0.37,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1640,mood,hussain 2011,adjuvant use of melatonin for treatment of fibromyalgia,fibromyalgia symptoms,melatonin,hormone,non-antidepressant pharmacological,melatonin 5mg,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fiq depression,baseline,NA,2.83,4.052998889711173,0.78,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1641,mood,hussain 2011,adjuvant use of melatonin for treatment of fibromyalgia,fibromyalgia symptoms,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fiq depression,baseline,NA,4.82,5.143928459844674,1.05,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1642,mood,hussain 2011,adjuvant use of melatonin for treatment of fibromyalgia,fibromyalgia symptoms,fluoxetine + melatonin,combined antidepressant intervention,antidepressant,fluoxetine 20mg + melatonin 3mg,ssri,20mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fiq depression,baseline,NA,5.25,3.117691453623979,0.6,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1643,mood,hussain 2011,adjuvant use of melatonin for treatment of fibromyalgia,fibromyalgia symptoms,fluoxetine + melatonin,combined antidepressant intervention,antidepressant,fluoxetine 20mg + melatonin 5mg,ssri,20mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fiq depression,baseline,NA,5.2,3.9805401643495566,0.83,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1644,mood,hussain 2011,adjuvant use of melatonin for treatment of fibromyalgia,fibromyalgia symptoms,melatonin,hormone,non-antidepressant pharmacological,melatonin 5mg,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fiq depression,post_int,NA,2.17,3.7412297443487748,0.72,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1645,mood,hussain 2011,adjuvant use of melatonin for treatment of fibromyalgia,fibromyalgia symptoms,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fiq depression,post_int,NA,3.64,4.26211215244273,0.87,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1646,mood,hussain 2011,adjuvant use of melatonin for treatment of fibromyalgia,fibromyalgia symptoms,fluoxetine + melatonin,combined antidepressant intervention,antidepressant,fluoxetine 20mg + melatonin 3mg,ssri,20mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fiq depression,post_int,NA,3.17,3.2735760263051783,0.63,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1647,mood,hussain 2011,adjuvant use of melatonin for treatment of fibromyalgia,fibromyalgia symptoms,fluoxetine + melatonin,combined antidepressant intervention,antidepressant,fluoxetine 20mg + melatonin 5mg,ssri,20mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fiq depression,post_int,NA,3,3.1172904901532674,0.65,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1648,physical,hussain 2011,adjuvant use of melatonin for treatment of fibromyalgia,fibromyalgia symptoms,melatonin,hormone,non-antidepressant pharmacological,melatonin 5mg,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fiq physical functioning,baseline,NA,6.66,1.6108072510390559,0.31,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1649,physical,hussain 2011,adjuvant use of melatonin for treatment of fibromyalgia,fibromyalgia symptoms,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fiq physical functioning,baseline,NA,6.6,1.0777754868245983,0.22,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1650,physical,hussain 2011,adjuvant use of melatonin for treatment of fibromyalgia,fibromyalgia symptoms,fluoxetine + melatonin,combined antidepressant intervention,antidepressant,fluoxetine 20mg + melatonin 3mg,ssri,20mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fiq physical functioning,baseline,NA,6.66,1.3509996299037244,0.26,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1651,physical,hussain 2011,adjuvant use of melatonin for treatment of fibromyalgia,fibromyalgia symptoms,fluoxetine + melatonin,combined antidepressant intervention,antidepressant,fluoxetine 20mg + melatonin 5mg,ssri,20mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fiq physical functioning,baseline,NA,4.9,1.3428328265275615,0.28,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1652,physical,hussain 2011,adjuvant use of melatonin for treatment of fibromyalgia,fibromyalgia symptoms,melatonin,hormone,non-antidepressant pharmacological,melatonin 5mg,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fiq physical functioning,post_int,NA,6.25,1.818653347947321,0.35,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1653,physical,hussain 2011,adjuvant use of melatonin for treatment of fibromyalgia,fibromyalgia symptoms,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fiq physical functioning,post_int,NA,5.5,1.322724461102916,0.27,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1654,physical,hussain 2011,adjuvant use of melatonin for treatment of fibromyalgia,fibromyalgia symptoms,fluoxetine + melatonin,combined antidepressant intervention,antidepressant,fluoxetine 20mg + melatonin 3mg,ssri,20mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fiq physical functioning,post_int,NA,5.08,1.454922678357857,0.28,NA,NA,NA,NA,NA,27,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1655,physical,hussain 2011,adjuvant use of melatonin for treatment of fibromyalgia,fibromyalgia symptoms,fluoxetine + melatonin,combined antidepressant intervention,antidepressant,fluoxetine 20mg + melatonin 5mg,ssri,20mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,fiq physical functioning,post_int,NA,3.1,1.1030412503619254,0.23,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1656,withdrawal,isomeri 1993,effects of amitriptyline and cardiovascular fitness training on pain in patients with primary fibromyalgia,experimental pain,physiotherapy + amitriptyline,combined antidepressant intervention,antidepressant,physiotherapy + amitriptyline 25mg,tca,25mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,1,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1657,withdrawal,isomeri 1993,effects of amitriptyline and cardiovascular fitness training on pain in patients with primary fibromyalgia,experimental pain,physical fitness training,physical fitness training,non-pharmacological,physical fitness training,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,2,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1658,withdrawal,isomeri 1993,effects of amitriptyline and cardiovascular fitness training on pain in patients with primary fibromyalgia,experimental pain,physical fitness training + amitriptyline,combined antidepressant intervention,antidepressant,physical fitness training + amitriptyline 25mg,tca,25mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,3,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1659,pain_int,iwaki 2020,"a double-blind, randomized controlled trial of duloxetine for pain in parkinson's disease",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,pain in parkinson's disease,neuropathic,neuropathic,no,parallel,itt unspecified method,0-100 vas,baseline,NA,47.83,23.61,4.923025315887536,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1660,pain_int,iwaki 2020,"a double-blind, randomized controlled trial of duloxetine for pain in parkinson's disease",pain,duloxetine,antidepressant,antidepressant,duloxetine 40mg,snri,40mg,low,fixed,12 weeks,pain in parkinson's disease,neuropathic,neuropathic,no,parallel,itt unspecified method,0-100 vas,baseline,NA,47.87,24.74,5.15864660377203,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1661,pain_int,iwaki 2020,"a double-blind, randomized controlled trial of duloxetine for pain in parkinson's disease",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,pain in parkinson's disease,neuropathic,neuropathic,no,parallel,itt unspecified method,0-100 vas,change_score,NA,-1.91,20.33432565884593,4.24,NA,NA,NA,NA,NA,23,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1662,pain_int,iwaki 2020,"a double-blind, randomized controlled trial of duloxetine for pain in parkinson's disease",pain,duloxetine,antidepressant,antidepressant,duloxetine 40mg,snri,40mg,low,fixed,12 weeks,pain in parkinson's disease,neuropathic,neuropathic,no,parallel,itt unspecified method,0-100 vas,change_score,NA,-0.83,22.972032996667924,4.79,NA,NA,NA,NA,NA,23,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1663,mood,iwaki 2020,"a double-blind, randomized controlled trial of duloxetine for pain in parkinson's disease",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,pain in parkinson's disease,neuropathic,neuropathic,no,parallel,itt unspecified method,beck depression inventory,baseline,NA,13.7,8.56,1.7848833843285603,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1664,mood,iwaki 2020,"a double-blind, randomized controlled trial of duloxetine for pain in parkinson's disease",pain,duloxetine,antidepressant,antidepressant,duloxetine 40mg,snri,40mg,low,fixed,12 weeks,pain in parkinson's disease,neuropathic,neuropathic,no,parallel,itt unspecified method,beck depression inventory,baseline,NA,13.48,6.86,1.4304088804315331,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1665,mood,iwaki 2020,"a double-blind, randomized controlled trial of duloxetine for pain in parkinson's disease",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,pain in parkinson's disease,neuropathic,neuropathic,no,parallel,itt unspecified method,beck depression inventory,change_score,NA,-0.43,6.618247502171552,1.38,NA,NA,NA,NA,NA,23,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1666,mood,iwaki 2020,"a double-blind, randomized controlled trial of duloxetine for pain in parkinson's disease",pain,duloxetine,antidepressant,antidepressant,duloxetine 40mg,snri,40mg,low,fixed,12 weeks,pain in parkinson's disease,neuropathic,neuropathic,no,parallel,itt unspecified method,beck depression inventory,change_score,NA,-1.22,5.850914458441517,1.22,NA,NA,NA,NA,NA,23,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1667,serious_adverse,iwaki 2020,"a double-blind, randomized controlled trial of duloxetine for pain in parkinson's disease",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,pain in parkinson's disease,neuropathic,neuropathic,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1668,serious_adverse,iwaki 2020,"a double-blind, randomized controlled trial of duloxetine for pain in parkinson's disease",pain,duloxetine,antidepressant,antidepressant,duloxetine 40mg,snri,40mg,low,fixed,12 weeks,pain in parkinson's disease,neuropathic,neuropathic,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,3,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1669,withdrawal,iwaki 2020,"a double-blind, randomized controlled trial of duloxetine for pain in parkinson's disease",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,pain in parkinson's disease,neuropathic,neuropathic,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,2,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1670,withdrawal,iwaki 2020,"a double-blind, randomized controlled trial of duloxetine for pain in parkinson's disease",pain,duloxetine,antidepressant,antidepressant,duloxetine 40mg,snri,40mg,low,fixed,12 weeks,pain in parkinson's disease,neuropathic,neuropathic,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,7,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1671,adverse,jia 2006,"effects of venlafaxine and carbamazepine for painful peripheral diabetic neuropathy: a randomized, double-blind and double-dummy, controlled multi-center trial",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 50mg,snri,50mg,low,fixed,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,66,29,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1672,adverse,jia 2006,"effects of venlafaxine and carbamazepine for painful peripheral diabetic neuropathy: a randomized, double-blind and double-dummy, controlled multi-center trial",pain,carbamazepine,anticonvulsant,non-antidepressant pharmacological,carbamazepine 200mg,n/a,n/a,n/a,n/a,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,66,17,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1673,adverse_dropout,jia 2006,"effects of venlafaxine and carbamazepine for painful peripheral diabetic neuropathy: a randomized, double-blind and double-dummy, controlled multi-center trial",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 50mg,snri,50mg,low,fixed,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,66,4,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1674,adverse_dropout,jia 2006,"effects of venlafaxine and carbamazepine for painful peripheral diabetic neuropathy: a randomized, double-blind and double-dummy, controlled multi-center trial",pain,carbamazepine,anticonvulsant,non-antidepressant pharmacological,carbamazepine 200mg,n/a,n/a,n/a,n/a,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,66,2,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1675,withdrawal,jia 2006,"effects of venlafaxine and carbamazepine for painful peripheral diabetic neuropathy: a randomized, double-blind and double-dummy, controlled multi-center trial",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 50mg,snri,50mg,low,fixed,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,66,6,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1676,withdrawal,jia 2006,"effects of venlafaxine and carbamazepine for painful peripheral diabetic neuropathy: a randomized, double-blind and double-dummy, controlled multi-center trial",pain,carbamazepine,anticonvulsant,non-antidepressant pharmacological,carbamazepine 200mg,n/a,n/a,n/a,n/a,2 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,66,7,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1677,pain_int,johansson 1979,a double-blind controlled study of seratonin uptake inhibitor (zimelidine) versus placebo in chronic pain patients,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,any chronic pain,unspecified,primary,no,parallel,completer analysis,0-100 vas,baseline,NA,44.8,22.264770378335367,5.4,NA,NA,NA,NA,NA,17,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1678,pain_int,johansson 1979,a double-blind controlled study of seratonin uptake inhibitor (zimelidine) versus placebo in chronic pain patients,pain,zimeldine,antidepressant,antidepressant,zimeldine 200mg,ssri,200mg,low,fixed,4 weeks,any chronic pain,unspecified,primary,no,parallel,completer analysis,0-100 vas,baseline,NA,64.9,25.97556544139126,6.3,NA,NA,NA,NA,NA,17,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1679,pain_int,johansson 1979,a double-blind controlled study of seratonin uptake inhibitor (zimelidine) versus placebo in chronic pain patients,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,any chronic pain,unspecified,primary,no,parallel,completer analysis,0-100 vas,post_int,NA,47.6,30.209270100417854,7.8,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1680,pain_int,johansson 1979,a double-blind controlled study of seratonin uptake inhibitor (zimelidine) versus placebo in chronic pain patients,pain,zimeldine,antidepressant,antidepressant,zimeldine 200mg,ssri,200mg,low,fixed,4 weeks,any chronic pain,unspecified,primary,no,parallel,completer analysis,0-100 vas,post_int,NA,46.8,19.752215065657825,5.1,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1681,adverse_dropout,johansson 1979,a double-blind controlled study of seratonin uptake inhibitor (zimelidine) versus placebo in chronic pain patients,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,any chronic pain,unspecified,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,1,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1682,adverse_dropout,johansson 1979,a double-blind controlled study of seratonin uptake inhibitor (zimelidine) versus placebo in chronic pain patients,pain,zimeldine,antidepressant,antidepressant,zimeldine 200mg,ssri,200mg,low,fixed,4 weeks,any chronic pain,unspecified,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,5,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1683,withdrawal,johansson 1979,a double-blind controlled study of seratonin uptake inhibitor (zimelidine) versus placebo in chronic pain patients,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,any chronic pain,unspecified,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,3,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1684,withdrawal,johansson 1979,a double-blind controlled study of seratonin uptake inhibitor (zimelidine) versus placebo in chronic pain patients,pain,zimeldine,antidepressant,antidepressant,zimeldine 200mg,ssri,200mg,low,fixed,4 weeks,any chronic pain,unspecified,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,5,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1685,pain_int,joharchi 2019,"efficacy and safety of duloxetine and pregabalin in iranian patients with diabetic peripheral neuropathic pain: a double-blind, randomized clinical trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 30-60mg,snri,42.5mg,low,flexible,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,completer analysis,0-100 vas,baseline,NA,67.2,19.3,2.3756657759011217,NA,NA,NA,NA,NA,66,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1686,pain_int,joharchi 2019,"efficacy and safety of duloxetine and pregabalin in iranian patients with diabetic peripheral neuropathic pain: a double-blind, randomized clinical trial",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 150-300mg,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,completer analysis,0-100 vas,baseline,NA,61.7,16.3,1.845611565655691,NA,NA,NA,NA,NA,78,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1687,pain_int,joharchi 2019,"efficacy and safety of duloxetine and pregabalin in iranian patients with diabetic peripheral neuropathic pain: a double-blind, randomized clinical trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 30-60mg,snri,42.5mg,low,flexible,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,completer analysis,0-100 vas,post_int,NA,16.2,4.2,0.5169842621131975,NA,NA,NA,NA,NA,66,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1688,pain_int,joharchi 2019,"efficacy and safety of duloxetine and pregabalin in iranian patients with diabetic peripheral neuropathic pain: a double-blind, randomized clinical trial",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 150-300mg,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,completer analysis,0-100 vas,post_int,NA,16,5.5,0.6227523687795276,NA,NA,NA,NA,NA,78,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1689,adverse,joharchi 2019,"efficacy and safety of duloxetine and pregabalin in iranian patients with diabetic peripheral neuropathic pain: a double-blind, randomized clinical trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 30-60mg,snri,42.5mg,low,flexible,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,90,67,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1690,adverse,joharchi 2019,"efficacy and safety of duloxetine and pregabalin in iranian patients with diabetic peripheral neuropathic pain: a double-blind, randomized clinical trial",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 150-300mg,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,90,34,NA,FALSE,number of participants with any ae,NA,NA,NA,NA,non_ad_pharm,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1691,adverse_dropout,joharchi 2019,"efficacy and safety of duloxetine and pregabalin in iranian patients with diabetic peripheral neuropathic pain: a double-blind, randomized clinical trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 30-60mg,snri,42.5mg,low,flexible,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,90,17,NA,FALSE,number of participants with any ae,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1692,adverse_dropout,joharchi 2019,"efficacy and safety of duloxetine and pregabalin in iranian patients with diabetic peripheral neuropathic pain: a double-blind, randomized clinical trial",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 150-300mg,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,90,6,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1693,withdrawal,joharchi 2019,"efficacy and safety of duloxetine and pregabalin in iranian patients with diabetic peripheral neuropathic pain: a double-blind, randomized clinical trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 30-60mg,snri,42.5mg,low,flexible,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,90,24,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1694,withdrawal,joharchi 2019,"efficacy and safety of duloxetine and pregabalin in iranian patients with diabetic peripheral neuropathic pain: a double-blind, randomized clinical trial",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 150-300mg,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,90,12,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1695,pain_int,jose 2007,randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy,pain,lamotrigine,anticonvulsant,non-antidepressant pharmacological,lamotrigine 50-200mg,n/a,n/a,n/a,n/a,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥50 on 100vas,crossover,itt with locf,0-100 vas,baseline,NA,74.16666666666667,7.652554309474399,1.1283075769704936,72.5,NA,NA,70,80,46,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1696,pain_int,jose 2007,randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10-50mg,tca,10-50mg,unable to be categorised,flexible,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥50 on 100vas,crossover,itt with locf,0-100 vas,baseline,NA,70,15.305108618948799,2.256615153940987,70,NA,NA,60,80,46,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1697,pain_int,jose 2007,randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy,pain,lamotrigine,anticonvulsant,non-antidepressant pharmacological,lamotrigine 50-200mg,n/a,n/a,n/a,n/a,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥50 on 100vas,crossover,itt with locf,0-100 vas,post_int,NA,50,30.610217237897597,4.513230307881974,50,NA,NA,30,70,46,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1698,pain_int,jose 2007,randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10-50mg,tca,10-50mg,unable to be categorised,flexible,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥50 on 100vas,crossover,itt with locf,0-100 vas,post_int,NA,54.166666666666664,22.957662928423197,3.38492273091148,52.5,NA,NA,40,70,46,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1699,adverse,jose 2007,randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy,pain,lamotrigine,anticonvulsant,non-antidepressant pharmacological,lamotrigine 50-200mg,n/a,n/a,n/a,n/a,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥50 on 100vas,crossover,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,46,33,0.74,FALSE,any ae,NA,NA,NA,NA,non_ad_pharm,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1700,adverse,jose 2007,randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10-50mg,tca,10-50mg,unable to be categorised,flexible,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥50 on 100vas,crossover,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,46,11,0.25,FALSE,any ae,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1701,withdrawal,jose 2007,randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy,pain,lamotrigine,anticonvulsant,non-antidepressant pharmacological,lamotrigine 50-200mg,n/a,n/a,n/a,n/a,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥50 on 100vas,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,53,0,0,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1702,withdrawal,jose 2007,randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10-50mg,tca,10-50mg,unable to be categorised,flexible,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥50 on 100vas,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,53,7,0.132,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1703,NA,kalso 1996,amitriptyline effectively relieves neuropathic pain following treatment of breast cancer,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,chemotherapy induced neuropathic pain,neuropathic,cancer-related,at least moderate in severity,crossover,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,placebo,NA,NA,NA,NA,NA,no_useable_data,NA
1704,NA,kalso 1996,amitriptyline effectively relieves neuropathic pain following treatment of breast cancer,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 100mg,tca,100mg,high,fixed,4 weeks,chemotherapy induced neuropathic pain,neuropathic,cancer-related,at least moderate in severity,crossover,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,ad,NA,NA,NA,NA,NA,no_useable_data,NA
1705,pain_int,katz 2005,"a randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,7 weeks,low back pain,musculoskeletal,primary,no,crossover,itt with locf,0-10 numerical rating scale,baseline,NA,5.07,1.88,0.2834206639030978,NA,NA,NA,NA,NA,44,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1706,pain_int,katz 2005,"a randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain",pain,bupropion,antidepressant,antidepressant,bupropion 300mg,ndri,300mg,standard,fixed,7 weeks,low back pain,musculoskeletal,primary,no,crossover,itt with locf,0-10 numerical rating scale,baseline,NA,5.07,1.88,0.2834206639030978,NA,NA,NA,NA,NA,44,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1707,pain_int,katz 2005,"a randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,7 weeks,low back pain,musculoskeletal,primary,no,crossover,itt with locf,0-10 numerical rating scale,post_int,NA,3.56,2.14,0.3226171386982071,NA,NA,NA,NA,NA,44,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1708,pain_int,katz 2005,"a randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain",pain,bupropion,antidepressant,antidepressant,bupropion 300mg,ndri,300mg,standard,fixed,7 weeks,low back pain,musculoskeletal,primary,no,crossover,itt with locf,0-10 numerical rating scale,post_int,NA,3.05,1.68,0.25326952944532144,NA,NA,NA,NA,NA,44,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1709,adverse_dropout,katz 2005,"a randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,7 weeks,low back pain,musculoskeletal,primary,no,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,54,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1710,adverse_dropout,katz 2005,"a randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain",pain,bupropion,antidepressant,antidepressant,bupropion 300mg,ndri,300mg,standard,fixed,7 weeks,low back pain,musculoskeletal,primary,no,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,54,3,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1711,serious_adverse,katz 2005,"a randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,7 weeks,low back pain,musculoskeletal,primary,no,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,54,1,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1712,serious_adverse,katz 2005,"a randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain",pain,bupropion,antidepressant,antidepressant,bupropion 300mg,ndri,300mg,standard,fixed,7 weeks,low back pain,musculoskeletal,primary,no,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,54,2,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1713,withdrawal,katz 2005,"a randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,7 weeks,low back pain,musculoskeletal,primary,no,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,54,5,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1714,withdrawal,katz 2005,"a randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain",pain,bupropion,antidepressant,antidepressant,bupropion 300mg,ndri,300mg,standard,fixed,7 weeks,low back pain,musculoskeletal,primary,no,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,54,9,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1715,pain_mod,kaur 2011,"a comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10-50mg,tca,10-50mg,unable to be categorised,flexible,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥50 on 100vas,crossover,unclear,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,58,36,0.62,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
1716,pain_mod,kaur 2011,"a comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 20-60mg,snri,20-60mg,low,flexible,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥50 on 100vas,crossover,unclear,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,58,37,0.64,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
1717,pain_sub,kaur 2011,"a comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10-50mg,tca,10-50mg,unable to be categorised,flexible,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥50 on 100vas,crossover,unclear,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,58,32,0.55,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
1718,pain_sub,kaur 2011,"a comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 20-60mg,snri,20-60mg,low,flexible,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥50 on 100vas,crossover,unclear,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,58,34,0.59,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
1721,pain_int,kayiran 2010,"neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",pain,neurofeedback,neurofeedback,non-pharmacological,neurofeedback,n/a,n/a,n/a,n/a,4 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,0-10 numerical rating scale,baseline,NA,8.94,0.8452336954949206,0.189,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,"study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1722,pain_int,kayiran 2010,"neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",pain,escitalopram,antidepressant,antidepressant,escitalopram 10mg,ssri,10mg,low,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,0-10 numerical rating scale,baseline,NA,9.11,1.0330634056049028,0.231,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,"study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1723,pain_int,kayiran 2010,"neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",pain,neurofeedback,neurofeedback,non-pharmacological,neurofeedback,n/a,n/a,n/a,n/a,4 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,0-10 numerical rating scale,post_int,NA,1.64,0.9036824663564076,0.213,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,"study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1724,pain_int,kayiran 2010,"neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",pain,escitalopram,antidepressant,antidepressant,escitalopram 10mg,ssri,10mg,low,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,0-10 numerical rating scale,post_int,NA,3.25,1.1412703448350876,0.269,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,"study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1725,pain_int,kayiran 2010,"neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",pain,neurofeedback,neurofeedback,non-pharmacological,neurofeedback,n/a,n/a,n/a,n/a,4 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,0-10 numerical rating scale,follow_up,16 weeks,2.42,1.4467404743076762,0.341,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,"study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,follow_up
1726,pain_int,kayiran 2010,"neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",pain,escitalopram,antidepressant,antidepressant,escitalopram 10mg,ssri,10mg,low,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,0-10 numerical rating scale,follow_up,16 weeks,4.47,1.4382551929334377,0.339,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,"study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,follow_up
1727,pain_int,kayiran 2010,"neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",pain,neurofeedback,neurofeedback,non-pharmacological,neurofeedback,n/a,n/a,n/a,n/a,4 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,0-10 numerical rating scale,follow_up,24 weeks,2.56,1.5146227253015847,0.357,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,"study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,follow_up
1728,pain_int,kayiran 2010,"neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",pain,escitalopram,antidepressant,antidepressant,escitalopram 10mg,ssri,10mg,low,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,0-10 numerical rating scale,follow_up,24 weeks,5.33,1.281277487510024,0.302,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,"study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,follow_up
1729,mood,kayiran 2010,"neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",pain,neurofeedback,neurofeedback,non-pharmacological,neurofeedback,n/a,n/a,n/a,n/a,4 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,beck depression inventory,baseline,NA,16.94,6.032911403294433,1.349,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,"study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1730,mood,kayiran 2010,"neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",pain,escitalopram,antidepressant,antidepressant,escitalopram 10mg,ssri,10mg,low,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,beck depression inventory,baseline,NA,20.83,3.2780756550146917,0.733,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,"study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1731,mood,kayiran 2010,"neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",pain,neurofeedback,neurofeedback,non-pharmacological,neurofeedback,n/a,n/a,n/a,n/a,4 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,beck depression inventory,post_int,NA,4.78,3.5086638482476484,0.827,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,"study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1732,mood,kayiran 2010,"neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",pain,escitalopram,antidepressant,antidepressant,escitalopram 10mg,ssri,10mg,low,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,beck depression inventory,post_int,NA,8.22,3.2456201256462527,0.765,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,"study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1733,mood,kayiran 2010,"neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",pain,neurofeedback,neurofeedback,non-pharmacological,neurofeedback,n/a,n/a,n/a,n/a,4 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,beck depression inventory,follow_up,16 weeks,5.39,2.4522463171549465,0.578,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,"study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,follow_up
1734,mood,kayiran 2010,"neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",pain,escitalopram,antidepressant,antidepressant,escitalopram 10mg,ssri,10mg,low,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,beck depression inventory,follow_up,16 weeks,11.78,3.5426049737446026,0.835,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,"study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,follow_up
1735,mood,kayiran 2010,"neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",pain,neurofeedback,neurofeedback,non-pharmacological,neurofeedback,n/a,n/a,n/a,n/a,4 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,beck depression inventory,follow_up,24 weeks,6.33,2.4734595205905427,0.583,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,"study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,follow_up
1736,mood,kayiran 2010,"neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",pain,escitalopram,antidepressant,antidepressant,escitalopram 10mg,ssri,10mg,low,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,beck depression inventory,follow_up,24 weeks,13.39,3.292289173204565,0.776,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,"study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,follow_up
1745,withdrawal,kayiran 2010,"neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",pain,neurofeedback,neurofeedback,non-pharmacological,neurofeedback,n/a,n/a,n/a,n/a,4 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,2,0.1,FALSE,NA,NA,"study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,non_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1746,withdrawal,kayiran 2010,"neurofeedback intervention in fibromyalgia syndrome; a randomized, controlled, rater blind clinical trial",pain,escitalopram,antidepressant,antidepressant,escitalopram 10mg,ssri,10mg,low,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,2,0.1,FALSE,NA,NA,"study had different intervention lengths, 4 weeks for neurofeedback, 8 weeks for escitalopram",NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1747,pain_int,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,0-100 vas,baseline,NA,17.96,20.67,3.9062628285503633,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1748,pain_int,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,sertraline,antidepressant,antidepressant,sertraline ≤200mg,ssri,50-200mg,high,flexible,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,0-100 vas,baseline,NA,10.81,15.09,2.7550444642509855,NA,NA,NA,NA,NA,30,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1749,pain_int,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,coping skills training,coping skills training,non-pharmacological,coping skills training,n/a,n/a,n/a,n/a,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,0-100 vas,baseline,NA,19.28,22.77,4.228282850291471,NA,NA,NA,NA,NA,29,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1750,pain_int,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,coping skills training + sertraline,combined antidepressant intervention,antidepressant,coping skills training + sertraline,ssri,50-200mg,high,flexible,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,0-100 vas,baseline,NA,13.3,23.23,4.390057354002174,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1751,pain_int,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,0-100 vas,post_int,NA,10.02,16.35,3.0898595668504325,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1752,pain_int,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,sertraline,antidepressant,antidepressant,sertraline ≤200mg,ssri,50-200mg,high,flexible,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,0-100 vas,post_int,NA,3.55,9.82,1.7928785049002438,NA,NA,NA,NA,NA,30,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1753,pain_int,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,coping skills training,coping skills training,non-pharmacological,coping skills training,n/a,n/a,n/a,n/a,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,0-100 vas,post_int,NA,8.57,14.87,2.761289678692761,NA,NA,NA,NA,NA,29,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1754,pain_int,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,coping skills training + sertraline,combined antidepressant intervention,antidepressant,coping skills training + sertraline,ssri,50-200mg,high,flexible,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,0-100 vas,post_int,NA,6.63,11.92,2.2526682591349942,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1763,mood,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,beck depression inventory,baseline,NA,8.96,7.66,1.4476039316253402,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1764,mood,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,sertraline,antidepressant,antidepressant,sertraline ≤200mg,ssri,50-200mg,high,flexible,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,beck depression inventory,baseline,NA,9.1,6.36,1.1611718219109521,NA,NA,NA,NA,NA,30,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1765,mood,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,coping skills training,coping skills training,non-pharmacological,coping skills training,n/a,n/a,n/a,n/a,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,beck depression inventory,baseline,NA,10.21,9,1.671258043593467,NA,NA,NA,NA,NA,29,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1766,mood,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,coping skills training + sertraline,combined antidepressant intervention,antidepressant,coping skills training + sertraline,ssri,50-200mg,high,flexible,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,beck depression inventory,baseline,NA,9.36,8.19,1.5477645169727854,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1767,mood,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,beck depression inventory,post_int,NA,4.48,3.74,0.706793564527255,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1768,mood,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,sertraline,antidepressant,antidepressant,sertraline ≤200mg,ssri,50-200mg,high,flexible,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,beck depression inventory,post_int,NA,7.05,8.45,1.5427518703062177,NA,NA,NA,NA,NA,30,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1769,mood,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,coping skills training,coping skills training,non-pharmacological,coping skills training,n/a,n/a,n/a,n/a,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,beck depression inventory,post_int,NA,7.05,8.45,1.5691256075960882,NA,NA,NA,NA,NA,29,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1770,mood,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,coping skills training + sertraline,combined antidepressant intervention,antidepressant,coping skills training + sertraline,ssri,50-200mg,high,flexible,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,beck depression inventory,post_int,NA,4.48,3.74,0.706793564527255,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1771,physical,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,sickness impact profile - physical subscale,baseline,NA,6.26,10,1.889822365046136,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1772,physical,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,sertraline,antidepressant,antidepressant,sertraline ≤200mg,ssri,50-200mg,high,flexible,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,sickness impact profile - physical subscale,baseline,NA,2.78,5.24,0.9566887337756902,NA,NA,NA,NA,NA,30,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1773,physical,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,coping skills training,coping skills training,non-pharmacological,coping skills training,n/a,n/a,n/a,n/a,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,sickness impact profile - physical subscale,baseline,NA,7.02,11.34,2.105785134927768,NA,NA,NA,NA,NA,29,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1774,physical,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,coping skills training + sertraline,combined antidepressant intervention,antidepressant,coping skills training + sertraline,ssri,50-200mg,high,flexible,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,sickness impact profile - physical subscale,baseline,NA,3.74,7.16,1.3531128133730335,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1775,physical,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,sickness impact profile - physical subscale,post_int,NA,4.46,9.37,1.7707635560482293,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1776,physical,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,sertraline,antidepressant,antidepressant,sertraline ≤200mg,ssri,50-200mg,high,flexible,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,sickness impact profile - physical subscale,post_int,NA,3.06,7.72,1.4094727146466275,NA,NA,NA,NA,NA,30,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1777,physical,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,coping skills training,coping skills training,non-pharmacological,coping skills training,n/a,n/a,n/a,n/a,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,sickness impact profile - physical subscale,post_int,NA,3.64,5.34,0.9916131058654569,NA,NA,NA,NA,NA,29,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1778,physical,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,coping skills training + sertraline,combined antidepressant intervention,antidepressant,coping skills training + sertraline,ssri,50-200mg,high,flexible,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,sickness impact profile - physical subscale,post_int,NA,2.15,3.78,0.7143528539874394,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1779,adverse,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,5,0.17,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1780,adverse,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,sertraline,antidepressant,antidepressant,sertraline ≤200mg,ssri,50-200mg,high,flexible,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,10,0.33,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1781,adverse,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,coping skills training,coping skills training,non-pharmacological,coping skills training,n/a,n/a,n/a,n/a,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,7,0.24,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1782,adverse,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,coping skills training + sertraline,combined antidepressant intervention,antidepressant,coping skills training + sertraline,ssri,50-200mg,high,flexible,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,7,0.26,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1783,serious_adverse,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,0,0,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1784,serious_adverse,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,sertraline,antidepressant,antidepressant,sertraline ≤200mg,ssri,50-200mg,high,flexible,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,0,0,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1785,serious_adverse,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,coping skills training,coping skills training,non-pharmacological,coping skills training,n/a,n/a,n/a,n/a,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,0,0,FALSE,NA,NA,NA,NA,NA,non_pharm,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1786,serious_adverse,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,coping skills training + sertraline,combined antidepressant intervention,antidepressant,coping skills training + sertraline,ssri,50-200mg,high,flexible,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,0,0,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1787,adverse_dropout,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,2,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1788,adverse_dropout,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,sertraline,antidepressant,antidepressant,sertraline ≤200mg,ssri,50-200mg,high,flexible,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,7,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1789,adverse_dropout,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,coping skills training,coping skills training,non-pharmacological,coping skills training,n/a,n/a,n/a,n/a,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,7,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1790,adverse_dropout,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,coping skills training + sertraline,combined antidepressant intervention,antidepressant,coping skills training + sertraline,ssri,50-200mg,high,flexible,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,2,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1791,withdrawal,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,6,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1792,withdrawal,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,sertraline,antidepressant,antidepressant,sertraline ≤200mg,ssri,50-200mg,high,flexible,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,5,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1793,withdrawal,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,coping skills training,coping skills training,non-pharmacological,coping skills training,n/a,n/a,n/a,n/a,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,8,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1794,withdrawal,keefe 2010,effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study,mood and pain,coping skills training + sertraline,combined antidepressant intervention,antidepressant,coping skills training + sertraline,ssri,50-200mg,high,flexible,34 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,12,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1795,adverse,keskinbora 2006,comparison of efficacy of gabapentin and amitriptyline in the management of peripheral neuropathic pain,pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin 900-3600mg,n/a,n/a,n/a,n/a,4 weeks,peripheral neuropathic pain,neuropathic,neuropathic,no,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,6,0.231,FALSE,any ae,NA,NA,NA,NA,non_ad_pharm,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1796,adverse,keskinbora 2006,comparison of efficacy of gabapentin and amitriptyline in the management of peripheral neuropathic pain,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25-100mg,tca,69.23mg,standard,flexible,4 weeks,peripheral neuropathic pain,neuropathic,neuropathic,no,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,18,0.6920000000000001,FALSE,any ae,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1797,pain_int,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,benzotropine mesylate,active placebo,placebo,benzotropine ≤1mg,n/a,n/a,n/a,n/a,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,completer analysis,0-10 numerical rating scale,baseline,NA,5,2.25,0.4252100321353806,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1798,pain_int,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,morphine,analgesic,non-antidepressant pharmacological,morphine 15-90mg,n/a,n/a,n/a,n/a,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,completer analysis,0-10 numerical rating scale,baseline,NA,5,2.25,0.4252100321353806,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1799,pain_int,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,nortriptyline,antidepressant,antidepressant,nortriptyline 25-100mg,tca,84mg,standard,flexible,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,completer analysis,0-10 numerical rating scale,baseline,NA,5,2.25,0.4252100321353806,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1800,pain_int,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,morphine + nortriptyline,combined antidepressant intervention,antidepressant,morphine 15-90mg + nortriptyline 25-100mg,tca,55mg,low,flexible,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,completer analysis,0-10 numerical rating scale,baseline,NA,5,2.25,0.4252100321353806,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1801,pain_int,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,benzotropine mesylate,active placebo,placebo,benzotropine ≤1mg,n/a,n/a,n/a,n/a,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,completer analysis,0-10 numerical rating scale,post_int,NA,3.9,2.4,0.4535573676110726,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1802,pain_int,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,morphine,analgesic,non-antidepressant pharmacological,morphine 15-90mg,n/a,n/a,n/a,n/a,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,completer analysis,0-10 numerical rating scale,post_int,NA,3.8,2.5,0.472455591261534,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1803,pain_int,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,nortriptyline,antidepressant,antidepressant,nortriptyline 25-100mg,tca,84mg,standard,flexible,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,completer analysis,0-10 numerical rating scale,post_int,NA,3.2,2.4,0.4535573676110726,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1804,pain_int,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,morphine + nortriptyline,combined antidepressant intervention,antidepressant,morphine 15-90mg + nortriptyline 25-100mg,tca,55mg,low,flexible,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,completer analysis,0-10 numerical rating scale,post_int,NA,3.4,2.5,0.472455591261534,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1805,mood,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,benzotropine mesylate,active placebo,placebo,benzotropine ≤1mg,n/a,n/a,n/a,n/a,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,completer analysis,beck depression inventory,baseline,NA,8,6.7,1.266180984580911,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1806,mood,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,morphine,analgesic,non-antidepressant pharmacological,morphine 15-90mg,n/a,n/a,n/a,n/a,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,completer analysis,beck depression inventory,baseline,NA,8,6.7,1.266180984580911,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1807,mood,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,nortriptyline,antidepressant,antidepressant,nortriptyline 25-100mg,tca,84mg,standard,flexible,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,completer analysis,beck depression inventory,baseline,NA,8,6.7,1.266180984580911,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1808,mood,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,morphine + nortriptyline,combined antidepressant intervention,antidepressant,morphine 15-90mg + nortriptyline 25-100mg,tca,55mg,low,flexible,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,completer analysis,beck depression inventory,baseline,NA,8,6.7,1.266180984580911,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1809,mood,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,benzotropine mesylate,active placebo,placebo,benzotropine ≤1mg,n/a,n/a,n/a,n/a,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,completer analysis,beck depression inventory,post_int,NA,9,8.5,1.6063490102892157,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1810,mood,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,morphine,analgesic,non-antidepressant pharmacological,morphine 15-90mg,n/a,n/a,n/a,n/a,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,completer analysis,beck depression inventory,post_int,NA,9.6,8.5,1.6063490102892157,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1811,mood,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,nortriptyline,antidepressant,antidepressant,nortriptyline 25-100mg,tca,84mg,standard,flexible,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,completer analysis,beck depression inventory,post_int,NA,7.3,7.1,1.3417738791827565,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1812,mood,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,morphine + nortriptyline,combined antidepressant intervention,antidepressant,morphine 15-90mg + nortriptyline 25-100mg,tca,55mg,low,flexible,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,completer analysis,beck depression inventory,post_int,NA,6,5,0.944911182523068,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1813,physical,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,benzotropine mesylate,active placebo,placebo,benzotropine ≤1mg,n/a,n/a,n/a,n/a,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,completer analysis,oswestry disability index,baseline,NA,30,15,2.834733547569204,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1814,physical,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,morphine,analgesic,non-antidepressant pharmacological,morphine 15-90mg,n/a,n/a,n/a,n/a,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,completer analysis,oswestry disability index,baseline,NA,30,15,2.834733547569204,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,non_ad_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1815,physical,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,nortriptyline,antidepressant,antidepressant,nortriptyline 25-100mg,tca,84mg,standard,flexible,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,completer analysis,oswestry disability index,baseline,NA,30,15,2.834733547569204,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1816,physical,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,morphine + nortriptyline,combined antidepressant intervention,antidepressant,morphine 15-90mg + nortriptyline 25-100mg,tca,55mg,low,flexible,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,completer analysis,oswestry disability index,baseline,NA,30,15,2.834733547569204,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1817,physical,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,benzotropine mesylate,active placebo,placebo,benzotropine ≤1mg,n/a,n/a,n/a,n/a,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,completer analysis,oswestry disability index,post_int,NA,30.5,15.9,3.0048175604233562,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1818,physical,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,morphine,analgesic,non-antidepressant pharmacological,morphine 15-90mg,n/a,n/a,n/a,n/a,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,completer analysis,oswestry disability index,post_int,NA,25.7,16.5,3.1182069023261243,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,non_ad_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1819,physical,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,nortriptyline,antidepressant,antidepressant,nortriptyline 25-100mg,tca,84mg,standard,flexible,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,completer analysis,oswestry disability index,post_int,NA,27.5,16.7,3.156003349627047,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1820,physical,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,morphine + nortriptyline,combined antidepressant intervention,antidepressant,morphine 15-90mg + nortriptyline 25-100mg,tca,55mg,low,flexible,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,completer analysis,oswestry disability index,post_int,NA,27.4,15.4,2.9103264421710495,NA,NA,NA,NA,NA,28,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1821,adverse,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,benzotropine mesylate,active placebo,placebo,benzotropine ≤1mg,n/a,n/a,n/a,n/a,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,14,NA,FALSE,NA,NA,NA,2021-09-28,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1822,adverse,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,morphine,analgesic,non-antidepressant pharmacological,morphine 15-90mg,n/a,n/a,n/a,n/a,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,26,NA,FALSE,NA,NA,NA,2021-09-28,NA,non_ad_pharm,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1823,adverse,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,nortriptyline,antidepressant,antidepressant,nortriptyline 25-100mg,tca,84mg,standard,flexible,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,19,NA,FALSE,NA,NA,NA,2021-09-28,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1824,adverse,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,morphine + nortriptyline,combined antidepressant intervention,antidepressant,morphine 15-90mg + nortriptyline 25-100mg,tca,55mg,low,flexible,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,25,NA,FALSE,NA,NA,NA,2021-09-28,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1825,adverse_dropout,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,benzotropine mesylate,active placebo,placebo,benzotropine ≤1mg,n/a,n/a,n/a,n/a,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,55,1,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1826,adverse_dropout,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,morphine,analgesic,non-antidepressant pharmacological,morphine 15-90mg,n/a,n/a,n/a,n/a,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,55,4,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1827,adverse_dropout,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,nortriptyline,antidepressant,antidepressant,nortriptyline 25-100mg,tca,84mg,standard,flexible,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,55,2,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1828,adverse_dropout,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,morphine + nortriptyline,combined antidepressant intervention,antidepressant,morphine 15-90mg + nortriptyline 25-100mg,tca,55mg,low,flexible,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,55,4,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1829,withdrawal,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,benzotropine mesylate,active placebo,placebo,benzotropine ≤1mg,n/a,n/a,n/a,n/a,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,55,9,NA,FALSE,NA,NA,NA,2021-09-28,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1830,withdrawal,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,morphine,analgesic,non-antidepressant pharmacological,morphine 15-90mg,n/a,n/a,n/a,n/a,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,55,9,NA,FALSE,NA,NA,NA,2021-09-28,NA,non_ad_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1831,withdrawal,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,nortriptyline,antidepressant,antidepressant,nortriptyline 25-100mg,tca,84mg,standard,flexible,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,55,3,NA,FALSE,NA,NA,NA,2021-09-28,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1832,withdrawal,khoromi 2007,"morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain",pain,morphine + nortriptyline,combined antidepressant intervention,antidepressant,morphine 15-90mg + nortriptyline 25-100mg,tca,55mg,low,flexible,9 weeks,lumbar root pain,neuropathic,neuropathic,≥4 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,55,6,NA,FALSE,NA,NA,NA,2021-09-28,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1833,adverse,kim 2013,"effects of milnacipran on neurocognition, pain, and fatigue in fibromyalgia: a 13-week, randomized, placebo-controlled, crossover trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,no,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,18,0.9,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1834,adverse,kim 2013,"effects of milnacipran on neurocognition, pain, and fatigue in fibromyalgia: a 13-week, randomized, placebo-controlled, crossover trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 12.5-200mg,snri,12.5-200mg,unable to be categorised,flexible,6 weeks,fibromyalgia,fibromyalgia,primary,no,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,12,0.6,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1835,serious_adverse,kim 2013,"effects of milnacipran on neurocognition, pain, and fatigue in fibromyalgia: a 13-week, randomized, placebo-controlled, crossover trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,no,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,0,0,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1836,serious_adverse,kim 2013,"effects of milnacipran on neurocognition, pain, and fatigue in fibromyalgia: a 13-week, randomized, placebo-controlled, crossover trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 12.5-200mg,snri,12.5-200mg,unable to be categorised,flexible,6 weeks,fibromyalgia,fibromyalgia,primary,no,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,0,0,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1837,pain_int,lee 2010,"efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,crossover,completer analysis,sf-36 bodily pain subscale,baseline,NA,51.9,14.3,3.1205158303746914,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,first stage of crossover extracted,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1838,pain_int,lee 2010,"efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 75mg,snri,75mg,low,fixed,4 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,crossover,completer analysis,sf-36 bodily pain subscale,baseline,NA,51.4,12.9,2.7502892409873745,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,first stage of crossover extracted,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1839,pain_int,lee 2010,"efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,crossover,completer analysis,sf-36 bodily pain subscale,post_int,NA,52.4,14.3,3.1205158303746914,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,first stage of crossover extracted,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1840,pain_int,lee 2010,"efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 75mg,snri,75mg,low,fixed,4 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,crossover,completer analysis,sf-36 bodily pain subscale,post_int,NA,52.7,13,2.7716093126229358,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,first stage of crossover extracted,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1841,mood,lee 2010,"efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,crossover,completer analysis,sf-36 mental health subscale,baseline,NA,49.1,13.6,2.967763307209496,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,first stage of crossover extracted,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
1842,mood,lee 2010,"efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 75mg,snri,75mg,low,fixed,4 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,crossover,completer analysis,sf-36 mental health subscale,baseline,NA,52.9,19.5,4.157413968934403,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,first stage of crossover extracted,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
1843,mood,lee 2010,"efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,crossover,completer analysis,sf-36 mental health subscale,post_int,NA,50.3,14.2,3.098694041351092,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,first stage of crossover extracted,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
1844,mood,lee 2010,"efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 75mg,snri,75mg,low,fixed,4 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,crossover,completer analysis,sf-36 mental health subscale,post_int,NA,55.1,19.6,4.178734040569965,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,first stage of crossover extracted,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
1845,physical,lee 2010,"efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,crossover,completer analysis,sf-36 physical functioning subscale,baseline,NA,53.3,15.5,3.382377298657882,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,first stage of crossover extracted,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1846,physical,lee 2010,"efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 75mg,snri,75mg,low,fixed,4 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,crossover,completer analysis,sf-36 physical functioning subscale,baseline,NA,52.9,14.2,3.027450172249668,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,first stage of crossover extracted,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1847,physical,lee 2010,"efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,crossover,completer analysis,sf-36 physical functioning subscale,post_int,NA,55.1,14.7,3.207802986469088,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,first stage of crossover extracted,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1848,physical,lee 2010,"efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 75mg,snri,75mg,low,fixed,4 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,crossover,completer analysis,sf-36 physical functioning subscale,post_int,NA,55,14.8,3.1553706020630345,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,first stage of crossover extracted,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
1849,adverse,lee 2010,"efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,3,0.12,FALSE,number of participants with any ae,NA,first stage of crossover extracted,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1850,adverse,lee 2010,"efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 75mg,snri,75mg,low,fixed,4 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,11,0.52,FALSE,number of participants with any ae,NA,first stage of crossover extracted,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1851,withdrawal,lee 2010,"efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,3,0.12,FALSE,NA,NA,first stage of crossover extracted,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1852,withdrawal,lee 2010,"efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 75mg,snri,75mg,low,fixed,4 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,1,0.04,FALSE,NA,NA,first stage of crossover extracted,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1855,adverse_dropout,lee 2010,"efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,first stage of crossover extracted,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1856,adverse_dropout,lee 2010,"efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 75mg,snri,75mg,low,fixed,4 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,1,NA,FALSE,NA,NA,first stage of crossover extracted,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1857,pain_int,lee 2016,effect of milnacipran on pain in patients with rheumatoid arthritis with widespread pain: a randomized blinded crossover trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,≥4 on bpi; ≥5 on regional pain scale,crossover,itt with locf,0-10 numerical rating scale,baseline,NA,5.2,2.1,0.37123106012293744,NA,NA,NA,NA,NA,32,NA,NA,FALSE,NA,NA,NA,2021-09-27,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1858,pain_int,lee 2016,effect of milnacipran on pain in patients with rheumatoid arthritis with widespread pain: a randomized blinded crossover trial,pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,6 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,≥4 on bpi; ≥5 on regional pain scale,crossover,itt with locf,0-10 numerical rating scale,baseline,NA,5.6,2,0.35355339059327373,NA,NA,NA,NA,NA,32,NA,NA,FALSE,NA,NA,NA,2021-09-27,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1859,pain_int,lee 2016,effect of milnacipran on pain in patients with rheumatoid arthritis with widespread pain: a randomized blinded crossover trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,≥4 on bpi; ≥5 on regional pain scale,crossover,itt with locf,0-10 numerical rating scale,post_int,NA,4.9,2.1,0.37123106012293744,NA,NA,NA,NA,NA,32,NA,NA,FALSE,NA,NA,NA,2021-09-27,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1860,pain_int,lee 2016,effect of milnacipran on pain in patients with rheumatoid arthritis with widespread pain: a randomized blinded crossover trial,pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,6 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,≥4 on bpi; ≥5 on regional pain scale,crossover,itt with locf,0-10 numerical rating scale,post_int,NA,4.8,2.2,0.38890872965260115,NA,NA,NA,NA,NA,32,NA,NA,FALSE,NA,NA,NA,2021-09-27,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1861,adverse,lee 2016,effect of milnacipran on pain in patients with rheumatoid arthritis with widespread pain: a randomized blinded crossover trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,≥4 on bpi; ≥5 on regional pain scale,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,8,NA,FALSE,number of participants with any ae,NA,NA,2021-09-27,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1862,adverse,lee 2016,effect of milnacipran on pain in patients with rheumatoid arthritis with widespread pain: a randomized blinded crossover trial,pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,6 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,≥4 on bpi; ≥5 on regional pain scale,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,17,NA,FALSE,number of participants with any ae,NA,NA,2021-09-27,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1863,serious_adverse,lee 2016,effect of milnacipran on pain in patients with rheumatoid arthritis with widespread pain: a randomized blinded crossover trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,≥4 on bpi; ≥5 on regional pain scale,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,1,NA,FALSE,NA,NA,NA,2021-09-27,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1864,serious_adverse,lee 2016,effect of milnacipran on pain in patients with rheumatoid arthritis with widespread pain: a randomized blinded crossover trial,pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,6 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,≥4 on bpi; ≥5 on regional pain scale,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,0,NA,FALSE,NA,NA,NA,2021-09-27,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1865,adverse_dropout,lee 2016,effect of milnacipran on pain in patients with rheumatoid arthritis with widespread pain: a randomized blinded crossover trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,≥4 on bpi; ≥5 on regional pain scale,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,2,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1866,adverse_dropout,lee 2016,effect of milnacipran on pain in patients with rheumatoid arthritis with widespread pain: a randomized blinded crossover trial,pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,6 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,≥4 on bpi; ≥5 on regional pain scale,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,5,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1867,withdrawal,lee 2016,effect of milnacipran on pain in patients with rheumatoid arthritis with widespread pain: a randomized blinded crossover trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,≥4 on bpi; ≥5 on regional pain scale,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,3,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1868,withdrawal,lee 2016,effect of milnacipran on pain in patients with rheumatoid arthritis with widespread pain: a randomized blinded crossover trial,pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,6 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,≥4 on bpi; ≥5 on regional pain scale,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,6,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1869,pain_mod,lee 2016,effect of milnacipran on pain in patients with rheumatoid arthritis with widespread pain: a randomized blinded crossover trial,pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,6 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,≥4 on bpi; ≥5 on regional pain scale,crossover,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,32,9,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
1870,pain_int,leijon 1989,central post-stroke pain - a controlled trial of amitriptyline and carbamazepine,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,post-stroke pain,neuropathic,neuropathic,no,crossover,not reported,0-10 numerical rating scale,post_int,NA,5.3,2,0.5163977794943222,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,no baseline values reported,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1871,pain_int,leijon 1989,central post-stroke pain - a controlled trial of amitriptyline and carbamazepine,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 75mg,tca,75mg,standard,fixed,4 weeks,post-stroke pain,neuropathic,neuropathic,no,crossover,not reported,0-10 numerical rating scale,post_int,NA,4.2,1.6,0.4131182235954578,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,no baseline values reported,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1872,pain_int,leijon 1989,central post-stroke pain - a controlled trial of amitriptyline and carbamazepine,pain,carbamazepine,anticonvulsant,non-antidepressant pharmacological,carbamazepine 800mg,n/a,n/a,n/a,n/a,4 weeks,post-stroke pain,neuropathic,neuropathic,no,crossover,not reported,0-10 numerical rating scale,post_int,NA,4.2,1.7,0.45434411125112145,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,no baseline values reported,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1873,adverse,leijon 1989,central post-stroke pain - a controlled trial of amitriptyline and carbamazepine,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,post-stroke pain,neuropathic,neuropathic,no,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,7,NA,FALSE,number of participants with any ae,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1874,adverse,leijon 1989,central post-stroke pain - a controlled trial of amitriptyline and carbamazepine,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 75mg,tca,75mg,standard,fixed,4 weeks,post-stroke pain,neuropathic,neuropathic,no,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,14,NA,FALSE,number of participants with any ae,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1875,adverse,leijon 1989,central post-stroke pain - a controlled trial of amitriptyline and carbamazepine,pain,carbamazepine,anticonvulsant,non-antidepressant pharmacological,carbamazepine 800mg,n/a,n/a,n/a,n/a,4 weeks,post-stroke pain,neuropathic,neuropathic,no,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,12,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1876,serious_adverse,leijon 1989,central post-stroke pain - a controlled trial of amitriptyline and carbamazepine,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,post-stroke pain,neuropathic,neuropathic,no,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1877,serious_adverse,leijon 1989,central post-stroke pain - a controlled trial of amitriptyline and carbamazepine,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 75mg,tca,75mg,standard,fixed,4 weeks,post-stroke pain,neuropathic,neuropathic,no,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1878,serious_adverse,leijon 1989,central post-stroke pain - a controlled trial of amitriptyline and carbamazepine,pain,carbamazepine,anticonvulsant,non-antidepressant pharmacological,carbamazepine 800mg,n/a,n/a,n/a,n/a,4 weeks,post-stroke pain,neuropathic,neuropathic,no,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,1,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1879,adverse_dropout,leijon 1989,central post-stroke pain - a controlled trial of amitriptyline and carbamazepine,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,post-stroke pain,neuropathic,neuropathic,no,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1880,adverse_dropout,leijon 1989,central post-stroke pain - a controlled trial of amitriptyline and carbamazepine,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 75mg,tca,75mg,standard,fixed,4 weeks,post-stroke pain,neuropathic,neuropathic,no,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1881,adverse_dropout,leijon 1989,central post-stroke pain - a controlled trial of amitriptyline and carbamazepine,pain,carbamazepine,anticonvulsant,non-antidepressant pharmacological,carbamazepine 800mg,n/a,n/a,n/a,n/a,4 weeks,post-stroke pain,neuropathic,neuropathic,no,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,0,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1882,withdrawal,leijon 1989,central post-stroke pain - a controlled trial of amitriptyline and carbamazepine,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,post-stroke pain,neuropathic,neuropathic,no,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1883,withdrawal,leijon 1989,central post-stroke pain - a controlled trial of amitriptyline and carbamazepine,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 75mg,tca,75mg,standard,fixed,4 weeks,post-stroke pain,neuropathic,neuropathic,no,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,0,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1884,withdrawal,leijon 1989,central post-stroke pain - a controlled trial of amitriptyline and carbamazepine,pain,carbamazepine,anticonvulsant,non-antidepressant pharmacological,carbamazepine 800mg,n/a,n/a,n/a,n/a,4 weeks,post-stroke pain,neuropathic,neuropathic,no,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,1,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1885,pain_int,lipone 2020,efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin 2400mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,5.7,1.14,0.16454482671904333,NA,NA,NA,NA,NA,48,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1886,pain_int,lipone 2020,efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,pain,trazodone + gabapentin,combined antidepressant intervention,antidepressant,trazodone 30mg + gabapentin 2400mg,sari,30mg,low,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,5.7,1.01,0.1540235560359307,NA,NA,NA,NA,NA,43,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1887,pain_int,lipone 2020,efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,pain,trazodone + gabapentin,combined antidepressant intervention,antidepressant,trazodone 60mg + gabapentin 2400mg,sari,60mg,low,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,5.6,1.05,0.14849242404917498,NA,NA,NA,NA,NA,50,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1888,pain_int,lipone 2020,efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin 2400mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,post_int,NA,3.2,1.8,0.2598076211353316,NA,NA,NA,NA,NA,48,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1889,pain_int,lipone 2020,efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,pain,trazodone + gabapentin,combined antidepressant intervention,antidepressant,trazodone 30mg + gabapentin 2400mg,sari,30mg,low,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,post_int,NA,2.6,1.68,0.25619759815877585,NA,NA,NA,NA,NA,43,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1890,pain_int,lipone 2020,efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,pain,trazodone + gabapentin,combined antidepressant intervention,antidepressant,trazodone 60mg + gabapentin 2400mg,sari,60mg,low,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,post_int,NA,3,1.86,0.2630437226013957,NA,NA,NA,NA,NA,50,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1891,pain_sub,lipone 2020,efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin 2400mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,48,22,0.45799999999999996,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
1892,pain_sub,lipone 2020,efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,pain,trazodone + gabapentin,combined antidepressant intervention,antidepressant,trazodone 30mg + gabapentin 2400mg,sari,30mg,low,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,43,27,0.628,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
1893,pain_sub,lipone 2020,efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,pain,trazodone + gabapentin,combined antidepressant intervention,antidepressant,trazodone 60mg + gabapentin 2400mg,sari,60mg,low,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,50,27,0.54,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
1894,adverse,lipone 2020,efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin 2400mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,48,20,0.41700000000000004,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1895,adverse,lipone 2020,efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,pain,trazodone + gabapentin,combined antidepressant intervention,antidepressant,trazodone 30mg + gabapentin 2400mg,sari,30mg,low,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,43,27,0.628,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1896,adverse,lipone 2020,efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,pain,trazodone + gabapentin,combined antidepressant intervention,antidepressant,trazodone 60mg + gabapentin 2400mg,sari,60mg,low,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,21,0.41200000000000003,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1897,serious_adverse,lipone 2020,efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin 2400mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1898,serious_adverse,lipone 2020,efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,pain,trazodone + gabapentin,combined antidepressant intervention,antidepressant,trazodone 30mg + gabapentin 2400mg,sari,30mg,low,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1899,serious_adverse,lipone 2020,efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,pain,trazodone + gabapentin,combined antidepressant intervention,antidepressant,trazodone 60mg + gabapentin 2400mg,sari,60mg,low,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1900,adverse_dropout,lipone 2020,efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin 2400mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,48,3,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1901,adverse_dropout,lipone 2020,efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,pain,trazodone + gabapentin,combined antidepressant intervention,antidepressant,trazodone 30mg + gabapentin 2400mg,sari,30mg,low,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,43,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1902,adverse_dropout,lipone 2020,efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,pain,trazodone + gabapentin,combined antidepressant intervention,antidepressant,trazodone 60mg + gabapentin 2400mg,sari,60mg,low,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1903,withdrawal,lipone 2020,efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin 2400mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,48,13,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1904,withdrawal,lipone 2020,efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,pain,trazodone + gabapentin,combined antidepressant intervention,antidepressant,trazodone 30mg + gabapentin 2400mg,sari,30mg,low,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,43,10,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1905,withdrawal,lipone 2020,efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy and treated with gabapentin: a randomized controlled pilot study,pain,trazodone + gabapentin,combined antidepressant intervention,antidepressant,trazodone 60mg + gabapentin 2400mg,sari,60mg,low,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,15,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1906,pain_sub,loldrup 1989,clomipramine and mianserin in chronic idiopathic pain syndrome. a placebo controlled study.,mood and pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,idiopathic pain syndrome,primary,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,66,25,0.38,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
1907,pain_sub,loldrup 1989,clomipramine and mianserin in chronic idiopathic pain syndrome. a placebo controlled study.,mood and pain,clomipramine,antidepressant,antidepressant,clomipramine 75-100mg,tca,125mg,standard,flexible,6 weeks,idiopathic pain syndrome,primary,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,62,30,0.48,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
1908,pain_sub,loldrup 1989,clomipramine and mianserin in chronic idiopathic pain syndrome. a placebo controlled study.,mood and pain,mianserin,antidepressant,antidepressant,mianserin 30-60mg,teca,45mg,high,flexible,6 weeks,idiopathic pain syndrome,primary,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,64,29,0.45,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
1909,withdrawal,loldrup 1989,clomipramine and mianserin in chronic idiopathic pain syndrome. a placebo controlled study.,mood and pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,idiopathic pain syndrome,primary,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,87,15,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1910,withdrawal,loldrup 1989,clomipramine and mianserin in chronic idiopathic pain syndrome. a placebo controlled study.,mood and pain,clomipramine,antidepressant,antidepressant,clomipramine 75-100mg,tca,125mg,standard,flexible,6 weeks,idiopathic pain syndrome,primary,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,84,28,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1911,withdrawal,loldrup 1989,clomipramine and mianserin in chronic idiopathic pain syndrome. a placebo controlled study.,mood and pain,mianserin,antidepressant,antidepressant,mianserin 30-60mg,teca,45mg,high,flexible,6 weeks,idiopathic pain syndrome,primary,primary,no,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,82,28,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1912,pain_int,luo 2009,a randomized double-blind clinical trial on analgesic efficacy of fluoxetine for persistent somatoform pain disorder,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,somatoform pain disorder,primary,primary,no,parallel,itt with locf,medical outcomes study pain measures,baseline,NA,65.75,24.87,3.9322922704193797,NA,NA,NA,NA,NA,40,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1913,pain_int,luo 2009,a randomized double-blind clinical trial on analgesic efficacy of fluoxetine for persistent somatoform pain disorder,pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,8 weeks,somatoform pain disorder,primary,primary,no,parallel,itt with locf,medical outcomes study pain measures,baseline,NA,59.53,22.76,3.5986719772716156,NA,NA,NA,NA,NA,40,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1914,pain_int,luo 2009,a randomized double-blind clinical trial on analgesic efficacy of fluoxetine for persistent somatoform pain disorder,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,somatoform pain disorder,primary,primary,no,parallel,itt with locf,medical outcomes study pain measures,post_int,NA,55.33,25.44,4.022417183734179,NA,NA,NA,NA,NA,40,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1915,pain_int,luo 2009,a randomized double-blind clinical trial on analgesic efficacy of fluoxetine for persistent somatoform pain disorder,pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,8 weeks,somatoform pain disorder,primary,primary,no,parallel,itt with locf,medical outcomes study pain measures,post_int,NA,33.08,18.81,2.9741221393883603,NA,NA,NA,NA,NA,40,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1916,mood,luo 2009,a randomized double-blind clinical trial on analgesic efficacy of fluoxetine for persistent somatoform pain disorder,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,somatoform pain disorder,primary,primary,no,parallel,itt with locf,hamilton depression rating scale,post_int,NA,14.75,8.25,1.3044395348194564,NA,NA,NA,NA,NA,40,NA,NA,FALSE,NA,NA,baseline only,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1917,mood,luo 2009,a randomized double-blind clinical trial on analgesic efficacy of fluoxetine for persistent somatoform pain disorder,pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,8 weeks,somatoform pain disorder,primary,primary,no,parallel,itt with locf,hamilton depression rating scale,post_int,NA,14.33,8.63,1.3645228103626557,NA,NA,NA,NA,NA,40,NA,NA,FALSE,NA,NA,baseline only,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1918,pain_int,maarrawi 2018,randomized double-blind controlled study of bedtime low-dose amitriptyline in chronic neck pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,neck pain,musculoskeletal,primary,no,parallel,completer analysis,0-10 numerical rating scale,baseline,NA,7.12,0.65,0.06254627916220946,NA,NA,NA,NA,NA,108,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1919,pain_int,maarrawi 2018,randomized double-blind controlled study of bedtime low-dose amitriptyline in chronic neck pain,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 5mg,tca,5mg,low,fixed,8 weeks,neck pain,musculoskeletal,primary,no,parallel,completer analysis,0-10 numerical rating scale,baseline,NA,7.1,0.73,0.06897851632418396,NA,NA,NA,NA,NA,112,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1920,pain_int,maarrawi 2018,randomized double-blind controlled study of bedtime low-dose amitriptyline in chronic neck pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,neck pain,musculoskeletal,primary,no,parallel,completer analysis,0-10 numerical rating scale,post_int,NA,6.12,0.92,0.08852704127574262,NA,NA,NA,NA,NA,108,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1921,pain_int,maarrawi 2018,randomized double-blind controlled study of bedtime low-dose amitriptyline in chronic neck pain,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 5mg,tca,5mg,low,fixed,8 weeks,neck pain,musculoskeletal,primary,no,parallel,completer analysis,0-10 numerical rating scale,post_int,NA,3.34,1.45,0.14218419797518342,NA,NA,NA,NA,NA,104,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1922,pain_int,macfarlane 1986,trimipramine in rheumatoid arthritis: a randomized double-blind trial in relieving pain and joint tenderness,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,no,parallel,not reported,0-4 numerical rating scale,baseline,NA,2.9,0.46,0.1084230397819373,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1923,pain_int,macfarlane 1986,trimipramine in rheumatoid arthritis: a randomized double-blind trial in relieving pain and joint tenderness,pain,trimipramine,antidepressant,antidepressant,trimipramine 25-75mg,tca,25-75mg,low,flexible,12 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,no,parallel,not reported,0-4 numerical rating scale,baseline,NA,2.8,0.42,0.09899494936611666,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1924,pain_int,macfarlane 1986,trimipramine in rheumatoid arthritis: a randomized double-blind trial in relieving pain and joint tenderness,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,no,parallel,not reported,0-4 numerical rating scale,post_int,NA,2.6,0.72,0.1996920706410825,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1925,pain_int,macfarlane 1986,trimipramine in rheumatoid arthritis: a randomized double-blind trial in relieving pain and joint tenderness,pain,trimipramine,antidepressant,antidepressant,trimipramine 25-75mg,tca,25-75mg,low,flexible,12 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,no,parallel,not reported,0-4 numerical rating scale,post_int,NA,1.8,0.53,0.14164845821358493,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1926,mood,macfarlane 1986,trimipramine in rheumatoid arthritis: a randomized double-blind trial in relieving pain and joint tenderness,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,no,parallel,not reported,zung depression rating scale,baseline,NA,61.9,8,1.885618083164127,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1927,mood,macfarlane 1986,trimipramine in rheumatoid arthritis: a randomized double-blind trial in relieving pain and joint tenderness,pain,trimipramine,antidepressant,antidepressant,trimipramine 25-75mg,tca,25-75mg,low,flexible,12 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,no,parallel,not reported,zung depression rating scale,baseline,NA,63.2,8.1,1.9091883092036783,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1928,mood,macfarlane 1986,trimipramine in rheumatoid arthritis: a randomized double-blind trial in relieving pain and joint tenderness,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,no,parallel,not reported,zung depression rating scale,post_int,NA,60.5,10,2.773500981126146,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1929,mood,macfarlane 1986,trimipramine in rheumatoid arthritis: a randomized double-blind trial in relieving pain and joint tenderness,pain,trimipramine,antidepressant,antidepressant,trimipramine 25-75mg,tca,25-75mg,low,flexible,12 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,no,parallel,not reported,zung depression rating scale,post_int,NA,57.3,8.7,2.325172804638092,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1930,adverse_dropout,macfarlane 1986,trimipramine in rheumatoid arthritis: a randomized double-blind trial in relieving pain and joint tenderness,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,2,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1931,adverse_dropout,macfarlane 1986,trimipramine in rheumatoid arthritis: a randomized double-blind trial in relieving pain and joint tenderness,pain,trimipramine,antidepressant,antidepressant,trimipramine 25-75mg,tca,25-75mg,low,flexible,12 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,4,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1932,withdrawal,macfarlane 1986,trimipramine in rheumatoid arthritis: a randomized double-blind trial in relieving pain and joint tenderness,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,4,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1933,withdrawal,macfarlane 1986,trimipramine in rheumatoid arthritis: a randomized double-blind trial in relieving pain and joint tenderness,pain,trimipramine,antidepressant,antidepressant,trimipramine 25-75mg,tca,25-75mg,low,flexible,12 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,5,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1934,pain_int,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,waitlist,waitlist,non-pharmacological,waitlist,n/a,n/a,n/a,n/a,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,completer analysis,0-10 numerical rating scale,baseline,NA,7.62,0.86,0.18766738560295346,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1935,pain_int,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10mg,tca,10mg,low,fixed,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,completer analysis,0-10 numerical rating scale,baseline,NA,7.9,1,0.2182178902359924,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1936,pain_int,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,amitriptyline + splint,combined antidepressant intervention,antidepressant,amitriptyline 10mg + splint,tca,10mg,low,fixed,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,completer analysis,0-10 numerical rating scale,baseline,NA,8.52,1.2,0.2502172968684897,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1937,pain_int,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,acupuncture,alternative therapy,non-pharmacological,acupuncture,n/a,n/a,n/a,n/a,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,completer analysis,0-10 numerical rating scale,baseline,NA,8,1.52,0.42157214913117413,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1938,pain_int,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,waitlist,waitlist,non-pharmacological,waitlist,n/a,n/a,n/a,n/a,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,completer analysis,0-10 numerical rating scale,post_int,NA,7.48,1.29,0.28150107840443017,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1939,pain_int,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10mg,tca,10mg,low,fixed,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,completer analysis,0-10 numerical rating scale,post_int,NA,3.43,2.5,0.545544725589981,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1940,pain_int,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,amitriptyline + splint,combined antidepressant intervention,antidepressant,amitriptyline 10mg + splint,tca,10mg,low,fixed,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,completer analysis,0-10 numerical rating scale,post_int,NA,3.65,3.32,0.6922678546694883,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1941,pain_int,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,acupuncture,alternative therapy,non-pharmacological,acupuncture,n/a,n/a,n/a,n/a,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,completer analysis,0-10 numerical rating scale,post_int,NA,3.23,2.74,0.759939268828564,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1942,qol,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,waitlist,waitlist,non-pharmacological,waitlist,n/a,n/a,n/a,n/a,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,completer analysis,oral health impact profile,baseline,NA,24.9,13.14,2.86738307770094,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,non_pharm,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
1943,qol,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10mg,tca,10mg,low,fixed,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,completer analysis,oral health impact profile,baseline,NA,26.57,12.39,2.7037196600239457,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
1944,qol,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,amitriptyline + splint,combined antidepressant intervention,antidepressant,amitriptyline 10mg + splint,tca,10mg,low,fixed,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,completer analysis,oral health impact profile,baseline,NA,29.83,11.44,2.3854048968129353,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
1945,qol,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,acupuncture,alternative therapy,non-pharmacological,acupuncture,n/a,n/a,n/a,n/a,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,completer analysis,oral health impact profile,baseline,NA,24.46,10.1,2.801235990937407,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,non_pharm,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
1946,qol,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,waitlist,waitlist,non-pharmacological,waitlist,n/a,n/a,n/a,n/a,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,completer analysis,oral health impact profile,post_int,NA,20.52,14.03,3.061597000010973,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,non_pharm,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
1947,qol,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10mg,tca,10mg,low,fixed,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,completer analysis,oral health impact profile,post_int,NA,17.67,10.58,2.3087452786967995,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
1948,qol,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,amitriptyline + splint,combined antidepressant intervention,antidepressant,amitriptyline 10mg + splint,tca,10mg,low,fixed,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,completer analysis,oral health impact profile,post_int,NA,14.91,13.56,2.827455454613934,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
1949,qol,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,acupuncture,alternative therapy,non-pharmacological,acupuncture,n/a,n/a,n/a,n/a,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,completer analysis,oral health impact profile,post_int,NA,22.85,13.13,3.6416067882186294,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,non_pharm,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
1950,mood,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,waitlist,waitlist,non-pharmacological,waitlist,n/a,n/a,n/a,n/a,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,completer analysis,beck depression inventory,baseline,NA,15.95,10.34,2.2563729850401613,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1951,mood,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10mg,tca,10mg,low,fixed,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,completer analysis,beck depression inventory,baseline,NA,16.76,11.27,2.4593156229596342,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1952,mood,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,amitriptyline + splint,combined antidepressant intervention,antidepressant,amitriptyline 10mg + splint,tca,10mg,low,fixed,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,completer analysis,beck depression inventory,baseline,NA,18.61,13.52,2.819114878051651,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1953,mood,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,acupuncture,alternative therapy,non-pharmacological,acupuncture,n/a,n/a,n/a,n/a,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,completer analysis,beck depression inventory,baseline,NA,17.38,9.35,2.593223417352946,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
1954,mood,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,waitlist,waitlist,non-pharmacological,waitlist,n/a,n/a,n/a,n/a,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,completer analysis,beck depression inventory,post_int,NA,14.62,9.43,2.057794704925408,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1955,mood,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10mg,tca,10mg,low,fixed,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,completer analysis,beck depression inventory,post_int,NA,11.86,9.24,2.0163333057805697,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1956,mood,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,amitriptyline + splint,combined antidepressant intervention,antidepressant,amitriptyline 10mg + splint,tca,10mg,low,fixed,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,completer analysis,beck depression inventory,post_int,NA,12.17,13.1,2.7315388241476795,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1957,mood,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,acupuncture,alternative therapy,non-pharmacological,acupuncture,n/a,n/a,n/a,n/a,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,completer analysis,beck depression inventory,post_int,NA,16.38,11.3,3.134056108672545,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
1958,sleep,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,waitlist,waitlist,non-pharmacological,waitlist,n/a,n/a,n/a,n/a,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,completer analysis,pittsburgh sleep quality index,baseline,NA,9.38,2.71,0.5913704825395394,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,non_pharm,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
1959,sleep,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10mg,tca,10mg,low,fixed,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,completer analysis,pittsburgh sleep quality index,baseline,NA,11,4.33,0.944883464721847,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
1960,sleep,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,amitriptyline + splint,combined antidepressant intervention,antidepressant,amitriptyline 10mg + splint,tca,10mg,low,fixed,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,completer analysis,pittsburgh sleep quality index,baseline,NA,10.27,4.01,0.8361428003688698,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
1961,sleep,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,acupuncture,alternative therapy,non-pharmacological,acupuncture,n/a,n/a,n/a,n/a,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,completer analysis,pittsburgh sleep quality index,baseline,NA,7.77,3.81,1.0567038738090615,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,non_pharm,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
1962,sleep,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,waitlist,waitlist,non-pharmacological,waitlist,n/a,n/a,n/a,n/a,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,completer analysis,pittsburgh sleep quality index,post_int,NA,10.29,3.64,0.7943131204590124,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,non_pharm,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1963,sleep,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10mg,tca,10mg,low,fixed,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,completer analysis,pittsburgh sleep quality index,post_int,NA,5.7,2.39,0.5215407576640219,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1964,sleep,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,amitriptyline + splint,combined antidepressant intervention,antidepressant,amitriptyline 10mg + splint,tca,10mg,low,fixed,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,completer analysis,pittsburgh sleep quality index,post_int,NA,6.41,3.43,0.7152044402157666,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1965,sleep,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,acupuncture,alternative therapy,non-pharmacological,acupuncture,n/a,n/a,n/a,n/a,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,completer analysis,pittsburgh sleep quality index,post_int,NA,5.46,3.55,0.9845928482997817,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,non_pharm,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1966,withdrawal,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,waitlist,waitlist,non-pharmacological,waitlist,n/a,n/a,n/a,n/a,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,3,0.125,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,non_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1967,withdrawal,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10mg,tca,10mg,low,fixed,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,3,0.125,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1968,withdrawal,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,amitriptyline + splint,combined antidepressant intervention,antidepressant,amitriptyline 10mg + splint,tca,10mg,low,fixed,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,1,0.042,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1969,withdrawal,machado 2018,comparative study of conservative therapies for dysfunctional chronic muscular temporomandibular disorder: blind controlled randomized clinical trial,pain,acupuncture,alternative therapy,non-pharmacological,acupuncture,n/a,n/a,n/a,n/a,16 weeks,temporomandibular disorder,musculoskeletal,primary,≥7 on 0-10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,11,0.4583,FALSE,NA,NA,study reference in covidence is dshrv 2018,NA,NA,non_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1970,pain_int,majdinasab 2019,a comparative double-blind randomized study on the effectiveness of duloxetine and gabapentin on painful diabetic peripheral polyneuropathy,pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin 300-900mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,0-100 vas,baseline,NA,64,20.03,2.777661232597835,NA,NA,NA,NA,NA,52,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1971,pain_int,majdinasab 2019,a comparative double-blind randomized study on the effectiveness of duloxetine and gabapentin on painful diabetic peripheral polyneuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 30-60mg,snri,30-60mg,low,flexible,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,0-100 vas,baseline,NA,62,21.18,2.9371375390125882,NA,NA,NA,NA,NA,52,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1972,pain_int,majdinasab 2019,a comparative double-blind randomized study on the effectiveness of duloxetine and gabapentin on painful diabetic peripheral polyneuropathy,pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin 300-900mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,0-100 vas,post_int,NA,39.43,14.32,2.236408270244839,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1973,pain_int,majdinasab 2019,a comparative double-blind randomized study on the effectiveness of duloxetine and gabapentin on painful diabetic peripheral polyneuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 30-60mg,snri,30-60mg,low,flexible,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,0-100 vas,post_int,NA,36.78,15.62,2.278411167197113,NA,NA,NA,NA,NA,47,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1974,sleep,majdinasab 2019,a comparative double-blind randomized study on the effectiveness of duloxetine and gabapentin on painful diabetic peripheral polyneuropathy,pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin 300-900mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,0-10 numerical rating scale,baseline,NA,7.12,1.63,0.22604032996178086,NA,NA,NA,NA,NA,52,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
1975,sleep,majdinasab 2019,a comparative double-blind randomized study on the effectiveness of duloxetine and gabapentin on painful diabetic peripheral polyneuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 30-60mg,snri,30-60mg,low,flexible,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,0-10 numerical rating scale,baseline,NA,6.86,1.57,0.21771982701840245,NA,NA,NA,NA,NA,52,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
1976,sleep,majdinasab 2019,a comparative double-blind randomized study on the effectiveness of duloxetine and gabapentin on painful diabetic peripheral polyneuropathy,pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin 300-900mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,0-10 numerical rating scale,post_int,NA,3.43,1.32,0.20614936569296002,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1977,sleep,majdinasab 2019,a comparative double-blind randomized study on the effectiveness of duloxetine and gabapentin on painful diabetic peripheral polyneuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 30-60mg,snri,30-60mg,low,flexible,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,0-10 numerical rating scale,post_int,NA,2.78,1.62,0.2363012862265892,NA,NA,NA,NA,NA,47,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
1978,adverse,majdinasab 2019,a comparative double-blind randomized study on the effectiveness of duloxetine and gabapentin on painful diabetic peripheral polyneuropathy,pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin 300-900mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,52,9,NA,FALSE,participants with 'the most common side effects',NA,NA,NA,NA,non_ad_pharm,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1979,adverse,majdinasab 2019,a comparative double-blind randomized study on the effectiveness of duloxetine and gabapentin on painful diabetic peripheral polyneuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 30-60mg,snri,30-60mg,low,flexible,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,52,2,NA,FALSE,participants with 'the most common side effects',NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
1980,adverse_dropout,majdinasab 2019,a comparative double-blind randomized study on the effectiveness of duloxetine and gabapentin on painful diabetic peripheral polyneuropathy,pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin 300-900mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,52,7,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1981,adverse_dropout,majdinasab 2019,a comparative double-blind randomized study on the effectiveness of duloxetine and gabapentin on painful diabetic peripheral polyneuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 30-60mg,snri,30-60mg,low,flexible,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,52,2,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1982,withdrawal,majdinasab 2019,a comparative double-blind randomized study on the effectiveness of duloxetine and gabapentin on painful diabetic peripheral polyneuropathy,pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin 300-900mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,52,11,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1983,withdrawal,majdinasab 2019,a comparative double-blind randomized study on the effectiveness of duloxetine and gabapentin on painful diabetic peripheral polyneuropathy,pain,duloxetine,antidepressant,antidepressant,duloxetine 30-60mg,snri,30-60mg,low,flexible,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,52,5,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1984,serious_adverse,masand 2009,"a double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome",pain and ibs symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,no,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,36,0,0,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1985,serious_adverse,masand 2009,"a double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome",pain and ibs symptoms,paroxetine,antidepressant,antidepressant,paroxetine 12.5-50mg,ssri,30mg,low,flexible,12 weeks,irritable bowel syndrome,gastrointestinal,primary,no,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,36,0,0,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
1986,adverse_dropout,masand 2009,"a double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome",pain and ibs symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,no,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,36,2,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1987,adverse_dropout,masand 2009,"a double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome",pain and ibs symptoms,paroxetine,antidepressant,antidepressant,paroxetine 12.5-50mg,ssri,30mg,low,flexible,12 weeks,irritable bowel syndrome,gastrointestinal,primary,no,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,36,3,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
1988,withdrawal,masand 2009,"a double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome",pain and ibs symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,no,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,36,8,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1989,withdrawal,masand 2009,"a double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome",pain and ibs symptoms,paroxetine,antidepressant,antidepressant,paroxetine 12.5-50mg,ssri,30mg,low,flexible,12 weeks,irritable bowel syndrome,gastrointestinal,primary,no,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,36,6,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
1990,pain_int,matthey 2013,"dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,7 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-100 vas,baseline,NA,62.1,14.5,2.3218582301737634,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1991,pain_int,matthey 2013,"dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100-200mg,snri,100-200mg,high,flexible,7 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-100 vas,baseline,NA,63.7,15.1,2.4495434590745147,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
1992,pain_int,matthey 2013,"dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,7 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-100 vas,post_int,NA,58.3,24.6,3.9391525836051438,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1993,pain_int,matthey 2013,"dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100-200mg,snri,100-200mg,high,flexible,7 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-100 vas,post_int,NA,46.7,26.3,4.2664233757390555,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
1994,qol,matthey 2013,"dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,7 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,fibromyalgia impact questionnaire total score,baseline,NA,54.7,14.4,2.3058454147932546,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
1995,qol,matthey 2013,"dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100-200mg,snri,100-200mg,high,flexible,7 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,fibromyalgia impact questionnaire total score,baseline,NA,53.6,17,2.757764159222963,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
1996,qol,matthey 2013,"dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,7 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,fibromyalgia impact questionnaire total score,post_int,NA,54.1,18.6,2.978383660774621,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
1997,qol,matthey 2013,"dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100-200mg,snri,100-200mg,high,flexible,7 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,fibromyalgia impact questionnaire total score,post_int,NA,44.1,20.8,3.374205559519861,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
1998,physical,matthey 2013,"dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,7 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 physical component score,baseline,NA,37.6,6.9,1.1048842612551013,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
1999,physical,matthey 2013,"dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100-200mg,snri,100-200mg,high,flexible,7 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 physical component score,baseline,NA,34.9,7.5,1.2166606584807191,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2000,physical,matthey 2013,"dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,7 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 physical component score,post_int,NA,38.7,7.3,1.168935522777136,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2001,physical,matthey 2013,"dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100-200mg,snri,100-200mg,high,flexible,7 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 physical component score,post_int,NA,38,7.7,1.2491049427068717,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2002,mood,matthey 2013,"dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,7 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 mental component score,baseline,NA,38.4,9.6,1.5372302765288364,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
2003,mood,matthey 2013,"dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100-200mg,snri,100-200mg,high,flexible,7 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 mental component score,baseline,NA,41,9.7,1.5735477849683965,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
2004,mood,matthey 2013,"dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,7 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 mental component score,post_int,NA,36,10.4,1.6653327995729061,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2005,mood,matthey 2013,"dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100-200mg,snri,100-200mg,high,flexible,7 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,sf-36 mental component score,post_int,NA,45,11.9,1.9304349114560744,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2014,sleep,matthey 2013,"dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,7 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,mos sleep problems index i,baseline,NA,58.5,17.9,2.8662939531110596,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
2015,sleep,matthey 2013,"dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100-200mg,snri,100-200mg,high,flexible,7 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,mos sleep problems index i,baseline,NA,57.1,18.1,2.9362077224668024,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
2016,sleep,matthey 2013,"dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,7 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,mos sleep problems index i,post_int,NA,52.9,19.8,3.170537445340725,NA,NA,NA,NA,NA,39,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
2017,sleep,matthey 2013,"dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100-200mg,snri,100-200mg,high,flexible,7 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,mos sleep problems index i,post_int,NA,52.3,19,3.0822070014844885,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
2018,adverse_dropout,matthey 2013,"dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,7 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,11,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2019,adverse_dropout,matthey 2013,"dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100-200mg,snri,100-200mg,high,flexible,7 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,8,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2020,withdrawal,matthey 2013,"dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,7 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,16,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2021,withdrawal,matthey 2013,"dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial",pain,milnacipran,antidepressant,antidepressant,milnacipran 100-200mg,snri,100-200mg,high,flexible,7 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,21,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2022,adverse,max 1988,"amitriptyline, but not lorazepam, relieves postherpetic neuralgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,30,0.72,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2023,adverse,max 1988,"amitriptyline, but not lorazepam, relieves postherpetic neuralgia",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 12.5-150mg,tca,65mg,standard,flexible,6 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,36,0.88,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2024,adverse,max 1988,"amitriptyline, but not lorazepam, relieves postherpetic neuralgia",pain,lorazepam,benzodiazapine,non-antidepressant pharmacological,lorazepam 0.5-6mg,n/a,n/a,n/a,n/a,6 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,36,0.87,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2025,adverse_dropout,max 1988,"amitriptyline, but not lorazepam, relieves postherpetic neuralgia",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,3,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2026,adverse_dropout,max 1988,"amitriptyline, but not lorazepam, relieves postherpetic neuralgia",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 12.5-150mg,tca,65mg,standard,flexible,6 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,5,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2027,adverse_dropout,max 1988,"amitriptyline, but not lorazepam, relieves postherpetic neuralgia",pain,lorazepam,benzodiazapine,non-antidepressant pharmacological,lorazepam 0.5-6mg,n/a,n/a,n/a,n/a,6 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,6,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2028,pain_int,max 1992,"effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy",pain,desipramine,antidepressant,antidepressant,desipramine 12.5-200mg,tca,111mg,standard,flexible,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,"daily pain of at least ""moderate"" severity",crossover,completer analysis,verbal pain descriptors index score,change_score,NA,-0.31,0.36986484017813853,0.06,NA,NA,NA,NA,NA,38,NA,NA,TRUE,NA,no baseline values given,reports scores by depressed/non-depressed --> come back to extract,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2029,pain_int,max 1992,"effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 12.5-200mg,tca,105mg,high,flexible,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,"daily pain of at least ""moderate"" severity",crossover,completer analysis,verbal pain descriptors index score,change_score,NA,-0.38,0.36986484017813853,0.06,NA,NA,NA,NA,NA,38,NA,NA,TRUE,NA,no baseline values given,reports scores by depressed/non-depressed --> come back to extract,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2030,adverse,max 1992,"effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy",pain,desipramine,antidepressant,antidepressant,desipramine 12.5-200mg,tca,111mg,standard,flexible,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,"daily pain of at least ""moderate"" severity",crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,54,30,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2031,adverse,max 1992,"effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 12.5-200mg,tca,105mg,high,flexible,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,"daily pain of at least ""moderate"" severity",crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,54,31,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2032,pain_int,mease 2009,"the efficacy and safety or milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,27 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt with locf and bocf,0-100 vas,baseline,NA,68.3,177.70489582451015,11.9,NA,NA,NA,NA,NA,223,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2033,pain_int,mease 2009,"the efficacy and safety or milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,27 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt with locf and bocf,0-100 vas,baseline,NA,68.3,172.1162397916013,11.5,NA,NA,NA,NA,NA,224,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2034,pain_int,mease 2009,"the efficacy and safety or milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.",pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,27 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt with locf and bocf,0-100 vas,baseline,NA,69.4,249.9,11.9,NA,NA,NA,NA,NA,441,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2035,pain_int,mease 2009,"the efficacy and safety or milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,27 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt with locf and bocf,0-100 vas,post_int,NA,50.86,23.871924932857844,2.11,NA,NA,NA,NA,NA,128,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2036,pain_int,mease 2009,"the efficacy and safety or milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,27 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt with locf and bocf,0-100 vas,post_int,NA,43.31,23.699609701427573,2.21,NA,NA,NA,NA,NA,115,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2037,pain_int,mease 2009,"the efficacy and safety or milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.",pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,27 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt with locf and bocf,0-100 vas,post_int,NA,43.42,25.28065663704169,1.77,NA,NA,NA,NA,NA,204,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2038,pain_mod,mease 2009,"the efficacy and safety or milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,27 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,145,58,0.402,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
2039,pain_mod,mease 2009,"the efficacy and safety or milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,27 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,128,68,0.528,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
2040,pain_mod,mease 2009,"the efficacy and safety or milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.",pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,27 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,239,134,0.562,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
2041,pain_sub,mease 2009,"the efficacy and safety or milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,27 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,145,38,0.262,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2042,pain_sub,mease 2009,"the efficacy and safety or milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,27 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,128,44,0.34700000000000003,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2043,pain_sub,mease 2009,"the efficacy and safety or milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.",pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,27 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,239,88,0.37,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2044,mood,mease 2009,"the efficacy and safety or milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,27 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt with locf and bocf,beck depression inventory,baseline,NA,14.1,9.5,0.6361670536733038,NA,NA,NA,NA,NA,223,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2045,mood,mease 2009,"the efficacy and safety or milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,27 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt with locf and bocf,beck depression inventory,baseline,NA,13.2,7.7,0.5144778906814169,NA,NA,NA,NA,NA,224,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2046,mood,mease 2009,"the efficacy and safety or milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.",pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,27 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,itt with locf and bocf,beck depression inventory,baseline,NA,14.4,8.6,0.4095238095238095,NA,NA,NA,NA,NA,441,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2047,adverse,mease 2009,"the efficacy and safety or milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,27 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,223,190,0.852,FALSE,aes occuring in ≥5% of participants,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2048,adverse,mease 2009,"the efficacy and safety or milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,27 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,224,186,0.8290000000000001,FALSE,aes occuring in ≥5% of participants,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2049,adverse,mease 2009,"the efficacy and safety or milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.",pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,27 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,441,400,0.907,FALSE,aes occuring in ≥5% of participants,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2050,serious_adverse,mease 2009,"the efficacy and safety or milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,27 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,223,6,0.027000000000000003,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2051,serious_adverse,mease 2009,"the efficacy and safety or milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,27 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,224,3,0.013000000000000001,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2052,serious_adverse,mease 2009,"the efficacy and safety or milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.",pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,27 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,441,11,0.025,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2053,adverse_dropout,mease 2009,"the efficacy and safety or milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,27 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,223,23,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2054,adverse_dropout,mease 2009,"the efficacy and safety or milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,27 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,224,44,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2055,adverse_dropout,mease 2009,"the efficacy and safety or milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.",pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,27 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,441,119,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2056,withdrawal,mease 2009,"the efficacy and safety or milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,27 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,223,78,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2057,withdrawal,mease 2009,"the efficacy and safety or milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.",pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,27 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,224,96,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2058,withdrawal,mease 2009,"the efficacy and safety or milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.",pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,27 weeks,fibromyalgia,fibromyalgia,primary,≥50 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,441,202,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2059,pain_int,miki 2016,"efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase iia study in japan",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs and ≥40 on 100vas,parallel,itt unspecified method,0-10 numerical rating scale,baseline,NA,6,1.1,0.07572712299036657,NA,NA,NA,NA,NA,211,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2060,pain_int,miki 2016,"efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase iia study in japan",pain,mirtazapine,antidepressant,antidepressant,mirtazapine 30mg,nassa,30mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs and ≥40 on 100vas,parallel,itt unspecified method,0-10 numerical rating scale,baseline,NA,5.9,1.1,0.07572712299036657,NA,NA,NA,NA,NA,211,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2061,pain_int,miki 2016,"efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase iia study in japan",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs and ≥40 on 100vas,parallel,itt unspecified method,0-10 numerical rating scale,change_score,NA,-1.17,0.1,0.006884283908215143,NA,NA,NA,NA,NA,211,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2062,pain_int,miki 2016,"efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase iia study in japan",pain,mirtazapine,antidepressant,antidepressant,mirtazapine 30mg,nassa,30mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs and ≥40 on 100vas,parallel,itt unspecified method,0-10 numerical rating scale,change_score,NA,-1.61,0.1,0.006884283908215143,NA,NA,NA,NA,NA,211,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2063,qol,miki 2016,"efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase iia study in japan",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs and ≥40 on 100vas,parallel,itt unspecified method,fibromyalgia impact questionnaire total score,baseline,NA,49.1,14.3,0.9844525988747654,NA,NA,NA,NA,NA,211,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
2064,qol,miki 2016,"efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase iia study in japan",pain,mirtazapine,antidepressant,antidepressant,mirtazapine 30mg,nassa,30mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs and ≥40 on 100vas,parallel,itt unspecified method,fibromyalgia impact questionnaire total score,baseline,NA,48.6,14.6,1.0051054505994108,NA,NA,NA,NA,NA,211,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
2067,physical,miki 2016,"efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase iia study in japan",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs and ≥40 on 100vas,parallel,itt unspecified method,sf-36 physical component score,change_score,NA,4.3,0.55,0.038697864960166056,NA,NA,NA,NA,NA,202,NA,NA,TRUE,NA,no baseline values given,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2068,physical,miki 2016,"efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase iia study in japan",pain,mirtazapine,antidepressant,antidepressant,mirtazapine 30mg,nassa,30mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs and ≥40 on 100vas,parallel,itt unspecified method,sf-36 physical component score,change_score,NA,3.96,0.55,0.03850770231077027,NA,NA,NA,NA,NA,204,NA,NA,TRUE,NA,no baseline values given,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2069,mood,miki 2016,"efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase iia study in japan",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs and ≥40 on 100vas,parallel,itt unspecified method,sf-36 mental component score,change_score,NA,2.54,0.47,0.03306908460232372,NA,NA,NA,NA,NA,202,NA,NA,TRUE,NA,no baseline values given,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2070,mood,miki 2016,"efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase iia study in japan",pain,mirtazapine,antidepressant,antidepressant,mirtazapine 30mg,nassa,30mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs and ≥40 on 100vas,parallel,itt unspecified method,sf-36 mental component score,change_score,NA,2.77,0.46,0.03220644193264423,NA,NA,NA,NA,NA,204,NA,NA,TRUE,NA,no baseline values given,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2071,mood,miki 2016,"efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase iia study in japan",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs and ≥40 on 100vas,parallel,itt unspecified method,beck depression inventory,baseline,NA,11.8,8.3,0.5713955643818569,NA,NA,NA,NA,NA,211,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2072,mood,miki 2016,"efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase iia study in japan",pain,mirtazapine,antidepressant,antidepressant,mirtazapine 30mg,nassa,30mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs and ≥40 on 100vas,parallel,itt unspecified method,beck depression inventory,baseline,NA,11.6,8.7,0.5989327000147173,NA,NA,NA,NA,NA,211,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2073,pain_mod,miki 2016,"efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase iia study in japan",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs and ≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,211,65,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
2074,pain_mod,miki 2016,"efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase iia study in japan",pain,mirtazapine,antidepressant,antidepressant,mirtazapine 30mg,nassa,30mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs and ≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,211,96,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
2075,pain_sub,miki 2016,"efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase iia study in japan",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs and ≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,211,33,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2076,pain_sub,miki 2016,"efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase iia study in japan",pain,mirtazapine,antidepressant,antidepressant,mirtazapine 30mg,nassa,30mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs and ≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,211,41,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2077,adverse,miki 2016,"efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase iia study in japan",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs and ≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,215,122,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2078,adverse,miki 2016,"efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase iia study in japan",pain,mirtazapine,antidepressant,antidepressant,mirtazapine 30mg,nassa,30mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs and ≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,215,148,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2079,serious_adverse,miki 2016,"efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase iia study in japan",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs and ≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,215,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2080,serious_adverse,miki 2016,"efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase iia study in japan",pain,mirtazapine,antidepressant,antidepressant,mirtazapine 30mg,nassa,30mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs and ≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,215,1,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2081,adverse_dropout,miki 2016,"efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase iia study in japan",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs and ≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,215,5,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2082,adverse_dropout,miki 2016,"efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase iia study in japan",pain,mirtazapine,antidepressant,antidepressant,mirtazapine 30mg,nassa,30mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs and ≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,215,6,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2083,withdrawal,miki 2016,"efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase iia study in japan",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs and ≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,215,23,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2084,withdrawal,miki 2016,"efficacy of mirtazapine for the treatment of fibromyalgia without concomitant depression: a randomized, double-blind, placebo-controlled phase iia study in japan",pain,mirtazapine,antidepressant,antidepressant,mirtazapine 30mg,nassa,30mg,standard,fixed,12 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs and ≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,215,25,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2085,pain_int,morello 1999,randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain,pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin 900-1800mg,n/a,n/a,n/a,n/a,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,crossover,completer analysis,pain scale rating system index score,change_score,NA,-0.31,0.27896953238660316,0.064,NA,NA,NA,NA,NA,19,NA,NA,TRUE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2086,pain_int,morello 1999,randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25-75mg,tca,59mg,standard,flexible,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,crossover,completer analysis,pain scale rating system index score,change_score,NA,-0.44,0.38794200597511996,0.089,NA,NA,NA,NA,NA,19,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2087,adverse,morello 1999,randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain,pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin 900-1800mg,n/a,n/a,n/a,n/a,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,18,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2088,adverse,morello 1999,randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25-75mg,tca,59mg,standard,flexible,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,17,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2089,adverse_dropout,morello 1999,randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain,pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin 900-1800mg,n/a,n/a,n/a,n/a,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,2,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2090,adverse_dropout,morello 1999,randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25-75mg,tca,59mg,standard,flexible,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,2,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2091,withdrawal,morello 1999,randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain,pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin 900-1800mg,n/a,n/a,n/a,n/a,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,2,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2092,withdrawal,morello 1999,randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25-75mg,tca,59mg,standard,flexible,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,no,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,2,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2097,mood,muller 2008,"escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial",somatic symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,somatoform pain disorder,primary,primary,no,parallel,itt with locf,madrs,baseline,NA,12.3,1.4,0.27456258919345766,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2098,mood,muller 2008,"escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial",somatic symptoms,escitalopram,antidepressant,antidepressant,escitalopram 10-20mg,ssri,10-20mg,standard,flexible,12 weeks,somatoform pain disorder,primary,primary,no,parallel,itt with locf,madrs,baseline,NA,10.6,1.5,0.3,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2099,mood,muller 2008,"escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial",somatic symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,somatoform pain disorder,primary,primary,no,parallel,itt with locf,madrs,post_int,NA,8.2,1.1,0.21572774865200248,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
2100,mood,muller 2008,"escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial",somatic symptoms,escitalopram,antidepressant,antidepressant,escitalopram 10-20mg,ssri,10-20mg,standard,flexible,12 weeks,somatoform pain disorder,primary,primary,no,parallel,itt with locf,madrs,post_int,NA,4.3,1.1,0.22000000000000003,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
2101,pain_int,muller 2008,"escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial",somatic symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,somatoform pain disorder,primary,primary,no,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.4,0.5,0.09805806756909202,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2102,pain_int,muller 2008,"escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial",somatic symptoms,escitalopram,antidepressant,antidepressant,escitalopram 10-20mg,ssri,10-20mg,standard,flexible,12 weeks,somatoform pain disorder,primary,primary,no,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.1,0.5,0.1,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2103,pain_int,muller 2008,"escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial",somatic symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,somatoform pain disorder,primary,primary,no,parallel,itt with locf,0-10 numerical rating scale,post_int,NA,5.8,0.6,0.11766968108291043,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2104,pain_int,muller 2008,"escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial",somatic symptoms,escitalopram,antidepressant,antidepressant,escitalopram 10-20mg,ssri,10-20mg,standard,flexible,12 weeks,somatoform pain disorder,primary,primary,no,parallel,itt with locf,0-10 numerical rating scale,post_int,NA,2.8,0.6,0.12,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2105,physical,muller 2008,"escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial",somatic symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,somatoform pain disorder,primary,primary,no,parallel,itt with locf,sheehan disability scale,baseline,NA,18.5,1.4,0.27456258919345766,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2106,physical,muller 2008,"escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial",somatic symptoms,escitalopram,antidepressant,antidepressant,escitalopram 10-20mg,ssri,10-20mg,standard,flexible,12 weeks,somatoform pain disorder,primary,primary,no,parallel,itt with locf,sheehan disability scale,baseline,NA,15.4,1.5,0.3,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2107,physical,muller 2008,"escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial",somatic symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,somatoform pain disorder,primary,primary,no,parallel,itt with locf,sheehan disability scale,post_int,NA,13.4,1.5,0.29417420270727607,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2108,physical,muller 2008,"escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial",somatic symptoms,escitalopram,antidepressant,antidepressant,escitalopram 10-20mg,ssri,10-20mg,standard,flexible,12 weeks,somatoform pain disorder,primary,primary,no,parallel,itt with locf,sheehan disability scale,post_int,NA,6.9,1.6,0.32,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2109,adverse_dropout,muller 2008,"escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial",somatic symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,somatoform pain disorder,primary,primary,no,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2110,adverse_dropout,muller 2008,"escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial",somatic symptoms,escitalopram,antidepressant,antidepressant,escitalopram 10-20mg,ssri,10-20mg,standard,flexible,12 weeks,somatoform pain disorder,primary,primary,no,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,1,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2111,withdrawal,muller 2008,"escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial",somatic symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,somatoform pain disorder,primary,primary,no,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2112,withdrawal,muller 2008,"escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial",somatic symptoms,escitalopram,antidepressant,antidepressant,escitalopram 10-20mg,ssri,10-20mg,standard,flexible,12 weeks,somatoform pain disorder,primary,primary,no,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,1,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2113,pain_int,murakami 2015,"a randomized, double-blind, placebo-controlled phase iii trial of duloxetine in japanese fibromyalgia patients",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.13,1.35,0.09667550799532344,NA,NA,NA,NA,NA,195,NA,NA,FALSE,NA,NA,compared locf and bocf with no significant differences,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2114,pain_int,murakami 2015,"a randomized, double-blind, placebo-controlled phase iii trial of duloxetine in japanese fibromyalgia patients",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.05,1.29,0.0933411240827224,NA,NA,NA,NA,NA,191,NA,NA,FALSE,NA,NA,compared locf and bocf with no significant differences,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2115,pain_int,murakami 2015,"a randomized, double-blind, placebo-controlled phase iii trial of duloxetine in japanese fibromyalgia patients",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-1.58,3.2117752100668566,0.23,NA,NA,NA,NA,NA,195,NA,NA,TRUE,NA,least squares,compared locf and bocf with no significant differences,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2116,pain_int,murakami 2015,"a randomized, double-blind, placebo-controlled phase iii trial of duloxetine in japanese fibromyalgia patients",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-1.9,3.1786632410496085,0.23,NA,NA,NA,NA,NA,191,NA,NA,TRUE,NA,least squares,compared locf and bocf with no significant differences,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2117,mood,murakami 2015,"a randomized, double-blind, placebo-controlled phase iii trial of duloxetine in japanese fibromyalgia patients",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sf-36 mental health subscale,baseline,NA,56.1,19.84,1.4207719100942349,NA,NA,NA,NA,NA,195,NA,NA,FALSE,NA,NA,compared locf and bocf with no significant differences,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
2118,mood,murakami 2015,"a randomized, double-blind, placebo-controlled phase iii trial of duloxetine in japanese fibromyalgia patients",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sf-36 mental health subscale,baseline,NA,55.5,18.85,1.3639381309762149,NA,NA,NA,NA,NA,191,NA,NA,FALSE,NA,NA,compared locf and bocf with no significant differences,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
2119,mood,murakami 2015,"a randomized, double-blind, placebo-controlled phase iii trial of duloxetine in japanese fibromyalgia patients",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sf-36 mental health subscale,change_score,NA,-2,35.18988491029773,2.52,NA,NA,NA,NA,NA,195,NA,NA,TRUE,NA,least squares,compared locf and bocf with no significant differences,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2120,mood,murakami 2015,"a randomized, double-blind, placebo-controlled phase iii trial of duloxetine in japanese fibromyalgia patients",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sf-36 mental health subscale,change_score,NA,5.91,34.688890152323985,2.51,NA,NA,NA,NA,NA,191,NA,NA,TRUE,NA,least squares,compared locf and bocf with no significant differences,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2121,sleep,murakami 2015,"a randomized, double-blind, placebo-controlled phase iii trial of duloxetine in japanese fibromyalgia patients",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,bpi sleep,baseline,NA,5.22,2.91,0.208389428345475,NA,NA,NA,NA,NA,195,NA,NA,FALSE,NA,NA,compared locf and bocf with no significant differences,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
2122,sleep,murakami 2015,"a randomized, double-blind, placebo-controlled phase iii trial of duloxetine in japanese fibromyalgia patients",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,bpi sleep,baseline,NA,5.3,2.81,0.20332446408717048,NA,NA,NA,NA,NA,191,NA,NA,FALSE,NA,NA,compared locf and bocf with no significant differences,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
2123,sleep,murakami 2015,"a randomized, double-blind, placebo-controlled phase iii trial of duloxetine in japanese fibromyalgia patients",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,bpi sleep,change_score,NA,-1.57,5.027126415756818,0.36,NA,NA,NA,NA,NA,195,NA,NA,TRUE,NA,least squares,compared locf and bocf with no significant differences,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
2124,sleep,murakami 2015,"a randomized, double-blind, placebo-controlled phase iii trial of duloxetine in japanese fibromyalgia patients",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,bpi sleep,change_score,NA,-1.82,4.837096236379838,0.35,NA,NA,NA,NA,NA,191,NA,NA,TRUE,NA,least squares,compared locf and bocf with no significant differences,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
2125,qol,murakami 2015,"a randomized, double-blind, placebo-controlled phase iii trial of duloxetine in japanese fibromyalgia patients",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,fibromyalgia impact questionnaire total score,baseline,NA,56.82,16.14,1.1558094066996447,NA,NA,NA,NA,NA,195,NA,NA,FALSE,NA,NA,compared locf and bocf with no significant differences,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
2126,qol,murakami 2015,"a randomized, double-blind, placebo-controlled phase iii trial of duloxetine in japanese fibromyalgia patients",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,fibromyalgia impact questionnaire total score,baseline,NA,55.95,16.25,1.1758087336001852,NA,NA,NA,NA,NA,191,NA,NA,FALSE,NA,NA,compared locf and bocf with no significant differences,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
2127,qol,murakami 2015,"a randomized, double-blind, placebo-controlled phase iii trial of duloxetine in japanese fibromyalgia patients",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,fibromyalgia impact questionnaire total score,change_score,NA,-13.05,37.00523611598769,2.65,NA,NA,NA,NA,NA,195,NA,NA,TRUE,NA,least squares,compared locf and bocf with no significant differences,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
2128,qol,murakami 2015,"a randomized, double-blind, placebo-controlled phase iii trial of duloxetine in japanese fibromyalgia patients",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,fibromyalgia impact questionnaire total score,change_score,NA,-18.41,35.5181066499891,2.57,NA,NA,NA,NA,NA,191,NA,NA,TRUE,NA,least squares,compared locf and bocf with no significant differences,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
2129,physical,murakami 2015,"a randomized, double-blind, placebo-controlled phase iii trial of duloxetine in japanese fibromyalgia patients",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sf-36 physical functioning subscale,baseline,NA,62.51,19.82,1.419339680346156,NA,NA,NA,NA,NA,195,NA,NA,FALSE,NA,NA,compared locf and bocf with no significant differences,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2130,physical,murakami 2015,"a randomized, double-blind, placebo-controlled phase iii trial of duloxetine in japanese fibromyalgia patients",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sf-36 physical functioning subscale,baseline,NA,63.72,18.75,1.3567023849232906,NA,NA,NA,NA,NA,191,NA,NA,FALSE,NA,NA,compared locf and bocf with no significant differences,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2131,physical,murakami 2015,"a randomized, double-blind, placebo-controlled phase iii trial of duloxetine in japanese fibromyalgia patients",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sf-36 physical functioning subscale,change_score,NA,3.04,30.023116094103223,2.15,NA,NA,NA,NA,NA,195,NA,NA,TRUE,NA,least squares,compared locf and bocf with no significant differences,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2132,physical,murakami 2015,"a randomized, double-blind, placebo-controlled phase iii trial of duloxetine in japanese fibromyalgia patients",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sf-36 physical functioning subscale,change_score,NA,7.4,29.43718566711159,2.13,NA,NA,NA,NA,NA,191,NA,NA,TRUE,NA,least squares,compared locf and bocf with no significant differences,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2141,adverse,murakami 2015,"a randomized, double-blind, placebo-controlled phase iii trial of duloxetine in japanese fibromyalgia patients",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,197,123,NA,FALSE,number of people with any ae,NA,compared locf and bocf with no significant differences,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2142,adverse,murakami 2015,"a randomized, double-blind, placebo-controlled phase iii trial of duloxetine in japanese fibromyalgia patients",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,196,148,NA,FALSE,number of people with any ae,NA,compared locf and bocf with no significant differences,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2143,serious_adverse,murakami 2015,"a randomized, double-blind, placebo-controlled phase iii trial of duloxetine in japanese fibromyalgia patients",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,197,1,NA,FALSE,NA,NA,compared locf and bocf with no significant differences,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2144,serious_adverse,murakami 2015,"a randomized, double-blind, placebo-controlled phase iii trial of duloxetine in japanese fibromyalgia patients",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,196,1,NA,FALSE,NA,NA,compared locf and bocf with no significant differences,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2145,adverse_dropout,murakami 2015,"a randomized, double-blind, placebo-controlled phase iii trial of duloxetine in japanese fibromyalgia patients",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,197,15,NA,FALSE,NA,NA,compared locf and bocf with no significant differences,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2146,adverse_dropout,murakami 2015,"a randomized, double-blind, placebo-controlled phase iii trial of duloxetine in japanese fibromyalgia patients",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,196,14,NA,FALSE,NA,NA,compared locf and bocf with no significant differences,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2147,withdrawal,murakami 2015,"a randomized, double-blind, placebo-controlled phase iii trial of duloxetine in japanese fibromyalgia patients",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,197,48,NA,FALSE,NA,NA,compared locf and bocf with no significant differences,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2148,withdrawal,murakami 2015,"a randomized, double-blind, placebo-controlled phase iii trial of duloxetine in japanese fibromyalgia patients",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,196,30,NA,FALSE,NA,NA,compared locf and bocf with no significant differences,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2150,pain_int,natelson 2015,"effect of milnacipran treatment on ventricular lactate in fibromyalgia: a randomized, double-blind, placebo-controlled trial",experimental pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,≥10/18 tender points at ≥2 out of 10 pain,parallel,completer analysis,0-10 numerical rating scale,baseline,"effect of milnacipran treatment on ventricular lactate in fibromyalgia: a randomized, double-blind, placebo-controlled trial",6.43,1.54,0.42711915109342646,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2151,pain_int,natelson 2015,"effect of milnacipran treatment on ventricular lactate in fibromyalgia: a randomized, double-blind, placebo-controlled trial",experimental pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,≥10/18 tender points at ≥2 out of 10 pain,parallel,completer analysis,0-10 numerical rating scale,post_int,"effect of milnacipran treatment on ventricular lactate in fibromyalgia: a randomized, double-blind, placebo-controlled trial",0.66,1.75,0.48536267169707553,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2152,pain_int,natelson 2015,"effect of milnacipran treatment on ventricular lactate in fibromyalgia: a randomized, double-blind, placebo-controlled trial",experimental pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,≥10/18 tender points at ≥2 out of 10 pain,parallel,completer analysis,0-10 numerical rating scale,post_int,NA,-1.24,1.57,0.4354396540368049,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2153,adverse,natelson 2015,"effect of milnacipran treatment on ventricular lactate in fibromyalgia: a randomized, double-blind, placebo-controlled trial",experimental pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,≥10/18 tender points at ≥2 out of 10 pain,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,1,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2154,adverse,natelson 2015,"effect of milnacipran treatment on ventricular lactate in fibromyalgia: a randomized, double-blind, placebo-controlled trial",experimental pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,≥10/18 tender points at ≥2 out of 10 pain,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,2,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2155,serious_adverse,natelson 2015,"effect of milnacipran treatment on ventricular lactate in fibromyalgia: a randomized, double-blind, placebo-controlled trial",experimental pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,≥10/18 tender points at ≥2 out of 10 pain,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2156,serious_adverse,natelson 2015,"effect of milnacipran treatment on ventricular lactate in fibromyalgia: a randomized, double-blind, placebo-controlled trial",experimental pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,≥10/18 tender points at ≥2 out of 10 pain,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2157,adverse_dropout,natelson 2015,"effect of milnacipran treatment on ventricular lactate in fibromyalgia: a randomized, double-blind, placebo-controlled trial",experimental pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,≥10/18 tender points at ≥2 out of 10 pain,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,3,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2158,adverse_dropout,natelson 2015,"effect of milnacipran treatment on ventricular lactate in fibromyalgia: a randomized, double-blind, placebo-controlled trial",experimental pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,≥10/18 tender points at ≥2 out of 10 pain,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,3,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2159,withdrawal,natelson 2015,"effect of milnacipran treatment on ventricular lactate in fibromyalgia: a randomized, double-blind, placebo-controlled trial",experimental pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,≥10/18 tender points at ≥2 out of 10 pain,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,4,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2160,withdrawal,natelson 2015,"effect of milnacipran treatment on ventricular lactate in fibromyalgia: a randomized, double-blind, placebo-controlled trial",experimental pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,≥10/18 tender points at ≥2 out of 10 pain,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,4,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2161,pain_int,nct 2011,milnacipran for chronic pain in knee osteoarthritis.,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,completer analysis,0-100 vas,baseline,NA,55,28,8.082903768654761,NA,NA,NA,NA,NA,12,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2162,pain_int,nct 2011,milnacipran for chronic pain in knee osteoarthritis.,pain,milnacipran,antidepressant,antidepressant,milnacipran 100-200mg,snri,100-200mg,high,flexible,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,completer analysis,0-100 vas,baseline,NA,44,24,4.706787243316417,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2163,pain_int,nct 2011,milnacipran for chronic pain in knee osteoarthritis.,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,completer analysis,0-100 vas,post_int,NA,51,24,6.92820323027551,NA,NA,NA,NA,NA,12,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2164,pain_int,nct 2011,milnacipran for chronic pain in knee osteoarthritis.,pain,milnacipran,antidepressant,antidepressant,milnacipran 100-200mg,snri,100-200mg,high,flexible,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,completer analysis,0-100 vas,post_int,NA,20,22,4.314554973040049,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2169,mood,nct 2011,milnacipran for chronic pain in knee osteoarthritis.,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,completer analysis,ces-d,baseline,NA,6,4,1.1547005383792517,NA,NA,NA,NA,NA,12,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2170,mood,nct 2011,milnacipran for chronic pain in knee osteoarthritis.,pain,milnacipran,antidepressant,antidepressant,milnacipran 100-200mg,snri,100-200mg,high,flexible,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,completer analysis,ces-d,baseline,NA,7,5,0.9805806756909202,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2171,mood,nct 2011,milnacipran for chronic pain in knee osteoarthritis.,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,completer analysis,ces-d,post_int,NA,9,7,2.0207259421636903,NA,NA,NA,NA,NA,12,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
2172,mood,nct 2011,milnacipran for chronic pain in knee osteoarthritis.,pain,milnacipran,antidepressant,antidepressant,milnacipran 100-200mg,snri,100-200mg,high,flexible,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,completer analysis,ces-d,post_int,NA,6,4,0.7844645405527362,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
2173,physical,nct 2011,milnacipran for chronic pain in knee osteoarthritis.,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,completer analysis,pain disability index,baseline,NA,31,11,3.1754264805429417,NA,NA,NA,NA,NA,12,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2174,physical,nct 2011,milnacipran for chronic pain in knee osteoarthritis.,pain,milnacipran,antidepressant,antidepressant,milnacipran 100-200mg,snri,100-200mg,high,flexible,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,completer analysis,pain disability index,baseline,NA,28,14,2.745625891934577,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2175,physical,nct 2011,milnacipran for chronic pain in knee osteoarthritis.,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,completer analysis,pain disability index,post_int,NA,26,18,5.196152422706632,NA,NA,NA,NA,NA,12,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2176,physical,nct 2011,milnacipran for chronic pain in knee osteoarthritis.,pain,milnacipran,antidepressant,antidepressant,milnacipran 100-200mg,snri,100-200mg,high,flexible,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,completer analysis,pain disability index,post_int,NA,15,10,1.9611613513818404,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2177,adverse,nct 2011,milnacipran for chronic pain in knee osteoarthritis.,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,0,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2178,adverse,nct 2011,milnacipran for chronic pain in knee osteoarthritis.,pain,milnacipran,antidepressant,antidepressant,milnacipran 100-200mg,snri,100-200mg,high,flexible,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,9,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2179,serious_adverse,nct 2011,milnacipran for chronic pain in knee osteoarthritis.,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,0,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2180,serious_adverse,nct 2011,milnacipran for chronic pain in knee osteoarthritis.,pain,milnacipran,antidepressant,antidepressant,milnacipran 100-200mg,snri,100-200mg,high,flexible,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,0,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2181,withdrawal,nct 2011,milnacipran for chronic pain in knee osteoarthritis.,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,5,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2182,withdrawal,nct 2011,milnacipran for chronic pain in knee osteoarthritis.,pain,milnacipran,antidepressant,antidepressant,milnacipran 100-200mg,snri,100-200mg,high,flexible,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,3,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2183,pain_int,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioural therapy,n/a,n/a,n/a,n/a,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,0-10 numerical rating scale,baseline,NA,4.4,2.1,0.3655630775069655,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2184,pain_int,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,nortriptyline + cognitive behavioural therapy,combined antidepressant intervention,antidepressant,nortriptyline 25-150mg + cognitive behavioural therapy,tca,25-150mg,unable to be categorised,flexible,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,0-10 numerical rating scale,baseline,NA,4.7,2.2,0.3568871264876776,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2185,pain_int,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,disease management,education,non-pharmacological,disease management,n/a,n/a,n/a,n/a,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,0-10 numerical rating scale,baseline,NA,5,1.8,0.4129483209670112,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2186,pain_int,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,nortriptyline + disease management,combined antidepressant intervention,antidepressant,nortriptyline 25-150mg + disease management,tca,25-150mg,unable to be categorised,flexible,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,0-10 numerical rating scale,baseline,NA,4.5,2.2,0.43145549730400495,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2187,pain_int,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioural therapy,n/a,n/a,n/a,n/a,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,0-10 numerical rating scale,post_int,NA,2.7,2.1,0.3655630775069655,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2188,pain_int,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,nortriptyline + cognitive behavioural therapy,combined antidepressant intervention,antidepressant,nortriptyline 25-150mg + cognitive behavioural therapy,tca,25-150mg,unable to be categorised,flexible,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,0-10 numerical rating scale,post_int,NA,2.8,2.6,0.4217756949399826,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2189,pain_int,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,disease management,education,non-pharmacological,disease management,n/a,n/a,n/a,n/a,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,0-10 numerical rating scale,post_int,NA,2.8,2.1,0.4817730411281797,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2190,pain_int,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,nortriptyline + disease management,combined antidepressant intervention,antidepressant,nortriptyline 25-150mg + disease management,tca,25-150mg,unable to be categorised,flexible,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,0-10 numerical rating scale,post_int,NA,2,1.4,0.27456258919345766,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2191,pain_int,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioural therapy,n/a,n/a,n/a,n/a,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,0-10 numerical rating scale,follow_up,3 months,2.4,2.2,0.38297084310253526,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,follow_up
2192,pain_int,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,nortriptyline + cognitive behavioural therapy,combined antidepressant intervention,antidepressant,nortriptyline 25-150mg + cognitive behavioural therapy,tca,25-150mg,unable to be categorised,flexible,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,0-10 numerical rating scale,follow_up,3 months,2.1,1.6,0.2595542738092201,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,follow_up
2193,pain_int,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,disease management,education,non-pharmacological,disease management,n/a,n/a,n/a,n/a,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,0-10 numerical rating scale,follow_up,3 months,2.5,2.1,0.4817730411281797,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,follow_up
2194,pain_int,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,nortriptyline + disease management,combined antidepressant intervention,antidepressant,nortriptyline 25-150mg + disease management,tca,25-150mg,unable to be categorised,flexible,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,0-10 numerical rating scale,follow_up,3 months,2.2,2.1,0.4118438837901865,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,follow_up
2195,pain_int,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioural therapy,n/a,n/a,n/a,n/a,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,0-10 numerical rating scale,follow_up,6 months,2,2.1,0.3655630775069655,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,follow_up
2196,pain_int,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,nortriptyline + cognitive behavioural therapy,combined antidepressant intervention,antidepressant,nortriptyline 25-150mg + cognitive behavioural therapy,tca,25-150mg,unable to be categorised,flexible,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,0-10 numerical rating scale,follow_up,6 months,2,1.7,0.27577641592229635,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,follow_up
2197,pain_int,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,disease management,education,non-pharmacological,disease management,n/a,n/a,n/a,n/a,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,0-10 numerical rating scale,follow_up,6 months,2.2,2.5,0.5735393346764044,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,follow_up
2198,pain_int,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,nortriptyline + disease management,combined antidepressant intervention,antidepressant,nortriptyline 25-150mg + disease management,tca,25-150mg,unable to be categorised,flexible,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,0-10 numerical rating scale,follow_up,6 months,1.4,1.6,0.31378581622109447,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,follow_up
2199,mood,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioural therapy,n/a,n/a,n/a,n/a,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,sf-36 mental component score,baseline,NA,49.2,9.3,1.61892220038799,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
2200,mood,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,nortriptyline + cognitive behavioural therapy,combined antidepressant intervention,antidepressant,nortriptyline 25-150mg + cognitive behavioural therapy,tca,25-150mg,unable to be categorised,flexible,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,sf-36 mental component score,baseline,NA,50.5,8.1,1.3139935111591765,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
2201,mood,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,disease management,education,non-pharmacological,disease management,n/a,n/a,n/a,n/a,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,sf-36 mental component score,baseline,NA,48,8.9,2.0418000314479996,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
2202,mood,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,nortriptyline + disease management,combined antidepressant intervention,antidepressant,nortriptyline 25-150mg + disease management,tca,25-150mg,unable to be categorised,flexible,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,sf-36 mental component score,baseline,NA,51.2,8.8,1.7258219892160198,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
2203,mood,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioural therapy,n/a,n/a,n/a,n/a,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,sf-36 mental component score,post_int,NA,48.4,8.1,1.4100290132411524,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2204,mood,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,nortriptyline + cognitive behavioural therapy,combined antidepressant intervention,antidepressant,nortriptyline 25-150mg + cognitive behavioural therapy,tca,25-150mg,unable to be categorised,flexible,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,sf-36 mental component score,post_int,NA,50.8,10.4,1.6871027797599305,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2205,mood,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,disease management,education,non-pharmacological,disease management,n/a,n/a,n/a,n/a,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,sf-36 mental component score,post_int,NA,53.3,10.6,2.4318067790279545,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2206,mood,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,nortriptyline + disease management,combined antidepressant intervention,antidepressant,nortriptyline 25-150mg + disease management,tca,25-150mg,unable to be categorised,flexible,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,sf-36 mental component score,post_int,NA,52.6,10,1.9611613513818404,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2207,mood,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioural therapy,n/a,n/a,n/a,n/a,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,sf-36 mental component score,follow_up,3 months,50.2,8.7,1.514475606814571,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_overall,follow_up
2208,mood,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,nortriptyline + cognitive behavioural therapy,combined antidepressant intervention,antidepressant,nortriptyline 25-150mg + cognitive behavioural therapy,tca,25-150mg,unable to be categorised,flexible,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,sf-36 mental component score,follow_up,3 months,51.5,8.9,1.4437706480637869,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,follow_up
2209,mood,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,disease management,education,non-pharmacological,disease management,n/a,n/a,n/a,n/a,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,sf-36 mental component score,follow_up,3 months,53.8,10.1,2.3170989120926735,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_overall,follow_up
2210,mood,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,nortriptyline + disease management,combined antidepressant intervention,antidepressant,nortriptyline 25-150mg + disease management,tca,25-150mg,unable to be categorised,flexible,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,sf-36 mental component score,follow_up,3 months,52.6,10,1.9611613513818404,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,follow_up
2211,mood,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioural therapy,n/a,n/a,n/a,n/a,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,sf-36 mental component score,follow_up,6 months,53.3,12.8,2.2281939962329327,NA,NA,NA,NA,NA,33,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_overall,follow_up
2212,mood,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,nortriptyline + cognitive behavioural therapy,combined antidepressant intervention,antidepressant,nortriptyline 25-150mg + cognitive behavioural therapy,tca,25-150mg,unable to be categorised,flexible,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,sf-36 mental component score,follow_up,6 months,52.2,7.8,1.2653270848199478,NA,NA,NA,NA,NA,38,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,follow_up
2213,mood,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,disease management,education,non-pharmacological,disease management,n/a,n/a,n/a,n/a,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,sf-36 mental component score,follow_up,6 months,53.6,7.3,1.6747348572551006,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_overall,follow_up
2214,mood,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,nortriptyline + disease management,combined antidepressant intervention,antidepressant,nortriptyline 25-150mg + disease management,tca,25-150mg,unable to be categorised,flexible,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,sf-36 mental component score,follow_up,6 months,52.3,7.2,1.4120361729949251,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,follow_up
2215,adverse,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioural therapy,n/a,n/a,n/a,n/a,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,24,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,non_pharm,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2216,adverse,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,nortriptyline + cognitive behavioural therapy,combined antidepressant intervention,antidepressant,nortriptyline 25-150mg + cognitive behavioural therapy,tca,25-150mg,unable to be categorised,flexible,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,32,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2217,adverse,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,disease management,education,non-pharmacological,disease management,n/a,n/a,n/a,n/a,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,15,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,non_pharm,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2218,adverse,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,nortriptyline + disease management,combined antidepressant intervention,antidepressant,nortriptyline 25-150mg + disease management,tca,25-150mg,unable to be categorised,flexible,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,37,21,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2219,serious_adverse,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioural therapy,n/a,n/a,n/a,n/a,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,0,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,non_pharm,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2220,serious_adverse,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,nortriptyline + cognitive behavioural therapy,combined antidepressant intervention,antidepressant,nortriptyline 25-150mg + cognitive behavioural therapy,tca,25-150mg,unable to be categorised,flexible,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,0,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2221,serious_adverse,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,disease management,education,non-pharmacological,disease management,n/a,n/a,n/a,n/a,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,0,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,non_pharm,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2222,serious_adverse,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,nortriptyline + disease management,combined antidepressant intervention,antidepressant,nortriptyline 25-150mg + disease management,tca,25-150mg,unable to be categorised,flexible,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,37,0,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2223,withdrawal,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioural therapy,n/a,n/a,n/a,n/a,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,5,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,non_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2224,withdrawal,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,nortriptyline + cognitive behavioural therapy,combined antidepressant intervention,antidepressant,nortriptyline 25-150mg + cognitive behavioural therapy,tca,25-150mg,unable to be categorised,flexible,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,3,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2225,withdrawal,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,disease management,education,non-pharmacological,disease management,n/a,n/a,n/a,n/a,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,5,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,non_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2226,withdrawal,nct2003,comparison of psychological and pharmacological treatments for pain due to temporomandibular joint disorder (tmd),pain,nortriptyline + disease management,combined antidepressant intervention,antidepressant,nortriptyline 25-150mg + disease management,tca,25-150mg,unable to be categorised,flexible,8 weeks,temporomandibular disorder,musculoskeletal,musculoskeletal,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,37,11,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2227,adverse,nct2010,effect of milnacipran in chronic neuropathic low back pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,neuropathic low back pain,neuropathic,neuropathic,≥50 on 100vas,parallel,per-protocol analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,10,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2228,adverse,nct2010,effect of milnacipran in chronic neuropathic low back pain,pain,milnacipran,antidepressant,antidepressant,milnacipran 100-200mg,snri,100-200mg,high,flexible,6 weeks,neuropathic low back pain,neuropathic,neuropathic,≥50 on 100vas,parallel,per-protocol analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,14,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2229,serious_adverse,nct2010,effect of milnacipran in chronic neuropathic low back pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,neuropathic low back pain,neuropathic,neuropathic,≥50 on 100vas,parallel,per-protocol analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,1,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2230,serious_adverse,nct2010,effect of milnacipran in chronic neuropathic low back pain,pain,milnacipran,antidepressant,antidepressant,milnacipran 100-200mg,snri,100-200mg,high,flexible,6 weeks,neuropathic low back pain,neuropathic,neuropathic,≥50 on 100vas,parallel,per-protocol analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,0,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2231,withdrawal,nct2010,effect of milnacipran in chronic neuropathic low back pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,neuropathic low back pain,neuropathic,neuropathic,≥50 on 100vas,parallel,per-protocol analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,1,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2232,withdrawal,nct2010,effect of milnacipran in chronic neuropathic low back pain,pain,milnacipran,antidepressant,antidepressant,milnacipran 100-200mg,snri,100-200mg,high,flexible,6 weeks,neuropathic low back pain,neuropathic,neuropathic,≥50 on 100vas,parallel,per-protocol analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,4,NA,FALSE,NA,NA,trial registry only - no published papers,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2233,mood,norregaard 1995,a randomized controlled trial of citalopram in the treatment of fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,beck depression inventory,baseline,NA,16.3,8.3,1.811208488958737,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2234,mood,norregaard 1995,a randomized controlled trial of citalopram in the treatment of fibromyalgia,pain,citalopram,antidepressant,antidepressant,citalopram 20-40mg,ssri,20-40mg,standard,flexible,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,beck depression inventory,baseline,NA,16.4,8.3,1.811208488958737,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2235,mood,norregaard 1995,a randomized controlled trial of citalopram in the treatment of fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,beck depression inventory,change_score,NA,0.9,7.9,1.72392133286434,NA,NA,NA,NA,NA,21,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
2236,mood,norregaard 1995,a randomized controlled trial of citalopram in the treatment of fibromyalgia,pain,citalopram,antidepressant,antidepressant,citalopram 20-40mg,ssri,20-40mg,standard,flexible,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,beck depression inventory,change_score,NA,1,6.1,1.3311291304395536,NA,NA,NA,NA,NA,21,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
2237,physical,norregaard 1995,a randomized controlled trial of citalopram in the treatment of fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,fiq physical functioning,baseline,NA,1.7,0.5,0.1091089451179962,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,0-3 range,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2238,physical,norregaard 1995,a randomized controlled trial of citalopram in the treatment of fibromyalgia,pain,citalopram,antidepressant,antidepressant,citalopram 20-40mg,ssri,20-40mg,standard,flexible,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,fiq physical functioning,baseline,NA,1.7,0.6,0.13093073414159542,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,0-3 range,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2239,physical,norregaard 1995,a randomized controlled trial of citalopram in the treatment of fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,fiq physical functioning,change_score,NA,0,0.4,0.08728715609439697,NA,NA,NA,NA,NA,21,NA,NA,TRUE,NA,NA,0-3 range,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2240,physical,norregaard 1995,a randomized controlled trial of citalopram in the treatment of fibromyalgia,pain,citalopram,antidepressant,antidepressant,citalopram 20-40mg,ssri,20-40mg,standard,flexible,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,fiq physical functioning,change_score,NA,0,0.4,0.08728715609439697,NA,NA,NA,NA,NA,21,NA,NA,TRUE,NA,NA,0-3 range,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2241,pain_int,norregaard 1995,a randomized controlled trial of citalopram in the treatment of fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,0-10 numerical rating scale,baseline,NA,7.5,1.8,0.3927922024247863,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2242,pain_int,norregaard 1995,a randomized controlled trial of citalopram in the treatment of fibromyalgia,pain,citalopram,antidepressant,antidepressant,citalopram 20-40mg,ssri,20-40mg,standard,flexible,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,0-10 numerical rating scale,baseline,NA,7.3,2,0.4364357804719848,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2243,pain_int,norregaard 1995,a randomized controlled trial of citalopram in the treatment of fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,0-10 numerical rating scale,change_score,NA,-0.1,2,0.4364357804719848,NA,NA,NA,NA,NA,21,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2244,pain_int,norregaard 1995,a randomized controlled trial of citalopram in the treatment of fibromyalgia,pain,citalopram,antidepressant,antidepressant,citalopram 20-40mg,ssri,20-40mg,standard,flexible,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,0-10 numerical rating scale,change_score,NA,-0.5,2.2,0.4800793585191833,NA,NA,NA,NA,NA,21,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2245,sleep,norregaard 1995,a randomized controlled trial of citalopram in the treatment of fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,0-10 numerical rating scale [higher=better],baseline,NA,7.7,2.5,0.545544725589981,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
2246,sleep,norregaard 1995,a randomized controlled trial of citalopram in the treatment of fibromyalgia,pain,citalopram,antidepressant,antidepressant,citalopram 20-40mg,ssri,20-40mg,standard,flexible,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,0-10 numerical rating scale [higher=better],baseline,NA,7.9,2.2,0.4800793585191833,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
2247,sleep,norregaard 1995,a randomized controlled trial of citalopram in the treatment of fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,0-10 numerical rating scale [higher=better],change_score,NA,0.1,2.5,0.545544725589981,NA,NA,NA,NA,NA,21,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
2248,sleep,norregaard 1995,a randomized controlled trial of citalopram in the treatment of fibromyalgia,pain,citalopram,antidepressant,antidepressant,citalopram 20-40mg,ssri,20-40mg,standard,flexible,8 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,itt unspecified method,0-10 numerical rating scale [higher=better],change_score,NA,1,2.9,0.6328318816843779,NA,NA,NA,NA,NA,21,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
2249,pain_int,otto 2008,"escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt with locf,0-10 numerical rating scale,baseline,NA,5.8,1.5,0.2342606428329091,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2250,pain_int,otto 2008,"escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",pain,escitalopram,antidepressant,antidepressant,escitalopram 20mg,ssri,20mg,high,fixed,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt with locf,0-10 numerical rating scale,baseline,NA,5.8,1.5,0.2342606428329091,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2251,pain_int,otto 2008,"escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt with locf,0-10 numerical rating scale,post_int,NA,5.5,2.1,0.32796489996607275,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2252,pain_int,otto 2008,"escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",pain,escitalopram,antidepressant,antidepressant,escitalopram 20mg,ssri,20mg,high,fixed,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt with locf,0-10 numerical rating scale,post_int,NA,4.5,2.3,0.3591996523437939,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2253,sleep,otto 2008,"escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt with locf,0-10 numerical rating scale,baseline,NA,3.8,2.6,0.4060517809103758,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
2254,sleep,otto 2008,"escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",pain,escitalopram,antidepressant,antidepressant,escitalopram 20mg,ssri,20mg,high,fixed,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt with locf,0-10 numerical rating scale,baseline,NA,3.8,2.6,0.4060517809103758,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
2255,sleep,otto 2008,"escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt with locf,0-10 numerical rating scale,post_int,NA,4,2.7,0.4216691570992364,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
2256,sleep,otto 2008,"escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",pain,escitalopram,antidepressant,antidepressant,escitalopram 20mg,ssri,20mg,high,fixed,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt with locf,0-10 numerical rating scale,post_int,NA,3,2.4,0.37481702853265453,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
2257,mood,otto 2008,"escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt with locf,major depression inventory,baseline,NA,12.1,9.6,1.4992681141306181,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2258,mood,otto 2008,"escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",pain,escitalopram,antidepressant,antidepressant,escitalopram 20mg,ssri,20mg,high,fixed,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt with locf,major depression inventory,baseline,NA,12.1,9.6,1.4992681141306181,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2259,mood,otto 2008,"escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt with locf,major depression inventory,post_int,NA,10.8,10.7,1.671059252208085,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
2260,mood,otto 2008,"escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",pain,escitalopram,antidepressant,antidepressant,escitalopram 20mg,ssri,20mg,high,fixed,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,itt with locf,major depression inventory,post_int,NA,10.3,10.7,1.671059252208085,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
2261,adverse,otto 2008,"escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,18,NA,FALSE,number of participants with any adverse event,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2262,adverse,otto 2008,"escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",pain,escitalopram,antidepressant,antidepressant,escitalopram 20mg,ssri,20mg,high,fixed,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,21,NA,FALSE,number of participants with any adverse event,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2263,adverse_dropout,otto 2008,"escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,1,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2264,adverse_dropout,otto 2008,"escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",pain,escitalopram,antidepressant,antidepressant,escitalopram 20mg,ssri,20mg,high,fixed,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,5,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2265,withdrawal,otto 2008,"escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,4,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2266,withdrawal,otto 2008,"escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial",pain,escitalopram,antidepressant,antidepressant,escitalopram 20mg,ssri,20mg,high,fixed,5 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,6,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2267,NA,ozerbil 2006,comparison of the effects of two antidepressants on exercise performance of the female patients with fibromyalgia,exercise performance,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,2 weeks,fibromyalgia,fibromyalgia,primary,no,crossover,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,ad,NA,NA,NA,NA,NA,no_useable_data,NA
2268,NA,ozerbil 2006,comparison of the effects of two antidepressants on exercise performance of the female patients with fibromyalgia,exercise performance,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,2 weeks,fibromyalgia,fibromyalgia,primary,no,crossover,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,ad,NA,NA,NA,NA,NA,no_useable_data,NA
2269,pain_int,pakfetrat 2019,evaluation of the effectiveness of crocin isolated from saffron in treatment of burning mouth syndrome: a randomized controlled trial,pain and mood,saffron/crocin,plant extract,non-pharmacological,crocin 30mg,n/a,n/a,n/a,n/a,11 weeks,burning mouth syndrome,burning mouth syndrome,primary,≥5 on 10nrs,parallel,no dropout,0-10 numerical rating scale,baseline,NA,8.9,1.2,0.23533936216582085,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2270,pain_int,pakfetrat 2019,evaluation of the effectiveness of crocin isolated from saffron in treatment of burning mouth syndrome: a randomized controlled trial,pain and mood,citalopram,antidepressant,antidepressant,citalopram 30mg,ssri,30mg,standard,fixed,11 weeks,burning mouth syndrome,burning mouth syndrome,primary,≥5 on 10nrs,parallel,no dropout,0-10 numerical rating scale,baseline,NA,9,1.3,0.2836832573067901,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2271,pain_int,pakfetrat 2019,evaluation of the effectiveness of crocin isolated from saffron in treatment of burning mouth syndrome: a randomized controlled trial,pain and mood,saffron/crocin,plant extract,non-pharmacological,crocin 30mg,n/a,n/a,n/a,n/a,11 weeks,burning mouth syndrome,burning mouth syndrome,primary,≥5 on 10nrs,parallel,no dropout,0-10 numerical rating scale,post_int,NA,1.1,1.57,0.30790233216694896,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2272,pain_int,pakfetrat 2019,evaluation of the effectiveness of crocin isolated from saffron in treatment of burning mouth syndrome: a randomized controlled trial,pain and mood,citalopram,antidepressant,antidepressant,citalopram 30mg,ssri,30mg,standard,fixed,11 weeks,burning mouth syndrome,burning mouth syndrome,primary,≥5 on 10nrs,parallel,no dropout,0-10 numerical rating scale,post_int,NA,1.2,1.67,0.36442387669410725,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2273,mood,pakfetrat 2019,evaluation of the effectiveness of crocin isolated from saffron in treatment of burning mouth syndrome: a randomized controlled trial,pain and mood,saffron/crocin,plant extract,non-pharmacological,crocin 30mg,n/a,n/a,n/a,n/a,11 weeks,burning mouth syndrome,burning mouth syndrome,primary,≥5 on 10nrs,parallel,no dropout,hamilton depression rating scale,baseline,NA,28.07,5.75,1.1276677770445582,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2274,mood,pakfetrat 2019,evaluation of the effectiveness of crocin isolated from saffron in treatment of burning mouth syndrome: a randomized controlled trial,pain and mood,citalopram,antidepressant,antidepressant,citalopram 30mg,ssri,30mg,standard,fixed,11 weeks,burning mouth syndrome,burning mouth syndrome,primary,≥5 on 10nrs,parallel,no dropout,hamilton depression rating scale,baseline,NA,29.9,6.37,1.3900479608032716,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2275,mood,pakfetrat 2019,evaluation of the effectiveness of crocin isolated from saffron in treatment of burning mouth syndrome: a randomized controlled trial,pain and mood,saffron/crocin,plant extract,non-pharmacological,crocin 30mg,n/a,n/a,n/a,n/a,11 weeks,burning mouth syndrome,burning mouth syndrome,primary,≥5 on 10nrs,parallel,no dropout,hamilton depression rating scale,post_int,NA,19,3.97,0.7785810564985907,NA,NA,NA,NA,NA,26,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
2276,mood,pakfetrat 2019,evaluation of the effectiveness of crocin isolated from saffron in treatment of burning mouth syndrome: a randomized controlled trial,pain and mood,citalopram,antidepressant,antidepressant,citalopram 30mg,ssri,30mg,standard,fixed,11 weeks,burning mouth syndrome,burning mouth syndrome,primary,≥5 on 10nrs,parallel,no dropout,hamilton depression rating scale,post_int,NA,19.4,4.65,1.0147131895973647,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
2281,withdrawal,pakfetrat 2019,evaluation of the effectiveness of crocin isolated from saffron in treatment of burning mouth syndrome: a randomized controlled trial,pain and mood,saffron/crocin,plant extract,non-pharmacological,crocin 30mg,n/a,n/a,n/a,n/a,11 weeks,burning mouth syndrome,burning mouth syndrome,primary,≥5 on 10nrs,parallel,no dropout,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,0,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2282,withdrawal,pakfetrat 2019,evaluation of the effectiveness of crocin isolated from saffron in treatment of burning mouth syndrome: a randomized controlled trial,pain and mood,citalopram,antidepressant,antidepressant,citalopram 30mg,ssri,30mg,standard,fixed,11 weeks,burning mouth syndrome,burning mouth syndrome,primary,≥5 on 10nrs,parallel,no dropout,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,0,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2283,pain_int,patkar 2007,"a randomized, controlled, trial of controlled release paroxetine in fibromyalgia",fibromyalgia symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥5 on 10nrs,parallel,itt with locf,0-100 vas,baseline,NA,75.3,19.8,2.5998673706225066,NA,NA,NA,NA,NA,58,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2284,pain_int,patkar 2007,"a randomized, controlled, trial of controlled release paroxetine in fibromyalgia",fibromyalgia symptoms,paroxetine,antidepressant,antidepressant,paroxetine 12.5-62.5mg,ssri,39.1mg,unable to be categorised,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥5 on 10nrs,parallel,itt with locf,0-100 vas,baseline,NA,74.2,22.7,2.980656025915702,NA,NA,NA,NA,NA,58,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2285,pain_int,patkar 2007,"a randomized, controlled, trial of controlled release paroxetine in fibromyalgia",fibromyalgia symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥5 on 10nrs,parallel,itt with locf,0-100 vas,change_score,NA,-8.8,16.6,2.1796867854713944,NA,NA,NA,NA,NA,58,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2286,pain_int,patkar 2007,"a randomized, controlled, trial of controlled release paroxetine in fibromyalgia",fibromyalgia symptoms,paroxetine,antidepressant,antidepressant,paroxetine 12.5-62.5mg,ssri,39.1mg,unable to be categorised,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥5 on 10nrs,parallel,itt with locf,0-100 vas,change_score,NA,-12.2,18.5,2.4291690079048673,NA,NA,NA,NA,NA,58,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2287,mood,patkar 2007,"a randomized, controlled, trial of controlled release paroxetine in fibromyalgia",fibromyalgia symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥5 on 10nrs,parallel,itt with locf,beck depression inventory,baseline,NA,11.4,6.4,0.8403611703022243,NA,NA,NA,NA,NA,58,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2288,mood,patkar 2007,"a randomized, controlled, trial of controlled release paroxetine in fibromyalgia",fibromyalgia symptoms,paroxetine,antidepressant,antidepressant,paroxetine 12.5-62.5mg,ssri,39.1mg,unable to be categorised,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥5 on 10nrs,parallel,itt with locf,beck depression inventory,baseline,NA,12.5,5.9,0.7747079538723631,NA,NA,NA,NA,NA,58,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2291,adverse,patkar 2007,"a randomized, controlled, trial of controlled release paroxetine in fibromyalgia",fibromyalgia symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥5 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,58,34,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2292,adverse,patkar 2007,"a randomized, controlled, trial of controlled release paroxetine in fibromyalgia",fibromyalgia symptoms,paroxetine,antidepressant,antidepressant,paroxetine 12.5-62.5mg,ssri,39.1mg,unable to be categorised,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥5 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,58,38,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2293,serious_adverse,patkar 2007,"a randomized, controlled, trial of controlled release paroxetine in fibromyalgia",fibromyalgia symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥5 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,58,2,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2294,serious_adverse,patkar 2007,"a randomized, controlled, trial of controlled release paroxetine in fibromyalgia",fibromyalgia symptoms,paroxetine,antidepressant,antidepressant,paroxetine 12.5-62.5mg,ssri,39.1mg,unable to be categorised,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥5 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,58,2,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2295,adverse_dropout,patkar 2007,"a randomized, controlled, trial of controlled release paroxetine in fibromyalgia",fibromyalgia symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥5 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,58,1,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2296,adverse_dropout,patkar 2007,"a randomized, controlled, trial of controlled release paroxetine in fibromyalgia",fibromyalgia symptoms,paroxetine,antidepressant,antidepressant,paroxetine 12.5-62.5mg,ssri,39.1mg,unable to be categorised,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥5 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,58,4,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2297,withdrawal,patkar 2007,"a randomized, controlled, trial of controlled release paroxetine in fibromyalgia",fibromyalgia symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥5 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,58,10,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2298,withdrawal,patkar 2007,"a randomized, controlled, trial of controlled release paroxetine in fibromyalgia",fibromyalgia symptoms,paroxetine,antidepressant,antidepressant,paroxetine 12.5-62.5mg,ssri,39.1mg,unable to be categorised,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥5 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,58,20,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2299,adverse,petzke 2013,using fmri to evaluate the effects of milnacipran on central pain processing in patients with fibromyalgia,experimental pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomised sample,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,46,40,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2300,adverse,petzke 2013,using fmri to evaluate the effects of milnacipran on central pain processing in patients with fibromyalgia,experimental pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomised sample,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,46,45,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2301,serious_adverse,petzke 2013,using fmri to evaluate the effects of milnacipran on central pain processing in patients with fibromyalgia,experimental pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomised sample,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,46,2,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2302,serious_adverse,petzke 2013,using fmri to evaluate the effects of milnacipran on central pain processing in patients with fibromyalgia,experimental pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomised sample,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,46,4,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2303,adverse_dropout,petzke 2013,using fmri to evaluate the effects of milnacipran on central pain processing in patients with fibromyalgia,experimental pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomised sample,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,46,4,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2304,adverse_dropout,petzke 2013,using fmri to evaluate the effects of milnacipran on central pain processing in patients with fibromyalgia,experimental pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomised sample,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,46,11,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2305,withdrawal,petzke 2013,using fmri to evaluate the effects of milnacipran on central pain processing in patients with fibromyalgia,experimental pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomised sample,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,46,8,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2306,withdrawal,petzke 2013,using fmri to evaluate the effects of milnacipran on central pain processing in patients with fibromyalgia,experimental pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomised sample,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,46,13,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2307,pain_int,pickering 2018,milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study,experimental pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,0-10 numerical rating scale,baseline,NA,6.6,1.6,0.32659863237109044,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2308,pain_int,pickering 2018,milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study,experimental pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,4 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,0-10 numerical rating scale,baseline,NA,6.3,2,0.4082482904638631,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2309,pain_int,pickering 2018,milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study,experimental pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,0-10 numerical rating scale,post_int,NA,5.6,1.8,0.3674234614174768,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2310,pain_int,pickering 2018,milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study,experimental pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,4 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,0-10 numerical rating scale,post_int,NA,5.3,2.5,0.5103103630798288,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2311,pain_mod,pickering 2018,milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study,experimental pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,6,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
2312,pain_mod,pickering 2018,milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study,experimental pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,4 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,7,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
2313,adverse,pickering 2018,milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study,experimental pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,27,0.92,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2314,adverse,pickering 2018,milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study,experimental pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,4 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,24,0.96,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2315,serious_adverse,pickering 2018,milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study,experimental pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2316,serious_adverse,pickering 2018,milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study,experimental pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,4 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2317,adverse_dropout,pickering 2018,milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study,experimental pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2318,adverse_dropout,pickering 2018,milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study,experimental pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,4 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,5,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2319,withdrawal,pickering 2018,milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study,experimental pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,1,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2320,withdrawal,pickering 2018,milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study,experimental pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,4 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,5,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2321,pain_int,pilowsky 1990,"a controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable, 'psychogenic' pain",pain,amitriptyline + psychotherapy,combined antidepressant intervention,antidepressant,amitriptyline ≤150mg + psychotherapy,tca,≤150mg,unable to be categorised,flexible,12 weeks,psychogenic pain,primary,primary,no,parallel,completer analysis,0-100 vas,baseline,NA,62.45,27.09,6.05750815104693,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2322,pain_int,pilowsky 1990,"a controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable, 'psychogenic' pain",pain,amitriptyline + support,combined antidepressant intervention,antidepressant,amitriptyline ≤150mg + support,tca,≤150mg,unable to be categorised,flexible,12 weeks,psychogenic pain,primary,primary,no,parallel,completer analysis,0-100 vas,baseline,NA,66.85,22.8,5.09823498869952,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2323,pain_int,pilowsky 1990,"a controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable, 'psychogenic' pain",pain,psychotherapy,psychological therapy,non-pharmacological,psychotherapy,n/a,n/a,n/a,n/a,12 weeks,psychogenic pain,primary,primary,no,parallel,completer analysis,0-100 vas,baseline,NA,60.61,19.32,4.028498479582685,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2324,pain_int,pilowsky 1990,"a controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable, 'psychogenic' pain",pain,support,support,non-pharmacological,support,n/a,n/a,n/a,n/a,12 weeks,psychogenic pain,primary,primary,no,parallel,completer analysis,0-100 vas,baseline,NA,68.16,20.61,4.728258275072277,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2325,pain_int,pilowsky 1990,"a controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable, 'psychogenic' pain",pain,amitriptyline + psychotherapy,combined antidepressant intervention,antidepressant,amitriptyline ≤150mg + psychotherapy,tca,≤150mg,unable to be categorised,flexible,12 weeks,psychogenic pain,primary,primary,no,parallel,completer analysis,0-100 vas,post_int,NA,61.3,27.03,6.044091743181932,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2326,pain_int,pilowsky 1990,"a controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable, 'psychogenic' pain",pain,amitriptyline + support,combined antidepressant intervention,antidepressant,amitriptyline ≤150mg + support,tca,≤150mg,unable to be categorised,flexible,12 weeks,psychogenic pain,primary,primary,no,parallel,completer analysis,0-100 vas,post_int,NA,58.18,23.88,5.339730330269497,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2327,pain_int,pilowsky 1990,"a controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable, 'psychogenic' pain",pain,psychotherapy,psychological therapy,non-pharmacological,psychotherapy,n/a,n/a,n/a,n/a,12 weeks,psychogenic pain,primary,primary,no,parallel,completer analysis,0-100 vas,post_int,NA,70.65,16.62,3.465509561628583,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2328,pain_int,pilowsky 1990,"a controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable, 'psychogenic' pain",pain,support,support,non-pharmacological,support,n/a,n/a,n/a,n/a,12 weeks,psychogenic pain,primary,primary,no,parallel,completer analysis,0-100 vas,post_int,NA,68,21.24,4.872790187410731,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2329,withdrawal,pilowsky 1990,"a controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable, 'psychogenic' pain",pain,amitriptyline + psychotherapy,combined antidepressant intervention,antidepressant,amitriptyline ≤150mg + psychotherapy,tca,≤150mg,unable to be categorised,flexible,12 weeks,psychogenic pain,primary,primary,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,6,0.24,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2330,withdrawal,pilowsky 1990,"a controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable, 'psychogenic' pain",pain,amitriptyline + support,combined antidepressant intervention,antidepressant,amitriptyline ≤150mg + support,tca,≤150mg,unable to be categorised,flexible,12 weeks,psychogenic pain,primary,primary,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,6,0.25,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2331,withdrawal,pilowsky 1990,"a controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable, 'psychogenic' pain",pain,psychotherapy,psychological therapy,non-pharmacological,psychotherapy,n/a,n/a,n/a,n/a,12 weeks,psychogenic pain,primary,primary,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,26,5,0.19,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2332,withdrawal,pilowsky 1990,"a controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable, 'psychogenic' pain",pain,support,support,non-pharmacological,support,n/a,n/a,n/a,n/a,12 weeks,psychogenic pain,primary,primary,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,7,0.31,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2333,pain_int,pirbudak 2003,epidural corticosteroid injection and amitriptyline for the treatment of chronic low back pain associated with radiculopathy,pain,epidural injection,epidural injection,non-antidepressant pharmacological,epidural injection,n/a,n/a,n/a,n/a,9 months,low back pain with radiculopathy,musculoskeletal,musculoskeletal,no,parallel,completer analysis,0-10 numerical rating scale,baseline,NA,8.4,1.7,0.25065132546332514,NA,NA,NA,NA,NA,46,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2334,pain_int,pirbudak 2003,epidural corticosteroid injection and amitriptyline for the treatment of chronic low back pain associated with radiculopathy,pain,epidural injection + amitriptyline,combined antidepressant intervention,antidepressant,epidural injection + amitriptyline 10-50mg,tca,10-50mg,unable to be categorised,flexible,9 months,low back pain with radiculopathy,musculoskeletal,musculoskeletal,no,parallel,completer analysis,0-10 numerical rating scale,baseline,NA,7.81,4,0.5897678246195885,NA,NA,NA,NA,NA,46,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2335,pain_int,pirbudak 2003,epidural corticosteroid injection and amitriptyline for the treatment of chronic low back pain associated with radiculopathy,pain,epidural injection,epidural injection,non-antidepressant pharmacological,epidural injection,n/a,n/a,n/a,n/a,9 months,low back pain with radiculopathy,musculoskeletal,musculoskeletal,no,parallel,completer analysis,0-10 numerical rating scale,post_int,NA,-0.9,1.8,0.26539552107881487,NA,NA,NA,NA,NA,46,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2336,pain_int,pirbudak 2003,epidural corticosteroid injection and amitriptyline for the treatment of chronic low back pain associated with radiculopathy,pain,epidural injection + amitriptyline,combined antidepressant intervention,antidepressant,epidural injection + amitriptyline 10-50mg,tca,10-50mg,unable to be categorised,flexible,9 months,low back pain with radiculopathy,musculoskeletal,musculoskeletal,no,parallel,completer analysis,0-10 numerical rating scale,post_int,NA,-6.2,0.8,0.11795356492391772,NA,NA,NA,NA,NA,46,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2337,physical,pirbudak 2003,epidural corticosteroid injection and amitriptyline for the treatment of chronic low back pain associated with radiculopathy,pain,epidural injection,epidural injection,non-antidepressant pharmacological,epidural injection,n/a,n/a,n/a,n/a,9 months,low back pain with radiculopathy,musculoskeletal,musculoskeletal,no,parallel,completer analysis,oswestry disability index - performance of daily activities,baseline,NA,49.6,15.5,2.2853503204009056,NA,NA,NA,NA,NA,46,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2338,physical,pirbudak 2003,epidural corticosteroid injection and amitriptyline for the treatment of chronic low back pain associated with radiculopathy,pain,epidural injection + amitriptyline,combined antidepressant intervention,antidepressant,epidural injection + amitriptyline 10-50mg,tca,10-50mg,unable to be categorised,flexible,9 months,low back pain with radiculopathy,musculoskeletal,musculoskeletal,no,parallel,completer analysis,oswestry disability index - performance of daily activities,baseline,NA,50.2,15.2,2.2411177335544363,NA,NA,NA,NA,NA,46,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2339,physical,pirbudak 2003,epidural corticosteroid injection and amitriptyline for the treatment of chronic low back pain associated with radiculopathy,pain,epidural injection,epidural injection,non-antidepressant pharmacological,epidural injection,n/a,n/a,n/a,n/a,9 months,low back pain with radiculopathy,musculoskeletal,musculoskeletal,no,parallel,completer analysis,oswestry disability index - performance of daily activities,post_int,NA,-7.6,15.3,2.2558619291699262,NA,NA,NA,NA,NA,46,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2340,physical,pirbudak 2003,epidural corticosteroid injection and amitriptyline for the treatment of chronic low back pain associated with radiculopathy,pain,epidural injection + amitriptyline,combined antidepressant intervention,antidepressant,epidural injection + amitriptyline 10-50mg,tca,10-50mg,unable to be categorised,flexible,9 months,low back pain with radiculopathy,musculoskeletal,musculoskeletal,no,parallel,completer analysis,oswestry disability index - performance of daily activities,post_int,NA,-13.2,15.5,2.2853503204009056,NA,NA,NA,NA,NA,46,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2341,pain_int,rani 1996,an evaluation of antidepressants in rheumatic pain conditions,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,multiple chronic pain conditions,musculoskeletal,musculoskeletal,≥60 on 100vas,parallel,no dropout,0-4 numerical rating scale,baseline,NA,2.2,0.5,0.11785113019775793,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2342,pain_int,rani 1996,an evaluation of antidepressants in rheumatic pain conditions,pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,4 weeks,multiple chronic pain conditions,musculoskeletal,musculoskeletal,≥60 on 100vas,parallel,no dropout,0-4 numerical rating scale,baseline,NA,2.74,0.45,0.09819805060619657,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2343,pain_int,rani 1996,an evaluation of antidepressants in rheumatic pain conditions,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,4 weeks,multiple chronic pain conditions,musculoskeletal,musculoskeletal,≥60 on 100vas,parallel,no dropout,0-4 numerical rating scale,baseline,NA,2.26,0.45,0.10062305898749054,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2344,pain_int,rani 1996,an evaluation of antidepressants in rheumatic pain conditions,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,multiple chronic pain conditions,musculoskeletal,musculoskeletal,≥60 on 100vas,parallel,no dropout,0-4 numerical rating scale,post_int,NA,1.67,0.74,0.17441967269268174,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2345,pain_int,rani 1996,an evaluation of antidepressants in rheumatic pain conditions,pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,4 weeks,multiple chronic pain conditions,musculoskeletal,musculoskeletal,≥60 on 100vas,parallel,no dropout,0-4 numerical rating scale,post_int,NA,1.24,0.56,0.12220201853215575,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2346,pain_int,rani 1996,an evaluation of antidepressants in rheumatic pain conditions,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,4 weeks,multiple chronic pain conditions,musculoskeletal,musculoskeletal,≥60 on 100vas,parallel,no dropout,0-4 numerical rating scale,post_int,NA,1.33,0.61,0.13640014662748717,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2347,adverse_dropout,rani 1996,an evaluation of antidepressants in rheumatic pain conditions,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,multiple chronic pain conditions,musculoskeletal,musculoskeletal,≥60 on 100vas,parallel,no dropout,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2348,adverse_dropout,rani 1996,an evaluation of antidepressants in rheumatic pain conditions,pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,4 weeks,multiple chronic pain conditions,musculoskeletal,musculoskeletal,≥60 on 100vas,parallel,no dropout,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2349,adverse_dropout,rani 1996,an evaluation of antidepressants in rheumatic pain conditions,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,4 weeks,multiple chronic pain conditions,musculoskeletal,musculoskeletal,≥60 on 100vas,parallel,no dropout,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2350,withdrawal,rani 1996,an evaluation of antidepressants in rheumatic pain conditions,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,multiple chronic pain conditions,musculoskeletal,musculoskeletal,≥60 on 100vas,parallel,no dropout,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2351,withdrawal,rani 1996,an evaluation of antidepressants in rheumatic pain conditions,pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,4 weeks,multiple chronic pain conditions,musculoskeletal,musculoskeletal,≥60 on 100vas,parallel,no dropout,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,0,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2352,withdrawal,rani 1996,an evaluation of antidepressants in rheumatic pain conditions,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,4 weeks,multiple chronic pain conditions,musculoskeletal,musculoskeletal,≥60 on 100vas,parallel,no dropout,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,0,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2353,pain_int,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,5.5,1.3,0.12070196981508372,NA,NA,NA,NA,NA,116,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2354,pain_int,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,5.5,1.1,0.10213243599737853,NA,NA,NA,NA,NA,116,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2355,pain_int,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,5.7,1.3,0.12070196981508372,NA,NA,NA,NA,NA,116,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2356,pain_int,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-1.6,1.913426246292237,0.18,NA,NA,NA,NA,NA,113,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2357,pain_int,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-2.5,1.913426246292237,0.18,NA,NA,NA,NA,NA,113,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2358,pain_int,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-2.47,1.921874085365636,0.18,NA,NA,NA,NA,NA,114,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2359,mood,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,hamilton depression rating scale,baseline,NA,3.8,3.2,0.297112541083283,NA,NA,NA,NA,NA,116,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2360,mood,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,hamilton depression rating scale,baseline,NA,3.8,3.7,0.34353637562754596,NA,NA,NA,NA,NA,116,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2361,mood,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,hamilton depression rating scale,baseline,NA,4.2,3.1,0.2878277741744304,NA,NA,NA,NA,NA,116,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2365,sleep,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,bpi sleep,change_score,NA,-2.25,0.7589466384404111,0.24,NA,NA,NA,NA,NA,10,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
2366,sleep,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,bpi sleep,change_score,NA,-3.3,2.3902301144450506,0.23,NA,NA,NA,NA,NA,108,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
2367,sleep,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,bpi sleep,change_score,NA,-3,2.4825793038692643,0.24,NA,NA,NA,NA,NA,107,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
2368,mood,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,bpi mood,change_score,NA,-1.76,2.08806130178211,0.2,NA,NA,NA,NA,NA,109,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2369,mood,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,bpi mood,change_score,NA,-2.32,2.078460969082653,0.2,NA,NA,NA,NA,NA,108,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2370,mood,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,bpi mood,change_score,NA,-2.6,2.078460969082653,0.2,NA,NA,NA,NA,NA,108,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2371,pain_mod,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,113,49,0.4336,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
2372,pain_mod,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,113,77,0.6814,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
2373,pain_mod,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,114,73,0.6404000000000001,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
2374,pain_sub,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,113,34,0.3,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2375,pain_sub,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,113,56,0.5,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2376,pain_sub,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,114,44,0.39,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2377,adverse,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,57,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2378,adverse,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,71,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2379,adverse,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,73,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2380,serious_adverse,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,4,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2381,serious_adverse,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,4,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2382,serious_adverse,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,2,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2383,adverse_dropout,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,3,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2384,adverse_dropout,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,5,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2385,adverse_dropout,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,14,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2386,withdrawal,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,16,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2387,withdrawal,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,15,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2388,withdrawal,raskin 2005,"a double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,21,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2389,sleep,razazian 2014,"evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. a randomized, double-blind trial",pain,carbamazepine,anticonvulsant,non-antidepressant pharmacological,carbamazepine 400mg,n/a,n/a,n/a,n/a,4 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,bpi sleep,baseline,NA,4.45,1.1,0.1193117518002609,NA,NA,NA,NA,NA,85,NA,NA,FALSE,NA,NA,post-intervention scores are 1 week post-intervention,NA,NA,non_ad_pharm,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
2390,sleep,razazian 2014,"evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. a randomized, double-blind trial",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 150mg,n/a,n/a,n/a,n/a,4 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,bpi sleep,baseline,NA,4.8,0.9,0.09704949588309457,NA,NA,NA,NA,NA,86,NA,NA,FALSE,NA,NA,post-intervention scores are 1 week post-intervention,NA,NA,non_ad_pharm,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
2391,sleep,razazian 2014,"evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. a randomized, double-blind trial",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 150mg,snri,150mg,standard,fixed,4 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,bpi sleep,baseline,NA,4.48,1.2,0.12939932784412608,NA,NA,NA,NA,NA,86,NA,NA,FALSE,NA,NA,post-intervention scores are 1 week post-intervention,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
2392,sleep,razazian 2014,"evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. a randomized, double-blind trial",pain,carbamazepine,anticonvulsant,non-antidepressant pharmacological,carbamazepine 400mg,n/a,n/a,n/a,n/a,4 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,bpi sleep,post_int,NA,2.4,0.9,0.10190493307301361,NA,NA,NA,NA,NA,78,NA,NA,FALSE,NA,NA,post-intervention scores are 1 week post-intervention,NA,NA,non_ad_pharm,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
2393,sleep,razazian 2014,"evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. a randomized, double-blind trial",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 150mg,n/a,n/a,n/a,n/a,4 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,bpi sleep,post_int,NA,1.77,0.8,0.09116846116771035,NA,NA,NA,NA,NA,77,NA,NA,FALSE,NA,NA,post-intervention scores are 1 week post-intervention,NA,NA,non_ad_pharm,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
2394,sleep,razazian 2014,"evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. a randomized, double-blind trial",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 150mg,snri,150mg,standard,fixed,4 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,bpi sleep,post_int,NA,2.66,1.4,0.16854019432007686,NA,NA,NA,NA,NA,69,NA,NA,FALSE,NA,NA,post-intervention scores are 1 week post-intervention,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
2395,mood,razazian 2014,"evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. a randomized, double-blind trial",pain,carbamazepine,anticonvulsant,non-antidepressant pharmacological,carbamazepine 400mg,n/a,n/a,n/a,n/a,4 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,bpi mood,baseline,NA,2.6,0.7,0.07592566023652966,NA,NA,NA,NA,NA,85,NA,NA,FALSE,NA,NA,post-intervention scores are 1 week post-intervention,NA,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
2396,mood,razazian 2014,"evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. a randomized, double-blind trial",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 150mg,n/a,n/a,n/a,n/a,4 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,bpi mood,baseline,NA,2.68,0.6,0.06469966392206304,NA,NA,NA,NA,NA,86,NA,NA,FALSE,NA,NA,post-intervention scores are 1 week post-intervention,NA,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
2397,mood,razazian 2014,"evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. a randomized, double-blind trial",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 150mg,snri,150mg,standard,fixed,4 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,bpi mood,baseline,NA,2.53,0.6,0.06469966392206304,NA,NA,NA,NA,NA,86,NA,NA,FALSE,NA,NA,post-intervention scores are 1 week post-intervention,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
2398,mood,razazian 2014,"evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. a randomized, double-blind trial",pain,carbamazepine,anticonvulsant,non-antidepressant pharmacological,carbamazepine 400mg,n/a,n/a,n/a,n/a,4 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,bpi mood,post_int,NA,2.4,0.6,0.06793662204867573,NA,NA,NA,NA,NA,78,NA,NA,FALSE,NA,NA,post-intervention scores are 1 week post-intervention,NA,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2399,mood,razazian 2014,"evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. a randomized, double-blind trial",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 150mg,n/a,n/a,n/a,n/a,4 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,bpi mood,post_int,NA,1.41,0.5,0.05698028822981897,NA,NA,NA,NA,NA,77,NA,NA,FALSE,NA,NA,post-intervention scores are 1 week post-intervention,NA,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2400,mood,razazian 2014,"evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. a randomized, double-blind trial",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 150mg,snri,150mg,standard,fixed,4 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,bpi mood,post_int,NA,1.63,0.8,0.09630868246861536,NA,NA,NA,NA,NA,69,NA,NA,FALSE,NA,NA,post-intervention scores are 1 week post-intervention,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2401,pain_mod,razazian 2014,"evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. a randomized, double-blind trial",pain,carbamazepine,anticonvulsant,non-antidepressant pharmacological,carbamazepine 400mg,n/a,n/a,n/a,n/a,4 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,85,39,NA,FALSE,NA,NA,post-intervention scores are 1 week post-intervention,NA,NA,non_ad_pharm,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
2402,pain_mod,razazian 2014,"evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. a randomized, double-blind trial",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 150mg,n/a,n/a,n/a,n/a,4 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,14,NA,FALSE,NA,NA,post-intervention scores are 1 week post-intervention,NA,NA,non_ad_pharm,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
2403,pain_mod,razazian 2014,"evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. a randomized, double-blind trial",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 150mg,snri,150mg,standard,fixed,4 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,20,NA,FALSE,NA,NA,post-intervention scores are 1 week post-intervention,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
2404,pain_sub,razazian 2014,"evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. a randomized, double-blind trial",pain,carbamazepine,anticonvulsant,non-antidepressant pharmacological,carbamazepine 400mg,n/a,n/a,n/a,n/a,4 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,85,35,NA,FALSE,NA,NA,post-intervention scores are 1 week post-intervention,NA,NA,non_ad_pharm,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2405,pain_sub,razazian 2014,"evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. a randomized, double-blind trial",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 150mg,n/a,n/a,n/a,n/a,4 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,66,NA,FALSE,NA,NA,post-intervention scores are 1 week post-intervention,NA,NA,non_ad_pharm,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2406,pain_sub,razazian 2014,"evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. a randomized, double-blind trial",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 150mg,snri,150mg,standard,fixed,4 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,36,NA,FALSE,NA,NA,post-intervention scores are 1 week post-intervention,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2407,adverse,razazian 2014,"evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. a randomized, double-blind trial",pain,carbamazepine,anticonvulsant,non-antidepressant pharmacological,carbamazepine 400mg,n/a,n/a,n/a,n/a,4 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,85,11,NA,FALSE,NA,NA,post-intervention scores are 1 week post-intervention,NA,NA,non_ad_pharm,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2408,adverse,razazian 2014,"evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. a randomized, double-blind trial",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 150mg,n/a,n/a,n/a,n/a,4 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,63,NA,FALSE,NA,NA,post-intervention scores are 1 week post-intervention,NA,NA,non_ad_pharm,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2409,adverse,razazian 2014,"evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. a randomized, double-blind trial",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 150mg,snri,150mg,standard,fixed,4 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,55,NA,FALSE,NA,NA,post-intervention scores are 1 week post-intervention,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2410,serious_adverse,razazian 2014,"evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. a randomized, double-blind trial",pain,carbamazepine,anticonvulsant,non-antidepressant pharmacological,carbamazepine 400mg,n/a,n/a,n/a,n/a,4 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,85,0,NA,FALSE,NA,NA,post-intervention scores are 1 week post-intervention,NA,NA,non_ad_pharm,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2411,serious_adverse,razazian 2014,"evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. a randomized, double-blind trial",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 150mg,n/a,n/a,n/a,n/a,4 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,0,NA,FALSE,NA,NA,post-intervention scores are 1 week post-intervention,NA,NA,non_ad_pharm,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2412,serious_adverse,razazian 2014,"evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. a randomized, double-blind trial",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 150mg,snri,150mg,standard,fixed,4 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,0,NA,FALSE,NA,NA,post-intervention scores are 1 week post-intervention,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2413,adverse_dropout,razazian 2014,"evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. a randomized, double-blind trial",pain,carbamazepine,anticonvulsant,non-antidepressant pharmacological,carbamazepine 400mg,n/a,n/a,n/a,n/a,4 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,85,2,NA,FALSE,NA,NA,post-intervention scores are 1 week post-intervention,NA,NA,non_ad_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2414,adverse_dropout,razazian 2014,"evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. a randomized, double-blind trial",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 150mg,n/a,n/a,n/a,n/a,4 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,7,NA,FALSE,NA,NA,post-intervention scores are 1 week post-intervention,NA,NA,non_ad_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2415,adverse_dropout,razazian 2014,"evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. a randomized, double-blind trial",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 150mg,snri,150mg,standard,fixed,4 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,14,NA,FALSE,NA,NA,post-intervention scores are 1 week post-intervention,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2416,withdrawal,razazian 2014,"evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. a randomized, double-blind trial",pain,carbamazepine,anticonvulsant,non-antidepressant pharmacological,carbamazepine 400mg,n/a,n/a,n/a,n/a,4 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,85,7,NA,FALSE,NA,NA,post-intervention scores are 1 week post-intervention,NA,NA,non_ad_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2417,withdrawal,razazian 2014,"evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. a randomized, double-blind trial",pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 150mg,n/a,n/a,n/a,n/a,4 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,9,NA,FALSE,NA,NA,post-intervention scores are 1 week post-intervention,NA,NA,non_ad_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2418,withdrawal,razazian 2014,"evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. a randomized, double-blind trial",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 150mg,snri,150mg,standard,fixed,4 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,17,NA,FALSE,NA,NA,post-intervention scores are 1 week post-intervention,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2419,mood,richards 2015,"efficacy of venlafaxine xr for the treatment of pain in patients with spinal cord injury and major depression: a randomized, controlled trial",mood,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,spinal cord injury,neuropathic,neuropathic,no,parallel,unclear,hamilton rating depression scale,baseline,NA,20.1,5.1,0.6639634460022017,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2420,mood,richards 2015,"efficacy of venlafaxine xr for the treatment of pain in patients with spinal cord injury and major depression: a randomized, controlled trial",mood,venlafaxine,antidepressant,antidepressant,venlafaxine 37.5-300mg,tca,37.5-300mg,unable to be categorised,flexible,12 weeks,spinal cord injury,neuropathic,neuropathic,no,parallel,unclear,hamilton rating depression scale,baseline,NA,19.5,5.5,0.6875,NA,NA,NA,NA,NA,64,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2421,mood,richards 2015,"efficacy of venlafaxine xr for the treatment of pain in patients with spinal cord injury and major depression: a randomized, controlled trial",mood,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,spinal cord injury,neuropathic,neuropathic,no,parallel,unclear,hamilton rating depression scale,post_int,NA,9.5,7.3,0.9503790501600142,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
2422,mood,richards 2015,"efficacy of venlafaxine xr for the treatment of pain in patients with spinal cord injury and major depression: a randomized, controlled trial",mood,venlafaxine,antidepressant,antidepressant,venlafaxine 37.5-300mg,tca,37.5-300mg,unable to be categorised,flexible,12 weeks,spinal cord injury,neuropathic,neuropathic,no,parallel,unclear,hamilton rating depression scale,post_int,NA,9.5,6.5,0.8125,NA,NA,NA,NA,NA,64,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
2423,pain_sub,richards 2015,"efficacy of venlafaxine xr for the treatment of pain in patients with spinal cord injury and major depression: a randomized, controlled trial",mood,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,spinal cord injury,neuropathic,neuropathic,no,parallel,unclear,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,59,14,0.24,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2424,pain_sub,richards 2015,"efficacy of venlafaxine xr for the treatment of pain in patients with spinal cord injury and major depression: a randomized, controlled trial",mood,venlafaxine,antidepressant,antidepressant,venlafaxine 37.5-300mg,tca,37.5-300mg,unable to be categorised,flexible,12 weeks,spinal cord injury,neuropathic,neuropathic,no,parallel,unclear,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,64,32,0.5,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2425,withdrawal,richards 2015,"efficacy of venlafaxine xr for the treatment of pain in patients with spinal cord injury and major depression: a randomized, controlled trial",mood,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,spinal cord injury,neuropathic,neuropathic,no,parallel,unclear,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,59,14,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2426,withdrawal,richards 2015,"efficacy of venlafaxine xr for the treatment of pain in patients with spinal cord injury and major depression: a randomized, controlled trial",mood,venlafaxine,antidepressant,antidepressant,venlafaxine 37.5-300mg,tca,37.5-300mg,unable to be categorised,flexible,12 weeks,spinal cord injury,neuropathic,neuropathic,no,parallel,unclear,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,64,15,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2427,adverse,riesner 2008,an additive therapy for chronic pain in advanced gon-/coxarthrosis with the selective serotonin reuptake inhibitor fluvoxamine (fevarin),pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥50 on 100vas,parallel,itt method unspecified,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,21,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2428,adverse,riesner 2008,an additive therapy for chronic pain in advanced gon-/coxarthrosis with the selective serotonin reuptake inhibitor fluvoxamine (fevarin),pain,fluvoxamine,antidepressant,antidepressant,fluvoxamine 50-150mg,ssri,50-150mg,unable to be categorised,flexible,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥50 on 100vas,parallel,itt method unspecified,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,28,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2429,serious_adverse,riesner 2008,an additive therapy for chronic pain in advanced gon-/coxarthrosis with the selective serotonin reuptake inhibitor fluvoxamine (fevarin),pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥50 on 100vas,parallel,itt method unspecified,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,4,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2430,serious_adverse,riesner 2008,an additive therapy for chronic pain in advanced gon-/coxarthrosis with the selective serotonin reuptake inhibitor fluvoxamine (fevarin),pain,fluvoxamine,antidepressant,antidepressant,fluvoxamine 50-150mg,ssri,50-150mg,unable to be categorised,flexible,8 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥50 on 100vas,parallel,itt method unspecified,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,1,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2431,pain_int,rintala 2007,comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury,pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin ≤3600mg,n/a,n/a,n/a,n/a,8 weeks,neuropathic pain,neuropathic,neuropathic,≥5 on 10nrs,crossover,completer analysis,0-10 numerical rating scale,baseline,NA,5.6,2.2,0.469041575982343,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2432,pain_int,rintala 2007,comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury,pain,amitriptyline,antidepressant,antidepressant,amitriptyline ≤150mg,tca,≤150mg,unable to be categorised,flexible,8 weeks,neuropathic pain,neuropathic,neuropathic,≥5 on 10nrs,crossover,completer analysis,0-10 numerical rating scale,baseline,NA,5.6,2.2,0.469041575982343,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2433,pain_int,rintala 2007,comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury,pain,diphenhydramine,antihistamine,non-antidepressant pharmacological,diphenhydramine ≤75mg,n/a,n/a,n/a,n/a,8 weeks,neuropathic pain,neuropathic,neuropathic,≥5 on 10nrs,crossover,completer analysis,0-10 numerical rating scale,baseline,NA,5.6,2.2,0.469041575982343,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2434,pain_int,rintala 2007,comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury,pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin ≤3600mg,n/a,n/a,n/a,n/a,8 weeks,neuropathic pain,neuropathic,neuropathic,≥5 on 10nrs,crossover,completer analysis,0-10 numerical rating scale,post_int,NA,4.85,2.86,0.6097540487770458,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2435,pain_int,rintala 2007,comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury,pain,amitriptyline,antidepressant,antidepressant,amitriptyline ≤150mg,tca,≤150mg,unable to be categorised,flexible,8 weeks,neuropathic pain,neuropathic,neuropathic,≥5 on 10nrs,crossover,completer analysis,0-10 numerical rating scale,post_int,NA,3.46,2.09,0.44558949718322577,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2436,pain_int,rintala 2007,comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury,pain,diphenhydramine,antihistamine,non-antidepressant pharmacological,diphenhydramine ≤75mg,n/a,n/a,n/a,n/a,8 weeks,neuropathic pain,neuropathic,neuropathic,≥5 on 10nrs,crossover,completer analysis,0-10 numerical rating scale,post_int,NA,5.11,2.54,0.5415298195432505,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2437,mood,rintala 2007,comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury,pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin ≤3600mg,n/a,n/a,n/a,n/a,8 weeks,neuropathic pain,neuropathic,neuropathic,≥5 on 10nrs,crossover,completer analysis,ces-d,baseline,NA,7.2,6.2,1.3218444414047847,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2438,mood,rintala 2007,comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury,pain,amitriptyline,antidepressant,antidepressant,amitriptyline ≤150mg,tca,≤150mg,unable to be categorised,flexible,8 weeks,neuropathic pain,neuropathic,neuropathic,≥5 on 10nrs,crossover,completer analysis,ces-d,baseline,NA,7.2,6.2,1.3218444414047847,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2439,mood,rintala 2007,comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury,pain,diphenhydramine,antihistamine,non-antidepressant pharmacological,diphenhydramine ≤75mg,n/a,n/a,n/a,n/a,8 weeks,neuropathic pain,neuropathic,neuropathic,≥5 on 10nrs,crossover,completer analysis,ces-d,baseline,NA,7.2,6.2,1.3218444414047847,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2440,pain_mod,rintala 2007,comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury,pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin ≤3600mg,n/a,n/a,n/a,n/a,8 weeks,neuropathic pain,neuropathic,neuropathic,≥5 on 10nrs,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,7,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
2441,pain_mod,rintala 2007,comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury,pain,amitriptyline,antidepressant,antidepressant,amitriptyline ≤150mg,tca,≤150mg,unable to be categorised,flexible,8 weeks,neuropathic pain,neuropathic,neuropathic,≥5 on 10nrs,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,12,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
2442,pain_mod,rintala 2007,comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury,pain,diphenhydramine,antihistamine,non-antidepressant pharmacological,diphenhydramine ≤75mg,n/a,n/a,n/a,n/a,8 weeks,neuropathic pain,neuropathic,neuropathic,≥5 on 10nrs,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,7,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
2443,adverse_dropout,rintala 2007,comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury,pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin ≤3600mg,n/a,n/a,n/a,n/a,8 weeks,neuropathic pain,neuropathic,neuropathic,≥5 on 10nrs,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,2,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2444,adverse_dropout,rintala 2007,comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury,pain,amitriptyline,antidepressant,antidepressant,amitriptyline ≤150mg,tca,≤150mg,unable to be categorised,flexible,8 weeks,neuropathic pain,neuropathic,neuropathic,≥5 on 10nrs,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,2,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2445,adverse_dropout,rintala 2007,comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury,pain,diphenhydramine,antihistamine,non-antidepressant pharmacological,diphenhydramine ≤75mg,n/a,n/a,n/a,n/a,8 weeks,neuropathic pain,neuropathic,neuropathic,≥5 on 10nrs,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,0,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2446,withdrawal,rintala 2007,comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury,pain,gabapentin,anticonvulsant,non-antidepressant pharmacological,gabapentin ≤3600mg,n/a,n/a,n/a,n/a,8 weeks,neuropathic pain,neuropathic,neuropathic,≥5 on 10nrs,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,12,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2447,withdrawal,rintala 2007,comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury,pain,amitriptyline,antidepressant,antidepressant,amitriptyline ≤150mg,tca,≤150mg,unable to be categorised,flexible,8 weeks,neuropathic pain,neuropathic,neuropathic,≥5 on 10nrs,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,10,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2448,withdrawal,rintala 2007,comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury,pain,diphenhydramine,antihistamine,non-antidepressant pharmacological,diphenhydramine ≤75mg,n/a,n/a,n/a,n/a,8 weeks,neuropathic pain,neuropathic,neuropathic,≥5 on 10nrs,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,13,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2449,pain_int,robinson 2004,trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study,pain,benzotropine mesylate,active placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,phantom/residual limb pain,phantom/residual limb pain,postsurgical,≥2 on 0-10nrs,parallel,itt unspecified method,sf-mpq total score,baseline,NA,12,11.1,2.546514645963235,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2450,pain_int,robinson 2004,trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study,pain,amitriptyline,antidepressant,antidepressant,amitriptyline ≤125mg,tca,10-125mg,unable to be categorised,flexible,6 weeks,phantom/residual limb pain,phantom/residual limb pain,postsurgical,≥2 on 0-10nrs,parallel,itt unspecified method,sf-mpq total score,baseline,NA,13,10.5,2.347871376374779,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2451,pain_int,robinson 2004,trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study,pain,benzotropine mesylate,active placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,phantom/residual limb pain,phantom/residual limb pain,postsurgical,≥2 on 0-10nrs,parallel,itt unspecified method,sf-mpq total score,post_int,NA,12.5,8.6,1.972975311286831,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2452,pain_int,robinson 2004,trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study,pain,amitriptyline,antidepressant,antidepressant,amitriptyline ≤125mg,tca,10-125mg,unable to be categorised,flexible,6 weeks,phantom/residual limb pain,phantom/residual limb pain,postsurgical,≥2 on 0-10nrs,parallel,itt unspecified method,sf-mpq total score,post_int,NA,11.6,10,2.3570226039551585,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2453,mood,robinson 2004,trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study,pain,benzotropine mesylate,active placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,phantom/residual limb pain,phantom/residual limb pain,postsurgical,≥2 on 0-10nrs,parallel,itt unspecified method,ces-d,baseline,NA,16.4,12.4,2.844755099994966,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2454,mood,robinson 2004,trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study,pain,amitriptyline,antidepressant,antidepressant,amitriptyline ≤125mg,tca,10-125mg,unable to be categorised,flexible,6 weeks,phantom/residual limb pain,phantom/residual limb pain,postsurgical,≥2 on 0-10nrs,parallel,itt unspecified method,ces-d,baseline,NA,16.2,11.9,2.6609208932247497,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2455,mood,robinson 2004,trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study,pain,benzotropine mesylate,active placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,phantom/residual limb pain,phantom/residual limb pain,postsurgical,≥2 on 0-10nrs,parallel,itt unspecified method,ces-d,post_int,NA,16.1,13.1,3.087699611181258,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
2456,mood,robinson 2004,trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study,pain,amitriptyline,antidepressant,antidepressant,amitriptyline ≤125mg,tca,10-125mg,unable to be categorised,flexible,6 weeks,phantom/residual limb pain,phantom/residual limb pain,postsurgical,≥2 on 0-10nrs,parallel,itt unspecified method,ces-d,post_int,NA,12.9,8.5,1.9500337378997747,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
2457,physical,robinson 2004,trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study,pain,benzotropine mesylate,active placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,phantom/residual limb pain,phantom/residual limb pain,postsurgical,≥2 on 0-10nrs,parallel,itt unspecified method,functional independence measure,baseline,NA,78.3,4.2,0.9635460822563594,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2458,physical,robinson 2004,trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study,pain,amitriptyline,antidepressant,antidepressant,amitriptyline ≤125mg,tca,10-125mg,unable to be categorised,flexible,6 weeks,phantom/residual limb pain,phantom/residual limb pain,postsurgical,≥2 on 0-10nrs,parallel,itt unspecified method,functional independence measure,baseline,NA,78.4,3.8,0.84970583144992,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2459,physical,robinson 2004,trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study,pain,benzotropine mesylate,active placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,phantom/residual limb pain,phantom/residual limb pain,postsurgical,≥2 on 0-10nrs,parallel,itt unspecified method,functional independence measure,post_int,NA,79.1,3.3,0.7778174593052023,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2460,physical,robinson 2004,trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study,pain,amitriptyline,antidepressant,antidepressant,amitriptyline ≤125mg,tca,10-125mg,unable to be categorised,flexible,6 weeks,phantom/residual limb pain,phantom/residual limb pain,postsurgical,≥2 on 0-10nrs,parallel,itt unspecified method,functional independence measure,post_int,NA,74.5,18.8,4.313015796766561,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2461,adverse_dropout,robinson 2004,trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study,pain,benzotropine mesylate,active placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,phantom/residual limb pain,phantom/residual limb pain,postsurgical,≥2 on 0-10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2462,adverse_dropout,robinson 2004,trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study,pain,amitriptyline,antidepressant,antidepressant,amitriptyline ≤125mg,tca,10-125mg,unable to be categorised,flexible,6 weeks,phantom/residual limb pain,phantom/residual limb pain,postsurgical,≥2 on 0-10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,2,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2463,withdrawal,robinson 2004,trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study,pain,benzotropine mesylate,active placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,phantom/residual limb pain,phantom/residual limb pain,postsurgical,≥2 on 0-10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2464,withdrawal,robinson 2004,trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study,pain,amitriptyline,antidepressant,antidepressant,amitriptyline ≤125mg,tca,10-125mg,unable to be categorised,flexible,6 weeks,phantom/residual limb pain,phantom/residual limb pain,postsurgical,≥2 on 0-10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,2,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2465,pain_sub,rowbotham 2004,"venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,80,27,0.34,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2467,pain_sub,rowbotham 2004,"venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 150-225mg,snri,150-225mg,high,flexible,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,82,46,0.56,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2468,adverse,rowbotham 2004,"venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,81,61,0.75,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2469,adverse,rowbotham 2004,"venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 75mg,snri,75mg,low,fixed,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,82,72,0.88,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2470,adverse,rowbotham 2004,"venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 150-225mg,snri,150-225mg,high,flexible,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,82,73,0.89,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2471,serious_adverse,rowbotham 2004,"venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,81,8,0.1,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2472,serious_adverse,rowbotham 2004,"venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 75mg,snri,75mg,low,fixed,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,82,7,0.09,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2473,serious_adverse,rowbotham 2004,"venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 150-225mg,snri,150-225mg,high,flexible,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,82,10,0.12,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2474,adverse_dropout,rowbotham 2004,"venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,81,3,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2475,adverse_dropout,rowbotham 2004,"venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 75mg,snri,75mg,low,fixed,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,82,6,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2476,adverse_dropout,rowbotham 2004,"venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 150-225mg,snri,150-225mg,high,flexible,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,82,8,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2477,withdrawal,rowbotham 2004,"venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,81,12,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2478,withdrawal,rowbotham 2004,"venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 75mg,snri,75mg,low,fixed,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,82,13,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2479,withdrawal,rowbotham 2004,"venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 150-225mg,snri,150-225mg,high,flexible,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,82,18,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2480,withdrawal,rowbotham 2005,"treatment response in antidepressant-naïve postherpetic neuralgia patients: double-blind, randomized trial",pain,desipramine,antidepressant,antidepressant,desipramine 25-150mg,tca,93mg,low,flexible,6 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,2,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2481,withdrawal,rowbotham 2005,"treatment response in antidepressant-naïve postherpetic neuralgia patients: double-blind, randomized trial",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25-150mg,tca,77mg,standard,flexible,6 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,2,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2482,withdrawal,rowbotham 2005,"treatment response in antidepressant-naïve postherpetic neuralgia patients: double-blind, randomized trial",pain,fluoxetine,antidepressant,antidepressant,fluoxetine 10-60mg,ssri,44mg,high,flexible,6 weeks,post-herpetic neuralgia,neuropathic,neuropathic,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,5,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2483,pain_int,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.62,1.23,0.17223445033544518,NA,NA,NA,NA,NA,51,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2484,pain_int,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.61,1.37,0.18146093291791102,NA,NA,NA,NA,NA,57,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2485,pain_int,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 2mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.76,1.51,0.19333568869867293,NA,NA,NA,NA,NA,61,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2486,pain_int,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 4mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.43,1.43,0.19109178796738344,NA,NA,NA,NA,NA,56,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2487,pain_int,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 8mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.23,1.35,0.18203396286507537,NA,NA,NA,NA,NA,55,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2488,pain_int,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-2.1,2.1213203435596424,0.3,NA,NA,NA,NA,NA,50,NA,NA,TRUE,NA,least squares,NA,2021-09-28,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2489,pain_int,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-2.8,2.2045407685048604,0.3,NA,NA,NA,NA,NA,54,NA,NA,TRUE,NA,least squares,NA,2021-09-28,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2490,pain_int,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 2mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-2,1.5491933384829668,0.2,NA,NA,NA,NA,NA,60,NA,NA,TRUE,NA,least squares,NA,2021-09-28,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2491,pain_int,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 4mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-1.6,2.244994432064365,0.3,NA,NA,NA,NA,NA,56,NA,NA,TRUE,NA,least squares,NA,2021-09-28,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2492,pain_int,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 8mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-2.1,2.2045407685048604,0.3,NA,NA,NA,NA,NA,54,NA,NA,TRUE,NA,least squares,NA,2021-09-28,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2493,physical,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sf-36 physical component score,baseline,NA,33.2,6.9,0.9661932579793268,NA,NA,NA,NA,NA,51,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2494,physical,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sf-36 physical component score,baseline,NA,34.3,8.4,1.1224972160321824,NA,NA,NA,NA,NA,56,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2495,physical,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 2mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sf-36 physical component score,baseline,NA,34,8.6,1.1102552259127927,NA,NA,NA,NA,NA,60,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,non_ad_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2496,physical,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 4mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sf-36 physical component score,baseline,NA,35.5,7.7,1.0478372788572483,NA,NA,NA,NA,NA,54,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,non_ad_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2497,physical,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 8mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sf-36 physical component score,baseline,NA,35.2,7.4,0.9978157964455984,NA,NA,NA,NA,NA,55,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,non_ad_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2498,physical,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sf-36 physical component score,change_score,NA,3.8,6.3,0.9,NA,NA,NA,NA,NA,49,NA,NA,TRUE,NA,least squares,NA,2021-09-28,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2499,physical,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sf-36 physical component score,change_score,NA,6.8,5.932958789676531,0.8,NA,NA,NA,NA,NA,55,NA,NA,TRUE,NA,least squares,NA,2021-09-28,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2500,physical,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 2mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sf-36 physical component score,change_score,NA,4.9,6.196773353931867,0.8,NA,NA,NA,NA,NA,60,NA,NA,TRUE,NA,least squares,NA,2021-09-28,NA,non_ad_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2501,physical,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 4mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sf-36 physical component score,change_score,NA,4.7,5.824087911424415,0.8,NA,NA,NA,NA,NA,53,NA,NA,TRUE,NA,least squares,NA,2021-09-28,NA,non_ad_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2502,physical,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 8mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sf-36 physical component score,change_score,NA,5,5.824087911424415,0.8,NA,NA,NA,NA,NA,53,NA,NA,TRUE,NA,least squares,NA,2021-09-28,NA,non_ad_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2503,mood,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sf-36 mental component score,baseline,NA,42.3,11.5,1.6103220966322112,NA,NA,NA,NA,NA,51,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
2504,mood,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sf-36 mental component score,baseline,NA,45.1,10.9,1.456573768422713,NA,NA,NA,NA,NA,56,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
2505,mood,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 2mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sf-36 mental component score,baseline,NA,43.9,12.8,1.6524728943818312,NA,NA,NA,NA,NA,60,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
2506,mood,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 4mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sf-36 mental component score,baseline,NA,43.7,12.3,1.6738179909018385,NA,NA,NA,NA,NA,54,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
2507,mood,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 8mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sf-36 mental component score,baseline,NA,43.8,12.4,1.6720156589088404,NA,NA,NA,NA,NA,55,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
2508,mood,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sf-36 mental component score,change_score,NA,2.8,8.4,1.2,NA,NA,NA,NA,NA,49,NA,NA,TRUE,NA,least squares,NA,2021-09-28,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2509,mood,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sf-36 mental component score,change_score,NA,2.3,8.899438184514795,1.2,NA,NA,NA,NA,NA,55,NA,NA,TRUE,NA,least squares,NA,2021-09-28,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2510,mood,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 2mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sf-36 mental component score,change_score,NA,4.8,8.520563361656318,1.1,NA,NA,NA,NA,NA,60,NA,NA,TRUE,NA,least squares,NA,2021-09-28,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2511,mood,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 4mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sf-36 mental component score,change_score,NA,0.9,8.73613186713662,1.2,NA,NA,NA,NA,NA,53,NA,NA,TRUE,NA,least squares,NA,2021-09-28,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2512,mood,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 8mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sf-36 mental component score,change_score,NA,3.2,8.73613186713662,1.2,NA,NA,NA,NA,NA,53,NA,NA,TRUE,NA,least squares,NA,2021-09-28,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2513,qol,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,eq-5d,post_int,NA,0.66,0.16,0.022404481344448154,NA,NA,NA,NA,NA,51,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
2514,qol,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,eq-5d,post_int,NA,0.67,0.16,0.021380899352993952,NA,NA,NA,NA,NA,56,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
2515,qol,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 2mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,eq-5d,post_int,NA,0.63,0.21,0.027110883423451915,NA,NA,NA,NA,NA,60,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,non_ad_pharm,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
2516,qol,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 4mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,eq-5d,post_int,NA,0.63,0.2,0.02721655269759087,NA,NA,NA,NA,NA,54,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,non_ad_pharm,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
2517,qol,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 8mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,eq-5d,post_int,NA,0.67,0.2,0.026967994498529685,NA,NA,NA,NA,NA,55,NA,NA,FALSE,NA,NA,NA,2021-09-28,NA,non_ad_pharm,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
2518,qol,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,eq-5d,change_score,NA,0.07,0.14,0.02,NA,NA,NA,NA,NA,49,NA,NA,TRUE,NA,least squares,NA,2021-09-28,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
2519,qol,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,eq-5d,change_score,NA,0.07,0.14832396974191325,0.02,NA,NA,NA,NA,NA,55,NA,NA,TRUE,NA,least squares,NA,2021-09-28,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
2520,qol,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 2mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,eq-5d,change_score,NA,0.07,0.15491933384829668,0.02,NA,NA,NA,NA,NA,60,NA,NA,TRUE,NA,least squares,NA,2021-09-28,NA,non_ad_pharm,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
2521,qol,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 4mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,eq-5d,change_score,NA,0.07,0.14560219778561037,0.02,NA,NA,NA,NA,NA,53,NA,NA,TRUE,NA,least squares,NA,2021-09-28,NA,non_ad_pharm,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
2522,qol,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 8mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,eq-5d,change_score,NA,0.07,0.14560219778561037,0.02,NA,NA,NA,NA,NA,53,NA,NA,TRUE,NA,least squares,NA,2021-09-28,NA,non_ad_pharm,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
2523,adverse,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,32,0.627,FALSE,in ≥5% of participants,NA,NA,2021-09-28,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2524,adverse,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,57,42,0.737,FALSE,in ≥5% of participants,NA,NA,2021-09-28,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2525,adverse,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 2mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,61,41,0.672,FALSE,in ≥5% of participants,NA,NA,2021-09-28,NA,non_ad_pharm,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2526,adverse,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 4mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,56,35,0.625,FALSE,in ≥5% of participants,NA,NA,2021-09-28,NA,non_ad_pharm,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2527,adverse,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 8mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,55,32,0.5820000000000001,FALSE,in ≥5% of participants,NA,NA,2021-09-28,NA,non_ad_pharm,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2528,adverse_dropout,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2529,adverse_dropout,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2530,adverse_dropout,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 2mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2531,adverse_dropout,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 4mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2532,adverse_dropout,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 8mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2533,withdrawal,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,7,0.13699999999999998,FALSE,NA,NA,NA,2021-09-28,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2534,withdrawal,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,57,13,0.228,FALSE,NA,NA,NA,2021-09-28,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2535,withdrawal,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 2mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,61,8,0.131,FALSE,NA,NA,NA,2021-09-28,NA,non_ad_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2536,withdrawal,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 4mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,56,8,0.14300000000000002,FALSE,NA,NA,NA,2021-09-28,NA,non_ad_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2537,withdrawal,rowbotham 2012,efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist abt-894 in patients with diabetic peripheral neuropathic pain,pain,abt-894,nnr agonist,non-antidepressant pharmacological,abt-894 8mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,55,7,0.127,FALSE,NA,NA,NA,2021-09-28,NA,non_ad_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2538,pain_int,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.6,1.7,0.14166666666666666,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2539,pain_int,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg then 60mg,snri,"20mg for 3 months, 60mg for 3 months",standard,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.8,1.6,0.18001406414816384,NA,NA,NA,NA,NA,79,NA,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2540,pain_int,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.5,1.4,0.11430952132988163,NA,NA,NA,NA,NA,150,NA,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2541,pain_int,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.4,1.6,0.13196577581477162,NA,NA,NA,NA,NA,147,NA,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2542,pain_int,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-1.43,2.52,0.21,NA,NA,NA,NA,NA,144,NA,NA,TRUE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2543,pain_int,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg then 60mg,snri,"20mg for 3 months, 60mg for 3 months",standard,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-2.22,2.4886944368483652,0.28,NA,NA,NA,NA,NA,79,NA,NA,TRUE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2544,pain_int,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-1.98,2.571964229922337,0.21,NA,NA,NA,NA,NA,150,NA,NA,TRUE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2545,pain_int,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-2.26,2.5461146871262494,0.21,NA,NA,NA,NA,NA,147,NA,NA,TRUE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2546,qol,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,fibromyalgia impact questionnaire total score,baseline,NA,53,11.2,0.9333333333333332,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
2547,qol,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg then 60mg,snri,"20mg for 3 months, 60mg for 3 months",standard,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,fibromyalgia impact questionnaire total score,baseline,NA,54,11.4,1.2826002070556672,NA,NA,NA,NA,NA,79,NA,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
2548,qol,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,fibromyalgia impact questionnaire total score,baseline,NA,51.7,11.8,0.9634659654947167,NA,NA,NA,NA,NA,150,NA,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
2549,qol,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,fibromyalgia impact questionnaire total score,baseline,NA,51.7,14.1,1.1629483993676748,NA,NA,NA,NA,NA,147,NA,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
2550,qol,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,fibromyalgia impact questionnaire total score,change_score,NA,-10.42,1.46,0.12166666666666666,NA,NA,NA,NA,NA,144,NA,NA,TRUE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
2551,qol,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg then 60mg,snri,"20mg for 3 months, 60mg for 3 months",standard,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,fibromyalgia impact questionnaire total score,change_score,NA,-14.77,1.88,0.2115165253740925,NA,NA,NA,NA,NA,79,NA,NA,TRUE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
2552,qol,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,fibromyalgia impact questionnaire total score,change_score,NA,-12.28,1.44,0.11757550765359255,NA,NA,NA,NA,NA,150,NA,NA,TRUE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
2553,qol,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,fibromyalgia impact questionnaire total score,change_score,NA,-13.86,1.41,0.11629483993676747,NA,NA,NA,NA,NA,147,NA,NA,TRUE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
2554,physical,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sheehan disability scale,baseline,NA,16.76,6.69,0.5575,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2555,physical,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg then 60mg,snri,"20mg for 3 months, 60mg for 3 months",standard,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sheehan disability scale,baseline,NA,18.53,7.09,0.797687321756551,NA,NA,NA,NA,NA,79,NA,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2556,physical,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sheehan disability scale,baseline,NA,17.31,6.82,0.5568506681927092,NA,NA,NA,NA,NA,150,NA,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2557,physical,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sheehan disability scale,baseline,NA,16.48,7.9,0.6515810180854348,NA,NA,NA,NA,NA,147,NA,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2558,physical,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sheehan disability scale,change_score,NA,-4.85,8.16,0.68,NA,NA,NA,NA,NA,144,NA,NA,TRUE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2559,physical,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg then 60mg,snri,"20mg for 3 months, 60mg for 3 months",standard,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sheehan disability scale,change_score,NA,-5.63,7.6438471988914065,0.86,NA,NA,NA,NA,NA,79,NA,NA,TRUE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2560,physical,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sheehan disability scale,change_score,NA,-5.38,8.083316151184487,0.66,NA,NA,NA,NA,NA,150,NA,NA,TRUE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2561,physical,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sheehan disability scale,change_score,NA,-5.23,7.880831174438391,0.65,NA,NA,NA,NA,NA,147,NA,NA,TRUE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2562,mood,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sf-36 mental component score,change_score,NA,1.75,12,1,NA,NA,NA,NA,NA,144,NA,NA,TRUE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2563,mood,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg then 60mg,snri,"20mg for 3 months, 60mg for 3 months",standard,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sf-36 mental component score,change_score,NA,2.56,11.376888854163953,1.28,NA,NA,NA,NA,NA,79,NA,NA,TRUE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2564,mood,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sf-36 mental component score,change_score,NA,3.68,11.880025252498413,0.97,NA,NA,NA,NA,NA,150,NA,NA,TRUE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2565,mood,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,sf-36 mental component score,change_score,NA,4.41,11.760624983392676,0.97,NA,NA,NA,NA,NA,147,NA,NA,TRUE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2566,mood,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,hamilton depression rating scale,baseline,NA,10.6,5.8,0.48333333333333334,NA,NA,NA,NA,NA,144,NA,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2567,mood,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg then 60mg,snri,"20mg for 3 months, 60mg for 3 months",standard,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,hamilton depression rating scale,baseline,NA,10.6,5.8,0.6525509825370939,NA,NA,NA,NA,NA,79,NA,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2568,mood,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,hamilton depression rating scale,baseline,NA,9.9,6.1,0.4980629143659129,NA,NA,NA,NA,NA,150,NA,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2569,mood,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,hamilton depression rating scale,baseline,NA,9.9,6.1,0.5031195202938167,NA,NA,NA,NA,NA,147,NA,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2570,pain_mod,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,144,37,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
2571,pain_mod,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg then 60mg,snri,"20mg for 3 months, 60mg for 3 months",standard,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,79,51,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
2572,pain_mod,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,150,47,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
2573,pain_mod,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,147,29,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
2574,pain_sub,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,144,21,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2575,pain_sub,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg then 60mg,snri,"20mg for 3 months, 60mg for 3 months",standard,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,79,36,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2576,pain_sub,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,150,32,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2577,pain_sub,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,147,35,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2578,adverse,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,144,118,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2579,adverse,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg then 60mg,snri,"20mg for 3 months, 60mg for 3 months",standard,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,79,68,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2580,adverse,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,150,128,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2581,adverse,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,147,132,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2582,adverse_dropout,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,144,19,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2583,adverse_dropout,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg then 60mg,snri,"20mg for 3 months, 60mg for 3 months",standard,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,79,9,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2584,adverse_dropout,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,150,23,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2585,adverse_dropout,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,147,39,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2586,withdrawal,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,144,72,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2587,withdrawal,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg then 60mg,snri,"20mg for 3 months, 60mg for 3 months",standard,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,79,35,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2588,withdrawal,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,150,68,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2589,withdrawal,russell 2008,"efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,28 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,147,68,NA,FALSE,NA,NA,study reports results for depressed/non depressed --> come back later to extract,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2590,NA,sarzi-puttini 1988,a comparison of dothiepin versus placebo in the treatment of pain in rheumatoid arthritis and the association of pain with depression,mood and pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,≥50 on 100vas,parallel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,placebo,NA,NA,NA,NA,NA,no_useable_data,NA
2591,NA,sarzi-puttini 1988,a comparison of dothiepin versus placebo in the treatment of pain in rheumatoid arthritis and the association of pain with depression,mood and pain,dothiepin,antidepressant,antidepressant,dothiepin 75mg,tca,75mg,standard,fixed,4 weeks,rheumatoid arthritis,musculoskeletal,musculoskeletal,≥50 on 100vas,parallel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,ad,NA,NA,NA,NA,NA,no_useable_data,NA
2592,pain_int,schukro 2016,"efficacy of duloxetine in chronic low back pain with a neuropathic component: a randomized, double-blind, placebo-controlled crossover trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,low back pain,musculoskeletal,primary,≥5 on 10nrs,crossover,completer analysis,0-10 numerical rating scale,baseline,NA,6.8,1.5,0.2342606428329091,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2593,pain_int,schukro 2016,"efficacy of duloxetine in chronic low back pain with a neuropathic component: a randomized, double-blind, placebo-controlled crossover trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,4 weeks,low back pain,musculoskeletal,primary,≥5 on 10nrs,crossover,completer analysis,0-10 numerical rating scale,baseline,NA,6.8,1.5,0.2342606428329091,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2594,pain_int,schukro 2016,"efficacy of duloxetine in chronic low back pain with a neuropathic component: a randomized, double-blind, placebo-controlled crossover trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,low back pain,musculoskeletal,primary,≥5 on 10nrs,crossover,completer analysis,0-10 numerical rating scale,post_int,NA,6,2.7,0.54,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2595,pain_int,schukro 2016,"efficacy of duloxetine in chronic low back pain with a neuropathic component: a randomized, double-blind, placebo-controlled crossover trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,4 weeks,low back pain,musculoskeletal,primary,≥5 on 10nrs,crossover,completer analysis,0-10 numerical rating scale,post_int,NA,4.1,2.9,0.58,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2596,physical,schukro 2016,"efficacy of duloxetine in chronic low back pain with a neuropathic component: a randomized, double-blind, placebo-controlled crossover trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,low back pain,musculoskeletal,primary,≥5 on 10nrs,crossover,completer analysis,sf-36 physical component score,baseline,NA,28.4,8.7,1.3587117284308727,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2597,physical,schukro 2016,"efficacy of duloxetine in chronic low back pain with a neuropathic component: a randomized, double-blind, placebo-controlled crossover trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,4 weeks,low back pain,musculoskeletal,primary,≥5 on 10nrs,crossover,completer analysis,sf-36 physical component score,baseline,NA,28.4,8.7,1.3587117284308727,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2598,physical,schukro 2016,"efficacy of duloxetine in chronic low back pain with a neuropathic component: a randomized, double-blind, placebo-controlled crossover trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,low back pain,musculoskeletal,primary,≥5 on 10nrs,crossover,completer analysis,sf-36 physical component score,post_int,NA,31.3,9.3,2.0294263791947293,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2599,physical,schukro 2016,"efficacy of duloxetine in chronic low back pain with a neuropathic component: a randomized, double-blind, placebo-controlled crossover trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,4 weeks,low back pain,musculoskeletal,primary,≥5 on 10nrs,crossover,completer analysis,sf-36 physical component score,post_int,NA,36,10.9,2.378575003572317,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2600,mood,schukro 2016,"efficacy of duloxetine in chronic low back pain with a neuropathic component: a randomized, double-blind, placebo-controlled crossover trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,low back pain,musculoskeletal,primary,≥5 on 10nrs,crossover,completer analysis,sf-36 mental component score,baseline,NA,48.9,11.4,1.7803808855301093,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
2601,mood,schukro 2016,"efficacy of duloxetine in chronic low back pain with a neuropathic component: a randomized, double-blind, placebo-controlled crossover trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,4 weeks,low back pain,musculoskeletal,primary,≥5 on 10nrs,crossover,completer analysis,sf-36 mental component score,baseline,NA,48.9,11.4,1.7803808855301093,NA,NA,NA,NA,NA,41,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
2602,mood,schukro 2016,"efficacy of duloxetine in chronic low back pain with a neuropathic component: a randomized, double-blind, placebo-controlled crossover trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,low back pain,musculoskeletal,primary,≥5 on 10nrs,crossover,completer analysis,sf-36 mental component score,post_int,NA,46.5,12.5,2.727723627949905,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2603,mood,schukro 2016,"efficacy of duloxetine in chronic low back pain with a neuropathic component: a randomized, double-blind, placebo-controlled crossover trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,4 weeks,low back pain,musculoskeletal,primary,≥5 on 10nrs,crossover,completer analysis,sf-36 mental component score,post_int,NA,50,11.6,2.5313275267375115,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2604,pain_sub,schukro 2016,"efficacy of duloxetine in chronic low back pain with a neuropathic component: a randomized, double-blind, placebo-controlled crossover trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,low back pain,musculoskeletal,primary,≥5 on 10nrs,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,2,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2605,pain_sub,schukro 2016,"efficacy of duloxetine in chronic low back pain with a neuropathic component: a randomized, double-blind, placebo-controlled crossover trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,4 weeks,low back pain,musculoskeletal,primary,≥5 on 10nrs,crossover,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,10,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2606,adverse,schukro 2016,"efficacy of duloxetine in chronic low back pain with a neuropathic component: a randomized, double-blind, placebo-controlled crossover trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,low back pain,musculoskeletal,primary,≥5 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,31,18,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2607,adverse,schukro 2016,"efficacy of duloxetine in chronic low back pain with a neuropathic component: a randomized, double-blind, placebo-controlled crossover trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,4 weeks,low back pain,musculoskeletal,primary,≥5 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,29,20,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2608,withdrawal,schukro 2016,"efficacy of duloxetine in chronic low back pain with a neuropathic component: a randomized, double-blind, placebo-controlled crossover trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,low back pain,musculoskeletal,primary,≥5 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,6,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2609,withdrawal,schukro 2016,"efficacy of duloxetine in chronic low back pain with a neuropathic component: a randomized, double-blind, placebo-controlled crossover trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,4 weeks,low back pain,musculoskeletal,primary,≥5 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,6,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2610,withdrawal,scudds 1989,improvements in pain responsiveness in patients with fibrositis after successful treatment with amitriptyline,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,fibromyalgia,fibromyalgia,primary,no,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,39,2,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2611,withdrawal,scudds 1989,improvements in pain responsiveness in patients with fibrositis after successful treatment with amitriptyline,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 50mg,tca,50mg,standard,fixed,4 weeks,fibromyalgia,fibromyalgia,primary,no,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,39,1,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2612,adverse_dropout,scudds 1989,improvements in pain responsiveness in patients with fibrositis after successful treatment with amitriptyline,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,fibromyalgia,fibromyalgia,primary,no,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,39,1,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2613,adverse_dropout,scudds 1989,improvements in pain responsiveness in patients with fibrositis after successful treatment with amitriptyline,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 50mg,tca,50mg,standard,fixed,4 weeks,fibromyalgia,fibromyalgia,primary,no,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,39,1,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2614,pain_int,sencan 2004,a study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,pain,aerobic exercise,exercise,non-pharmacological,aerobic exercise,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,0-10 numerical rating scale,baseline,NA,6.85,1.23,0.2750363612324741,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2615,pain_int,sencan 2004,a study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,pain,paroxetine,antidepressant,antidepressant,paroxetine 20mg,ssri,20mg,low,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,0-10 numerical rating scale,baseline,NA,6.62,1.42,0.3175216528049701,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2616,pain_int,sencan 2004,a study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,pain,tens,tens,non-pharmacological,tens,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,0-10 numerical rating scale,baseline,NA,7.7,1.72,0.3846036921299638,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2617,pain_int,sencan 2004,a study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,pain,aerobic exercise,exercise,non-pharmacological,aerobic exercise,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,0-10 numerical rating scale,post_int,NA,4.05,0.91,0.20348218595248085,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2618,pain_int,sencan 2004,a study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,pain,paroxetine,antidepressant,antidepressant,paroxetine 20mg,ssri,20mg,low,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,0-10 numerical rating scale,post_int,NA,3.55,1.35,0.3018691769624716,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2619,pain_int,sencan 2004,a study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,pain,tens,tens,non-pharmacological,tens,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,0-10 numerical rating scale,post_int,NA,6.2,1.81,0.40472830392746195,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2620,pain_int,sencan 2004,a study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,pain,aerobic exercise,exercise,non-pharmacological,aerobic exercise,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,0-10 numerical rating scale,follow_up,6 months,4.75,1.21,0.3233861027140335,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,follow_up
2621,pain_int,sencan 2004,a study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,pain,paroxetine,antidepressant,antidepressant,paroxetine 20mg,ssri,20mg,low,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,0-10 numerical rating scale,follow_up,6 months,5.01,1.91,0.45019131735543527,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,follow_up
2622,pain_int,sencan 2004,a study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,pain,tens,tens,non-pharmacological,tens,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,0-10 numerical rating scale,follow_up,6 months,5.84,2.11,0.4718103432524556,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,follow_up
2623,mood,sencan 2004,a study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,pain,aerobic exercise,exercise,non-pharmacological,aerobic exercise,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,beck depression inventory,baseline,NA,16.2,4.88,1.0912011730198974,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2624,mood,sencan 2004,a study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,pain,paroxetine,antidepressant,antidepressant,paroxetine 20mg,ssri,20mg,low,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,beck depression inventory,baseline,NA,20.8,5.25,1.1739356881873895,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2625,mood,sencan 2004,a study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,pain,tens,tens,non-pharmacological,tens,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,beck depression inventory,baseline,NA,18.5,5.31,1.1873520960523882,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2626,mood,sencan 2004,a study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,pain,aerobic exercise,exercise,non-pharmacological,aerobic exercise,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,beck depression inventory,post_int,NA,9.15,2.92,0.6529318494299385,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
2627,mood,sencan 2004,a study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,pain,paroxetine,antidepressant,antidepressant,paroxetine 20mg,ssri,20mg,low,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,beck depression inventory,post_int,NA,9.9,2.11,0.4718103432524556,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
2628,mood,sencan 2004,a study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,pain,tens,tens,non-pharmacological,tens,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,beck depression inventory,post_int,NA,15.4,3.6,0.8049844718999243,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
2629,mood,sencan 2004,a study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,pain,aerobic exercise,exercise,non-pharmacological,aerobic exercise,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,beck depression inventory,follow_up,6 months,9.95,2.81,0.7510040897739125,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,follow_up
2630,mood,sencan 2004,a study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,pain,paroxetine,antidepressant,antidepressant,paroxetine 20mg,ssri,20mg,low,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,beck depression inventory,follow_up,6 months,10.12,2.64,0.622253967444162,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,follow_up
2631,mood,sencan 2004,a study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,pain,tens,tens,non-pharmacological,tens,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,beck depression inventory,follow_up,6 months,15.15,3.21,0.7177778207774325,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,follow_up
2632,withdrawal,sencan 2004,a study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,pain,aerobic exercise,exercise,non-pharmacological,aerobic exercise,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,count,follow_up,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,6,NA,FALSE,NA,NA,"withdrawal is baseline->follow-up, no-one withdrew at post-intervention",NA,NA,non_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,follow_up
2633,withdrawal,sencan 2004,a study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,pain,paroxetine,antidepressant,antidepressant,paroxetine 20mg,ssri,20mg,low,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,count,follow_up,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,2,NA,FALSE,NA,NA,"withdrawal is baseline->follow-up, no-one withdrew at post-intervention",NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,follow_up
2634,withdrawal,sencan 2004,a study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome,pain,tens,tens,non-pharmacological,tens,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,not reported,count,follow_up,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,0,NA,FALSE,NA,NA,"withdrawal is baseline->follow-up, no-one withdrew at post-intervention",NA,NA,non_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,follow_up
2635,mood,shakiba 2018,saffron (crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: a randomized double-blind clinical trial,depression and pain,saffron/crocin,plant extract,non-pharmacological,saffron 15mg,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,hamilton depression rating scale,baseline,NA,14.83,4.86,1.0133800523173835,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2636,mood,shakiba 2018,saffron (crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: a randomized double-blind clinical trial,depression and pain,duloxetine,antidepressant,antidepressant,duloxetine 30mg,snri,30mg,low,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,hamilton depression rating scale,baseline,NA,14.74,4.69,0.9779326019276808,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2637,mood,shakiba 2018,saffron (crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: a randomized double-blind clinical trial,depression and pain,saffron/crocin,plant extract,non-pharmacological,saffron 15mg,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,hamilton depression rating scale,post_int,NA,8.96,3.48,0.7256301609186202,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
2638,mood,shakiba 2018,saffron (crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: a randomized double-blind clinical trial,depression and pain,duloxetine,antidepressant,antidepressant,duloxetine 30mg,snri,30mg,low,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,hamilton depression rating scale,post_int,NA,8.71,3.95,0.8236319355254454,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
2639,qol,shakiba 2018,saffron (crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: a randomized double-blind clinical trial,depression and pain,saffron/crocin,plant extract,non-pharmacological,saffron 15mg,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,fibromyalgia impact questionnaire total score,baseline,NA,52.65,13.34,2.7815822835213777,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
2640,qol,shakiba 2018,saffron (crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: a randomized double-blind clinical trial,depression and pain,duloxetine,antidepressant,antidepressant,duloxetine 30mg,snri,30mg,low,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,fibromyalgia impact questionnaire total score,baseline,NA,54.25,11.87,2.4750660948574774,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
2641,qol,shakiba 2018,saffron (crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: a randomized double-blind clinical trial,depression and pain,saffron/crocin,plant extract,non-pharmacological,saffron 15mg,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,fibromyalgia impact questionnaire total score,post_int,NA,42.13,10.75,2.241529951113554,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
2642,qol,shakiba 2018,saffron (crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: a randomized double-blind clinical trial,depression and pain,duloxetine,antidepressant,antidepressant,duloxetine 30mg,snri,30mg,low,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,fibromyalgia impact questionnaire total score,post_int,NA,41.35,10.48,2.1852310593181437,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
2643,pain_int,shakiba 2018,saffron (crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: a randomized double-blind clinical trial,depression and pain,saffron/crocin,plant extract,non-pharmacological,saffron 15mg,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-100 vas,baseline,NA,60.43,15.51,3.23405856202523,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2644,pain_int,shakiba 2018,saffron (crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: a randomized double-blind clinical trial,depression and pain,duloxetine,antidepressant,antidepressant,duloxetine 30mg,snri,30mg,low,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-100 vas,baseline,NA,58.13,24.39,5.085666558852054,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2645,pain_int,shakiba 2018,saffron (crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: a randomized double-blind clinical trial,depression and pain,saffron/crocin,plant extract,non-pharmacological,saffron 15mg,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-100 vas,post_int,NA,38.48,16.2,3.3779335077246113,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2646,pain_int,shakiba 2018,saffron (crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: a randomized double-blind clinical trial,depression and pain,duloxetine,antidepressant,antidepressant,duloxetine 30mg,snri,30mg,low,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,0-100 vas,post_int,NA,40.43,12.61,2.6293667612597127,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2651,withdrawal,shakiba 2018,saffron (crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: a randomized double-blind clinical trial,depression and pain,saffron/crocin,plant extract,non-pharmacological,saffron 15mg,n/a,n/a,n/a,n/a,8 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,27,4,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2652,withdrawal,shakiba 2018,saffron (crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: a randomized double-blind clinical trial,depression and pain,duloxetine,antidepressant,antidepressant,duloxetine 30mg,snri,30mg,low,fixed,8 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,27,4,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2653,pain_int,shinichi 2016,"randomized, double-blind, placebo-controlled phase iii trial of duloxetine monotherapy in japanese patients with chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,mmrm,0-10 numerical rating scale,baseline,NA,5.09,1.04,0.0691797709447249,NA,NA,NA,NA,NA,226,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2654,pain_int,shinichi 2016,"randomized, double-blind, placebo-controlled phase iii trial of duloxetine monotherapy in japanese patients with chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,mmrm,0-10 numerical rating scale,baseline,NA,5.14,1.11,0.07319123254693237,NA,NA,NA,NA,NA,230,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2655,pain_int,shinichi 2016,"randomized, double-blind, placebo-controlled phase iii trial of duloxetine monotherapy in japanese patients with chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,mmrm,0-10 numerical rating scale,change_score,NA,-1.96,1.5556349186104046,0.11,NA,NA,NA,NA,NA,200,NA,NA,TRUE,NA,least squares,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2656,pain_int,shinichi 2016,"randomized, double-blind, placebo-controlled phase iii trial of duloxetine monotherapy in japanese patients with chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,mmrm,0-10 numerical rating scale,change_score,NA,-2.43,1.5902515524281058,0.11,NA,NA,NA,NA,NA,209,NA,NA,TRUE,NA,least squares,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2657,sleep,shinichi 2016,"randomized, double-blind, placebo-controlled phase iii trial of duloxetine monotherapy in japanese patients with chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,mmrm,bpi sleep,baseline,NA,2.65,2.42,0.1609760054675329,NA,NA,NA,NA,NA,226,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
2658,sleep,shinichi 2016,"randomized, double-blind, placebo-controlled phase iii trial of duloxetine monotherapy in japanese patients with chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,mmrm,bpi sleep,baseline,NA,2.63,2.33,0.15363565030121837,NA,NA,NA,NA,NA,230,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
2659,sleep,shinichi 2016,"randomized, double-blind, placebo-controlled phase iii trial of duloxetine monotherapy in japanese patients with chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,mmrm,bpi sleep,change_score,NA,-1.4,1.5556349186104046,0.11,NA,NA,NA,NA,NA,200,NA,NA,TRUE,NA,least squares,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
2660,sleep,shinichi 2016,"randomized, double-blind, placebo-controlled phase iii trial of duloxetine monotherapy in japanese patients with chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,mmrm,bpi sleep,change_score,NA,-1.41,1.5902515524281058,0.11,NA,NA,NA,NA,NA,209,NA,NA,TRUE,NA,least squares,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
2661,qol,shinichi 2016,"randomized, double-blind, placebo-controlled phase iii trial of duloxetine monotherapy in japanese patients with chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,locf,eq-5d,baseline,NA,0.69,0.1,0.006651901052377393,NA,NA,NA,NA,NA,226,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
2662,qol,shinichi 2016,"randomized, double-blind, placebo-controlled phase iii trial of duloxetine monotherapy in japanese patients with chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,locf,eq-5d,baseline,NA,0.69,0.11,0.007253185207353657,NA,NA,NA,NA,NA,230,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
2663,qol,shinichi 2016,"randomized, double-blind, placebo-controlled phase iii trial of duloxetine monotherapy in japanese patients with chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,locf,eq-5d,change_score,NA,0.08,0.1503329637837291,0.01,NA,NA,NA,NA,NA,226,NA,NA,TRUE,NA,least squares,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
2664,qol,shinichi 2016,"randomized, double-blind, placebo-controlled phase iii trial of duloxetine monotherapy in japanese patients with chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,locf,eq-5d,change_score,NA,0.09,0.15165750888103102,0.01,NA,NA,NA,NA,NA,230,NA,NA,TRUE,NA,least squares,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
2665,physical,shinichi 2016,"randomized, double-blind, placebo-controlled phase iii trial of duloxetine monotherapy in japanese patients with chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,locf,rmdq-24,baseline,NA,7.77,4.77,0.3172956801984016,NA,NA,NA,NA,NA,226,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2666,physical,shinichi 2016,"randomized, double-blind, placebo-controlled phase iii trial of duloxetine monotherapy in japanese patients with chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,locf,rmdq-24,baseline,NA,7.59,4.38,0.2888086473473547,NA,NA,NA,NA,NA,230,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2667,physical,shinichi 2016,"randomized, double-blind, placebo-controlled phase iii trial of duloxetine monotherapy in japanese patients with chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,locf,rmdq-24,change_score,NA,-3.23,3.3073252032420397,0.22,NA,NA,NA,NA,NA,226,NA,NA,TRUE,NA,least squares,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2668,physical,shinichi 2016,"randomized, double-blind, placebo-controlled phase iii trial of duloxetine monotherapy in japanese patients with chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,locf,rmdq-24,change_score,NA,-3.86,3.3364651953826825,0.22,NA,NA,NA,NA,NA,230,NA,NA,TRUE,NA,least squares,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2669,mood,shinichi 2016,"randomized, double-blind, placebo-controlled phase iii trial of duloxetine monotherapy in japanese patients with chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,mmrm,bpi mood,baseline,NA,3.31,2.27,0.1509981538889668,NA,NA,NA,NA,NA,226,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
2670,mood,shinichi 2016,"randomized, double-blind, placebo-controlled phase iii trial of duloxetine monotherapy in japanese patients with chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,mmrm,bpi mood,baseline,NA,3.43,2.39,0.1575919331415931,NA,NA,NA,NA,NA,230,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
2671,mood,shinichi 2016,"randomized, double-blind, placebo-controlled phase iii trial of duloxetine monotherapy in japanese patients with chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,mmrm,bpi mood,change_score,NA,-1.83,1.5556349186104046,0.11,NA,NA,NA,NA,NA,200,NA,NA,TRUE,NA,least squares,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2672,mood,shinichi 2016,"randomized, double-blind, placebo-controlled phase iii trial of duloxetine monotherapy in japanese patients with chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,mmrm,bpi mood,change_score,NA,-2.15,1.5902515524281058,0.11,NA,NA,NA,NA,NA,209,NA,NA,TRUE,NA,least squares,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2673,pain_mod,shinichi 2016,"randomized, double-blind, placebo-controlled phase iii trial of duloxetine monotherapy in japanese patients with chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,mmrm,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,226,118,0.522,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
2674,pain_mod,shinichi 2016,"randomized, double-blind, placebo-controlled phase iii trial of duloxetine monotherapy in japanese patients with chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,mmrm,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,232,159,0.687,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
2675,pain_sub,shinichi 2016,"randomized, double-blind, placebo-controlled phase iii trial of duloxetine monotherapy in japanese patients with chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,mmrm,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,226,89,0.39399999999999996,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2676,pain_sub,shinichi 2016,"randomized, double-blind, placebo-controlled phase iii trial of duloxetine monotherapy in japanese patients with chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,mmrm,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,232,131,0.565,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2677,adverse,shinichi 2016,"randomized, double-blind, placebo-controlled phase iii trial of duloxetine monotherapy in japanese patients with chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,221,132,0.598,FALSE,5% of participants,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2678,adverse,shinichi 2016,"randomized, double-blind, placebo-controlled phase iii trial of duloxetine monotherapy in japanese patients with chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,234,167,0.7140000000000001,FALSE,5% of participants,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2679,serious_adverse,shinichi 2016,"randomized, double-blind, placebo-controlled phase iii trial of duloxetine monotherapy in japanese patients with chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,222,4,0.018000000000000002,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2680,serious_adverse,shinichi 2016,"randomized, double-blind, placebo-controlled phase iii trial of duloxetine monotherapy in japanese patients with chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,222,4,0.018000000000000002,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2681,adverse_dropout,shinichi 2016,"randomized, double-blind, placebo-controlled phase iii trial of duloxetine monotherapy in japanese patients with chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,226,8,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2682,adverse_dropout,shinichi 2016,"randomized, double-blind, placebo-controlled phase iii trial of duloxetine monotherapy in japanese patients with chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,232,16,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2683,withdrawal,shinichi 2016,"randomized, double-blind, placebo-controlled phase iii trial of duloxetine monotherapy in japanese patients with chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,226,26,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2684,withdrawal,shinichi 2016,"randomized, double-blind, placebo-controlled phase iii trial of duloxetine monotherapy in japanese patients with chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,232,23,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2685,adverse_dropout,sindrup 2003,"venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial.",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,2,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2686,adverse_dropout,sindrup 2003,"venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial.",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 250mg,snri,250mg,high,fixed,4 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,4,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2687,adverse_dropout,sindrup 2003,"venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial.",pain,imipramine,antidepressant,antidepressant,imipramine 150mg,tca,150mg,high,fixed,4 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,1,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2688,adverse,sindrup 2003,"venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial.",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,14,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2689,adverse,sindrup 2003,"venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial.",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 250mg,snri,250mg,high,fixed,4 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,20,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2690,adverse,sindrup 2003,"venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial.",pain,imipramine,antidepressant,antidepressant,imipramine 150mg,tca,150mg,high,fixed,4 weeks,polyneuropathy,neuropathic,neuropathic,≥4 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,40,20,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2691,pain_int,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.1,1.7,0.15716505559714825,NA,NA,NA,NA,NA,117,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2692,pain_int,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg,snri,20mg,low,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.3,1.6,0.20830225756931822,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2693,pain_int,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,5.9,1.7,0.15784103745049408,NA,NA,NA,NA,NA,116,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2694,pain_int,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6,1.6,0.15118578920369088,NA,NA,NA,NA,NA,112,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2695,pain_int,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-1.87,2.338632078801623,0.22,NA,NA,NA,NA,NA,113,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2696,pain_int,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg,snri,20mg,low,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-1.79,2.244994432064365,0.3,NA,NA,NA,NA,NA,56,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2697,pain_int,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-2.5,2.286307065990918,0.22,NA,NA,NA,NA,NA,108,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2698,pain_int,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-2.45,2.286307065990918,0.22,NA,NA,NA,NA,NA,108,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2703,sleep,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,bpi sleep,change_score,NA,-1.63,2.4449335369289695,0.23,NA,NA,NA,NA,NA,113,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
2704,sleep,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg,snri,20mg,low,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,bpi sleep,change_score,NA,-1.59,2.3946607275353227,0.32,NA,NA,NA,NA,NA,56,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
2705,sleep,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,bpi sleep,change_score,NA,-2.48,2.4825793038692643,0.24,NA,NA,NA,NA,NA,107,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
2706,sleep,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,bpi sleep,change_score,NA,-2.12,2.4941531628991833,0.24,NA,NA,NA,NA,NA,108,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
2707,physical,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,rmdq-24,baseline,NA,8.32,4.92,0.45485416090468783,NA,NA,NA,NA,NA,117,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2708,physical,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg,snri,20mg,low,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,rmdq-24,baseline,NA,10,4.82,0.6275105509275711,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2709,physical,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,rmdq-24,baseline,NA,8.91,4.56,0.42338537104367824,NA,NA,NA,NA,NA,116,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2710,physical,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,rmdq-24,baseline,NA,8.72,4.82,0.4554471899761188,NA,NA,NA,NA,NA,112,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2711,physical,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,rmdq-24,change_score,NA,-1.33,4.124415110048939,0.43,NA,NA,NA,NA,NA,92,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2712,physical,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg,snri,20mg,low,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,rmdq-24,change_score,NA,-2.29,4.038217428519668,0.56,NA,NA,NA,NA,NA,52,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2713,physical,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,rmdq-24,change_score,NA,-2.74,4.0085907748234915,0.44,NA,NA,NA,NA,NA,83,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2714,physical,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,rmdq-24,change_score,NA,-2.88,4.099695110614935,0.45,NA,NA,NA,NA,NA,83,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2715,qol,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,eq-5d,change_score,NA,0.05,0.1019803902718557,0.01,NA,NA,NA,NA,NA,104,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
2716,qol,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg,snri,20mg,low,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,eq-5d,change_score,NA,0.04,0.14696938456699069,0.02,NA,NA,NA,NA,NA,54,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
2717,qol,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,eq-5d,change_score,NA,0.07,0.10099504938362078,0.01,NA,NA,NA,NA,NA,102,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
2718,qol,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,eq-5d,change_score,NA,0.08,0.2,0.02,NA,NA,NA,NA,NA,100,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
2719,mood,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,beck depression inventory,baseline,NA,6.15,7.52,0.6952242459356204,NA,NA,NA,NA,NA,117,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2720,mood,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg,snri,20mg,low,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,beck depression inventory,baseline,NA,6.02,6.33,0.8240958065086151,NA,NA,NA,NA,NA,59,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2721,mood,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,beck depression inventory,baseline,NA,7.05,7.17,0.665717787364731,NA,NA,NA,NA,NA,116,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2722,mood,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,beck depression inventory,baseline,NA,5.2,5,0.472455591261534,NA,NA,NA,NA,NA,112,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2723,mood,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,beck depression inventory,change_score,NA,-1.02,5.231768343495342,0.49,NA,NA,NA,NA,NA,114,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
2724,mood,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg,snri,20mg,low,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,beck depression inventory,change_score,NA,-1.24,5.13388741598411,0.68,NA,NA,NA,NA,NA,57,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
2725,mood,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,beck depression inventory,change_score,NA,-1.54,5.220153254455275,0.5,NA,NA,NA,NA,NA,109,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
2726,mood,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,beck depression inventory,change_score,NA,0.37,5.196152422706632,0.5,NA,NA,NA,NA,NA,108,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
2731,pain_mod,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,113,49,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
2732,pain_mod,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg,snri,20mg,low,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,56,23,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
2733,pain_mod,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,110,59,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
2734,pain_mod,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,109,63,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
2735,pain_sub,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,113,33,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2736,pain_sub,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg,snri,20mg,low,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,56,12,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2737,pain_sub,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,110,38,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2738,pain_sub,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,109,40,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2739,adverse,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,117,69,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2740,adverse,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg,snri,20mg,low,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,59,39,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2741,adverse,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,78,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2742,adverse,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,112,80,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2743,serious_adverse,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,117,3,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2744,serious_adverse,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg,snri,20mg,low,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,59,1,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2745,serious_adverse,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,1,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2746,serious_adverse,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,112,3,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2747,adverse_dropout,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,117,10,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2748,adverse_dropout,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg,snri,20mg,low,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,59,9,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2749,adverse_dropout,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,17,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2750,adverse_dropout,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,112,27,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2751,withdrawal,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,117,35,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2752,withdrawal,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 20mg,snri,20mg,low,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,59,16,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2753,withdrawal,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,116,36,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2754,withdrawal,skljarevski 2009,"a double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain",pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,13 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,112,50,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2755,pain_int,skljarevski 2010: 2,"duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,5.75,1.37,0.09615514966907272,NA,NA,NA,NA,NA,203,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2756,pain_int,skljarevski 2010: 2,"duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,5.84,1.43,0.1016256747961743,NA,NA,NA,NA,NA,198,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2757,pain_int,skljarevski 2010: 2,"duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-1.65,2.1160103969498825,0.15,NA,NA,NA,NA,NA,199,NA,NA,TRUE,NA,least squares,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2758,pain_int,skljarevski 2010: 2,"duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-2.25,2.094636006565341,0.15,NA,NA,NA,NA,NA,195,NA,NA,TRUE,NA,least squares,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2759,sleep,skljarevski 2010: 2,"duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,bpi sleep,change_score,NA,-1.45,2.3981451165432004,0.17,NA,NA,NA,NA,NA,199,NA,NA,TRUE,NA,least squares,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
2760,sleep,skljarevski 2010: 2,"duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,bpi sleep,change_score,NA,-2.14,2.37392080744072,0.17,NA,NA,NA,NA,NA,195,NA,NA,TRUE,NA,least squares,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
2761,physical,skljarevski 2010: 2,"duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,rmdq-24,baseline,NA,9.3,4.8,0.3368939550449263,NA,NA,NA,NA,NA,203,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2762,physical,skljarevski 2010: 2,"duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,rmdq-24,baseline,NA,9.6,4.6,0.32690776507860264,NA,NA,NA,NA,NA,198,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2763,physical,skljarevski 2010: 2,"duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,rmdq-24,change_score,NA,-2.22,4.281308211283089,0.32,NA,NA,NA,NA,NA,179,NA,NA,TRUE,NA,least squares,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2764,physical,skljarevski 2010: 2,"duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,rmdq-24,change_score,NA,-2.69,4.135915859879163,0.31,NA,NA,NA,NA,NA,178,NA,NA,TRUE,NA,least squares,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2765,mood,skljarevski 2010: 2,"duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,profile of mood states - brief form,baseline,NA,14.27,17.39,1.2961740709573781,NA,NA,NA,NA,NA,180,NA,NA,FALSE,NA,NA,this doesn't match up with what's extracted as the covidence data was extracted from clinicaltrials.gov but better to go with what's in the paper - i'm on it with claire,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
2766,mood,skljarevski 2010: 2,"duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,profile of mood states - brief form,baseline,NA,13.31,16.67,1.2390713417940264,NA,NA,NA,NA,NA,181,NA,NA,FALSE,NA,NA,this doesn't match up with what's extracted as the covidence data was extracted from clinicaltrials.gov but better to go with what's in the paper - i'm on it with claire,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
2767,mood,skljarevski 2010: 2,"duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,profile of mood states - brief form,change_score,NA,-2.77,12.7455874717488,0.95,NA,NA,NA,NA,NA,180,NA,NA,TRUE,NA,least squares,this doesn't match up with what's extracted as the covidence data was extracted from clinicaltrials.gov but better to go with what's in the paper - i'm on it with claire,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2768,mood,skljarevski 2010: 2,"duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,profile of mood states - brief form,change_score,NA,-6.77,12.51187036377855,0.93,NA,NA,NA,NA,NA,181,NA,NA,TRUE,NA,least squares,this doesn't match up with what's extracted as the covidence data was extracted from clinicaltrials.gov but better to go with what's in the paper - i'm on it with claire,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2769,qol,skljarevski 2010: 2,"duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,eq-5d,baseline,NA,0.69,0.16,0.011547005383792516,NA,NA,NA,NA,NA,192,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
2770,qol,skljarevski 2010: 2,"duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,eq-5d,baseline,NA,0.66,0.17,0.0123330962518702,NA,NA,NA,NA,NA,190,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
2771,qol,skljarevski 2010: 2,"duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,eq-5d,change_score,NA,0.05,0.17,0.012268693220279549,NA,NA,NA,NA,NA,192,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
2772,qol,skljarevski 2010: 2,"duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,eq-5d,change_score,NA,0.12,0.21,0.015235001252310245,NA,NA,NA,NA,NA,190,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
2773,pain_mod,skljarevski 2010: 2,"duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,199,97,0.48700000000000004,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
2774,pain_mod,skljarevski 2010: 2,"duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,11,0.569,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
2775,pain_sub,skljarevski 2010: 2,"duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,199,69,0.34700000000000003,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2776,pain_sub,skljarevski 2010: 2,"duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,195,95,0.48700000000000004,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2777,adverse,skljarevski 2010: 2,"duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,203,112,0.5517,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2778,adverse,skljarevski 2010: 2,"duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,198,123,0.6212,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2779,serious_adverse,skljarevski 2010: 2,"duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2780,serious_adverse,skljarevski 2010: 2,"duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,198,5,0.0253,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2781,adverse_dropout,skljarevski 2010: 2,"duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,203,11,0.054000000000000006,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2782,adverse_dropout,skljarevski 2010: 2,"duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,198,20,0.152,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2783,withdrawal,skljarevski 2010: 2,"duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,203,47,0.23199999999999998,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2784,withdrawal,skljarevski 2010: 2,"duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,198,51,0.258,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2785,pain_int,smith 2013,"effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,5 weeks,chemotherapy induced peripheral neuropathy,neuropathic,cancer-related,≥4 on 10nrs,crossover,unclear,0-10 numerical rating scale,change_score,NA,0.34,1.5829449587944957,0.1632683062158893,NA,0.01,0.66,NA,NA,94,NA,NA,TRUE,NA,no baseline values reported || least squares,first stage of crossover extracted,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2786,pain_int,smith 2013,"effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,5 weeks,chemotherapy induced peripheral neuropathy,neuropathic,cancer-related,≥4 on 10nrs,crossover,unclear,0-10 numerical rating scale,change_score,NA,1.06,1.6180444656458366,0.1734725753543823,NA,0.72,1.4,NA,NA,87,NA,NA,TRUE,NA,no baseline values reported || least squares,first stage of crossover extracted,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2787,qol,smith 2013,"effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,5 weeks,chemotherapy induced peripheral neuropathy,neuropathic,cancer-related,≥4 on 10nrs,crossover,unclear,fact/gog-ntx,change_score,NA,0.87,9.646070842653957,0.9949162410030753,NA,-1.09,2.82,NA,NA,94,NA,NA,TRUE,NA,no baseline values reported || least squares,first stage of crossover extracted,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
2788,qol,smith 2013,"effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,5 weeks,chemotherapy induced peripheral neuropathy,neuropathic,cancer-related,≥4 on 10nrs,crossover,unclear,fact/gog-ntx,change_score,NA,2.44,9.565498164553334,1.0255290484185549,NA,0.43,4.45,NA,NA,87,NA,NA,TRUE,NA,no baseline values reported || least squares,first stage of crossover extracted,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
2789,pain_mod,smith 2013,"effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,5 weeks,chemotherapy induced peripheral neuropathy,neuropathic,cancer-related,≥4 on 10nrs,crossover,unclear,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,94,16,NA,FALSE,NA,NA,first stage of crossover extracted,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
2790,pain_mod,smith 2013,"effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,5 weeks,chemotherapy induced peripheral neuropathy,neuropathic,cancer-related,≥4 on 10nrs,crossover,unclear,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,87,29,NA,FALSE,NA,NA,first stage of crossover extracted,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
2791,pain_sub,smith 2013,"effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,5 weeks,chemotherapy induced peripheral neuropathy,neuropathic,cancer-related,≥4 on 10nrs,crossover,unclear,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,94,8,NA,FALSE,NA,NA,first stage of crossover extracted,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2792,pain_sub,smith 2013,"effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,5 weeks,chemotherapy induced peripheral neuropathy,neuropathic,cancer-related,≥4 on 10nrs,crossover,unclear,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,87,18,NA,FALSE,NA,NA,first stage of crossover extracted,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2793,serious_adverse,smith 2013,"effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,5 weeks,chemotherapy induced peripheral neuropathy,neuropathic,cancer-related,≥4 on 10nrs,crossover,unclear,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,111,0,0,FALSE,NA,NA,first stage of crossover extracted,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2794,serious_adverse,smith 2013,"effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,5 weeks,chemotherapy induced peripheral neuropathy,neuropathic,cancer-related,≥4 on 10nrs,crossover,unclear,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,109,0,0,FALSE,NA,NA,first stage of crossover extracted,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2795,adverse_dropout,smith 2013,"effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,5 weeks,chemotherapy induced peripheral neuropathy,neuropathic,cancer-related,≥4 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,111,1,NA,FALSE,NA,NA,first stage of crossover extracted,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2796,adverse_dropout,smith 2013,"effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,5 weeks,chemotherapy induced peripheral neuropathy,neuropathic,cancer-related,≥4 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,109,12,NA,FALSE,NA,NA,first stage of crossover extracted,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2797,withdrawal,smith 2013,"effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,5 weeks,chemotherapy induced peripheral neuropathy,neuropathic,cancer-related,≥4 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,111,12,NA,FALSE,NA,NA,first stage of crossover extracted,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2798,withdrawal,smith 2013,"effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,5 weeks,chemotherapy induced peripheral neuropathy,neuropathic,cancer-related,≥4 on 10nrs,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,109,21,NA,FALSE,NA,NA,first stage of crossover extracted,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2799,pain_int,sofat 2016,pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: a double-blind randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.4,1.196556619616695,0.255106728462327,NA,5.7,6.9,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2800,pain_int,sofat 2016,pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: a double-blind randomized controlled trial,pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,12 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.1,1.4358679435400354,0.30612807415479276,NA,5.6,6.7,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2801,pain_int,sofat 2016,pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: a double-blind randomized controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.4,1.636664250859621,0.3571494198472575,NA,5.7,7.1,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2802,pain_int,sofat 2016,pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: a double-blind randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,post_int,NA,5.4,3.3503585349267446,0.7142988396945154,NA,4.1,6.8,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2803,pain_int,sofat 2016,pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: a double-blind randomized controlled trial,pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,12 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,post_int,NA,3.4,2.393113239233391,0.5102134569246543,NA,2.4,4.4,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2804,pain_int,sofat 2016,pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: a double-blind randomized controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,post_int,NA,4.3,3.7409468591077104,0.8163415310794468,NA,2.6,5.9,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2805,physical,sofat 2016,pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: a double-blind randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,itt with locf,auscan function score,baseline,NA,582.3,175.17588911188426,37.3476250468847,NA,509.1,655.5,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2806,physical,sofat 2016,pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: a double-blind randomized controlled trial,pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,12 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,itt with locf,auscan function score,baseline,NA,576.2,184.74834206881755,39.38847887458326,NA,499.1,653.4,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2807,physical,sofat 2016,pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: a double-blind randomized controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,itt with locf,auscan function score,baseline,NA,577.2,231.9387052646778,50.61317492692565,NA,478,676.4,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2808,physical,sofat 2016,pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: a double-blind randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,itt with locf,auscan function score,post_int,NA,508.7,309.19023050895396,65.9195786346653,NA,379.5,637.9,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2809,physical,sofat 2016,pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: a double-blind randomized controlled trial,pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,12 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,itt with locf,auscan function score,post_int,NA,362.2,192.6456157582879,41.07218328243465,NA,281.7,442.7,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2810,physical,sofat 2016,pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: a double-blind randomized controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,itt with locf,auscan function score,post_int,NA,496.4,360.2999443678113,78.62389371208921,NA,342.4,650.5,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2817,mood,sofat 2016,pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: a double-blind randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,itt with locf,hads-a,baseline,NA,4.9,3.111047211003407,0.6632774940020503,NA,3.6,6.2,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2818,mood,sofat 2016,pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: a double-blind randomized controlled trial,pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,12 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,itt with locf,hads-a,baseline,NA,5.1,3.8289811827734255,0.8163415310794468,NA,3.6,6.7,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2819,mood,sofat 2016,pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: a double-blind randomized controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,itt with locf,hads-a,baseline,NA,4.4,3.2733285017192437,0.7142988396945154,NA,2.9,5.8,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2820,mood,sofat 2016,pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: a double-blind randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,itt with locf,hads-a,post_int,NA,5.1,2.8717358870800687,0.612256148309585,NA,3.9,6.3,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
2821,mood,sofat 2016,pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: a double-blind randomized controlled trial,pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,12 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,itt with locf,hads-a,post_int,NA,4.1,3.589669858850085,0.7653201853869811,NA,2.6,5.6,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
2822,mood,sofat 2016,pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: a double-blind randomized controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,itt with locf,hads-a,post_int,NA,3.8,4.442374395190405,0.9694055681568429,NA,1.9,5.7,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
2823,adverse_number,sofat 2016,pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: a double-blind randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,NA,FALSE,"number of adverse events (not per person, more than one per person)",NA,NA,NA,NA,placebo,NA,adverse_number,adverse outcomes excluded from nma,NA,NA,adverse_number,post_int
2824,adverse_number,sofat 2016,pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: a double-blind randomized controlled trial,pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,12 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,55,NA,FALSE,"number of adverse events (not per person, more than one per person)",NA,NA,NA,NA,non_ad_pharm,NA,adverse_number,adverse outcomes excluded from nma,NA,NA,adverse_number,post_int
2825,adverse_number,sofat 2016,pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: a double-blind randomized controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,57,NA,FALSE,"number of adverse events (not per person, more than one per person)",NA,NA,NA,NA,ad,NA,adverse_number,adverse outcomes excluded from nma,NA,NA,adverse_number,post_int
2826,adverse_dropout,sofat 2016,pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: a double-blind randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2827,adverse_dropout,sofat 2016,pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: a double-blind randomized controlled trial,pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,12 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2828,adverse_dropout,sofat 2016,pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: a double-blind randomized controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2829,withdrawal,sofat 2016,pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: a double-blind randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,3,0.136,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2830,withdrawal,sofat 2016,pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: a double-blind randomized controlled trial,pain,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,12 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,5,0.22699999999999998,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2831,withdrawal,sofat 2016,pregabalin is more effective in treating hand osteoarthritis pain than duloxetine or placebo: a double-blind randomized controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥5 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,5,0.23800000000000002,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2832,pain_int,spinhoven 2010,heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt with locf,chest pain index,baseline,NA,28.9,15.6,3.2528248592903664,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2833,pain_int,spinhoven 2010,heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,pain,paroxetine,antidepressant,antidepressant,paroxetine 10-40mg,ssri,10-40mg,unable to be categorised,flexible,16 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt with locf,chest pain index,baseline,NA,25.7,18.3,3.8158137772444687,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2834,pain_int,spinhoven 2010,heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,pain,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioural therapy,n/a,n/a,n/a,n/a,16 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt with locf,chest pain index,baseline,NA,27.9,14.2,2.960904679610462,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2835,pain_int,spinhoven 2010,heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt with locf,chest pain index,post_int,NA,23.5,18.5,3.8575166600558837,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2836,pain_int,spinhoven 2010,heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,pain,paroxetine,antidepressant,antidepressant,paroxetine 10-40mg,ssri,10-40mg,unable to be categorised,flexible,16 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt with locf,chest pain index,post_int,NA,20.9,19.4,4.04517963270725,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2837,pain_int,spinhoven 2010,heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,pain,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioural therapy,n/a,n/a,n/a,n/a,16 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt with locf,chest pain index,post_int,NA,11.9,14,2.919201796799047,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2838,mood,spinhoven 2010,heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt with locf,hads-a,baseline,NA,7.3,3.6,0.7506518906054692,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_anxiety,baseline
2839,mood,spinhoven 2010,heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,pain,paroxetine,antidepressant,antidepressant,paroxetine 10-40mg,ssri,10-40mg,unable to be categorised,flexible,16 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt with locf,hads-a,baseline,NA,4.8,2.4,0.5004345937369794,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_anxiety,baseline
2840,mood,spinhoven 2010,heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,pain,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioural therapy,n/a,n/a,n/a,n/a,16 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt with locf,hads-a,baseline,NA,5.9,3.6,0.7506518906054692,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_anxiety,baseline
2841,mood,spinhoven 2010,heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt with locf,hads-a,post_int,NA,7,3.3,0.6880975663883467,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_anxiety,post_int
2842,mood,spinhoven 2010,heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,pain,paroxetine,antidepressant,antidepressant,paroxetine 10-40mg,ssri,10-40mg,unable to be categorised,flexible,16 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt with locf,hads-a,post_int,NA,4.7,3,0.6255432421712244,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_anxiety,post_int
2843,mood,spinhoven 2010,heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,pain,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioural therapy,n/a,n/a,n/a,n/a,16 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt with locf,hads-a,post_int,NA,4.9,3.9,0.8132062148225916,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,mood,mood,smd,standardised mean diference,mood_anxiety,post_int
2844,adverse_dropout,spinhoven 2010,heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,3,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2845,adverse_dropout,spinhoven 2010,heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,pain,paroxetine,antidepressant,antidepressant,paroxetine 10-40mg,ssri,10-40mg,unable to be categorised,flexible,16 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,3,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2846,adverse_dropout,spinhoven 2010,heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,pain,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioural therapy,n/a,n/a,n/a,n/a,16 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,0,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2847,withdrawal,spinhoven 2010,heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,4,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2848,withdrawal,spinhoven 2010,heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,pain,paroxetine,antidepressant,antidepressant,paroxetine 10-40mg,ssri,10-40mg,unable to be categorised,flexible,16 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,7,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2849,withdrawal,spinhoven 2010,heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine,pain,cognitive behavioural therapy,psychological therapy,non-pharmacological,cognitive behavioural therapy,n/a,n/a,n/a,n/a,16 weeks,non-cardiac chest pain,non-cardiac chest pain,primary,no,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,0,NA,FALSE,NA,NA,NA,NA,NA,non_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2850,pain_int,staud 2015,effects of milnacipran on clinical pain and hyperalgesia of patients with fibromyalgia: results of a 6-week randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,unclear,0-10 numerical rating scale,baseline,NA,5.1,1.8,0.3753259453027346,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2851,pain_int,staud 2015,effects of milnacipran on clinical pain and hyperalgesia of patients with fibromyalgia: results of a 6-week randomized controlled trial,pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,unclear,0-10 numerical rating scale,baseline,NA,5.8,1.8,0.3753259453027346,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2852,pain_int,staud 2015,effects of milnacipran on clinical pain and hyperalgesia of patients with fibromyalgia: results of a 6-week randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,unclear,0-10 numerical rating scale,post_int,NA,4.5,2.3,0.5421151989096864,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2853,pain_int,staud 2015,effects of milnacipran on clinical pain and hyperalgesia of patients with fibromyalgia: results of a 6-week randomized controlled trial,pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,unclear,0-10 numerical rating scale,post_int,NA,5.1,2.3,0.5578319375835658,NA,NA,NA,NA,NA,17,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2854,mood,staud 2015,effects of milnacipran on clinical pain and hyperalgesia of patients with fibromyalgia: results of a 6-week randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,unclear,0-10 numerical rating scale,baseline,NA,2.3,2.7,0.562988917954102,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2855,mood,staud 2015,effects of milnacipran on clinical pain and hyperalgesia of patients with fibromyalgia: results of a 6-week randomized controlled trial,pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,unclear,0-10 numerical rating scale,baseline,NA,2.9,2.8,0.5838403593598094,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2856,mood,staud 2015,effects of milnacipran on clinical pain and hyperalgesia of patients with fibromyalgia: results of a 6-week randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,unclear,0-10 numerical rating scale,post_int,NA,2.3,2.6,0.6128258770283412,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
2857,mood,staud 2015,effects of milnacipran on clinical pain and hyperalgesia of patients with fibromyalgia: results of a 6-week randomized controlled trial,pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,unclear,0-10 numerical rating scale,post_int,NA,2.6,2.7,0.6548461875980991,NA,NA,NA,NA,NA,17,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
2862,withdrawal,staud 2015,effects of milnacipran on clinical pain and hyperalgesia of patients with fibromyalgia: results of a 6-week randomized controlled trial,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,unclear,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,5,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2863,withdrawal,staud 2015,effects of milnacipran on clinical pain and hyperalgesia of patients with fibromyalgia: results of a 6-week randomized controlled trial,pain,milnacipran,antidepressant,antidepressant,milnacipran 100mg,snri,100mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥4 on 10nrs,parallel,unclear,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,6,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2864,pain_int,suttiruksa 2016,"effects of mirtazapine on quality of life of thai patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled trial",quality of life,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt method unspecified,sf-36 bodily pain subscale,baseline,NA,34,15.5,4.298926520745526,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2865,pain_int,suttiruksa 2016,"effects of mirtazapine on quality of life of thai patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled trial",quality of life,mirtazapine,antidepressant,antidepressant,mirtazapine 15mg,nassa,15mg,low,fixed,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt method unspecified,sf-36 bodily pain subscale,baseline,NA,40,14.6,4.049311432444172,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2866,pain_int,suttiruksa 2016,"effects of mirtazapine on quality of life of thai patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled trial",quality of life,mirtazapine,antidepressant,antidepressant,mirtazapine 30mg,nassa,30mg,standard,fixed,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt method unspecified,sf-36 bodily pain subscale,baseline,NA,28,8.8,2.3518989288293346,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2867,pain_int,suttiruksa 2016,"effects of mirtazapine on quality of life of thai patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled trial",quality of life,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt method unspecified,sf-36 bodily pain subscale,post_int,NA,49,18.4,5.103241805272107,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2868,pain_int,suttiruksa 2016,"effects of mirtazapine on quality of life of thai patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled trial",quality of life,mirtazapine,antidepressant,antidepressant,mirtazapine 15mg,nassa,15mg,low,fixed,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt method unspecified,sf-36 bodily pain subscale,post_int,NA,58,18.2,5.047771785649585,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2869,pain_int,suttiruksa 2016,"effects of mirtazapine on quality of life of thai patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled trial",quality of life,mirtazapine,antidepressant,antidepressant,mirtazapine 30mg,nassa,30mg,standard,fixed,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt method unspecified,sf-36 bodily pain subscale,post_int,NA,57,19,5.077963596336064,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2870,mood,suttiruksa 2016,"effects of mirtazapine on quality of life of thai patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled trial",quality of life,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt method unspecified,sf-36 mental health subscale,baseline,NA,57,13.8,3.8274313539540814,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
2871,mood,suttiruksa 2016,"effects of mirtazapine on quality of life of thai patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled trial",quality of life,mirtazapine,antidepressant,antidepressant,mirtazapine 15mg,nassa,15mg,low,fixed,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt method unspecified,sf-36 mental health subscale,baseline,NA,71,14.7,4.077046442255434,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
2872,mood,suttiruksa 2016,"effects of mirtazapine on quality of life of thai patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled trial",quality of life,mirtazapine,antidepressant,antidepressant,mirtazapine 30mg,nassa,30mg,standard,fixed,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt method unspecified,sf-36 mental health subscale,baseline,NA,63,16.9,4.516714988319972,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
2873,mood,suttiruksa 2016,"effects of mirtazapine on quality of life of thai patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled trial",quality of life,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt method unspecified,sf-36 mental health subscale,post_int,NA,72,11.5,3.1895261282950678,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2874,mood,suttiruksa 2016,"effects of mirtazapine on quality of life of thai patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled trial",quality of life,mirtazapine,antidepressant,antidepressant,mirtazapine 15mg,nassa,15mg,low,fixed,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt method unspecified,sf-36 mental health subscale,post_int,NA,81,14.4,3.99384141282165,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2875,mood,suttiruksa 2016,"effects of mirtazapine on quality of life of thai patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled trial",quality of life,mirtazapine,antidepressant,antidepressant,mirtazapine 30mg,nassa,30mg,standard,fixed,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt method unspecified,sf-36 mental health subscale,post_int,NA,83,12.4,3.3140393997140625,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2876,physical,suttiruksa 2016,"effects of mirtazapine on quality of life of thai patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled trial",quality of life,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt method unspecified,sf-36 physical functioning subscale,baseline,NA,55,4.1,1.1371354022617197,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2877,physical,suttiruksa 2016,"effects of mirtazapine on quality of life of thai patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled trial",quality of life,mirtazapine,antidepressant,antidepressant,mirtazapine 15mg,nassa,15mg,low,fixed,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt method unspecified,sf-36 physical functioning subscale,baseline,NA,71,5.9,1.636365578864426,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2878,physical,suttiruksa 2016,"effects of mirtazapine on quality of life of thai patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled trial",quality of life,mirtazapine,antidepressant,antidepressant,mirtazapine 30mg,nassa,30mg,standard,fixed,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt method unspecified,sf-36 physical functioning subscale,baseline,NA,60.7,3.8,1.0155927192672127,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2879,physical,suttiruksa 2016,"effects of mirtazapine on quality of life of thai patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled trial",quality of life,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt method unspecified,sf-36 physical functioning subscale,post_int,NA,58,7.2,1.996920706410825,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2880,physical,suttiruksa 2016,"effects of mirtazapine on quality of life of thai patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled trial",quality of life,mirtazapine,antidepressant,antidepressant,mirtazapine 15mg,nassa,15mg,low,fixed,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt method unspecified,sf-36 physical functioning subscale,post_int,NA,80,5.1,1.4144855003743342,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2881,physical,suttiruksa 2016,"effects of mirtazapine on quality of life of thai patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled trial",quality of life,mirtazapine,antidepressant,antidepressant,mirtazapine 30mg,nassa,30mg,standard,fixed,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt method unspecified,sf-36 physical functioning subscale,post_int,NA,76.7,6,1.6035674514745464,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2882,serious_adverse,suttiruksa 2016,"effects of mirtazapine on quality of life of thai patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled trial",quality of life,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt method unspecified,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2883,serious_adverse,suttiruksa 2016,"effects of mirtazapine on quality of life of thai patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled trial",quality of life,mirtazapine,antidepressant,antidepressant,mirtazapine 15mg,nassa,15mg,low,fixed,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt method unspecified,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2884,serious_adverse,suttiruksa 2016,"effects of mirtazapine on quality of life of thai patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled trial",quality of life,mirtazapine,antidepressant,antidepressant,mirtazapine 30mg,nassa,30mg,standard,fixed,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt method unspecified,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2885,adverse_dropout,suttiruksa 2016,"effects of mirtazapine on quality of life of thai patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled trial",quality of life,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt method unspecified,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,2,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2886,adverse_dropout,suttiruksa 2016,"effects of mirtazapine on quality of life of thai patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled trial",quality of life,mirtazapine,antidepressant,antidepressant,mirtazapine 15mg,nassa,15mg,low,fixed,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt method unspecified,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,1,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2887,adverse_dropout,suttiruksa 2016,"effects of mirtazapine on quality of life of thai patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled trial",quality of life,mirtazapine,antidepressant,antidepressant,mirtazapine 30mg,nassa,30mg,standard,fixed,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt method unspecified,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,2,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2888,withdrawal,suttiruksa 2016,"effects of mirtazapine on quality of life of thai patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled trial",quality of life,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt method unspecified,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,3,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2889,withdrawal,suttiruksa 2016,"effects of mirtazapine on quality of life of thai patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled trial",quality of life,mirtazapine,antidepressant,antidepressant,mirtazapine 15mg,nassa,15mg,low,fixed,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt method unspecified,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,2,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2890,withdrawal,suttiruksa 2016,"effects of mirtazapine on quality of life of thai patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled trial",quality of life,mirtazapine,antidepressant,antidepressant,mirtazapine 30mg,nassa,30mg,standard,fixed,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt method unspecified,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,3,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2891,mood,talley 2008,"antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",ibs symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥3 on 10nrs,parallel,itt with locf,sf-36 mental component score,baseline,NA,49.6,11.4,2.85,NA,NA,NA,NA,NA,16,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
2892,mood,talley 2008,"antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",ibs symptoms,imipramine,antidepressant,antidepressant,imipramine 50mg,tca,50mg,low,fixed,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥3 on 10nrs,parallel,itt with locf,sf-36 mental component score,baseline,NA,43.9,13.8,3.252691193458119,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
2893,mood,talley 2008,"antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",ibs symptoms,citalopram,antidepressant,antidepressant,citalopram 40mg,ssri,40mg,standard,fixed,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥3 on 10nrs,parallel,itt with locf,sf-36 mental component score,baseline,NA,52.8,7.3,1.7705100627652306,NA,NA,NA,NA,NA,17,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
2894,mood,talley 2008,"antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",ibs symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥3 on 10nrs,parallel,itt with locf,sf-36 mental component score,change_score,NA,-1.9,7.2,1.8,NA,NA,NA,NA,NA,16,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2895,mood,talley 2008,"antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",ibs symptoms,imipramine,antidepressant,antidepressant,imipramine 50mg,tca,50mg,low,fixed,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥3 on 10nrs,parallel,itt with locf,sf-36 mental component score,change_score,NA,4.8,4.5,1.0606601717798214,NA,NA,NA,NA,NA,18,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2896,mood,talley 2008,"antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",ibs symptoms,citalopram,antidepressant,antidepressant,citalopram 40mg,ssri,40mg,standard,fixed,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥3 on 10nrs,parallel,itt with locf,sf-36 mental component score,change_score,NA,0,4.1,0.9943960626489651,NA,NA,NA,NA,NA,17,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
2897,physical,talley 2008,"antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",ibs symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥3 on 10nrs,parallel,itt with locf,sf-36 physical component score,baseline,NA,45,10.1,2.525,NA,NA,NA,NA,NA,16,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2898,physical,talley 2008,"antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",ibs symptoms,imipramine,antidepressant,antidepressant,imipramine 50mg,tca,50mg,low,fixed,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥3 on 10nrs,parallel,itt with locf,sf-36 physical component score,baseline,NA,45.8,8.3,1.9563287612827818,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2899,physical,talley 2008,"antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",ibs symptoms,citalopram,antidepressant,antidepressant,citalopram 40mg,ssri,40mg,standard,fixed,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥3 on 10nrs,parallel,itt with locf,sf-36 physical component score,baseline,NA,43,10.1,2.4496098128669628,NA,NA,NA,NA,NA,17,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2900,physical,talley 2008,"antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",ibs symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥3 on 10nrs,parallel,itt with locf,sf-36 physical component score,change_score,NA,6.5,4.6,1.15,NA,NA,NA,NA,NA,16,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2901,physical,talley 2008,"antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",ibs symptoms,imipramine,antidepressant,antidepressant,imipramine 50mg,tca,50mg,low,fixed,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥3 on 10nrs,parallel,itt with locf,sf-36 physical component score,change_score,NA,7.3,7.3,1.7206265008872657,NA,NA,NA,NA,NA,18,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2902,physical,talley 2008,"antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",ibs symptoms,citalopram,antidepressant,antidepressant,citalopram 40mg,ssri,40mg,standard,fixed,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥3 on 10nrs,parallel,itt with locf,sf-36 physical component score,change_score,NA,3.5,6.1,1.4794673127216311,NA,NA,NA,NA,NA,17,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2915,pain_int,talley 2008,"antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",ibs symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥3 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-7.4,46.9,11.725,NA,NA,NA,NA,NA,16,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2916,pain_int,talley 2008,"antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",ibs symptoms,imipramine,antidepressant,antidepressant,imipramine 50mg,tca,50mg,low,fixed,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥3 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-45.3,26.3,6.198969448402067,NA,NA,NA,NA,NA,18,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2917,pain_int,talley 2008,"antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",ibs symptoms,citalopram,antidepressant,antidepressant,citalopram 40mg,ssri,40mg,standard,fixed,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥3 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-14.4,32.9,7.979422063695354,NA,NA,NA,NA,NA,17,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2918,serious_adverse,talley 2008,"antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",ibs symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥3 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,16,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2919,serious_adverse,talley 2008,"antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",ibs symptoms,imipramine,antidepressant,antidepressant,imipramine 50mg,tca,50mg,low,fixed,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥3 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2920,serious_adverse,talley 2008,"antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",ibs symptoms,citalopram,antidepressant,antidepressant,citalopram 40mg,ssri,40mg,standard,fixed,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥3 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2921,withdrawal,talley 2008,"antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",ibs symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥3 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,16,3,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2922,withdrawal,talley 2008,"antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",ibs symptoms,imipramine,antidepressant,antidepressant,imipramine 50mg,tca,50mg,low,fixed,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥3 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,9,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2923,withdrawal,talley 2008,"antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial",ibs symptoms,citalopram,antidepressant,antidepressant,citalopram 40mg,ssri,40mg,standard,fixed,12 weeks,irritable bowel syndrome,gastrointestinal,primary,≥3 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,5,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2924,adverse_dropout,tammiala-salonen 1999,"trazodone in burning mouth pain: a placebo-controlled, double-blind study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,burning mouth syndrome,burning mouth syndrome,primary,≥30 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,2,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2925,adverse_dropout,tammiala-salonen 1999,"trazodone in burning mouth pain: a placebo-controlled, double-blind study",pain,trazodone,antidepressant,antidepressant,trazodone 200mg,sari,200mg,standard,fixed,8 weeks,burning mouth syndrome,burning mouth syndrome,primary,≥30 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,7,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2926,withdrawal,tammiala-salonen 1999,"trazodone in burning mouth pain: a placebo-controlled, double-blind study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,burning mouth syndrome,burning mouth syndrome,primary,≥30 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,2,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2927,withdrawal,tammiala-salonen 1999,"trazodone in burning mouth pain: a placebo-controlled, double-blind study",pain,trazodone,antidepressant,antidepressant,trazodone 200mg,sari,200mg,standard,fixed,8 weeks,burning mouth syndrome,burning mouth syndrome,primary,≥30 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,7,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2928,pain_int,tanum 1996,a new pharmacologic treatment of functional gastrointestinal disorder. a double-blind placebo-controlled study with mianserin,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,7 weeks,functional gastrointestinal disorder,gastrointestinal,primary,no,parallel,itt with locf,0-100 vas,baseline,NA,49.7,16.8,3.5817720347742554,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2929,pain_int,tanum 1996,a new pharmacologic treatment of functional gastrointestinal disorder. a double-blind placebo-controlled study with mianserin,pain,mianserin,antidepressant,antidepressant,mianserin 120mg,teca,120mg,high,fixed,7 weeks,functional gastrointestinal disorder,gastrointestinal,primary,no,parallel,itt with locf,0-100 vas,baseline,NA,49.9,18.3,3.66,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2930,pain_int,tanum 1996,a new pharmacologic treatment of functional gastrointestinal disorder. a double-blind placebo-controlled study with mianserin,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,7 weeks,functional gastrointestinal disorder,gastrointestinal,primary,no,parallel,itt with locf,0-100 vas,post_int,NA,42.8,20.9,4.455894971832258,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2931,pain_int,tanum 1996,a new pharmacologic treatment of functional gastrointestinal disorder. a double-blind placebo-controlled study with mianserin,pain,mianserin,antidepressant,antidepressant,mianserin 120mg,teca,120mg,high,fixed,7 weeks,functional gastrointestinal disorder,gastrointestinal,primary,no,parallel,itt with locf,0-100 vas,post_int,NA,16.9,24.3,4.86,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2932,pain_int,tanum 1996,a new pharmacologic treatment of functional gastrointestinal disorder. a double-blind placebo-controlled study with mianserin,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,7 weeks,functional gastrointestinal disorder,gastrointestinal,primary,no,parallel,itt with locf,0-100 vas,follow_up,"4 weeks after taper, 11 weeks from baseline",45.5,21.2,4.5198551867389405,NA,NA,NA,NA,NA,22,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,follow_up
2933,pain_int,tanum 1996,a new pharmacologic treatment of functional gastrointestinal disorder. a double-blind placebo-controlled study with mianserin,pain,mianserin,antidepressant,antidepressant,mianserin 120mg,teca,120mg,high,fixed,7 weeks,functional gastrointestinal disorder,gastrointestinal,primary,no,parallel,itt with locf,0-100 vas,follow_up,"4 weeks after taper, 11 weeks from baseline",20.6,28.4,5.68,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,follow_up
2934,pain_sub,tanum 1996,a new pharmacologic treatment of functional gastrointestinal disorder. a double-blind placebo-controlled study with mianserin,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,7 weeks,functional gastrointestinal disorder,gastrointestinal,primary,no,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,4,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2935,pain_sub,tanum 1996,a new pharmacologic treatment of functional gastrointestinal disorder. a double-blind placebo-controlled study with mianserin,pain,mianserin,antidepressant,antidepressant,mianserin 120mg,teca,120mg,high,fixed,7 weeks,functional gastrointestinal disorder,gastrointestinal,primary,no,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,19,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2936,withdrawal,tanum 1996,a new pharmacologic treatment of functional gastrointestinal disorder. a double-blind placebo-controlled study with mianserin,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,7 weeks,functional gastrointestinal disorder,gastrointestinal,primary,no,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2937,withdrawal,tanum 1996,a new pharmacologic treatment of functional gastrointestinal disorder. a double-blind placebo-controlled study with mianserin,pain,mianserin,antidepressant,antidepressant,mianserin 120mg,teca,120mg,high,fixed,7 weeks,functional gastrointestinal disorder,gastrointestinal,primary,no,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,27,2,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2938,NA,tasmuth 2002,venlafaxine in neuropathic pain following treatment of breast cancer,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,chemotherapy induced neuropathic pain,neuropathic,cancer-related,at least moderate in severity,crossover,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,placebo,NA,NA,NA,NA,NA,no_useable_data,NA
2939,NA,tasmuth 2002,venlafaxine in neuropathic pain following treatment of breast cancer,pain,venlafaxine,antidepressant,antidepressant,venlafaxine ≤70mg,tca,≤70mg,low,flexible,4 weeks,chemotherapy induced neuropathic pain,neuropathic,cancer-related,at least moderate in severity,crossover,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,ad,NA,NA,NA,NA,NA,no_useable_data,NA
2940,pain_int,tesfaye 2013,"duloxetine and pregabalin: high-dose monotherapy or their combination? the ""combo-dn study"" - a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6,1.57,0.07840205860191081,NA,NA,NA,NA,NA,401,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2941,pain_int,tesfaye 2013,"duloxetine and pregabalin: high-dose monotherapy or their combination? the ""combo-dn study"" - a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,-1.68,2.1455734676839042,0.10714482595417735,NA,-1.89,-1.47,NA,NA,401,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2942,pain_int,tesfaye 2013,"duloxetine and pregabalin: high-dose monotherapy or their combination? the ""combo-dn study"" - a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,6,1.55,0.07740330626303296,NA,NA,NA,NA,NA,401,NA,NA,TRUE,NA,NA,NA,NA,NA,non_ad_pharm,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2943,pain_int,tesfaye 2013,"duloxetine and pregabalin: high-dose monotherapy or their combination? the ""combo-dn study"" - a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-2.3,2.247743632811707,0.11224696052342377,NA,-2.51,-2.08,NA,NA,401,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2944,physical,tesfaye 2013,"duloxetine and pregabalin: high-dose monotherapy or their combination? the ""combo-dn study"" - a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sheehan disability scale,baseline,NA,13.3,7.59,0.37808483037251883,NA,NA,NA,NA,NA,403,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2945,physical,tesfaye 2013,"duloxetine and pregabalin: high-dose monotherapy or their combination? the ""combo-dn study"" - a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sheehan disability scale,baseline,NA,13.3,7.47,0.4883291764940782,NA,NA,NA,NA,NA,234,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2946,physical,tesfaye 2013,"duloxetine and pregabalin: high-dose monotherapy or their combination? the ""combo-dn study"" - a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sheehan disability scale,change_score,NA,-3.37,7.867102714840983,0.39286436183198364,NA,-4.13,-2.6,NA,NA,401,NA,NA,TRUE,NA,NA,NA,NA,NA,non_ad_pharm,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2947,physical,tesfaye 2013,"duloxetine and pregabalin: high-dose monotherapy or their combination? the ""combo-dn study"" - a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sheehan disability scale,change_score,NA,-4.39,6.257139350589985,0.40817076553972315,NA,-5.19,-3.59,NA,NA,235,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2952,mood,tesfaye 2013,"duloxetine and pregabalin: high-dose monotherapy or their combination? the ""combo-dn study"" - a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,hads-d,baseline,NA,5.5,3.88,0.19351681120488076,NA,NA,NA,NA,NA,402,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2953,mood,tesfaye 2013,"duloxetine and pregabalin: high-dose monotherapy or their combination? the ""combo-dn study"" - a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,hads-d,baseline,NA,-0.64,2.8643294406918383,0.14285976793890315,NA,-0.93,-0.36,NA,NA,402,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2954,mood,tesfaye 2013,"duloxetine and pregabalin: high-dose monotherapy or their combination? the ""combo-dn study"" - a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,hads-d,change_score,NA,5.5,4.19,0.209762367040817,NA,NA,NA,NA,NA,399,NA,NA,TRUE,NA,NA,NA,NA,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
2955,mood,tesfaye 2013,"duloxetine and pregabalin: high-dose monotherapy or their combination? the ""combo-dn study"" - a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,hads-d,change_score,NA,-1.06,2.853621629601119,0.14285976793890315,NA,-1.35,-0.78,NA,NA,399,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
2956,pain_mod,tesfaye 2013,"duloxetine and pregabalin: high-dose monotherapy or their combination? the ""combo-dn study"" - a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,374,138,0.369,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
2957,pain_mod,tesfaye 2013,"duloxetine and pregabalin: high-dose monotherapy or their combination? the ""combo-dn study"" - a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,375,195,0.52,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
2958,pain_sub,tesfaye 2013,"duloxetine and pregabalin: high-dose monotherapy or their combination? the ""combo-dn study"" - a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,374,104,0.278,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2959,pain_sub,tesfaye 2013,"duloxetine and pregabalin: high-dose monotherapy or their combination? the ""combo-dn study"" - a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,375,151,0.40299999999999997,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
2960,adverse,tesfaye 2013,"duloxetine and pregabalin: high-dose monotherapy or their combination? the ""combo-dn study"" - a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,403,232,0.5760000000000001,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2961,adverse,tesfaye 2013,"duloxetine and pregabalin: high-dose monotherapy or their combination? the ""combo-dn study"" - a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,401,223,0.556,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2962,adverse_dropout,tesfaye 2013,"duloxetine and pregabalin: high-dose monotherapy or their combination? the ""combo-dn study"" - a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,403,39,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2963,adverse_dropout,tesfaye 2013,"duloxetine and pregabalin: high-dose monotherapy or their combination? the ""combo-dn study"" - a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,401,35,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2964,serious_adverse,tesfaye 2013,"duloxetine and pregabalin: high-dose monotherapy or their combination? the ""combo-dn study"" - a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,406,13,0.032,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2965,serious_adverse,tesfaye 2013,"duloxetine and pregabalin: high-dose monotherapy or their combination? the ""combo-dn study"" - a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,400,12,0.03,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2966,withdrawal,tesfaye 2013,"duloxetine and pregabalin: high-dose monotherapy or their combination? the ""combo-dn study"" - a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,pregabalin,anticonvulsant,non-antidepressant pharmacological,pregabalin 300mg,n/a,n/a,n/a,n/a,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,403,70,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2967,withdrawal,tesfaye 2013,"duloxetine and pregabalin: high-dose monotherapy or their combination? the ""combo-dn study"" - a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain",NA,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,8 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,401,68,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2968,pain_int,tetreault 2018,brain connectivity predicts placebo response across chronic pain clinical trials,changes in brain scans,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,completer analysis,0-10 numerical rating scale,baseline,NA,6.83,1.56,0.34882660448996716,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2969,pain_int,tetreault 2018,brain connectivity predicts placebo response across chronic pain clinical trials,changes in brain scans,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,16 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,completer analysis,0-10 numerical rating scale,baseline,NA,6.48,1.46,0.33494697145102015,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
2970,pain_int,tetreault 2018,brain connectivity predicts placebo response across chronic pain clinical trials,changes in brain scans,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,completer analysis,0-10 numerical rating scale,post_int,NA,5.55,2.04,0.45615786740995706,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2971,pain_int,tetreault 2018,brain connectivity predicts placebo response across chronic pain clinical trials,changes in brain scans,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,16 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,completer analysis,0-10 numerical rating scale,post_int,NA,5.32,1.6,0.3670651741928988,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2972,physical,tetreault 2018,brain connectivity predicts placebo response across chronic pain clinical trials,changes in brain scans,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,completer analysis,womac total score,baseline,NA,48.9,15.41,3.445780753327176,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2973,physical,tetreault 2018,brain connectivity predicts placebo response across chronic pain clinical trials,changes in brain scans,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,16 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,completer analysis,womac total score,baseline,NA,49.32,13.74,3.1521721833815186,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
2974,pain_int,tetreault 2018,brain connectivity predicts placebo response across chronic pain clinical trials,changes in brain scans,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,completer analysis,womac total score,post_int,NA,39.05,18.85,4.2149881375871034,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2975,physical,tetreault 2018,brain connectivity predicts placebo response across chronic pain clinical trials,changes in brain scans,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,16 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,completer analysis,womac total score,post_int,NA,39.89,17.43,3.998716241363891,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
2976,mood,tetreault 2018,brain connectivity predicts placebo response across chronic pain clinical trials,changes in brain scans,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,completer analysis,beck depression inventory,baseline,NA,6.75,9.25,2.068362879187305,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2977,mood,tetreault 2018,brain connectivity predicts placebo response across chronic pain clinical trials,changes in brain scans,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,16 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,completer analysis,beck depression inventory,baseline,NA,6,8.71,1.998211042012593,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
2978,mood,tetreault 2018,brain connectivity predicts placebo response across chronic pain clinical trials,changes in brain scans,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,completer analysis,beck depression inventory,post_int,NA,7.15,7.04,1.5741918561598518,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
2979,mood,tetreault 2018,brain connectivity predicts placebo response across chronic pain clinical trials,changes in brain scans,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,16 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,completer analysis,beck depression inventory,post_int,NA,8.32,9.12,2.0922714928995227,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
2980,adverse,tetreault 2018,brain connectivity predicts placebo response across chronic pain clinical trials,changes in brain scans,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,6,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2981,adverse,tetreault 2018,brain connectivity predicts placebo response across chronic pain clinical trials,changes in brain scans,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,16 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,6,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2982,serious_adverse,tetreault 2018,brain connectivity predicts placebo response across chronic pain clinical trials,changes in brain scans,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2983,serious_adverse,tetreault 2018,brain connectivity predicts placebo response across chronic pain clinical trials,changes in brain scans,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,16 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2984,adverse,trugman 2014,"milnacipran effects on 24-hour ambulatory blood pressure and heart rate in fibromyalgia patients: a randomized, placebo-controlled, dose-escalation study",blood pressure,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,7 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,111,42,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2985,adverse,trugman 2014,"milnacipran effects on 24-hour ambulatory blood pressure and heart rate in fibromyalgia patients: a randomized, placebo-controlled, dose-escalation study",blood pressure,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,7 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,210,117,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
2986,serious_adverse,trugman 2014,"milnacipran effects on 24-hour ambulatory blood pressure and heart rate in fibromyalgia patients: a randomized, placebo-controlled, dose-escalation study",blood pressure,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,7 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,111,1,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2987,serious_adverse,trugman 2014,"milnacipran effects on 24-hour ambulatory blood pressure and heart rate in fibromyalgia patients: a randomized, placebo-controlled, dose-escalation study",blood pressure,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,7 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,210,3,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
2988,adverse_dropout,trugman 2014,"milnacipran effects on 24-hour ambulatory blood pressure and heart rate in fibromyalgia patients: a randomized, placebo-controlled, dose-escalation study",blood pressure,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,7 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,111,10,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2989,adverse_dropout,trugman 2014,"milnacipran effects on 24-hour ambulatory blood pressure and heart rate in fibromyalgia patients: a randomized, placebo-controlled, dose-escalation study",blood pressure,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,7 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,210,40,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
2990,withdrawal,trugman 2014,"milnacipran effects on 24-hour ambulatory blood pressure and heart rate in fibromyalgia patients: a randomized, placebo-controlled, dose-escalation study",blood pressure,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,7 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,111,25,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2991,withdrawal,trugman 2014,"milnacipran effects on 24-hour ambulatory blood pressure and heart rate in fibromyalgia patients: a randomized, placebo-controlled, dose-escalation study",blood pressure,milnacipran,antidepressant,antidepressant,milnacipran 200mg,snri,200mg,high,fixed,7 weeks,fibromyalgia,fibromyalgia,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,210,40,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
2992,pain_int,uchio 2018,"a randomized, double-blind, placebo-controlled, phase iii trial of duloxetine in japanese patients with knee pain due to osteoarthritis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with mixed bocf and locf,0-10 numerical rating scale,change_score,NA,-1.8,1.5919798993705918,0.12,NA,NA,NA,NA,NA,176,NA,NA,TRUE,NA,no baseline values reported,imputation: bocf for those discontinuing due to aes or lack of efficacy; locf for those discontinuing for any other reason || se extracted from clinicaltrials.gov registration,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2993,pain_int,uchio 2018,"a randomized, double-blind, placebo-controlled, phase iii trial of duloxetine in japanese patients with knee pain due to osteoarthritis",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with mixed bocf and locf,0-10 numerical rating scale,change_score,NA,-2.57,1.5964961634780084,0.12,NA,NA,NA,NA,NA,177,NA,NA,TRUE,NA,no baseline values reported,imputation: bocf for those discontinuing due to aes or lack of efficacy; locf for those discontinuing for any other reason || se extracted from clinicaltrials.gov registration,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
2994,sleep,uchio 2018,"a randomized, double-blind, placebo-controlled, phase iii trial of duloxetine in japanese patients with knee pain due to osteoarthritis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with mixed bocf and locf,0-10 numerical rating scale,change_score,NA,-1.19,1.4593149077563758,0.11,NA,NA,NA,NA,NA,176,NA,NA,TRUE,NA,no baseline values reported,imputation: bocf for those discontinuing due to aes or lack of efficacy; locf for those discontinuing for any other reason || se extracted from clinicaltrials.gov registration,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
2995,sleep,uchio 2018,"a randomized, double-blind, placebo-controlled, phase iii trial of duloxetine in japanese patients with knee pain due to osteoarthritis",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with mixed bocf and locf,0-10 numerical rating scale,change_score,NA,-1.65,1.4634548165215078,0.11,NA,NA,NA,NA,NA,177,NA,NA,TRUE,NA,no baseline values reported,imputation: bocf for those discontinuing due to aes or lack of efficacy; locf for those discontinuing for any other reason || se extracted from clinicaltrials.gov registration,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
2996,qol,uchio 2018,"a randomized, double-blind, placebo-controlled, phase iii trial of duloxetine in japanese patients with knee pain due to osteoarthritis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with mixed bocf and locf,eq-5d,change_score,NA,0.07,0.132664991614216,0.01,NA,NA,NA,NA,NA,176,NA,NA,TRUE,NA,no baseline values reported,imputation: bocf for those discontinuing due to aes or lack of efficacy; locf for those discontinuing for any other reason || se extracted from clinicaltrials.gov registration,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
2997,qol,uchio 2018,"a randomized, double-blind, placebo-controlled, phase iii trial of duloxetine in japanese patients with knee pain due to osteoarthritis",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with mixed bocf and locf,eq-5d,change_score,NA,0.12,0.13304134695650072,0.01,NA,NA,NA,NA,NA,177,NA,NA,TRUE,NA,no baseline values reported,imputation: bocf for those discontinuing due to aes or lack of efficacy; locf for those discontinuing for any other reason || se extracted from clinicaltrials.gov registration,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
3000,mood,uchio 2018,"a randomized, double-blind, placebo-controlled, phase iii trial of duloxetine in japanese patients with knee pain due to osteoarthritis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with mixed bocf and locf,sf-36 mental health subscale,change_score,NA,1.48,13.133834169807383,0.99,NA,NA,NA,NA,NA,176,NA,NA,TRUE,NA,no baseline values reported,imputation: bocf for those discontinuing due to aes or lack of efficacy; locf for those discontinuing for any other reason || se extracted from clinicaltrials.gov registration || this outcome extracted only from clinicaltrials.gov,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
3001,mood,uchio 2018,"a randomized, double-blind, placebo-controlled, phase iii trial of duloxetine in japanese patients with knee pain due to osteoarthritis",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with mixed bocf and locf,sf-36 mental health subscale,change_score,NA,3.02,13.171093348693569,0.99,NA,NA,NA,NA,NA,177,NA,NA,TRUE,NA,no baseline values reported,imputation: bocf for those discontinuing due to aes or lack of efficacy; locf for those discontinuing for any other reason || se extracted from clinicaltrials.gov registration || this outcome extracted only from clinicaltrials.gov,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
3002,physical,uchio 2018,"a randomized, double-blind, placebo-controlled, phase iii trial of duloxetine in japanese patients with knee pain due to osteoarthritis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with mixed bocf and locf,sf-36 physical functioning subscale,change_score,NA,6.23,16.84845393500543,1.27,NA,NA,NA,NA,NA,176,NA,NA,TRUE,NA,no baseline values reported,imputation: bocf for those discontinuing due to aes or lack of efficacy; locf for those discontinuing for any other reason || se extracted from clinicaltrials.gov registration || this outcome extracted only from clinicaltrials.gov,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
3003,physical,uchio 2018,"a randomized, double-blind, placebo-controlled, phase iii trial of duloxetine in japanese patients with knee pain due to osteoarthritis",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with mixed bocf and locf,sf-36 physical functioning subscale,change_score,NA,12.62,16.89625106347559,1.27,NA,NA,NA,NA,NA,177,NA,NA,TRUE,NA,no baseline values reported,imputation: bocf for those discontinuing due to aes or lack of efficacy; locf for those discontinuing for any other reason || se extracted from clinicaltrials.gov registration || this outcome extracted only from clinicaltrials.gov,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
3004,pain_mod,uchio 2018,"a randomized, double-blind, placebo-controlled, phase iii trial of duloxetine in japanese patients with knee pain due to osteoarthritis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with mixed bocf and locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,176,88,0.5,FALSE,NA,NA,imputation: bocf for those discontinuing due to aes or lack of efficacy; locf for those discontinuing for any other reason || se extracted from clinicaltrials.gov registration,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
3005,pain_mod,uchio 2018,"a randomized, double-blind, placebo-controlled, phase iii trial of duloxetine in japanese patients with knee pain due to osteoarthritis",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with mixed bocf and locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,177,124,0.701,FALSE,NA,NA,imputation: bocf for those discontinuing due to aes or lack of efficacy; locf for those discontinuing for any other reason || se extracted from clinicaltrials.gov registration,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
3006,pain_sub,uchio 2018,"a randomized, double-blind, placebo-controlled, phase iii trial of duloxetine in japanese patients with knee pain due to osteoarthritis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with mixed bocf and locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,176,69,0.392,FALSE,NA,NA,imputation: bocf for those discontinuing due to aes or lack of efficacy; locf for those discontinuing for any other reason || se extracted from clinicaltrials.gov registration,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
3007,pain_sub,uchio 2018,"a randomized, double-blind, placebo-controlled, phase iii trial of duloxetine in japanese patients with knee pain due to osteoarthritis",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with mixed bocf and locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,177,114,0.644,FALSE,NA,NA,imputation: bocf for those discontinuing due to aes or lack of efficacy; locf for those discontinuing for any other reason || se extracted from clinicaltrials.gov registration,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
3008,adverse,uchio 2018,"a randomized, double-blind, placebo-controlled, phase iii trial of duloxetine in japanese patients with knee pain due to osteoarthritis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with mixed bocf and locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,176,98,0.557,FALSE,NA,NA,imputation: bocf for those discontinuing due to aes or lack of efficacy; locf for those discontinuing for any other reason || se extracted from clinicaltrials.gov registration,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
3009,adverse,uchio 2018,"a randomized, double-blind, placebo-controlled, phase iii trial of duloxetine in japanese patients with knee pain due to osteoarthritis",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with mixed bocf and locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,177,120,0.674,FALSE,NA,NA,imputation: bocf for those discontinuing due to aes or lack of efficacy; locf for those discontinuing for any other reason || se extracted from clinicaltrials.gov registration,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
3010,serious_adverse,uchio 2018,"a randomized, double-blind, placebo-controlled, phase iii trial of duloxetine in japanese patients with knee pain due to osteoarthritis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with mixed bocf and locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,176,1,0.005699999999999999,FALSE,NA,NA,imputation: bocf for those discontinuing due to aes or lack of efficacy; locf for those discontinuing for any other reason || se extracted from clinicaltrials.gov registration,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
3011,serious_adverse,uchio 2018,"a randomized, double-blind, placebo-controlled, phase iii trial of duloxetine in japanese patients with knee pain due to osteoarthritis",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with mixed bocf and locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,177,1,0.005600000000000001,FALSE,NA,NA,imputation: bocf for those discontinuing due to aes or lack of efficacy; locf for those discontinuing for any other reason || se extracted from clinicaltrials.gov registration,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
3012,adverse_dropout,uchio 2018,"a randomized, double-blind, placebo-controlled, phase iii trial of duloxetine in japanese patients with knee pain due to osteoarthritis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with mixed bocf and locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,176,2,NA,FALSE,NA,NA,imputation: bocf for those discontinuing due to aes or lack of efficacy; locf for those discontinuing for any other reason || se extracted from clinicaltrials.gov registration,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3013,adverse_dropout,uchio 2018,"a randomized, double-blind, placebo-controlled, phase iii trial of duloxetine in japanese patients with knee pain due to osteoarthritis",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with mixed bocf and locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,178,11,NA,FALSE,NA,NA,imputation: bocf for those discontinuing due to aes or lack of efficacy; locf for those discontinuing for any other reason || se extracted from clinicaltrials.gov registration,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3014,withdrawal,uchio 2018,"a randomized, double-blind, placebo-controlled, phase iii trial of duloxetine in japanese patients with knee pain due to osteoarthritis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,14 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with mixed bocf and locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,176,14,0.0795,FALSE,NA,NA,imputation: bocf for those discontinuing due to aes or lack of efficacy; locf for those discontinuing for any other reason || se extracted from clinicaltrials.gov registration,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3015,withdrawal,uchio 2018,"a randomized, double-blind, placebo-controlled, phase iii trial of duloxetine in japanese patients with knee pain due to osteoarthritis",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,14 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with mixed bocf and locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,178,17,0.096,FALSE,NA,NA,imputation: bocf for those discontinuing due to aes or lack of efficacy; locf for those discontinuing for any other reason || se extracted from clinicaltrials.gov registration,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3016,pain_int,urquhart 2018,efficacy of low-dose amitriptyline for chronic low back pain: a randomized clinical trial,pain,benzotropine mesylate,active placebo,placebo,benzotropine mesylate 1mg,n/a,n/a,n/a,n/a,24 weeks,low back pain,musculoskeletal,primary,no,parallel,multiple imputation,0-100 vas,baseline,NA,43.4,2.4,0.2789943329851663,NA,NA,NA,NA,NA,74,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
3017,pain_int,urquhart 2018,efficacy of low-dose amitriptyline for chronic low back pain: a randomized clinical trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,24 weeks,low back pain,musculoskeletal,primary,no,parallel,multiple imputation,0-100 vas,baseline,NA,39.8,2.4,0.282842712474619,NA,NA,NA,NA,NA,72,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
3018,pain_int,urquhart 2018,efficacy of low-dose amitriptyline for chronic low back pain: a randomized clinical trial,pain,benzotropine mesylate,active placebo,placebo,benzotropine mesylate 1mg,n/a,n/a,n/a,n/a,24 weeks,low back pain,musculoskeletal,primary,no,parallel,multiple imputation,0-100 vas,post_int,NA,37.1,3.2,0.37199244398022174,NA,NA,NA,NA,NA,74,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
3019,pain_int,urquhart 2018,efficacy of low-dose amitriptyline for chronic low back pain: a randomized clinical trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,24 weeks,low back pain,musculoskeletal,primary,no,parallel,multiple imputation,0-100 vas,post_int,NA,28.9,2.6,0.33289588782552954,NA,NA,NA,NA,NA,61,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
3020,physical,urquhart 2018,efficacy of low-dose amitriptyline for chronic low back pain: a randomized clinical trial,pain,benzotropine mesylate,active placebo,placebo,benzotropine mesylate 1mg,n/a,n/a,n/a,n/a,24 weeks,low back pain,musculoskeletal,primary,no,parallel,multiple imputation,rmdq-24,baseline,NA,8.2,0.5,0.05812381937190964,NA,NA,NA,NA,NA,74,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
3021,physical,urquhart 2018,efficacy of low-dose amitriptyline for chronic low back pain: a randomized clinical trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,24 weeks,low back pain,musculoskeletal,primary,no,parallel,multiple imputation,rmdq-24,baseline,NA,7.5,0.5,0.05892556509887897,NA,NA,NA,NA,NA,72,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
3022,physical,urquhart 2018,efficacy of low-dose amitriptyline for chronic low back pain: a randomized clinical trial,pain,benzotropine mesylate,active placebo,placebo,benzotropine mesylate 1mg,n/a,n/a,n/a,n/a,24 weeks,low back pain,musculoskeletal,primary,no,parallel,multiple imputation,rmdq-24,post_int,NA,5.9,0.6,0.06974858324629157,NA,NA,NA,NA,NA,74,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
3023,physical,urquhart 2018,efficacy of low-dose amitriptyline for chronic low back pain: a randomized clinical trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,24 weeks,low back pain,musculoskeletal,primary,no,parallel,multiple imputation,rmdq-24,post_int,NA,4.7,0.5,0.05892556509887897,NA,NA,NA,NA,NA,72,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
3024,qol,urquhart 2018,efficacy of low-dose amitriptyline for chronic low back pain: a randomized clinical trial,pain,benzotropine mesylate,active placebo,placebo,benzotropine mesylate 1mg,n/a,n/a,n/a,n/a,24 weeks,low back pain,musculoskeletal,primary,no,parallel,multiple imputation,eq-5d vas,baseline,NA,71.3,1.7,0.19762098586449278,NA,NA,NA,NA,NA,74,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
3025,qol,urquhart 2018,efficacy of low-dose amitriptyline for chronic low back pain: a randomized clinical trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,24 weeks,low back pain,musculoskeletal,primary,no,parallel,multiple imputation,eq-5d vas,baseline,NA,69.3,1.8,0.21213203435596428,NA,NA,NA,NA,NA,72,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
3026,qol,urquhart 2018,efficacy of low-dose amitriptyline for chronic low back pain: a randomized clinical trial,pain,benzotropine mesylate,active placebo,placebo,benzotropine mesylate 1mg,n/a,n/a,n/a,n/a,24 weeks,low back pain,musculoskeletal,primary,no,parallel,multiple imputation,eq-5d vas,post_int,NA,70.1,2.2,0.29139711855430966,NA,NA,NA,NA,NA,57,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
3027,qol,urquhart 2018,efficacy of low-dose amitriptyline for chronic low back pain: a randomized clinical trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,24 weeks,low back pain,musculoskeletal,primary,no,parallel,multiple imputation,eq-5d vas,post_int,NA,73.9,1.8,0.23046638387921278,NA,NA,NA,NA,NA,61,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
3028,mood,urquhart 2018,efficacy of low-dose amitriptyline for chronic low back pain: a randomized clinical trial,pain,benzotropine mesylate,active placebo,placebo,benzotropine mesylate 1mg,n/a,n/a,n/a,n/a,24 weeks,low back pain,musculoskeletal,primary,no,parallel,multiple imputation,beck depression inventory,baseline,NA,11.2,1,0.11624763874381928,NA,NA,NA,NA,NA,74,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
3029,mood,urquhart 2018,efficacy of low-dose amitriptyline for chronic low back pain: a randomized clinical trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,24 weeks,low back pain,musculoskeletal,primary,no,parallel,multiple imputation,beck depression inventory,baseline,NA,10.5,0.8,0.09428090415820635,NA,NA,NA,NA,NA,72,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
3030,mood,urquhart 2018,efficacy of low-dose amitriptyline for chronic low back pain: a randomized clinical trial,pain,benzotropine mesylate,active placebo,placebo,benzotropine mesylate 1mg,n/a,n/a,n/a,n/a,24 weeks,low back pain,musculoskeletal,primary,no,parallel,multiple imputation,beck depression inventory,post_int,NA,8.71,1,0.13245323570650439,NA,NA,NA,NA,NA,57,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
3031,mood,urquhart 2018,efficacy of low-dose amitriptyline for chronic low back pain: a randomized clinical trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,24 weeks,low back pain,musculoskeletal,primary,no,parallel,multiple imputation,beck depression inventory,post_int,NA,7.78,0.8,0.1024295039463168,NA,NA,NA,NA,NA,61,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
3032,adverse,urquhart 2018,efficacy of low-dose amitriptyline for chronic low back pain: a randomized clinical trial,pain,benzotropine mesylate,active placebo,placebo,benzotropine mesylate 1mg,n/a,n/a,n/a,n/a,24 weeks,low back pain,musculoskeletal,primary,no,parallel,multiple imputation,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,74,14,NA,FALSE,number of participants with moderate-severe side effects,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
3033,adverse,urquhart 2018,efficacy of low-dose amitriptyline for chronic low back pain: a randomized clinical trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,24 weeks,low back pain,musculoskeletal,primary,no,parallel,multiple imputation,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,72,13,NA,FALSE,number of participants with moderate-severe side effects,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
3034,adverse_dropout,urquhart 2018,efficacy of low-dose amitriptyline for chronic low back pain: a randomized clinical trial,pain,benzotropine mesylate,active placebo,placebo,benzotropine mesylate 1mg,n/a,n/a,n/a,n/a,24 weeks,low back pain,musculoskeletal,primary,no,parallel,multiple imputation,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,74,9,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3035,adverse_dropout,urquhart 2018,efficacy of low-dose amitriptyline for chronic low back pain: a randomized clinical trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,24 weeks,low back pain,musculoskeletal,primary,no,parallel,multiple imputation,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,72,9,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3036,withdrawal,urquhart 2018,efficacy of low-dose amitriptyline for chronic low back pain: a randomized clinical trial,pain,benzotropine mesylate,active placebo,placebo,benzotropine mesylate 1mg,n/a,n/a,n/a,n/a,24 weeks,low back pain,musculoskeletal,primary,no,parallel,multiple imputation,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,74,15,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3037,withdrawal,urquhart 2018,efficacy of low-dose amitriptyline for chronic low back pain: a randomized clinical trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 25mg,tca,25mg,standard,fixed,24 weeks,low back pain,musculoskeletal,primary,no,parallel,multiple imputation,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,72,13,NA,FALSE,NA,NA,come back to work out mean dose,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3038,adverse_dropout,vahedi 2005,the effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study,ibs symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3039,adverse_dropout,vahedi 2005,the effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study,ibs symptoms,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,12 weeks,irritable bowel syndrome,gastrointestinal,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3040,withdrawal,vahedi 2005,the effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study,ibs symptoms,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,irritable bowel syndrome,gastrointestinal,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3041,withdrawal,vahedi 2005,the effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study,ibs symptoms,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,12 weeks,irritable bowel syndrome,gastrointestinal,primary,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,0,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3042,pain_int,van ophoven 2004,"a prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,interstitial cystitis,interstitial cystitis,visceral,no,parallel,not reported,0-100 vas,baseline,NA,52.6,28.4,5.68,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,come back to work out mean dose,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
3043,pain_int,van ophoven 2004,"a prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis",pain,amitriptyline,antidepressant,antidepressant,amitriptyline ≤100mg,tca,≤100mg,unable to be categorised,flexible,16 weeks,interstitial cystitis,interstitial cystitis,visceral,no,parallel,not reported,0-100 vas,baseline,NA,52.7,24.6,4.92,NA,NA,NA,NA,NA,25,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
3044,pain_int,van ophoven 2004,"a prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,interstitial cystitis,interstitial cystitis,visceral,no,parallel,not reported,0-100 vas,post_int,NA,1,14.8,3.0210373494325866,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
3045,pain_int,van ophoven 2004,"a prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis",pain,amitriptyline,antidepressant,antidepressant,amitriptyline ≤100mg,tca,≤100mg,unable to be categorised,flexible,16 weeks,interstitial cystitis,interstitial cystitis,visceral,no,parallel,not reported,0-100 vas,post_int,NA,-22.8,26.1,5.327640190553413,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
3046,adverse,van ophoven 2004,"a prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,interstitial cystitis,interstitial cystitis,visceral,no,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,22,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
3047,adverse,van ophoven 2004,"a prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis",pain,amitriptyline,antidepressant,antidepressant,amitriptyline ≤100mg,tca,≤100mg,unable to be categorised,flexible,16 weeks,interstitial cystitis,interstitial cystitis,visceral,no,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,5,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
3048,serious_adverse,van ophoven 2004,"a prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,interstitial cystitis,interstitial cystitis,visceral,no,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
3049,serious_adverse,van ophoven 2004,"a prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis",pain,amitriptyline,antidepressant,antidepressant,amitriptyline ≤100mg,tca,≤100mg,unable to be categorised,flexible,16 weeks,interstitial cystitis,interstitial cystitis,visceral,no,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
3050,adverse_dropout,van ophoven 2004,"a prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,interstitial cystitis,interstitial cystitis,visceral,no,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,1,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3051,adverse_dropout,van ophoven 2004,"a prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis",pain,amitriptyline,antidepressant,antidepressant,amitriptyline ≤100mg,tca,≤100mg,unable to be categorised,flexible,16 weeks,interstitial cystitis,interstitial cystitis,visceral,no,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,1,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3052,withdrawal,van ophoven 2004,"a prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,16 weeks,interstitial cystitis,interstitial cystitis,visceral,no,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,1,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3053,withdrawal,van ophoven 2004,"a prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis",pain,amitriptyline,antidepressant,antidepressant,amitriptyline ≤100mg,tca,≤100mg,unable to be categorised,flexible,16 weeks,interstitial cystitis,interstitial cystitis,visceral,no,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,1,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3054,adverse_dropout,ventafridda 1987,antidepressants for cancer pain and other painful syndromes with deafferentation component: comparison of amitriptyline and trazodone,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 75mg,tca,75mg,standard,fixed,2 weeks,cancer pain/deafferation pain,neuropathic,neuropathic,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3055,adverse_dropout,ventafridda 1987,antidepressants for cancer pain and other painful syndromes with deafferentation component: comparison of amitriptyline and trazodone,pain,trazodone,antidepressant,antidepressant,trazodone 225mg,sari,225mg,standard,fixed,2 weeks,cancer pain/deafferation pain,neuropathic,neuropathic,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,6,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3056,withdrawal,ventafridda 1987,antidepressants for cancer pain and other painful syndromes with deafferentation component: comparison of amitriptyline and trazodone,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 75mg,tca,75mg,standard,fixed,2 weeks,cancer pain/deafferation pain,neuropathic,neuropathic,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,4,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3057,withdrawal,ventafridda 1987,antidepressants for cancer pain and other painful syndromes with deafferentation component: comparison of amitriptyline and trazodone,pain,trazodone,antidepressant,antidepressant,trazodone 225mg,sari,225mg,standard,fixed,2 weeks,cancer pain/deafferation pain,neuropathic,neuropathic,no,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,10,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3058,pain_int,vitton 2004,a double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥10 on 20-point gracely pain scale,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-0.9,2.9,0.5480484858633794,NA,NA,NA,NA,NA,28,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
3059,pain_int,vitton 2004,a double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg qd,snri,25-200mg,unable to be categorised,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥10 on 20-point gracely pain scale,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-2,3.2,0.47181425969567087,NA,NA,NA,NA,NA,46,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
3060,pain_int,vitton 2004,a double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg bid,snri,25-200mg,unable to be categorised,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥10 on 20-point gracely pain scale,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-2.5,2.8,0.3920784235278427,NA,NA,NA,NA,NA,51,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
3061,sleep,vitton 2004,a double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥10 on 20-point gracely pain scale,parallel,itt with locf,jenkins sleep scale composite score,change_score,NA,-0.5,2.9,0.5480484858633794,NA,NA,NA,NA,NA,28,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
3062,sleep,vitton 2004,a double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg qd,snri,25-200mg,unable to be categorised,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥10 on 20-point gracely pain scale,parallel,itt with locf,jenkins sleep scale composite score,change_score,NA,-1.3,3.6,0.5307910421576297,NA,NA,NA,NA,NA,46,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
3063,sleep,vitton 2004,a double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg bid,snri,25-200mg,unable to be categorised,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥10 on 20-point gracely pain scale,parallel,itt with locf,jenkins sleep scale composite score,change_score,NA,-1.3,2.6,0.3640728218472825,NA,NA,NA,NA,NA,51,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
3064,pain_mod,vitton 2004,a double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥10 on 20-point gracely pain scale,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,6,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
3065,pain_mod,vitton 2004,a double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg qd,snri,25-200mg,unable to be categorised,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥10 on 20-point gracely pain scale,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,46,16,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
3066,pain_mod,vitton 2004,a double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg bid,snri,25-200mg,unable to be categorised,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥10 on 20-point gracely pain scale,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,20,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
3067,pain_sub,vitton 2004,a double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥10 on 20-point gracely pain scale,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,6,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
3068,pain_sub,vitton 2004,a double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg qd,snri,25-200mg,unable to be categorised,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥10 on 20-point gracely pain scale,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,46,12,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
3069,pain_sub,vitton 2004,a double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg bid,snri,25-200mg,unable to be categorised,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥10 on 20-point gracely pain scale,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,15,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
3070,serious_adverse,vitton 2004,a double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥10 on 20-point gracely pain scale,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
3071,serious_adverse,vitton 2004,a double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg qd,snri,25-200mg,unable to be categorised,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥10 on 20-point gracely pain scale,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,46,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
3072,serious_adverse,vitton 2004,a double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg bid,snri,25-200mg,unable to be categorised,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥10 on 20-point gracely pain scale,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
3073,adverse_dropout,vitton 2004,a double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥10 on 20-point gracely pain scale,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,1,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3074,adverse_dropout,vitton 2004,a double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg qd,snri,25-200mg,unable to be categorised,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥10 on 20-point gracely pain scale,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,46,10,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3075,adverse_dropout,vitton 2004,a double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg bid,snri,25-200mg,unable to be categorised,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥10 on 20-point gracely pain scale,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,7,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3076,withdrawal,vitton 2004,a double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,fibromyalgia,fibromyalgia,primary,≥10 on 20-point gracely pain scale,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,7,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3077,withdrawal,vitton 2004,a double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg qd,snri,25-200mg,unable to be categorised,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥10 on 20-point gracely pain scale,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,46,14,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3078,withdrawal,vitton 2004,a double-blind placebo-controlled trial of milnacipranin the treatment of fibromyalgia,pain,milnacipran,antidepressant,antidepressant,milnacipran 200mg bid,snri,25-200mg,unable to be categorised,flexible,12 weeks,fibromyalgia,fibromyalgia,primary,≥10 on 20-point gracely pain scale,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,51,14,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3079,pain_int,vollmer 2014,"a randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.3,1.3,0.11818181818181818,NA,NA,NA,NA,NA,121,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
3080,pain_int,vollmer 2014,"a randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.5,1.4,0.12888044650576527,NA,NA,NA,NA,NA,118,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
3081,pain_int,vollmer 2014,"a randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-1.07,1.7453939383417143,0.16,NA,NA,NA,NA,NA,119,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
3082,pain_int,vollmer 2014,"a randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-1.83,1.8230469001098135,0.17,NA,NA,NA,NA,NA,115,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
3083,qol,vollmer 2014,"a randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,ms-qol-54,baseline,NA,44.3,15.5,1.4090909090909092,NA,NA,NA,NA,NA,121,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
3084,qol,vollmer 2014,"a randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,ms-qol-54,baseline,NA,42.5,15.1,1.3900676730264683,NA,NA,NA,NA,NA,118,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
3085,qol,vollmer 2014,"a randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,ms-qol-54,change_score,NA,5.1,12.100000000000001,1.1,NA,NA,NA,NA,NA,121,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
3086,qol,vollmer 2014,"a randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,ms-qol-54,change_score,NA,6.1,13.035336589440258,1.2,NA,NA,NA,NA,NA,118,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
3087,mood,vollmer 2014,"a randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,beck depression inventory,baseline,NA,12.8,9.6,0.8727272727272727,NA,NA,NA,NA,NA,121,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
3088,mood,vollmer 2014,"a randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,beck depression inventory,baseline,NA,14,9,0.8285171561084911,NA,NA,NA,NA,NA,118,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
3089,mood,vollmer 2014,"a randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,beck depression inventory,change_score,NA,-3,6.6,0.6,NA,NA,NA,NA,NA,121,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
3090,mood,vollmer 2014,"a randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,beck depression inventory,change_score,NA,-2.4,6.517668294720129,0.6,NA,NA,NA,NA,NA,118,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
3095,sleep,vollmer 2014,"a randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,bpi sleep,baseline,NA,5.4,2.6,0.23636363636363636,NA,NA,NA,NA,NA,121,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
3096,sleep,vollmer 2014,"a randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,bpi sleep,baseline,NA,5.5,2.5,0.23014365447458085,NA,NA,NA,NA,NA,118,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
3097,sleep,vollmer 2014,"a randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,bpi sleep,change_score,NA,-1.6,2.2,0.2,NA,NA,NA,NA,NA,121,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
3098,sleep,vollmer 2014,"a randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,bpi sleep,change_score,NA,-2,2.1725560982400434,0.2,NA,NA,NA,NA,NA,118,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
3099,pain_mod,vollmer 2014,"a randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with bocf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,120,29,0.242,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
3100,pain_mod,vollmer 2014,"a randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with bocf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,115,44,0.38299999999999995,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
3101,pain_sub,vollmer 2014,"a randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with bocf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,121,16,0.1324,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
3102,pain_sub,vollmer 2014,"a randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with bocf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,115,24,0.209,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
3103,adverse,vollmer 2014,"a randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,120,59,0.49,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
3104,adverse,vollmer 2014,"a randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,117,70,0.6,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
3105,adverse_dropout,vollmer 2014,"a randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,121,5,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3106,adverse_dropout,vollmer 2014,"a randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,118,16,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3107,serious_adverse,vollmer 2014,"a randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
3108,serious_adverse,vollmer 2014,"a randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,118,4,0.034,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
3109,withdrawal,vollmer 2014,"a randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,121,12,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3110,withdrawal,vollmer 2014,"a randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,6 weeks,multiple sclerosis,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,118,18,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3111,pain_int,vranken 2011,"duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,neuropathic pain,neuropathic,neuropathic,≥6 on 10nrs,parallel,itt unspecified method,0-10 numerical rating scale,baseline,NA,7.2,0.8,0.16329931618554522,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
3112,pain_int,vranken 2011,"duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,99.1mg,high,flexible,8 weeks,neuropathic pain,neuropathic,neuropathic,≥6 on 10nrs,parallel,itt unspecified method,0-10 numerical rating scale,baseline,NA,7.1,0.8,0.16329931618554522,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
3113,pain_int,vranken 2011,"duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,neuropathic pain,neuropathic,neuropathic,≥6 on 10nrs,parallel,itt unspecified method,0-10 numerical rating scale,post_int,NA,6.1,1.7,0.3544745038970271,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
3114,pain_int,vranken 2011,"duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,99.1mg,high,flexible,8 weeks,neuropathic pain,neuropathic,neuropathic,≥6 on 10nrs,parallel,itt unspecified method,0-10 numerical rating scale,post_int,NA,5,2,0.4364357804719848,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
3115,qol,vranken 2011,"duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,neuropathic pain,neuropathic,neuropathic,≥6 on 10nrs,parallel,itt unspecified method,eq-5d,baseline,NA,0.24,0.3,0.06123724356957946,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
3116,qol,vranken 2011,"duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,99.1mg,high,flexible,8 weeks,neuropathic pain,neuropathic,neuropathic,≥6 on 10nrs,parallel,itt unspecified method,eq-5d,baseline,NA,0.36,0.33,0.06736096792653741,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,baseline
3117,qol,vranken 2011,"duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,neuropathic pain,neuropathic,neuropathic,≥6 on 10nrs,parallel,itt unspecified method,eq-5d,post_int,NA,0.37,0.34,0.07089490077940543,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
3118,qol,vranken 2011,"duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,99.1mg,high,flexible,8 weeks,neuropathic pain,neuropathic,neuropathic,≥6 on 10nrs,parallel,itt unspecified method,eq-5d,post_int,NA,0.4,0.31,0.06764754597315764,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
3119,physical,vranken 2011,"duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,neuropathic pain,neuropathic,neuropathic,≥6 on 10nrs,parallel,itt unspecified method,sf-36 physical functioning subscale,baseline,NA,38,28,5.715476066494083,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
3120,physical,vranken 2011,"duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,99.1mg,high,flexible,8 weeks,neuropathic pain,neuropathic,neuropathic,≥6 on 10nrs,parallel,itt unspecified method,sf-36 physical functioning subscale,baseline,NA,39,25,5.103103630798288,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
3121,physical,vranken 2011,"duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,neuropathic pain,neuropathic,neuropathic,≥6 on 10nrs,parallel,itt unspecified method,sf-36 physical functioning subscale,post_int,NA,38,25,5.21286035142687,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
3122,physical,vranken 2011,"duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,99.1mg,high,flexible,8 weeks,neuropathic pain,neuropathic,neuropathic,≥6 on 10nrs,parallel,itt unspecified method,sf-36 physical functioning subscale,post_int,NA,41,27,5.8918830363717944,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
3123,mood,vranken 2011,"duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,neuropathic pain,neuropathic,neuropathic,≥6 on 10nrs,parallel,itt unspecified method,sf-36 mental health subscale,baseline,NA,72,19,3.878358759406699,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
3124,mood,vranken 2011,"duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,99.1mg,high,flexible,8 weeks,neuropathic pain,neuropathic,neuropathic,≥6 on 10nrs,parallel,itt unspecified method,sf-36 mental health subscale,baseline,NA,68,17,3.470110468942836,NA,NA,NA,NA,NA,24,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
3125,mood,vranken 2011,"duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,neuropathic pain,neuropathic,neuropathic,≥6 on 10nrs,parallel,itt unspecified method,sf-36 mental health subscale,post_int,NA,73,19,3.9617738670844207,NA,NA,NA,NA,NA,23,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
3126,mood,vranken 2011,"duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,99.1mg,high,flexible,8 weeks,neuropathic pain,neuropathic,neuropathic,≥6 on 10nrs,parallel,itt unspecified method,sf-36 mental health subscale,post_int,NA,73,19,4.1461399144838555,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
3127,adverse_dropout,vranken 2011,"duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,neuropathic pain,neuropathic,neuropathic,≥6 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,1,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3128,adverse_dropout,vranken 2011,"duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,99.1mg,high,flexible,8 weeks,neuropathic pain,neuropathic,neuropathic,≥6 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,2,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3129,withdrawal,vranken 2011,"duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,neuropathic pain,neuropathic,neuropathic,≥6 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,1,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3130,withdrawal,vranken 2011,"duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial",pain,duloxetine,antidepressant,antidepressant,duloxetine 60-120mg,snri,99.1mg,high,flexible,8 weeks,neuropathic pain,neuropathic,neuropathic,≥6 on 10nrs,parallel,itt unspecified method,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,3,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3131,pain_int,vrethem 1997: 1,a comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 75mg,tca,75mg,standard,fixed,4 weeks,polyneuropathy + diabetes,neuropathic,neuropathic,no,crossover,not reported,0-10 numerical rating scale,baseline,NA,5,1.4,0.3299831645537222,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,vrethem 1: people with diabetes,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
3132,pain_int,vrethem 1997: 1,a comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics,pain,maprotiline,antidepressant,antidepressant,maprotiline 75mg,teca,75mg,low,fixed,4 weeks,polyneuropathy + diabetes,neuropathic,neuropathic,no,crossover,not reported,0-10 numerical rating scale,baseline,NA,5,1.4,0.3299831645537222,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,vrethem 1: people with diabetes,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
3133,pain_int,vrethem 1997: 1,a comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,polyneuropathy + diabetes,neuropathic,neuropathic,no,crossover,not reported,0-10 numerical rating scale,baseline,NA,5,1.4,0.3299831645537222,NA,NA,NA,NA,NA,18,NA,NA,FALSE,NA,NA,vrethem 1: people with diabetes,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
3134,pain_int,vrethem 1997: 1,a comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 75mg,tca,75mg,standard,fixed,4 weeks,polyneuropathy + diabetes,neuropathic,neuropathic,no,crossover,not reported,0-10 numerical rating scale,post_int,NA,3.5,1.6,0.38805700005813276,NA,NA,NA,NA,NA,17,NA,NA,FALSE,NA,NA,vrethem 1: people with diabetes,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
3135,pain_int,vrethem 1997: 1,a comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics,pain,maprotiline,antidepressant,antidepressant,maprotiline 75mg,teca,75mg,low,fixed,4 weeks,polyneuropathy + diabetes,neuropathic,neuropathic,no,crossover,not reported,0-10 numerical rating scale,post_int,NA,4,2.3,0.575,NA,NA,NA,NA,NA,16,NA,NA,FALSE,NA,NA,vrethem 1: people with diabetes,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
3136,pain_int,vrethem 1997: 1,a comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,polyneuropathy + diabetes,neuropathic,neuropathic,no,crossover,not reported,0-10 numerical rating scale,post_int,NA,5.4,1.5,0.36380343755449945,NA,NA,NA,NA,NA,17,NA,NA,FALSE,NA,NA,vrethem 1: people with diabetes,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
3137,pain_int,vrethem 1997: 2,a comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 75mg,tca,75mg,standard,fixed,4 weeks,polyneuropathy,neuropathic,neuropathic,no,crossover,not reported,0-10 numerical rating scale,baseline,NA,4.1,1.9,0.46081768756903263,NA,NA,NA,NA,NA,17,NA,NA,FALSE,NA,NA,vrethem 2: people without diabetes,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
3138,pain_int,vrethem 1997: 2,a comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics,pain,maprotiline,antidepressant,antidepressant,maprotiline 75mg,teca,75mg,low,fixed,4 weeks,polyneuropathy,neuropathic,neuropathic,no,crossover,not reported,0-10 numerical rating scale,baseline,NA,4.1,1.9,0.46081768756903263,NA,NA,NA,NA,NA,17,NA,NA,FALSE,NA,NA,vrethem 2: people without diabetes,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
3139,pain_int,vrethem 1997: 2,a comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,polyneuropathy,neuropathic,neuropathic,no,crossover,not reported,0-10 numerical rating scale,baseline,NA,4.1,1.9,0.46081768756903263,NA,NA,NA,NA,NA,17,NA,NA,FALSE,NA,NA,vrethem 2: people without diabetes,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
3140,pain_int,vrethem 1997: 2,a comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 75mg,tca,75mg,standard,fixed,4 weeks,polyneuropathy,neuropathic,neuropathic,no,crossover,not reported,0-10 numerical rating scale,post_int,NA,3.3,2.1,0.525,NA,NA,NA,NA,NA,16,NA,NA,FALSE,NA,NA,vrethem 2: people without diabetes,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
3141,pain_int,vrethem 1997: 2,a comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics,pain,maprotiline,antidepressant,antidepressant,maprotiline 75mg,teca,75mg,low,fixed,4 weeks,polyneuropathy,neuropathic,neuropathic,no,crossover,not reported,0-10 numerical rating scale,post_int,NA,3.3,1.9,0.46081768756903263,NA,NA,NA,NA,NA,17,NA,NA,FALSE,NA,NA,vrethem 2: people without diabetes,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
3142,pain_int,vrethem 1997: 2,a comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,4 weeks,polyneuropathy,neuropathic,neuropathic,no,crossover,not reported,0-10 numerical rating scale,post_int,NA,3.7,2.3,0.575,NA,NA,NA,NA,NA,16,NA,NA,FALSE,NA,NA,vrethem 2: people without diabetes,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
3143,pain_int,wang 2017,"efficacy and safety of duloxetine in chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,5.41,1.21,0.08620893048537066,NA,NA,NA,NA,NA,197,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
3144,pain_int,wang 2017,"efficacy and safety of duloxetine in chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,5.49,1.27,0.09118068614445274,NA,NA,NA,NA,NA,194,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
3145,pain_int,wang 2017,"efficacy and safety of duloxetine in chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-1.73,1.4634548165215078,0.11,NA,NA,NA,NA,NA,177,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
3146,pain_int,wang 2017,"efficacy and safety of duloxetine in chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-2.23,1.44263647534644,0.11,NA,NA,NA,NA,NA,172,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
3147,physical,wang 2017,"efficacy and safety of duloxetine in chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,womac total score,baseline,NA,36.68,13.95,1.034042796742236,NA,NA,NA,NA,NA,182,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
3148,physical,wang 2017,"efficacy and safety of duloxetine in chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,womac total score,baseline,NA,37.35,13.97,1.0298820637419566,NA,NA,NA,NA,NA,184,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
3149,physical,wang 2017,"efficacy and safety of duloxetine in chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,womac total score,change_score,NA,-10.09,12.141663806908838,0.9,NA,NA,NA,NA,NA,182,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
3150,physical,wang 2017,"efficacy and safety of duloxetine in chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,womac total score,change_score,NA,-13.58,12.479487168950493,0.92,NA,NA,NA,NA,NA,184,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
3151,mood,wang 2017,"efficacy and safety of duloxetine in chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,bpi mood,baseline,NA,2.82,2.62,0.18666727096832328,NA,NA,NA,NA,NA,197,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
3152,mood,wang 2017,"efficacy and safety of duloxetine in chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,bpi mood,baseline,NA,2.6,2.61,0.18738707939922963,NA,NA,NA,NA,NA,194,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
3153,mood,wang 2017,"efficacy and safety of duloxetine in chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,bpi mood,change_score,NA,-1.04,1.7295375104345092,0.13,NA,NA,NA,NA,NA,177,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
3154,mood,wang 2017,"efficacy and safety of duloxetine in chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,bpi mood,change_score,NA,-1.43,1.7049340163185203,0.13,NA,NA,NA,NA,NA,172,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
3155,sleep,wang 2017,"efficacy and safety of duloxetine in chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,bpi sleep,baseline,NA,2.54,2.64,0.18809221196808149,NA,NA,NA,NA,NA,197,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
3156,sleep,wang 2017,"efficacy and safety of duloxetine in chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,bpi sleep,baseline,NA,2.39,2.66,0.19097687019231835,NA,NA,NA,NA,NA,194,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
3157,sleep,wang 2017,"efficacy and safety of duloxetine in chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,bpi sleep,change_score,NA,-0.99,1.7295375104345092,0.13,NA,NA,NA,NA,NA,177,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
3158,sleep,wang 2017,"efficacy and safety of duloxetine in chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,bpi sleep,change_score,NA,-1.21,1.8360827868045604,0.14,NA,NA,NA,NA,NA,172,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
3163,pain_mod,wang 2017,"efficacy and safety of duloxetine in chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,197,98,0.49700000000000005,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
3164,pain_mod,wang 2017,"efficacy and safety of duloxetine in chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,194,123,0.634,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
3165,pain_sub,wang 2017,"efficacy and safety of duloxetine in chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,197,68,0.345,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
3166,pain_sub,wang 2017,"efficacy and safety of duloxetine in chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,194,83,0.428,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
3167,adverse,wang 2017,"efficacy and safety of duloxetine in chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,202,84,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
3168,adverse,wang 2017,"efficacy and safety of duloxetine in chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,205,122,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
3169,serious_adverse,wang 2017,"efficacy and safety of duloxetine in chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,202,3,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
3170,serious_adverse,wang 2017,"efficacy and safety of duloxetine in chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,205,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
3171,adverse_dropout,wang 2017,"efficacy and safety of duloxetine in chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,202,10,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3172,adverse_dropout,wang 2017,"efficacy and safety of duloxetine in chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,205,20,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3173,withdrawal,wang 2017,"efficacy and safety of duloxetine in chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,202,26,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3174,withdrawal,wang 2017,"efficacy and safety of duloxetine in chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study",pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,13 weeks,osteoarthritis,musculoskeletal,musculoskeletal,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,205,39,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3175,NA,ward 1986,tricyclic antidepressants for chronic low-back pain,pain,doxepin,antidepressant,antidepressant,doxepin ≥50mg,tca,188mg,high,flexible,4 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,ad,NA,NA,NA,NA,NA,no_useable_data,NA
3176,NA,ward 1986,tricyclic antidepressants for chronic low-back pain,pain,desipramine,antidepressant,antidepressant,desipramine ≥50mg,tca,173mg,standard,flexible,4 weeks,low back pain,musculoskeletal,primary,≥4 on 10nrs,parallel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,ad,NA,NA,NA,NA,NA,no_useable_data,NA
3177,mood,ware 2010,nabilone versus amitriptyline in improving quality of sleep in patients with fibromyalgia,sleep,nabilone,synthetic cannabinoid,non-antidepressant pharmacological,nabilone 0.5-1mg,n/a,n/a,n/a,n/a,2 weeks,fibromyalgia,fibromyalgia,primary,no,crossover,completer analysis,profile of mood states - brief form,baseline,NA,5.8,4.4,0.7778174593052023,NA,NA,NA,NA,NA,32,NA,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
3178,mood,ware 2010,nabilone versus amitriptyline in improving quality of sleep in patients with fibromyalgia,sleep,amitriptyline,antidepressant,antidepressant,amitriptyline 10-20mg,tca,10-20mg,low,flexible,2 weeks,fibromyalgia,fibromyalgia,primary,no,crossover,completer analysis,profile of mood states - brief form,baseline,NA,5.8,4.4,0.7778174593052023,NA,NA,NA,NA,NA,32,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
3179,serious_adverse,ware 2010,nabilone versus amitriptyline in improving quality of sleep in patients with fibromyalgia,sleep,nabilone,synthetic cannabinoid,non-antidepressant pharmacological,nabilone 0.5-1mg,n/a,n/a,n/a,n/a,2 weeks,fibromyalgia,fibromyalgia,primary,no,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,32,0,NA,FALSE,NA,NA,NA,NA,NA,non_ad_pharm,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
3180,serious_adverse,ware 2010,nabilone versus amitriptyline in improving quality of sleep in patients with fibromyalgia,sleep,amitriptyline,antidepressant,antidepressant,amitriptyline 10-20mg,tca,10-20mg,low,flexible,2 weeks,fibromyalgia,fibromyalgia,primary,no,crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,32,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
3181,adverse_dropout,watson 1992,"amitriptyline versus maprotiline in postherpetic neuralgia: a randomized, double-blind, crossover trial",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 37.5-150mg,tca,100mg,high,flexible,5 weeks,post-herpetic neuralgia,neuropathic,neuropathic,"pain of at least moderate severity (disagreeable, unpleasant, uncomfortable) for at least one half of the day",crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,35,1,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3182,adverse_dropout,watson 1992,"amitriptyline versus maprotiline in postherpetic neuralgia: a randomized, double-blind, crossover trial",pain,maprotiline,antidepressant,antidepressant,maprotiline 50-150mg,teca,100mg,low,flexible,5 weeks,post-herpetic neuralgia,neuropathic,neuropathic,"pain of at least moderate severity (disagreeable, unpleasant, uncomfortable) for at least one half of the day",crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,35,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3183,withdrawal,watson 1992,"amitriptyline versus maprotiline in postherpetic neuralgia: a randomized, double-blind, crossover trial",pain,amitriptyline,antidepressant,antidepressant,amitriptyline 37.5-150mg,tca,100mg,high,flexible,5 weeks,post-herpetic neuralgia,neuropathic,neuropathic,"pain of at least moderate severity (disagreeable, unpleasant, uncomfortable) for at least one half of the day",crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,35,2,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3184,withdrawal,watson 1992,"amitriptyline versus maprotiline in postherpetic neuralgia: a randomized, double-blind, crossover trial",pain,maprotiline,antidepressant,antidepressant,maprotiline 50-150mg,teca,100mg,low,flexible,5 weeks,post-herpetic neuralgia,neuropathic,neuropathic,"pain of at least moderate severity (disagreeable, unpleasant, uncomfortable) for at least one half of the day",crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,35,1,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3185,adverse,watson 1998,nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10-160mg,tca,10-160mg,unable to be categorised,flexible,5 weeks,post-herpetic neuralgia,neuropathic,neuropathic,"pain of at least moderate severity (disagreeable, unpleasant, uncomfortable) for at least one half of the day",crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,31,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
3186,adverse,watson 1998,nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial,pain,nortriptyline,antidepressant,antidepressant,nortriptyline 10-150mg,tca,10-160mg,unable to be categorised,fixed,5 weeks,post-herpetic neuralgia,neuropathic,neuropathic,"pain of at least moderate severity (disagreeable, unpleasant, uncomfortable) for at least one half of the day",crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,31,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
3187,adverse_dropout,watson 1998,nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10-160mg,tca,10-160mg,unable to be categorised,flexible,5 weeks,post-herpetic neuralgia,neuropathic,neuropathic,"pain of at least moderate severity (disagreeable, unpleasant, uncomfortable) for at least one half of the day",crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,1,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3188,adverse_dropout,watson 1998,nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial,pain,nortriptyline,antidepressant,antidepressant,nortriptyline 10-150mg,tca,10-160mg,unable to be categorised,fixed,5 weeks,post-herpetic neuralgia,neuropathic,neuropathic,"pain of at least moderate severity (disagreeable, unpleasant, uncomfortable) for at least one half of the day",crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,1,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3189,withdrawal,watson 1998,nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial,pain,amitriptyline,antidepressant,antidepressant,amitriptyline 10-160mg,tca,10-160mg,unable to be categorised,flexible,5 weeks,post-herpetic neuralgia,neuropathic,neuropathic,"pain of at least moderate severity (disagreeable, unpleasant, uncomfortable) for at least one half of the day",crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,1,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3190,withdrawal,watson 1998,nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial,pain,nortriptyline,antidepressant,antidepressant,nortriptyline 10-150mg,tca,10-160mg,unable to be categorised,fixed,5 weeks,post-herpetic neuralgia,neuropathic,neuropathic,"pain of at least moderate severity (disagreeable, unpleasant, uncomfortable) for at least one half of the day",crossover,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,1,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3191,pain_int,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,5.9,1.4,0.13471506281091267,NA,NA,NA,NA,NA,108,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
3192,pain_int,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.1,1.6,0.14985372985307105,NA,NA,NA,NA,NA,114,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
3193,pain_int,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,6.2,1.5,0.1417366773784602,NA,NA,NA,NA,NA,112,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
3194,pain_int,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-1.39,2.36799493242701,0.23,NA,NA,NA,NA,NA,106,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
3195,pain_int,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-2.72,2.3073794659743334,0.22,NA,NA,NA,NA,NA,110,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
3196,pain_int,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-2.84,2.42320036315613,0.23,NA,NA,NA,NA,NA,111,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
3197,mood,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,hamilton depression rating scale,baseline,NA,3.4,2.7,0.2598076211353316,NA,NA,NA,NA,NA,108,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
3198,mood,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,hamilton depression rating scale,baseline,NA,3.3,3.4,0.31843917593777593,NA,NA,NA,NA,NA,114,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
3199,mood,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,hamilton depression rating scale,baseline,NA,3.6,3,0.2834733547569204,NA,NA,NA,NA,NA,112,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
3200,mood,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,hamilton depression rating scale,change_score,NA,-0.64,2.5341665296503306,0.26,NA,NA,NA,NA,NA,95,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
3201,mood,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,hamilton depression rating scale,change_score,NA,0.65,2.560703028466987,0.26,NA,NA,NA,NA,NA,97,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
3202,mood,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,hamilton depression rating scale,change_score,NA,0.19,2.6129676614914317,0.26,NA,NA,NA,NA,NA,101,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
3203,qol,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,eq-5d,change_score,NA,0.08,0.198997487421324,0.02,NA,NA,NA,NA,NA,99,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
3204,qol,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,eq-5d,change_score,NA,0.15,0.20784609690826528,0.02,NA,NA,NA,NA,NA,108,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
3205,qol,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,eq-5d,change_score,NA,0.15,0.20493901531919195,0.02,NA,NA,NA,NA,NA,105,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,qol,quality of life,smd,standardised mean diference,qol,post_int
3209,physical,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sf-36 physical component score,change_score,NA,3.67,7.800000000000001,0.78,NA,NA,NA,NA,NA,100,NA,NA,TRUE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
3210,physical,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sf-36 physical component score,change_score,NA,6.85,7.861501128919337,0.76,NA,NA,NA,NA,NA,107,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
3211,physical,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,sf-36 physical component score,change_score,NA,7.46,7.927635208559991,0.77,NA,NA,NA,NA,NA,106,NA,NA,TRUE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
3212,pain_mod,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,106,45,0.42,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
3213,pain_mod,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,110,69,0.63,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
3214,pain_mod,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,111,77,0.69,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
3215,pain_sub,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,106,29,0.27,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
3216,pain_sub,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,110,47,0.43,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
3217,pain_sub,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,111,59,0.53,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
3218,adverse,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,108,79,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
3219,adverse,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,114,102,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
3220,adverse,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,112,96,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
3221,adverse_dropout,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,108,8,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3222,adverse_dropout,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,114,17,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3223,adverse_dropout,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,112,20,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3224,serious_adverse,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,108,5,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
3225,serious_adverse,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,114,5,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
3226,serious_adverse,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,112,2,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
3227,withdrawal,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,108,23,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3228,withdrawal,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,114,29,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3229,withdrawal,wernicke 2006,a randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain,pain,duloxetine,antidepressant,antidepressant,duloxetine 120mg,snri,120mg,high,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,112,34,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3230,sleep,wolfe 1994,a double-blind placebo controlled trial of fluoxetine in fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥1 on 0-3nrs,parallel,unclear,0-15 numerical rating scale,baseline,NA,9.7,4.09,0.8925111710652088,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
3231,sleep,wolfe 1994,a double-blind placebo controlled trial of fluoxetine in fibromyalgia,pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥1 on 0-3nrs,parallel,unclear,0-15 numerical rating scale,baseline,NA,9.6,2.12,0.4626219273003039,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
3232,sleep,wolfe 1994,a double-blind placebo controlled trial of fluoxetine in fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥1 on 0-3nrs,parallel,unclear,0-15 numerical rating scale,post_int,NA,7.6,3.83,1.2766666666666666,NA,NA,NA,NA,NA,9,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
3233,sleep,wolfe 1994,a double-blind placebo controlled trial of fluoxetine in fibromyalgia,pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥1 on 0-3nrs,parallel,unclear,0-15 numerical rating scale,post_int,NA,7.6,3.1,0.8004165582161995,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
3234,pain_int,wolfe 1994,a double-blind placebo controlled trial of fluoxetine in fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥1 on 0-3nrs,parallel,unclear,0-3 numerical rating scale,baseline,NA,1.8,0.81,0.17675649109115385,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
3235,pain_int,wolfe 1994,a double-blind placebo controlled trial of fluoxetine in fibromyalgia,pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥1 on 0-3nrs,parallel,unclear,0-3 numerical rating scale,baseline,NA,1.7,0.48,0.10474458731327635,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
3236,pain_int,wolfe 1994,a double-blind placebo controlled trial of fluoxetine in fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥1 on 0-3nrs,parallel,unclear,0-3 numerical rating scale,post_int,NA,1.6,0.79,0.26333333333333336,NA,NA,NA,NA,NA,9,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
3237,pain_int,wolfe 1994,a double-blind placebo controlled trial of fluoxetine in fibromyalgia,pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥1 on 0-3nrs,parallel,unclear,0-3 numerical rating scale,post_int,NA,1.6,0.79,0.2039771229002573,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
3238,physical,wolfe 1994,a double-blind placebo controlled trial of fluoxetine in fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥1 on 0-3nrs,parallel,unclear,health assessment questionnaire,baseline,NA,1.1,0.66,0.14402380755575497,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
3239,physical,wolfe 1994,a double-blind placebo controlled trial of fluoxetine in fibromyalgia,pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥1 on 0-3nrs,parallel,unclear,health assessment questionnaire,baseline,NA,0.9,0.48,0.10474458731327635,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,baseline
3240,physical,wolfe 1994,a double-blind placebo controlled trial of fluoxetine in fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥1 on 0-3nrs,parallel,unclear,health assessment questionnaire,post_int,NA,0.8,0.76,0.25333333333333335,NA,NA,NA,NA,NA,9,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
3241,physical,wolfe 1994,a double-blind placebo controlled trial of fluoxetine in fibromyalgia,pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥1 on 0-3nrs,parallel,unclear,health assessment questionnaire,post_int,NA,0.7,0.43,0.11102552259127928,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,physical,physical functioning,smd,standardised mean diference,physical,post_int
3242,mood,wolfe 1994,a double-blind placebo controlled trial of fluoxetine in fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥1 on 0-3nrs,parallel,unclear,aims - depression,baseline,NA,3.1,1.75,0.3818813079129867,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
3243,mood,wolfe 1994,a double-blind placebo controlled trial of fluoxetine in fibromyalgia,pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥1 on 0-3nrs,parallel,unclear,aims - depression,baseline,NA,2.6,2.11,0.46043974839794394,NA,NA,NA,NA,NA,21,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
3244,mood,wolfe 1994,a double-blind placebo controlled trial of fluoxetine in fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥1 on 0-3nrs,parallel,unclear,aims - depression,post_int,NA,3,2.58,0.86,NA,NA,NA,NA,NA,9,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
3245,mood,wolfe 1994,a double-blind placebo controlled trial of fluoxetine in fibromyalgia,pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥1 on 0-3nrs,parallel,unclear,aims - depression,post_int,NA,1.5,1.78,0.4595940237499468,NA,NA,NA,NA,NA,15,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
3250,adverse_dropout,wolfe 1994,a double-blind placebo controlled trial of fluoxetine in fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥1 on 0-3nrs,parallel,unclear,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,2,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3251,adverse_dropout,wolfe 1994,a double-blind placebo controlled trial of fluoxetine in fibromyalgia,pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥1 on 0-3nrs,parallel,unclear,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,1,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3252,withdrawal,wolfe 1994,a double-blind placebo controlled trial of fluoxetine in fibromyalgia,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,6 weeks,fibromyalgia,fibromyalgia,primary,≥1 on 0-3nrs,parallel,unclear,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,12,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3253,withdrawal,wolfe 1994,a double-blind placebo controlled trial of fluoxetine in fibromyalgia,pain,fluoxetine,antidepressant,antidepressant,fluoxetine 20mg,ssri,20mg,standard,fixed,6 weeks,fibromyalgia,fibromyalgia,primary,≥1 on 0-3nrs,parallel,unclear,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,6,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3254,pain_int,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,5.78,1.17,0.09053731820649401,NA,NA,NA,NA,NA,167,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
3255,pain_int,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,duloxetine,antidepressant,antidepressant,duloxetine 40mg,snri,40mg,low,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,5.79,1.23,0.13341223155847354,NA,NA,NA,NA,NA,85,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
3256,pain_int,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,baseline,NA,5.76,1.17,0.12616434464802292,NA,NA,NA,NA,NA,86,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
3257,pain_int,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-1.61,2.3261126369976153,0.18,NA,NA,NA,NA,NA,167,NA,NA,TRUE,NA,least squares,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
3258,pain_int,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,duloxetine,antidepressant,antidepressant,duloxetine 40mg,snri,40mg,low,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-2.41,1.9361043360315062,0.21,NA,NA,NA,NA,NA,85,NA,NA,TRUE,NA,least squares,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
3259,pain_int,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,0-10 numerical rating scale,change_score,NA,-2.53,1.9474598840540978,0.21,NA,NA,NA,NA,NA,86,NA,NA,TRUE,NA,least squares,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
3260,mood,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,bpi mood,baseline,NA,4.2,2.4,0.18571757580819284,NA,NA,NA,NA,NA,167,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
3261,mood,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,duloxetine,antidepressant,antidepressant,duloxetine 40mg,snri,40mg,low,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,bpi mood,baseline,NA,3.9,2.5,0.2711630722733202,NA,NA,NA,NA,NA,85,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
3262,mood,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,bpi mood,baseline,NA,4.2,2.5,0.269581933008596,NA,NA,NA,NA,NA,86,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,baseline
3263,mood,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,bpi mood,change_score,NA,-1.91,3.1014835159968204,0.24,NA,NA,NA,NA,NA,167,NA,NA,TRUE,NA,least squares,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
3264,mood,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,duloxetine,antidepressant,antidepressant,duloxetine 40mg,snri,40mg,low,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,bpi mood,change_score,NA,-2.18,2.673667892614937,0.29,NA,NA,NA,NA,NA,85,NA,NA,TRUE,NA,least squares,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
3265,mood,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,bpi mood,change_score,NA,-2.39,2.6893493636937538,0.29,NA,NA,NA,NA,NA,86,NA,NA,TRUE,NA,least squares,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_overall,post_int
3266,sleep,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,bpi sleep,baseline,NA,3.9,2.7,0.20893227278421697,NA,NA,NA,NA,NA,167,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
3267,sleep,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,duloxetine,antidepressant,antidepressant,duloxetine 40mg,snri,40mg,low,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,bpi sleep,baseline,NA,4,2.8,0.30370264094611865,NA,NA,NA,NA,NA,85,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
3268,sleep,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,bpi sleep,baseline,NA,4.3,2.7,0.29114848764928375,NA,NA,NA,NA,NA,86,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,baseline
3269,sleep,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,bpi sleep,change_score,NA,-1.69,2.5845695966640174,0.2,NA,NA,NA,NA,NA,167,NA,NA,TRUE,NA,least squares,NA,NA,NA,placebo,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
3270,sleep,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,duloxetine,antidepressant,antidepressant,duloxetine 40mg,snri,40mg,low,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,bpi sleep,change_score,NA,-2.26,2.673667892614937,0.29,NA,NA,NA,NA,NA,85,NA,NA,TRUE,NA,least squares,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
3271,sleep,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,bpi sleep,change_score,NA,-2.05,2.6893493636937538,0.29,NA,NA,NA,NA,NA,86,NA,NA,TRUE,NA,least squares,NA,NA,NA,ad,lower,sleep,sleep,smd,standardised mean diference,sleep,post_int
3278,pain_mod,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,167,59,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
3279,pain_mod,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,duloxetine,antidepressant,antidepressant,duloxetine 40mg,snri,40mg,low,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,85,47,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
3280,pain_mod,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,51,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
3281,pain_sub,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,167,33,NA,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
3282,pain_sub,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,duloxetine,antidepressant,antidepressant,duloxetine 40mg,snri,40mg,low,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,85,32,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
3283,pain_sub,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,35,NA,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
3284,adverse,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,167,123,NA,FALSE,≥5% of participants,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
3285,adverse,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,duloxetine,antidepressant,antidepressant,duloxetine 40mg,snri,40mg,low,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,72,NA,FALSE,≥5% of participants,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
3286,adverse,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,73,NA,FALSE,≥5% of participants,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
3287,serious_adverse,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,167,6,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
3288,serious_adverse,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,duloxetine,antidepressant,antidepressant,duloxetine 40mg,snri,40mg,low,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,3,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
3289,serious_adverse,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,2,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
3290,adverse_dropout,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,167,9,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3291,adverse_dropout,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,duloxetine,antidepressant,antidepressant,duloxetine 40mg,snri,40mg,low,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,9,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3292,adverse_dropout,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,10,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3293,withdrawal,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,167,17,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3294,withdrawal,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,duloxetine,antidepressant,antidepressant,duloxetine 40mg,snri,40mg,low,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,13,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3295,withdrawal,yasuda 2011,superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in japan,pain,duloxetine,antidepressant,antidepressant,duloxetine 60mg,snri,60mg,standard,fixed,12 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥4 on 10nrs,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,86,14,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3296,pain_mod,yeephu 2013,efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,5,0.4167,FALSE,NA,NA,NA,NA,NA,placebo,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
3297,pain_mod,yeephu 2013,efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,pain,mirtazapine,antidepressant,antidepressant,mirtazapine 15mg,nassa,15mg,low,fixed,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,6,0.5,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
3298,pain_mod,yeephu 2013,efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,pain,mirtazapine,antidepressant,antidepressant,mirtazapine 30mg,nassa,30mg,standard,fixed,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,itt with locf,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,9,0.6667000000000001,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
3299,adverse,yeephu 2013,efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,13,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
3300,adverse,yeephu 2013,efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,pain,mirtazapine,antidepressant,antidepressant,mirtazapine 15mg,nassa,15mg,low,fixed,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,13,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
3301,adverse,yeephu 2013,efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,pain,mirtazapine,antidepressant,antidepressant,mirtazapine 30mg,nassa,30mg,standard,fixed,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,14,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
3302,serious_adverse,yeephu 2013,efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
3303,serious_adverse,yeephu 2013,efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,pain,mirtazapine,antidepressant,antidepressant,mirtazapine 15mg,nassa,15mg,low,fixed,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
3304,serious_adverse,yeephu 2013,efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,pain,mirtazapine,antidepressant,antidepressant,mirtazapine 30mg,nassa,30mg,standard,fixed,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,0,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,serious_adverse,adverse outcomes excluded from nma,NA,NA,serious_adverse,post_int
3305,adverse_dropout,yeephu 2013,efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,2,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3306,adverse_dropout,yeephu 2013,efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,pain,mirtazapine,antidepressant,antidepressant,mirtazapine 15mg,nassa,15mg,low,fixed,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,1,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3307,adverse_dropout,yeephu 2013,efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,pain,mirtazapine,antidepressant,antidepressant,mirtazapine 30mg,nassa,30mg,standard,fixed,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,2,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3308,withdrawal,yeephu 2013,efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,3,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3309,withdrawal,yeephu 2013,efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,pain,mirtazapine,antidepressant,antidepressant,mirtazapine 15mg,nassa,15mg,low,fixed,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,2,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3310,withdrawal,yeephu 2013,efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study,pain,mirtazapine,antidepressant,antidepressant,mirtazapine 30mg,nassa,30mg,standard,fixed,13 weeks,fibromyalgia,fibromyalgia,primary,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,3,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3311,adverse,yucel 2005,"the effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,11,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
3312,adverse,yucel 2005,"the effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 75mg,snri,75mg,low,fixed,8 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,9,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
3313,adverse,yucel 2005,"the effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 150mg,snri,150mg,standard,fixed,8 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,14,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,adverse,adverse events,lor,log odds ratio,adverse,post_int
3314,adverse_dropout,yucel 2005,"the effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,1,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3315,adverse_dropout,yucel 2005,"the effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 75mg,snri,75mg,low,fixed,8 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,1,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3316,adverse_dropout,yucel 2005,"the effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 150mg,snri,150mg,standard,fixed,8 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,3,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3317,withdrawal,yucel 2005,"the effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study",pain,placebo,placebo,placebo,placebo,n/a,n/a,n/a,n/a,8 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,1,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3318,withdrawal,yucel 2005,"the effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 75mg,snri,75mg,low,fixed,8 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,1,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3319,withdrawal,yucel 2005,"the effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study",pain,venlafaxine,antidepressant,antidepressant,venlafaxine 150mg,snri,150mg,standard,fixed,8 weeks,neuropathic pain,neuropathic,neuropathic,≥4 on 10nrs,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,20,3,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3320,pain_int,zakerish 2017,comparative efficacy of duloxetine versus nortriptyline in patients with diabetic peripheral neuropathic pain: a double blind randomized controlled trial,pain,nortriptyline,antidepressant,antidepressant,nortriptyline 25-75mg,tca,25-75mg,low,flexible,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,0-100 vas,baseline,NA,71.82,16.54,2.020682609653288,NA,NA,NA,NA,NA,67,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
3321,pain_int,zakerish 2017,comparative efficacy of duloxetine versus nortriptyline in patients with diabetic peripheral neuropathic pain: a double blind randomized controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine 30-60mg,snri,30-60mg,low,flexible,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,0-100 vas,baseline,NA,74.7,19.21,2.346875026084623,NA,NA,NA,NA,NA,67,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
3322,pain_int,zakerish 2017,comparative efficacy of duloxetine versus nortriptyline in patients with diabetic peripheral neuropathic pain: a double blind randomized controlled trial,pain,nortriptyline,antidepressant,antidepressant,nortriptyline 25-75mg,tca,25-75mg,low,flexible,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,0-100 vas,post_int,NA,44.82,17.08,2.2623012658670945,NA,NA,NA,NA,NA,57,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
3323,pain_int,zakerish 2017,comparative efficacy of duloxetine versus nortriptyline in patients with diabetic peripheral neuropathic pain: a double blind randomized controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine 30-60mg,snri,30-60mg,low,flexible,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,0-100 vas,post_int,NA,35.95,15.98,2.046029341327678,NA,NA,NA,NA,NA,61,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
3324,pain_mod,zakerish 2017,comparative efficacy of duloxetine versus nortriptyline in patients with diabetic peripheral neuropathic pain: a double blind randomized controlled trial,pain,nortriptyline,antidepressant,antidepressant,nortriptyline 25-75mg,tca,25-75mg,low,flexible,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,57,43,0.755,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
3325,pain_mod,zakerish 2017,comparative efficacy of duloxetine versus nortriptyline in patients with diabetic peripheral neuropathic pain: a double blind randomized controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine 30-60mg,snri,30-60mg,low,flexible,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,61,60,0.9840000000000001,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_mod,moderate pain (30% reduction),lor,log odds ratio,pain_mod,post_int
3326,pain_sub,zakerish 2017,comparative efficacy of duloxetine versus nortriptyline in patients with diabetic peripheral neuropathic pain: a double blind randomized controlled trial,pain,nortriptyline,antidepressant,antidepressant,nortriptyline 25-75mg,tca,25-75mg,low,flexible,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,57,15,0.2631,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
3327,pain_sub,zakerish 2017,comparative efficacy of duloxetine versus nortriptyline in patients with diabetic peripheral neuropathic pain: a double blind randomized controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine 30-60mg,snri,30-60mg,low,flexible,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,not reported,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,61,37,0.6065,FALSE,NA,NA,NA,NA,NA,ad,higher,pain_sub,substantial pain (50% reduction),lor,log odds ratio,pain_sub,post_int
3328,withdrawal,zakerish 2017,comparative efficacy of duloxetine versus nortriptyline in patients with diabetic peripheral neuropathic pain: a double blind randomized controlled trial,pain,nortriptyline,antidepressant,antidepressant,nortriptyline 25-75mg,tca,25-75mg,low,flexible,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,67,10,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3329,withdrawal,zakerish 2017,comparative efficacy of duloxetine versus nortriptyline in patients with diabetic peripheral neuropathic pain: a double blind randomized controlled trial,pain,duloxetine,antidepressant,antidepressant,duloxetine 30-60mg,snri,30-60mg,low,flexible,6 weeks,diabetic peripheral neuropathy,neuropathic,neuropathic,≥40 on 100vas,parallel,randomized population,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,67,6,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3330,pain_int,zitman 1990,low dose amitriptyline in chronic pain: the gain is modest,pain,riboflavin (vitamin b2),active placebo,placebo,riboflavin 15mg,n/a,n/a,n/a,n/a,6 weeks,any chronic pain,unspecified,primary,no,parallel,completer analysis,0-10 numerical rating scale,baseline,NA,3.9,1.5,0.33541019662496846,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
3331,pain_int,zitman 1990,low dose amitriptyline in chronic pain: the gain is modest,pain,amitriptyline + riboflavin (vitamin b2),combined antidepressant intervention,antidepressant,amitriptyline 75mg + riboflavin 15mg,tca,75mg,standard,fixed,6 weeks,any chronic pain,unspecified,primary,no,parallel,completer analysis,0-10 numerical rating scale,baseline,NA,3,1.5,0.3441236008058426,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,baseline
3332,pain_int,zitman 1990,low dose amitriptyline in chronic pain: the gain is modest,pain,riboflavin (vitamin b2),active placebo,placebo,riboflavin 15mg,n/a,n/a,n/a,n/a,6 weeks,any chronic pain,unspecified,primary,no,parallel,completer analysis,0-10 numerical rating scale,post_int,NA,4.3,1.4,0.3130495168499705,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
3333,pain_int,zitman 1990,low dose amitriptyline in chronic pain: the gain is modest,pain,amitriptyline + riboflavin (vitamin b2),combined antidepressant intervention,antidepressant,amitriptyline 75mg + riboflavin 15mg,tca,75mg,standard,fixed,6 weeks,any chronic pain,unspecified,primary,no,parallel,completer analysis,0-10 numerical rating scale,post_int,NA,2.7,1.7,0.39000674757995496,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,post_int
3334,pain_int,zitman 1990,low dose amitriptyline in chronic pain: the gain is modest,pain,riboflavin (vitamin b2),active placebo,placebo,riboflavin 15mg,n/a,n/a,n/a,n/a,6 weeks,any chronic pain,unspecified,primary,no,parallel,completer analysis,0-10 numerical rating scale,follow_up,"6 weeks after post-intervention, 12 weeks from baseline",3.3,1.7,0.45434411125112145,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,follow_up
3335,pain_int,zitman 1990,low dose amitriptyline in chronic pain: the gain is modest,pain,amitriptyline + riboflavin (vitamin b2),combined antidepressant intervention,antidepressant,amitriptyline 75mg + riboflavin 15mg,tca,75mg,standard,fixed,6 weeks,any chronic pain,unspecified,primary,no,parallel,completer analysis,0-10 numerical rating scale,follow_up,"6 weeks after post-intervention, 12 weeks from baseline",2.9,2,0.5547001962252291,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,pain_int,pain intensity (continuous measure),smd,standardised mean diference,pain_int,follow_up
3336,mood,zitman 1990,low dose amitriptyline in chronic pain: the gain is modest,pain,riboflavin (vitamin b2),active placebo,placebo,riboflavin 15mg,n/a,n/a,n/a,n/a,6 weeks,any chronic pain,unspecified,primary,no,parallel,completer analysis,zung depression rating scale,baseline,NA,44,10.5,2.347871376374779,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
3337,mood,zitman 1990,low dose amitriptyline in chronic pain: the gain is modest,pain,amitriptyline + riboflavin (vitamin b2),combined antidepressant intervention,antidepressant,amitriptyline 75mg + riboflavin 15mg,tca,75mg,standard,fixed,6 weeks,any chronic pain,unspecified,primary,no,parallel,completer analysis,zung depression rating scale,baseline,NA,44.7,10.1,2.3170989120926735,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,baseline
3338,mood,zitman 1990,low dose amitriptyline in chronic pain: the gain is modest,pain,riboflavin (vitamin b2),active placebo,placebo,riboflavin 15mg,n/a,n/a,n/a,n/a,6 weeks,any chronic pain,unspecified,primary,no,parallel,completer analysis,zung depression rating scale,post_int,NA,39.2,10.2,2.2807893370497854,NA,NA,NA,NA,NA,20,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
3339,mood,zitman 1990,low dose amitriptyline in chronic pain: the gain is modest,pain,amitriptyline + riboflavin (vitamin b2),combined antidepressant intervention,antidepressant,amitriptyline 75mg + riboflavin 15mg,tca,75mg,standard,fixed,6 weeks,any chronic pain,unspecified,primary,no,parallel,completer analysis,zung depression rating scale,post_int,NA,39.2,10.5,2.408865205640898,NA,NA,NA,NA,NA,19,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,post_int
3340,mood,zitman 1990,low dose amitriptyline in chronic pain: the gain is modest,pain,riboflavin (vitamin b2),active placebo,placebo,riboflavin 15mg,n/a,n/a,n/a,n/a,6 weeks,any chronic pain,unspecified,primary,no,parallel,completer analysis,zung depression rating scale,follow_up,"6 weeks after post-intervention, 12 weeks from baseline",41,11,2.9398736610366685,NA,NA,NA,NA,NA,14,NA,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,mood,mood,smd,standardised mean diference,mood_depression,follow_up
3341,mood,zitman 1990,low dose amitriptyline in chronic pain: the gain is modest,pain,amitriptyline + riboflavin (vitamin b2),combined antidepressant intervention,antidepressant,amitriptyline 75mg + riboflavin 15mg,tca,75mg,standard,fixed,6 weeks,any chronic pain,unspecified,primary,no,parallel,completer analysis,zung depression rating scale,follow_up,"6 weeks after post-intervention, 12 weeks from baseline",41.3,11.5,3.1895261282950678,NA,NA,NA,NA,NA,13,NA,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,mood,mood,smd,standardised mean diference,mood_depression,follow_up
3342,adverse_dropout,zitman 1990,low dose amitriptyline in chronic pain: the gain is modest,pain,riboflavin (vitamin b2),active placebo,placebo,riboflavin 15mg,n/a,n/a,n/a,n/a,6 weeks,any chronic pain,unspecified,primary,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,0,NA,FALSE,NA,NA,NA,NA,NA,placebo,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3343,adverse_dropout,zitman 1990,low dose amitriptyline in chronic pain: the gain is modest,pain,amitriptyline + riboflavin (vitamin b2),combined antidepressant intervention,antidepressant,amitriptyline 75mg + riboflavin 15mg,tca,75mg,standard,fixed,6 weeks,any chronic pain,unspecified,primary,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,2,NA,FALSE,NA,NA,NA,NA,NA,ad,NA,adverse_dropout,adverse outcomes excluded from nma,NA,NA,adverse_dropout,post_int
3344,withdrawal,zitman 1990,low dose amitriptyline in chronic pain: the gain is modest,pain,riboflavin (vitamin b2),active placebo,placebo,riboflavin 15mg,n/a,n/a,n/a,n/a,6 weeks,any chronic pain,unspecified,primary,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,24,4,NA,FALSE,NA,NA,NA,NA,NA,placebo,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
3345,withdrawal,zitman 1990,low dose amitriptyline in chronic pain: the gain is modest,pain,amitriptyline + riboflavin (vitamin b2),combined antidepressant intervention,antidepressant,amitriptyline 75mg + riboflavin 15mg,tca,75mg,standard,fixed,6 weeks,any chronic pain,unspecified,primary,no,parallel,completer analysis,count,post_int,NA,NA,NA,NA,NA,NA,NA,NA,NA,25,6,NA,FALSE,NA,NA,NA,NA,NA,ad,lower,withdrawal,withdrawal,lor,log odds ratio,withdrawal,post_int
